Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Animal or plant cell

Subclass of:

424 - Drug, bio-affecting and body treating compositions

424930100 - WHOLE LIVE MICRO-ORGANISM, CELL, OR VIRUS CONTAINING

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
424930710 Leukocyte 201
424930720 Platelet 45
424930730 Erythrocyte 31
Entries
DocumentTitleDate
20090175836PRELAMIN A PRE PEPTIDE AS A UNIVERSAL STEM CELL DIFFERENTIATION SIGNAL - Disclosed is the use of prelamin A pre peptide and homologues or analogs thereof for the induction of cell differentiation and tissue or organ growth and repair processes. The invention extends to virtually any cell, including both embryonic and non-embryonic stem cells, such as stem cells that are progenitors for a wide variety of cell and tissue types. Also disclosed is the use of prelamin A pre peptide and prelamin A to determine and establish cell morphology and tissue architecture. Treatment of a variety of diseases and conditions, as well as cosmetic, general health, and anti-aging applications are described.07-09-2009
20080274088Mapc Generation of Lung Tissue - The present invention relates to methods of improving function in lung tissue by administering a population of multipotent adult progenitor cells (“MAPCs”) or differentiated progeny thereof.11-06-2008
20090016997Autologous/allogeneic human DNA grafting, anti-and reverse aging stem cell, and bone marrow compositions/methods - Anti-aging compositions and methods for delivering (engrafting) younger compatible human DNA to tissues, through the systematic periodic introduction of younger primordial whole (nucleated) stem cells and bone marrow into a recipient, resulting in re-establishment of an earlier relative biological clock set-point, with respect to the number of cell generations-divisions are disclosed.01-15-2009
20090214482Transgenic Mammals Expressing Human Preproinsulin - Transgenic mammals which express human preproinsulin, methods and reagents for producing the transgenic mammals, and therapeutic methods of providing patients with insulin and C-peptide using tissues and cells from the transgenic mammals.08-27-2009
20120201788METHODS AND COMPOSITIONS FOR CELL THERAPY - Improved methods of cell therapy are provided using cells and tissues that are histocompatible with a human or non-human transplant recipient. The cells and tissues for transplant produced by the present invention exhibit a youthful state and can be committed to specific cell lineages to better infiltrate and proliferate at a desired target, e.g., a tissue, or organ in need of cell replacement therapy. For providing cells and tissues for transplant to a non-human mammal, the cells and tissues can be isolated from a gastrulating embryo produced by same-species nuclear transfer.08-09-2012
20090123436CRYOPRESERVATIVE COMPOSITIONS AND METHODS - The invention relates to compositions for the cryogenic storage of biological materials and related methods. In an embodiment, the invention includes a cryopreservative composition including a chaotropic agent and a kosmotropic agent. In an embodiment, the invention includes a cryopreservative composition including urea and trimethylamine-N-oxide. In an embodiment, the invention includes a method of cryopreserving cells including contacting cells with a cryopreservative composition, the cryopreservative composition comprising a chaotropic agent and a kosmotropic agent. In an embodiment, the invention includes a method of transplanting cells into a subject, the method including administering a composition to the subject, the composition comprising an effective amount of a chaotropic agent, an effective amount of a kosmotropic agent, and cells. Other embodiments are also included herein.05-14-2009
20080279828Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby - Ex vivo and in vivo methods of expanding a population of stem and/or progenitor cells, while at the same time reversibly inhibiting differentiation of the stem and/or progenitor cells by providing the stem and/or progenitor cells with an effective amount of at least one copper chelate, so as to maintain a free copper concentration available to said cells substantially unchanged, to thereby expand the population of said stem and/or progenitor cells, while at the same time reversibly inhibit differentiation of said stem and/or progenitor cells.11-13-2008
20110206644METHODS FOR TRANS-DIFFERENTIATING CELLS - The present provides methods for affecting and/or altering the differentiation state of a cell. In certain embodiments, the present invention provides methods to transdifferentiate a cell into an endothelial cell or a hematopoietic cell. In the practice of the invention, a demethylating agent (e.g., 5-azacytidine) is used to affect and/or alter the differentiation state of a cell. The invention demonstrates the transdifferentiation of numerous cell types, including cell populations that are themselves somewhat differentiated (e.g., normal fibroblasts) into distinct cell types, including hematopoietic cells and endothelial cells, which transdifferentiation is effected further through the selection of particular growth factors which, together with the demethylating agents, directs the differentiation path. The invention provides a novel approach to providing useful cell types for many types of medical applications.08-25-2011
20090202498DIRECT DIFFERENTIATION OF CARDIOMYOCYTES FROM HUMAN EMBRYONIC STEM CELLS - The present invention relates to the induction of differentiation in stem cells to cardiomyocytes and factors such as prostaglandin alone or in combination with other factors including essential minerals selected from the group including transferrin and selenium, small molecules selected from the group including a p38 MAPK inhibitor such as SB203580 and protein growth factors of the FGF, IGF and BMP families such as but not limited to IGF1, FGF2, BMP2, BMP4 and BMP6. and insulin that influence the process of differentiation to cardiomyocytes. Media that is appropriate for the induction of differentiation of cardiomyocytes from stem cells is also provided wherein the media contains these factors. The use of cardiomyocytes and cardiac progenitors produced by the directed differentiation in transplantation and screening for cardiac compounds is also provided.08-13-2009
20090123433Compositions Comprising Human Embryonic Stem Cells and their Derivatives, Methods of Use, and Methods of Preparation - The present invention relates to a pharmaceutical composition comprising of preparations of human embryonic stem (hES) cells and their derivatives and methods for their transplantation into the human body, wherein transplantation results in the clinical reversal of symptoms, cure, stabilization or arrest of degeneration of a wide variety of presently incurable and terminal medical conditions, diseases and disorders. The invention further relates to novel processes of preparing novel stem cell lines which are free of animal products, feeder cells, growth factors, leukaemia inhibitory factor, supplementary mineral combinations, amino acid supplements, vitamin supplements, fibroblast growth factor, membrane associated steel factor, soluble steel factor and conditioned media. This invention further relates to the isolation, culture, maintenance, expansion, differentiation, storage, and preservation of such stem cells.05-14-2009
20090123431CELL/LIGAND MARKING SYSTEM, WHEREIN THE MARKER IS OF EPH TYPE, CELL MATERIAL COMPRISING SAID SYSTEM, METHOD FOR PREPARING SAME AND PROANGIOGENETIC USE - A cell/ligand specific marking system, the system being characterized in that it comprises: (a) an endothelial precursor cell (EPC) including a cell marker selected from among the group consisting of the Eph (in particular EphB4 or EphB1), and (b) a protein material of structure L-K, which consists of a ligand (L) specific of the marker and is associated or fused with a binding protein (K), the system being capable of providing a proangiogenetic cell material of structure EPC-Eph-L-K. The invention also concerns the cell material as product capable of stimulating angiogenesis, its preparation method and its therapeutic use, in particular with respect to vascular insufficiencies.05-14-2009
20090123435CULTURED THREE-DIMENSIONAL TISSUES AND USES THEREOF - The present disclosure provides compositions of three dimensional tissue that can be administered into tissues and organs using minimally invasive methods. The three dimensional tissues elaborate a repertoire of growth factors that facilitate repair or regeneration of damaged tissues and organs.05-14-2009
20090196859Oligodendrocyte Precursor Cell Composition and Methods of Use - The present invention provides a cell culture enriched for sphingolipid enhances neural stem cells (SENSe), particularly oligodendrocyte precursor cells (ODPCs), that do not form teratomas after transplanted in vivo. Methods for producing and use of the invention ODPCs or the cell culture enriched with these ODPCs for stem cell therapy are also provided. The invention method comprises culturing a stem cell culture with a cell culture medium comprising a ceramide compound and a S1P receptor agonist in sequence, overlapping intervals or concurrent manners. The present invention further provides a cellular or gene therapy using a composition comprising a ceramide compound in conjunction with a S1P08-06-2009
20090196858AMELIORATING AGENT FOR BRAIN DAMAGE - The present invention provides a pharmaceutical composition for ameliorating brain damage induced by oxygen deficiency, comprising a chondroitin sulfate-degrading enzyme and at least one of a neural stem cell(s) and a neural progenitor cell(s), as active ingredients.08-06-2009
20090196857Kidney-Derived Stem Cell Population, Identification and Therapeutic Use - A novel population of kidney-derived cells is described that exhibits surface co-expression of CD133 and CD24 markers; said cells possess stem cell capacity and are capable of undergoing tubulogenic, adipogenic, osteogenic and neurogenic differentiation.08-06-2009
20090196855Artificial "arterio-venous" permeable hollow fiber capillary system - An artificial “arterio-venous” permeable hollow fiber capillary membrane system for wound treatment is described, that can be placed onto a wound, under the wound dressing, to enable fluid-/mass exchange, and thus enables pH- and electrolyte regulation, the supply of factors/mediators/medications, the removal of secretion- and/or waste material, and the support of therapeutically applied cells in the wound.08-06-2009
20090196856Method for Generating Dendritic Cells Employing Decreased Temperature - The invention relates in certain embodiments to a method for generating dendritic cells by employing temperatures below 37° C. during the development of progenitor cells and immature dendritic cells. In some embodiments the invention relates to populations of dendritic cells and its use.08-06-2009
20120171175METHODS FOR TREATING REFRACTORY INFECTIONS IN NEUTROPENIC INDIVIDUALS - The invention is based, in part, on the discovery of a novel cell-based immunotherapy that can recapitulate neutrophil functions in neutropenic individuals afflicted with a microbial infection. The therapeutic methods of the invention are broadly applicable to treat any infection in a neutropenic individual, including infections caused by bacteria, fungi, protozoa, and viruses. The methods of the invention represent a practical, rapid cell-based immunotherapy for refractory infections comprising compositions of activated, irradiated HL-60 cells.07-05-2012
20090291065COLLECTION AND SELECTION METHODS OF AN EMBRYONIC-LIKE STEM CELL POPULATION FROM HUMAN ADULT PERIODONTAL FOLLICULAR TISSUES - Methods for the isolation, expansion and storage of a population of stem cells belonging to human dental follicles, called FENC (11-26-2009
20100061964METHOD FOR PREPARING PANCREATIC BETA CELLS STARTING FROM BETA CELL PROGENITORS AND BETA CELLS THEREBY OBTAINED - The present invention relates to a method for preparing pancreatic islet cells, and preferably pancreatic beta cells starting from progenitor cells obtained from the pancreas of an adult mammal. The invention also provides a method for isolating progenitor cells, and preferably beta cell progenitors, from the pancreas of an adult mammal. Other aspects of the invention comprise the pancreatic islet (beta) cells and the progenitor cells that can be obtained with the present invention and their use, e.g. in diagnostic, therapeutic or research applications.03-11-2010
20100021435PANCREATIC ISLET-LIKE CELLS - The generation of pancreatic islet-like cells from isolated monocyte-derived stem cells (MDSCs) is provided. MD-SCs may be differentiated into pancreatic islet cells by contacting the MDSCs with a differentiation factor or factors. Compositions comprising pancreatic islet cells and methods of using them are also provided.01-28-2010
20090291064Immortal unipotent porcine PICM-19H and PICM-19B stem cell lines - Two cell lines, PICM-19H and PICM-19B, were derived from the bipotent ARS-PICM-19 pig liver stem cell line and assessed for their potential application in artificial liver devices. The study included assessments of growth rate and cell density in culture, morphological features, and hepatocyte detoxification functions, i.e., inducible CYP450 activity, ammonia clearance, and urea production. The PICM-19H cells contain numerous mitochondria, Golgi apparatus, smooth and rough endoplasmic reticulum, vesicular bodies and occasional lipid vacuoles. PICM-19H cells display inducible CYP450 activity, clear ammonia, and produce urea in a glutamine-free medium. Ultrastructural analysis of the PICM-19B monolayers show that the roughly cuboidal cells display basal-apical polarization and are joined by tight junction-like complexes. Other ultrastructure features are similar to those of PICM-19H cells except that they possess numerous cell bodies resembling mucus vacuoles. The PICM-19B cells possess relatively high levels of GGT activity, but retain some inducible CYP450 activity, and some ammonia clearance and urea synthesis ability. These data indicate that both cell lines, either together or alone, may be useful as the cellular substrate for an artificial liver device. In vitro models of the liver are needed to replace animal models for the rapid assessment of drug biotransformation and toxicity. A unipotent porcine stem cell line PICM-19H differentiates exclusively into hepatocytes and can be induced to express CYP450 enzymes. These cells have many activities associated with xenobiotic phase I and phase II metabolism lacking in other liver cell lines. The PICM-19H cell line was also compared to the tumor-derived human HepG2 C3A cell line and to primary cultures of adult porcine hepatocytes. The results demonstrate the potential for the use of PICM-19H cells in drug biotransformation and toxicity testing and further support their use in artificial liver device technology.11-26-2009
20090022694SIRT1 INHIBITION - A method of culturing cells in the presence of a SIRT1 inhibitor is described.01-22-2009
20080260701ANTI-ANGIOGENIC CELLULAR AGENT FOR CANCER THERAPY - The invention provides cytokine induced killer (CIK) cell populations and methods of using CIK cells to treat cellular proliferative disorders. CIK cells generated in vitro include both bulk cultures and clones. Individual CIK cell clones display distinct but overlapping lytic specificities for tumor cells and endothelial cells in vitro. When injected in vivo, bulk CIK cell cultures selectively attack tumor tissue. CIK cells can be used to treat a variety of cellular proliferative disorders, including early and late stage cancers as well as hematopoietic cell and solid tissue tumors.10-23-2008
20080260700GENERATION OF PANCREATIC ENDOCRINE CELLS FROM PRIMARY DUCT CELL CULTURES AND METHODS OF USE FOR TREATMENT OF DIABETES - The invention is directed to spontaneously immortalized pancreatic duct cells and methods for generating pancreatic endocrine cells from spontaneously immortalized pancreatic duct cells that express the transcription factors Pdx1 and FoxO1. The invention also provides for methods for treating beta cell failure, the method comprising administering to a subject an effective amount of spontaneously immortalized pancreatic duct cells expressing a mutated version FoxO1.10-23-2008
20080260704Combination Treatment of Cardiovascular Disease - Disclosed are methods, compositions of matter and cells for treatment of cardiovascular disease through concurrent inhibition of oxidative stress while administration of a cell therapy. The invention also concerts the modulation of oxidative stress for preferential induction of differentiation while concurrently inhibiting inflammatory processes that decrease efficacy of cellular therapy.10-23-2008
20080260703Treatment of Insulin Resistance and Diabetes - Disclosed are methods, compositions, and cells useful for increasing insulin sensitivity, as well as lack of insulin production in a host in need thereof. One aspect of the invention discloses methods of increasing skeletal muscle perfusion through administration of cells capable of directly and/or indirectly stimulatory of angiogenesis and/or vascular responsiveness. Another aspect provides means of increasing sensitivity to insulin through administration of a cell composition capable of integrating into host insulin responsive tissue and upregulating responsiveness either through mobilization of host cells capable of responding to insulin, mobilization of host cells capable of endowing insulin responsiveness on other host cells, exogenously administered cells taking the role of insulin responsiveness, or exogenously administered cells endowing insulin responsiveness on other host cells. Another aspect comprises modifying said host to allow for concurrent insulin sensitization and upregulated production of insulin.10-23-2008
20080260702Treatment of Retinopathies Using Gfra3 Agonists - The present invention relates to the use of GFRα3 agonists for the treatment of disorders of the retina. A preferred GFRα3 agonist is Neublastin. Neublastin may be administered to the eye using protein formulations, in vivo or ex vivo gene therapy, or implantation of encapsulated cells delivering Neublastin locally to the retina.10-23-2008
20080260699Adminstration of intact mammalian cells to the brain by the intranasal route - The present invention provides an intranasal method for delivery of intact mammalian cells to the brain for treatment of neurological deficits. This approach applies an intranasal instillation to directly administer cells to the brain, and is useful as therapy for patients with neurological deficit or those who may benefit from cellular therapy as a result of stroke, Alzheimer's, Parkinson's, diabetes, traumatic injury, surgery, cancer, or other diseases of the brain. This non-invasive method of delivering neuronal cells is desirable and safe.10-23-2008
20090280092G-Protein Coupled Receptor 83 As a Molecular Switch for the Induction of Regulatory (immunosuppressive) T-cells - The present invention makes use of the role of the G-protein coupled receptor 83 (GPCR83) in the induction of regulatory T cells (Tregs) during the course of ongoing immune response. The present invention relates to means and methods for identifying compounds that are interacting with the GPCR83 polypeptide, and to compounds capable of functioning as immunomodulators in mammals, in particular humans. In addition, the present invention relates to methods of treatment of a subject, in particular a human, suffering from an undesired immunoreaction.11-12-2009
20090324559METHODS AND PLATFORMS FOR DRUG DISCOVERY - The present invention involves methods for identifying an agent that corrects a phenotype associated with a health condition or a predisposition for a health condition. The invention also involves methods for identifying a diagnostic cellular phenotype, determining the risk of a health condition in a subject, methods for reducing the risk of drug toxicity in a human subject, and methods for identifying a candidate gene that contributes to a human disease. The invention also discloses human induced pluripotent stem cell lines.12-31-2009
20110189139Hematopoietic Cell E-Selectin/L-Selectin Ligand Glycosylated CD44 Polypeptide - The invention feature methods and compositions for treating hematopoietic disorders, inflammatory conditions, and cancer and providing stem cell therapy in a mammal.08-04-2011
20080206206BONE MARROW-DERIVED NEURONAL CELLS - Bone marrow stromal cells (BMSC) differentiate into neuron-like phenotypes in vitro and in vivo, engrafted into normal or denervated rat striatum. The BMSC administered into the ventricle did not remain localized to the site of the graft, but migrated throughout the brain and integrated into specific brain regions in various architectonic patterns. The most orderly integration of BMSC was in the laminar distribution of cerebellar Purkinje cells, where the BMSC-derived cells took on the Purkinje phenotype. The BMSC exhibited site-dependent differentiation and expressed several neuronal markers including neuron-specific nuclear protein, tyrosine hydroxylase and calbindin. Treated BMSC implanted intrastriatally stayed in the cortex and the striatum, produced tyrosine hydroxylase which produces the dopamine needed in Parkinson's disease.08-28-2008
20090214486Serum Response Factor and Myocardin Control Alzheimer Cerebral Amyloid Angiopathy - Cerebral amyloid angiopathy is involved in Alzheimer dementia through reduction in arterial blood flow that may impair protein synthesis, which is required for learning and memory, and lower the threshold for ischemic injury. Elevated serum response factor (SRF) or myocardin (MYOCD) activity in subjects afflicted by or at risk for development of Alzheimer's disease (AD) promotes a “vascular smooth muscle cell” (VSMC) hypercontractile phenotype in brain arteries and enhance accumulation of Aβ in the vessel wall. This, in turn, can initiate a disease process in cerebral arteries which can cause brain arterial hypoperfusion and neurovascular uncoupling, that are commonly seen in AD. Thus, SRF and MYOCD represent novel targets for treating arterial dysfunction associated with cognitive decline in AD.08-27-2009
20090123430METHOD FOR DIFFERENTIATION OF STEM CELLS - A method for the differentiation of mammalian pluripotent stem (PS) cells into a mortal multi-lineage progenitor cell population is provided which comprises culturing the pluripotent stem cells in the presence of Hyaluronan (HA). The mortal multi-lineage progenitor cell population may be a population of mesenchymal stem cells. The mortal multi-lineage progenitor cell population may form cells of the mesodermal lineage, suitably osteoblasts. Alternatively, the mortal multi-lineage progenitor cell population may form cells of the endodermal lineage or of the ectodermal lineage, which may be neuronal progenitors.05-14-2009
20100086525Compositions and Methods for Altering Pancreas or Liver Function - Methods for altering pancreatic and liver cell function are provided, wherein the compositions and methods are based on use of osteopontin or on altering the activity of osteopontin.04-08-2010
20100080781Preventing Transfusion Related Complications in a Recipient of a Blood Transfusion - This invention is directed toward a process for reducing transfusion related complications in a recipient of an allogeneic blood transfusion by adding to the blood to be transfused a photosensitizer comprising riboflavin, irradiating the blood and riboflavin with light, transfusing the irradiated blood into a recipient, and reducing a transfusion related complication by the recipient to cells in the donor blood.04-01-2010
20100080779Methods related to wound healing - The invention is directed to methods for the treatment of wounds. Such methods utilize novel compositions, including but not limited to amnion-derived multipotent cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine suspension or ACCS), cell lysates derived therefrom, cell products derived therefrom, each alone or in combination.04-01-2010
20110195055Method and apparatus for holding cells - The present invention pertains to an apparatus for holding cells. The apparatus comprises a mechanism for incubating cells having a dynamically controlled environment in which the cells are grown, which are maintained in a desired condition and in which cells can be examined while the environment is dynamically controlled and maintained in the desired condition. The apparatus also comprises a mechanism for determining the state of the cells. The determining mechanism is in communication with the incubating mechanism. The present invention pertains to a method for holding cells. The method comprises the steps of incubating the cells in a dynamically controlled environment which is maintained in a desired condition and in which the cells can be examined while the environment is dynamically controlled and maintained in the desired condition. Additionally, there is the step of determining the state of the cells.08-11-2011
20110195054Preparation And Use Of Stromal Cells For Treatment Of Cardiac Diseases - This invention is directed to the preparation and use of stromal cells for treatment of cardiac tissue.08-11-2011
20090191163Primed tissue for tissue engineering and methods of priming tissue - Provided is a composition comprising a primed engineered tissue construct, methods of making the composition, methods of using the composition in dermatologic surgery, and a kit for supplying surgical tissue graft components.07-30-2009
20090191162Catecholamine Receptor Modulation - The invention relates to receptors of catecholamines and their role in stem cell development and function.07-30-2009
20090191161TENOCYTE CELL CULTURING METHOD - The present invention relates to a method for culturing tenocytes. In particular the present invention relates to a method for culturing tenocytes comprising the step of incubating tenocytes in a culture medium comprising insulin or functional derivative.07-30-2009
20090191159Multipotent/pluripotent cells and methods - Described herein are multipotent stem cells, e.g., human and other mammalian pluripotent stem cells, and related methods.07-30-2009
20090191167ADULT SERTOLI CELLS AND USES THEREOF - The invention relates, in part, to non-neonatal Sertoli cells derived from non-rodent animals, pharmaceutical compositions comprising such Sertoli cells, and uses thereof. The non-neonatal, non-rodent Sertoli cells express more FasL than neonatal Sertoli cells, and they provide greater immunoprivilege than neonatal Sertoli cells. In some embodiments the Sertoli cells are modified to express a biological factor. In other embodiments, the pharmaceutical compositions further comprise non-Sertoli cells. The invention also provides implantation devices comprising the pharmaceutical compositions, methods of making the pharmaceutical compositions, and methods of using the pharmaceutical compositions by administering an effective amount of the compositions.07-30-2009
20100158876PROCESS FOR THE PREPARATION OF STEM CELLS FROM HUMAN MUSCLE TISSUE AND ADIPOSE TISSUE, AND STEM CELLS OBTAINABLE BY THIS PROCESS - The invention relates to a process for the preparation of the human stem cells from muscle tissue or adipose tissue. The process provides for the incubation of cells obtained from a sample of muscle tissue or adipose tissue in a medium comprising BSA, Bfgf, EGF, VEGF, LIF, heparin and usual inorganic salts, natural acids and vitamins necessary for the growth of mamalian cells. The invention relates also to the human muscle stem cells (hMSC) and human adipose tissue cells (hFSC) obtainable by this process.06-24-2010
20100158874Compositions and Methods for Treating Peripheral Vascular Diseases - The invention relates to methods for producing endothelial cells, pericytes and/or muscle cells (in particular smooth muscle cells), cell preparations and pharmaceutical compositions comprising the cells or preparations, and the use of the cells, preparations and compositions in research or commercial applications. In aspects, the invention provides a method of treating a patient with a condition involving endothelial cells, endothelial precursor cells, pericytes and/or muscle cells, such as a peripheral vascular disease, comprising administering to the patient endothelial precursor cells, endothelial cells, pericytes and/or muscle cells obtained from multipotent CD4506-24-2010
20100158878TARGET POPULATIONS OF OLIGODENDROCYTE PRECURSOR CELLS AND METHODS OF MAKING AND USING SAME - This application provides for enriched target populations oligodendrocyte precursor cells (OPCs) that can differentiate into oligodendrocytes. The target OPCs may be expanded and optionally subjected to conditions to induce their differentiation into oligodendrocytes. The target OPCs and their progeny are useful for the treatment of disease associated with demyelination of central nervous system axons.06-24-2010
20100158877TREATMENT OF LUNG AND PULMONARY DISEASES AND DISORDERS - Compositions and methods of using cells derived from umbilical cord tissue to stimulate and support lung tissue angiogenesis, to improve blood flow to lung tissue, to regenerate, repair, and improve lung tissue damaged by lung disease, disorder and/or injury, and to protect lung tissue from damage caused by lung disease, disorder and/or injury in a patient.06-24-2010
20100158875MUSCLE DERIVED CELLS FOR THE TREATMENT OF GASTRO-ESOPHAGEAL PATHOLOGIES AND METHODS OF MAKING AND USING THE SAME - The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration of symptoms for gastro-esophageal pathologies like gastro-esophageal reflux.06-24-2010
20100158873METHOD FOR EXTRACTING AND SELECTING CELLS - Method for selecting cells, comprising at least one at least partially combined step of enzymatic digestion and of selection in culture.06-24-2010
20100158872Cardiomyocyte Cell Populations - The present invention provides methods for inducing the differentiation of cardiac progenitor cells and cell populations produced by the methods of the invention. The invention further provides a method of screening for agents that affect cardiomyocytes, and a method of cardiomyocyte replacement therapy.06-24-2010
20100047211METHOD OF GROWTH OF MESENCHYMAL CELLS UNDER NON-ADHERENT CONDITIONS FOR CLINICAL APPLICATIONS - The invention provides methods for expanding mesenchymal stem cells (MSCs) in non-adherent cultures. The methods include the propagation of MSCs in or on non-adherent matrices. The invention further provides administration and the use of cells propagated by the method of the invention for administration and preparation of a therapeutic agent. The invention further provides kits including cells propagated by the methods of the inventions.02-25-2010
20090304646Multipotent/Pluripotent Cells and Methods - Described herein are multipotent stem cells, e.g., human and other mammalian pluripotent stem cells, and related methods.12-10-2009
20100047212USE OF THE PEDF FACTOR TO INDUCE CELL REGENERATION - Use of the PEDF factor to induce cell regeneration. The present invention refers to the use of the molecule PEDF for the manufacture of medicines to activate processes included in the group of regenerative processes, such as skin regeneration, wound healing, cell therapy for cardiac, neural, or hematopoietic regeneration. It also refers to the manufacture/use of pharmaceutical compounds that contain an efficient quantity of the PEDF factor for stem cell self-renewal.02-25-2010
20120177615TISSUE PRESERVATION SYSTEM - The present invention provides a method and apparatus for tissue, such as an allograft, storage and preservation for extended periods of time at room temperature in a sterile tissue culture chamber. The invention further provides a process for maintaining the sterility of tissue using the apparatus as described.07-12-2012
20120177613USE OF GINGIVAL FIBROBLASTS FOR VASCULAR CELL THERAPY - The invention relates to the use of gingival fibroblasts for obtaining a cellular composition for treating arterial-remodelling pathology, for example an aneurysm, post-cryoplasty stenosis and restenosis, an aortic dissection or atherosclerosis.07-12-2012
20120177612METHODS FOR TREATING AND/OR REVERSING NEURODEGENERATIVE DISEASES AND/OR DISORDERS - The present disclosure provides methods for the treatment of neurological diseases/disorders using neural stem cells (NSCs) obtained from a spinal cord tissue. The methods may include the use of a NSC population to treat a neurological disease/disorder of the brain. Such methods may include introducing exogenously cultured and expanded NSCs into the brain, which differentiate into neurons capable of integrating in vivo into the brain tissue in a sufficient manner to ameliorate the symptoms associated with the neurological disease/disorder.07-12-2012
20130078222Intervertebral Disc Nucleus Pulposus Stem Cell/Progenitor Cell, The Cultivation Method And Intended Use Thereof - Provided are intervertebral disk nucleus pulposus stem cells or progenitor cells that may be used for treatment of intervertebral disk disorders. An intervertebral disk nucleus pulposus cell is characterized by being isolated from the intervertebral disk nucleus pulposus of a vertebrate and is positive for at least one surface marker from among Tie2 and GD2. That is, the intervertebral disk nucleus pulposus stem cell is characterized by being at least Tie2-positive for the surface marker and) possesses a self-renewal ability as well as multipotency capable of differentiating into adipocytes, osteocytes, chondrocytes and neurons. Also provided is an intervertebral disk nucleus pulposus progenitor cell characterized by being at least Tie2-negative and GD2-positive for the surface marker and capable of differentiating into any of adipocytes, osteocytes, chondrocytes and neurons.03-28-2013
20100119491DOPAMINERGIC NEURONAL SURVIVAL-PROMOTING FACTORS AND USES THEREOF - In general, the invention features substantially purified MANF and substantially purified nucleic acids encoding the same. The invention also features a pharmaceutical composition that includes MANF and a pharmaceutically-acceptable excipient, methods for treatment of a neurodegenerative disease, methods for improving dopaminergic neuronal survival during or following cell transplantation, methods for production of neurons for transplantation, and methods for identifying compounds that modulate or mimic MANF's biological activity.05-13-2010
20100135968Oligodendrocyte Production From Multipotent Neural Stem Cells - This invention relates to methods of producing oligodendrocytes from multipotent neural stem cells by using at least one oligodendrocyte promoting factor, particularly granulocyte-macrophage colony stimulating factor, granulocyte colony stimulating factor, interleukin 3 or interleukin 5. The neural stem cells may optionally be expanded prior to being subjected to the oligodendrocyte promoting factor.06-03-2010
20100074874SYNTHETIC MULTI-LAYER STRUCTURES COMPRISING BIOPOLYMER FIBRES - The invention relates to a method for the in vitro preparation of a synthetic multi-layer structure comprising biopolymer fibers, wherein the biopolymer fibers in each layer are unidirectionally and uniformly oriented, which comprises successive polymerisation of layers of a biopolymer fiber forming solution in the presence of a magnetic field, wherein the fiber orientation in at least one layer differs from that in at least one of its superior and/or inferior layer according to an angle alpha. The invention also relates to a biological tissue-like multi-layer structure comprising the synthetic multi-layer structure and cells inoculated therein, such as an orthogonal multi-layer collagen and/or fibrin tissue-like cornea, and the method for its preparation. The invention may be used for preventing or treating a damaged tissue, or for creating a model for biological testing, such as pharmacotoxicity testing.03-25-2010
20100074875COMPOSITION CONTAINING HUMAN UMBILICAL CORD BLOOD-DERIVED MESENCHYMAL STEM CELL FOR INDUCING DIFFERENTIATION AND PROLIFERATION OF NEURAL PRECURSOR CELLS OR NEURAL STEM CELLS TO NEURAL CELLS - A use of a composition comprising umbilical cord blood-derived mesenchymal stem cells for inducing differentiation and proliferation of neural precursor cells or neural stem cells to neural cells is provided, the composition being effective for the treatment of nerve injury diseases.03-25-2010
20100074876CALCIUM PHOSPHATE DELIVERY VEHICLES FOR OSTEOINDUCTIVE PROTEINS - A composition for delivery of osteogenic proteins is disclosed. The composition comprises an osteogenic protein, a calcium phosphate material as a carrier, and an effective amount of an effervescent agent. Methods of making the compositions and methods of using the osteogenic compositions to treat osteoporotic and/or osteopenic bone are also disclosed.03-25-2010
20120244129PLURIPOTENT STEM CELL THAT CAN BE ISOLATED FROM BODY TISSUE - Objects of the present invention are to provide a method for directly obtaining pluripotent stem cells which do not have tumorigenic property from body tissue and the thus obtained pluripotent stem cells. The present invention relates to SSEA-3 (+) pluripotent stem cells that can be isolated from body tissue.09-27-2012
20120244128Perivascular Stem Cell Composition For Bone - Embodiments of the present invention provide an osteogenic composition comprising perivascular stem cells or induced pluripotent cells (iPS) and an osteogenic agent and methods of making and using the same.09-27-2012
20080254003Differentiation of Human Embryonic Stem Cells and Cardiomyocytes and Cardiomyocyte Progenitors Derived Therefrom - The present invention provides a method to improve current culturing methods for the differentiation of cardiomyocytes from hES cells. The method includes culturing the hES cells in the presence of ascorbic acid or a derivative thereof. Preferably the culturing is conducted in serum free conditions. The invention also includes isolated cardiomyocytes and cardiac progenitors differentiated by the methods as well as the use of these cells in methods of treating and preventing cardiac diseases and conditions. Culture media and extracellular media are also provided which include ascorbic acid for the differentiation of hES cells to cardiomyocytes.10-16-2008
20130078223Method And Composition For Inducing Human Pluripotent Stem Cells - The present invention provides pluripotent stem cell like (PSCL) cells or clones, a culture medium therefore, and a supernatant thereof, and methods of making and using the same.03-28-2013
20130078220DOPAMINERGIC NEURONAL SURVIVAL-PROMOTING FACTORS AND USES THEREOF - In general, the invention features substantially purified MANF and substantially purified nucleic acids encoding the same. The invention also features a pharmaceutical composition that includes MANF and a pharmaceutically-acceptable excipient, methods for treatment of a neurodegenerative disease, methods for improving dopaminergic neuronal survival during or following cell transplantation, methods for production of neurons for transplantation, and methods for identifying compounds that modulate or mimic MANF's biological activity.03-28-2013
20120183509MICROGLIAL PRECURSOR CELLS FOR THE TREATMENT OF MALIGNANT NEOPLASMS OF THE CENTRAL NERVOUS SYSTEM - Microglial precursor cells for use in the treatment of malignant neoplasms of the central nervous system. A method of treating malignant neoplasms of the central nervous system comprising administering a pharmaceutically effective amount of microglial precursor cells to a subject in need thereof.07-19-2012
20120183510HIGH-THROUGHPUT CULTURE AND TRANSFER DEVICE AND METHOD - A method and device for creating hanging drop cell aggregates. The method and device includes a plurality of pegs that allow for high throughput culture of aggregates. Also disclosed are means of transferring formed aggregates to various destinations, such as well plates, scaffolding, tissues, or wounds. Use of the device permits aggregates to be prepared or created in larger quantities than current methods, and allows for them to be transferred more efficiently.07-19-2012
20130084269Methods and Compositions for Expanding and Stabilizing Natural Regulatory T Cells - The present invention is directed to methods and compositions for expanding and stabilizing the phenotype of natural regulatory T cells. In particular, the present invention provides methods and compositions for treating natural regulatory T cells that renders the cells resistant to factors present in the inflammatory milieu and stabilizes the suppressive properties of the cells.04-04-2013
20130084270STEM CELLS FROM ADIPOSE TISSUE, AND DIFFERENTIATED CELLS FROM SAID CELLS - The invention concerns adult multipotent human stem cells, characterized in that they have: 04-04-2013
20130084268PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT AND/OR THE PREVENTION OF OSTEOARTICULAR DISEASES - An intra-articular pharmaceutical composition is used for the treatment and/or the prevention of acute or chronic osteoarticular diseases and acute or chronic osteoarticular symptoms especially osteoarthritis. The composition includes a possibly adequate pharmaceutical carrier or diluent, a glycosaminoglycan, a compound activating the alpha 2 adrenergic receptor, an anti-inflammatory agent and stem cells.04-04-2013
20130084267METHOD FOR STEM CELL DIFFERENTIATION - The present invention relates generally to a method for generating mesenchymal stem cells from pluripotent cells, the method comprising (i) differentiating a population of pluripotent stem cells in the presence of an inhibitor of endogenous activin and TGF-β signalling and (ii) passaging the cells differentiated in step (i) in the presence of a mesenchymal stem cell medium for a time and under conditions sufficient to produce mesenchymal stem cells. The present invention also relates to mesenchymal stem cells produced by the methods of the present invention and uses thereof.04-04-2013
20130084266METHODS FOR GENERATING PANCREATIC TISSUE - This document provides methods and materials related to tissue generation. For example, methods for generating pancreatic tissue and providing a population of hormone-secreting cells, e.g., insulin-producing cells in a human subject are provided.04-04-2013
20130034524Non-Enzymatic Method for Harvesting Adipose-Derived Stromal Cells and Adipose-Derived Stem Cells from Fat and Lipo-Aspirate - The present disclosure relates generally to processes, devices and systems for separating and concentrating stem and stromal cells from adipose tissue using a combination of mechanical disruption and filtration-centrifugation to obtain a highly enriched population of stem cells.02-07-2013
20130078221MULTIPOTENT ADULT STEM CELL DERIVED FROM CANINE UMBILICAL CORD BLOOD, PLACENTA AND CANINE FETUS HEART, METHOD FOR PREPARING THE SAME AND CELLULAR THERAPEUTICS CONTAINING THE SAME - The present invention relates to multipotent adult stem cells derived from canine umbilical cord blood, placental blood and blood sample from canine fetal heart, and a method for preparing the same as well as a cellular therapeutic agent containing the same, more specifically, to a multipotent adult stem cell isolated by culturing an eukaryotic cell derived from canine umbilical cord blood, placental blood and blood sample from canine fetal heart in a FBS-containing medium and a method for preparing the same. Adult stem cells according to the present invention have characteristics highly similar to human mesenchymal stem cells as well as remarkable cell growth at the initial step compared to human UCB-derived mesenchymal stem cells so that the cells are useful to treat canine incurable diseases and difficult-to-cure diseases. Furthermore, multipotent adult stem cells are effective to treat musculoskeletal diseases and neural diseases.03-28-2013
20130039893ISOLATION AND CULTIVATION OF STEM/PROGENITOR CELLS FROM THE AMNIOTIC MEMBRANE OF UMBILICAL CORD AND USES OF CELLS DIFFERENTIATED THEREFROM - The present invention relates to the generation of a mucin-producing cell using stem/progenitor cells obtained from the amniotic membrane of umbilical cord and therapeutic uses of such mucin-producing cells.02-14-2013
20130039892ADHERENT STROMAL CELLS DERIVED FROM PLANCENTAS OF MULTIPLE DONORS AND USES THEREOF - Pharmaceutical compositions comprising adherent stromal cells (ASCs) are provided. The ASCs are obtained from at least two donors. Articles of manufacture comprising the pharmaceutical compositions together with a delivery device for administering the ASCs to a subject are also provided. Also provided are methods of treating various diseases and conditions that are treatable by administering ASCs to a subject in need of treatment.02-14-2013
20090110666Long pentraxin ptx3 functional derivatives for preparing an autologous vaccine for the treatment of tumours - The invention described herein refers to derivatives of the long pentraxin PTX3 with the sequence indicated in the text, capable of binding to the membranes of inactivated tumour cells. The inactivated tumour cells, bearing on their surface a derivative of PTX3 are used to prepare an autologous vaccine for the treatment of tumours.04-30-2009
20100111908Induction of Renal Cells for Treatment of Kidney Disease - Methods and systems for the generation of induced renal cells are provided. For example, methods for inducing renal cells from lineage undifferentiated hematopoietic stem and/or progenitor cell incubated with growth factors are described. Furthermore, the invention provides methods for using induced renal cells for treating a renal disease and/or injury.05-06-2010
20090060887Method for treating the pancreas of a human patient - The invention involves a method for treating a pancreas of a human patient by rejuvenating and restoring function of such pancreas by the steps of locally inserting a growth factor, such as stem cells and germinal cells, into the body of the patient into or around the pancreas and thereby growing Islets of Langerhans in the pancreas and restoring insulin production.03-05-2009
20080241112Therapy of Kidney Diseases and Multiorgan Failure with Mesenchymal Stem Cells and Mesenchymal Stem Cell Conditioned Media - Methods and a composition for the treatment of organ dysfunction, acute renal failure, multi-organ failure, early dysfunction of kidney transplant, graft rejection, chronic renal failure, wounds, and inflammatory disorders including media conditioned by mesenchymal stem cells are provided. Methods for modulation of growth factor and cytokine expression including administering a therapeutic amount of mesenchymal stem cells, endothelial cells derived from mesenchymal stem cells, or media conditioned by mesenchymal stem cells are also provided.10-02-2008
20100104542CELL TRANSPLANTATION - The present invention provides polymers for use in preventing damage to the membranes of cells in fat grafts. Mixing of a triblock copolymer such as poloxymer P188 with adipocytes or adipose tissue to be transplanted into a subject is thought to stabilize the membranes of the cells leading to more successful fat transplantation in soft tissue reconstruction or augmentation. Such methods may also be used in the transplantation of adult stem cells or other cells derived from fat tissue. Other agents such as lipoic acid may also be added to the polymer/cell compositions for cell transplantation.04-29-2010
20100104540METHODS AND COMPOSITIONS FOR TREATMENT OF FIBROSIS - Treatment methods and compositions for the treatment of fibrosis are provided. In some embodiments, these methods include augmentation of dendritic cells for treatment of fibrosis. In some embodiments, fms-like tyrosine kinase 3 ligand (Flt3L) is used for the treatment of fibrosis and/or the augmentation of dendritic cells. In certain embodiments, the invention relates to methods for the treatment of fibrosis using Flt3L-expanded dendritic cells. In certain embodiments, the fibrosis is hepatic or pulmonary fibrosis.04-29-2010
20100104539PLACENTAL TISSUE GRAFTS AND IMPROVED METHODS OF PREPARING AND USING THE SAME - Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located onto top and within of the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high level of laminin-5, a cell adhesion bio-active factor show to bind gingival epithelia-cells, found throughout upper portions of the basement membrane.04-29-2010
20100104544SELECTIVE CELL THERAPY FOR THE TREATMENT OF RENAL FAILURE - Provided herein are isolated populations of kidney cells harvested from differentiated cells of the kidney, wherein the cells have been expanded in vitro. The kidney cells preferably produce erythropoietin (EPO). The kidney cells may also be selected based upon EPO production. Methods of producing an isolated population of EPO producing cells are also provided, and methods of treating a kidney disease resulting in decreased EPO production in a patient in need thereof are provided, including administering the population to the patient, whereby the cells express EPO in vivo in an oxygen tension-dependent manner.04-29-2010
20100104541Method for Preventing and Treating Cardiovascular Diseases with BRCA1 - Methods for inhibiting cardiomyocyte apoptosis and/or to improving cardiac function and inhibiting inflammation-induced apoptosis in endothelial cells by delivering BRCA1 are provided. Such methods are useful in treatment and prevention of cardiovascular diseases.04-29-2010
20100104543CELLULAR COMPOSITIONS AND METHODS OF MAKING AND USING THEM - The invention relates to cellular compositions comprising hematopoietic cells with the potential or increased potential to form non-hematopoietic cells; methods for producing such cellular compositions; methods for differentiation of cells of cellular compositions of the invention into cells that exhibit morphological, physiological, functional, and/or immunological features of non-hematopoietic cells; and uses of the cellular compositions. The invention also relates to a method for the expansion of hematopoietic stem and progenitor cells.04-29-2010
20090155228COMPOUNDS, KITS AND METHODS FOR CONFERRING CYTOPROTECTION - hABCG2, a member of the ATP-Binding Cassette transporters has been identified as a protective pump against endogenous and exogenous toxic agents. ABCG2 was shown to be expressed at high levels in stem cells, and variably regulated during cell differentiation. It is demonstrated herein that functional ABCG2 is expressed in human monocyte-derived dendritic cells by the activation of a nuclear hormone receptor, PPARg. The present results uncovered a mechanism by which up-regulation of functional ABCG2 expression can be achieved via exogenous or endogenous activation of the lipid activated transcription factor, PPARg. Thus the invention relates to combined treatments by PPARg agonists and cytotoxic drugs transportable by ABCG2, various treatments in the field of neoplastic diseases as well as cell therapy, including autologous cell therapy, as well as kits and composition therefor. Method for protecting cells against cytotoxic drugs are also provided.06-18-2009
20090155222CELL CULTURE - There is provided a method of retarding differentiation of a biological cell, the method comprising culturing the cell in the presence of an inhibitor of E-cadherin activity. The method is particularly advantageous in retarding the differentiation of stem or progenitor cells, and allows suspension culture of such cells in a manner that enables large scale expansion of cell populations. There is also provided a stem or progenitor cell comprising a construct encoding an inhibitor of E-cadherin activity; and a cell culture medium, for use in the retardation of biological cell differentiation, comprising an inhibitor of E-cadherin activity.06-18-2009
20090155221BONE AUGMENTATION UTILIZING MUSCLE-DERIVED PROGENITOR COMPOSITIONS, AND TREATMENTS THEREOF - The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment non-soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of non-soft tissue (e.g. bone). Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, bone tissues in the treatment of various functional conditions, including osteoporosis, Paget's Disease, osteogenesis imperfecta, bone fracture, osteomalacia, decrease in bone trabecular strength, decrease in bone cortical strength and decrease in bone density with old age.06-18-2009
20090155220Use of Bone-Marrow Derived Stem Cells to Treat Ischemia - Disclosed are cellular compositions and methods for preventing, treating or reducing the severity of tissue ischemia, particularly limb ischemia in a mammal. One inventive method includes administering a therapeutically effective amount of a cellular composition comprising a novel isolated multi-potent human bone marrow-derived stem cell (BMSC) having undetectable or negligible levels of markers of other known stem cells isolated from bone marrow. These cells can be expanded in vitro and formulated into cellular compositions and grafts capable of differentiating into components of functional new blood vessels when directly administered into ischemic limb tissue.06-18-2009
20090155218COMPOSITIONS AND METHODS FOR GROWTH OF EMBRYONIC STEM CELLS - The present invention relates to methods, compositions, and kits for maintenance of the undifferentiated state and/or pluripotency in stem cells, including embryonic stem (ES) cells. It also relates to stem cells that have been maintained in an undifferentiated state. The present invention provides these aspects using culture medium enriched with a TGFβ family member protein, an FGF family member protein, and/or nicotinamide, without using fibroblast feeder layers, conditioned media, or leukemia inhibitory factor.06-18-2009
20100040588Procurement, Isolation, and Cryopreservation of Endometrial/Menstrual Cells - Compositions comprising menstrual stem cells (MSCs) and methods, processes, and system therefor are provided by the invention. MSCs are processed from menstrual flow collected during menses. MSCs may be cryopreserved, processed through various culturing and selection steps in preparation for cryopreservation, or processed for therapeutic or cosmeceutical use. Cryopreserved MSCs may be thawed in preparation for therapeutic and cosmeceutical use. MSCs express CD9, CD10, CD13, CD29, CD44, CD49e, CD49f, CD59, CD81, CD105, CD166, and HLA class I, and have low or no expression of CD3 and HLA class II.02-18-2010
20100040586Treatment of Injuries to the Central Nervous System - The disclosure provides compositions and methods useful for treating injuries to the central nervous system (e.g., spinal cord injuries). The compositions and methods described herein can be optionally used in combination with a variety of techniques (e.g., surgical techniques) and/or therapies (e.g., physical therapy regimens) to affect treatment of injuries to the central nervous system.02-18-2010
20100040581EPO DERIVATIVE-CONTAINING THERAPEUTIC AGENTS FOR BLOOD-RELATED DISEASES - Blood flow enhancers, vascular promoters or therapeutic agents for ischemic diseases containing an erythropoietin (EPO) derivative as an active ingredient.02-18-2010
20130045188REDUCTION OF TGF BETA SIGNALING IN MYELOID CELLS IN THE TREATMENT OF CANCER - Methods of inhibiting metastasis in cancer patients are provided, wherein the methods comprise reducing TGFβ signaling, for example, by reducing TGF receptor II expression in myeloid cells. Vectors comprising a TGFβ receptor II RNAi nucleic acid sequence operably linked to a myeloid specific promoter also are provided. A method of diagnosing cancer in an individual by determining TGFβ receptor II expression in myeloid cells in the individual is provided. Additionally, a method of modulating TGFβ activity in myeloid cells in a cancer patient comprising administering a regulator of at least one of the GSK02-21-2013
20130045189METHODS OF TREATING STROKE THROUGH ADMINISTRATION OF CTX0E03 CELLS - The subject invention pertains to methods to enhance the therapeutic effects of cellular or drug treatment in various diseases and disorders. More particularly, the present invention provides methods of treating disorders by administering CTX0E03 cells to the patient, intravenously or intraarterially. The treatment is useful for neurodegenerative diseases, such as stroke. The CTX0E03 cells may be cryopreserved and/or passaged before administration into the patient. Administration of the CTX0E03 cells into stroke rat models was at or within 48 hours after stroke. Testing of the rat models through elevated body swing test to measure of neurobehavioral status at the time of transplant and repeated triphenyltetrazolium chloride (TTC) staining as a measure of infarct volume showed short term survival that provided significant protection from the stroke.02-21-2013
20130045187METHODS AND COMPOSITIONS OF PRODUCING PATIENT-SPECIFIC MULTIPOTENT NEURONAL STEM CELLS - The present invention relates to the seminal discovery of compositions and a method of producing NSC obtained from stem cells derived from parthenogenically activated human oocytes (phNSC). The phNSC of the invention maintain proliferative and differentiation potential during cultivation and expansion.02-21-2013
20120213743TREATMENT OF PERIPHERAL VASCULAR DISEASE USING UMBILICAL CORD TISSUE-DERIVED CELLS - Compositions and methods of using cells derived from umbilical cord tissue, to stimulate and support angiogenesis, to improve blood flow, to regenerate, repair, and improve skeletal muscle damaged by a peripheral ischemic event, and to protect skeletal muscle from ischemic damage in peripheral vascular disease patients are disclosed. In particular, methods of treating a patient having a peripheral vascular disease with umbilical derived cells and fibrin glue are disclosed.08-23-2012
20100143310SPINAL NERVE REPAIR PROMOTING THERAPEUTICS CONTAINING GHRELIN OR ITS DERIVATIVES OR SUBSTANCES THAT ACT ON GHS-R1a AS AN ACTIVE INGREDIENT - The invention provides a spinal neuron damage treating agent for use in the treatment of spinal neuron damage, or an agent for promoting the proliferation of spinal neuronal precursor cells in the culture of spinal neuronal precursor cells, or an agent for promoting the regeneration of spinal nerves after transplantation of cultured spinal neuronal precursor cells, and the like.06-10-2010
20130034526POPULATIONS OF PANCREATIC PROGENITOR CELLS AND METHODS OF ISOLATING AND USING SAME - A method of generating pancreatic progenitor cells is disclosed. The method comprises: 02-07-2013
20130034525BETA ISELETS-LIKE CELLS DERIVED FROM WHOLE BONE MARROW - The invention provides for methods of producing pancreatic precursor cells and insulin-producing cells from bone marrow. In various embodiments, bone marrow derived stem cells are differentiated into pancreatic precursor cells and insulin-producing cells. In various embodiments, bone marrow derived stem cells are artificially induced to express VEGF and/or PDX-1. These cells can be used to treat or ameliorate diabetes or symptoms of diabetes.02-07-2013
20090263360Neuronal progenitors from feeder-free human embryonic stem cell culture - The present invention relates to methods for producing feeder cell-free neuroprogenitor cells (preferably adherent) from embryonic stems cells, preferably human embryonic stem cells, the feeder cell-free neuroprogenitor cells, preferably human cells themselves, as well as methods for producing feeder cell-free samples of neuronal cells, preferably adherent human neuronal cells and the feeder cell-free neuronal cells themselves. Pharmaceutical compositions and methods of treating neurodegenerative diseases as well as the use of the described cells in assay systems is also described.10-22-2009
20080241113Procurement, isolation and cryopreservation of endometrial/menstrual cells - Compositions comprising menstrual stem cells (MSCs) and methods, processes, and system therefor are provided by the invention. MSCs are processed from menstrual flow collected during menses. MSCs may be cryopreserved, processed through various culturing and selection steps in preparation for cryopreservation, or processed for therapeutic or cosmeceutical use. Cryopreserved MSCs may be thawed in preparation for therapeutic and cosmeceutical use. MSCs express CD9, CD10, CD13, CD29, CD44, CD49e, CD49f, CD59, CD81, CD105, CD166, and HLA class I, and have low or no expression of CD3 and HLA class II.10-02-2008
20100092436COMPOSITIONS AND METHODS FOR RESTORING IMMUNE RESPONSIVENESS IN PATIENTS WITH IMMUNOLOGICAL DEFECTS - The present invention relates generally to methods for stimulating, activating, and maintaining or increasing the polyclonality of expressed TCRs in a population of T cells. In the various embodiments, cells are stimulated with a surface, wherein the surface has attached thereto one or more agents that ligate a cell surface moiety of at least a portion of the T cells and stimulates at least a portion of the T cells, yielding enhanced proliferation, cell signal transduction, and/or cell surface moiety aggregation. In certain aspects methods for stimulating a population of cells such as T-cells, by cell surface moiety ligation are provided by contacting the population of cells with a surface, that has attached thereto one or more agents that ligate a cell surface moiety thereby inducing cell stimulation, cell surface moiety aggregation, and/or receptor signaling enhancement. Also provided are methods for producing T-cells for the use in diagnostics and the treatment of a variety of indications, including cancer, viral infection, and immune related disorders. Compositions of cells having increased polyclonality produced by these processes are further provided.04-15-2010
20100330048MESENCHYMAL STEM CELLS AND USES THEREFOR - Methods of treating autoimmune diseases, allergic responses, cancer, inflammatory diseases, or fibrosis in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.12-30-2010
20100330046HUMAN SKIN SUBSTITUTES EXPRESSING IL-12 - The present invention relates generally to compositions for treating patients that have skin cancer or have recently had skin cancers removed. More specifically, the present invention provides human skin substitutes engineered to express exogenous IL-12 and compositions and methods for making human skin substitutes engineered to express exogenous IL-12. In addition, the present invention provides methods for treatment of sites on a patient where skin cancers have been removed with human skin substitutes engineered to express exogenous IL-12.12-30-2010
20100330045Mesenchymal precursor cell - A method of enriching mesenchymal precursor cells including the step of enriching for cells based on at least two markers. The markers may be either i) the presence of markers specific for mesenchymal precursor cells, ii) the absence of markers specific for differentiated mesenchymal cells, or iii) expression levels of markers specific for mesenchymal precursor cells. The method may include a first solid phase sorting step utilising MACS recognising expression of the antigen to the STRO-1 Mab, followed by a second sorting step utilising two colour FACS to screen for the presence of high level STRO-1 antigen expression as well as the expression of VCAM-1.12-30-2010
20100330044MESP1 AS A MASTER REGULATOR OF MULTIPOTENT CARDIOVASCULAR PROGENITOR SPECIFICATION AND USES THEREOF - A method for differentiating or promoting or inducing differentiation of stem cells into pluripotent cardiovascular progenitors (MCPs) by transiently inducing the expression of a single gene, namely Mesp1, is disclosed. Cells obtained by the method and their uses in research and clinical settings are also disclosed. Using genome wide transcriptional analysis, the inventors found that Mesp1 rapidly activates and represses a discrete set of genes, which form potential new targets for both therapy and for the identification of MCPs. Insights into the molecular mechanisms underlying the earliest step of cardiovascular specification and potential methods for dramatically increasing the number of cardiovascular cells for cellular therapy in humans are provided.12-30-2010
20100330043GPR125 AS A MARKER FOR STEM AND PROGENITOR CELLS AND METHODS USE THEREOF - The present invention relates to GPR1 25 as a marker of stem and progenitor cells, including multipotent adult spermatogonial-derived stem cells (MASCs), spermatogonial stem and progenitor cells, skin stem or progenitor cells, intestinal stem or progenitor cells, neural stem or progenitor cells, and cancer stem cells. The invention provides, inter alia, methods for enriching or isolating GPR125-positive stem or progenitor cells, methods for detecting GPR125-positive stem or progenitor cells, methods for culturing GPR125-positive stem or progenitor cells, purified GPR125-positive stem or progenitor cells, therapeutic compositions containing purified GPR125-positive stem or progenitor cells, methods for targeting therapeutic agents to GPR125-positive stem and progenitor cells, and methods of treatment comprising administering GPR125-positive stem and progenitor cells, or differentiated cells derived therefrom, to subjects in need thereof. The present invention also provides methods of detecting cancer cells based on GPR1 25 expression, and methods of targeting therapeutic agents to cancer cells to GPR125-positive cancer cells.12-30-2010
20100330042Use of Proinsulin for the Preparation of a Neuroprotective Pharmaceutical Composition, Therapeutic Composition Containing it and Applications Thereof - The present invention relates to the use of a compound that induces the activity of proinsulin, preferably human proinuslin, for the preparation of a medicinal product or pharmaceutical composition for the prevention and treatment of neurodegenerative conditions, disorders or diseases involving programmed cell death, preferably neurodegenerative pathologies of the central and peripheral nervous systems, and, more preferably, of the heredodegenerative diseases known as retinosis pigmentosa. The activator compound may consist of a chemical molecule, a peptide, a protein or a nucleotide sequence.12-30-2010
20120164115Methods related to surgery - The invention is directed to methods related to surgery, for example gastrointestinal surgery. In particular, the invention is methods of treating fistulae, promoting accelerated healing of anastomoses and preventing failure of anastomoses. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), cell lysates derived therefrom, and cell products derived therefrom, each alone or in combination.06-28-2012
20120164110DIFFERENTIALLY METHYLATED REGIONS OF REPROGRAMMED INDUCED PLURIPOTENT STEM CELLS, METHOD AND COMPOSITIONS THEREOF - Provided herein are differentially methylated regions (DMRs) of reprogrammed iPS cells (R-DMRs) and methods of use thereof. The invention provides methods for detecting and analyzing alterations in the methylation status of DMRs in iPS cells, somatic cells and embryonic stem (ES) cells as well as methods for reprogramming somatic cells to generate an iPS cell.06-28-2012
20130028872COMPOSITION AND METHOD FOR DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS - Described are methods for inducing differentiation of a human embryonic stem cell or a population of human embryonic stem cells toward a cell or population of cells characteristic of the definitive endoderm, the method comprising incubating the cell or population of cells with a GSK-3 inhibitor. Also described are methods for inducing differentiation of a cell or population of cells, characteristic of the definitive endoderm, towards a hepatocyte-like cell or a population of hepatocyte-like cells, and methods for inducing differentiation of a human embryonic stem cell or a population of human embryonic stem cells toward a hepatocyte-like cell or a population of hepatocyte-like cells. Further described are cells obtained by the methods and uses thereof in therapy and toxicity screening.01-31-2013
20130028871PLACENTAL STEM CELL POPULATIONS - The present invention provides placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of differentiating the placental stem cells. The invention further provides methods of using the placental stem cells in assays and for transplanting.01-31-2013
20130028874METHODS, PHARMACEUTICAL COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR ADMINISTERING THERAPEUTIC CELLS TO THE ANIMAL CENTRAL NERVOUS SYSTEM - Methods and compositions for preventing and treating the damaged and/or degenerating CNS experiencing loss or death of CNS cells. Various embodiments of the invention transport a therapeutically effective amount of, inter alia, at least one therapeutic cell to the CNS by intranasal application to the upper-third of the nasal cavity, thereby bypassing the blood-brain barrier. A pharmaceutical composition according to the invention may comprise at least one therapeutic cell, at least one delivery-enhancement agent, at least one antibiotic, at least one regulatory factor and/or at least one immunosuppressive agent, wherein the composition is delivered to the upper-third of the nasal cavity. The therapeutic cells, once delivered to the CNS, migrate preferentially to the area of damage or degeneration or injury.01-31-2013
20130028873METHOD FOR INCREASING ACTIVITY IN HUMAN STEM CELL - Provided are a method for preparing a highly active human mesenchymal stem cell, which includes forming a spherical cell aggregate by cultivating human mesenchymal stem cells against gravity; a highly active stem cell prepared thereby; a cell therapeutic agent including the stem cell aggregate; and a method for forming a spherical cell aggregate by cultivating human mesenchymal stem cells, wherein the amount of E-cadherin in the mesenchymal stem cell is increased during the cultivation.01-31-2013
20130028870PLURIPOTENT STEM CELLS AND METHOD OF STIMULATING AND EXTRACTING NON-EMBRYONIC PLURIPOTENT STEM CELLS FROM MAMMAL BLOOD AND USING RECONSTITUTED PLURIPOTENT STEM CELLS TO TREAT DISEASES INCLUDING CHRONIC OBSTRUCTIVE PULMONARY DISEASE - Stimulating tissue resident pluripotent stem cells in a manner that the respective subject (e.g., human) acts as its own sterile bioreactor for in vivo stem cell proliferation thus eliminating the need to isolate, cultivate, maintain, proliferate and release stem cells ex vivo. The stimulation mobilizes excess pluripotent stem cells into the peripheral vasculature where the pluripotent stem cells can either migrate to damaged tissues and/or be harvested by simple venipuncture, thus eliminating potential morbidity and mortality elicited from harvesting tissue from solid tissue sites. The pluripotent stem cells are separated from the blood by gravity sedimentation, after which the pluripotent stem cells can easily be aspirated from the white blood cells and red blood cells. Billions of pluripotent stem cells can be generated in this fashion for infusion/injection into the body, via the vasculature, and into the organ(s) in need of tissue repair and regeneration.01-31-2013
20080274086Use of Cxcr4 Protein Expression on the Surface of Stem Cells as a Marker for Tumor Tropic Potential - The present invention relates to tumor tropic stem cells, and particularly to neural stem cells, and their use as delivery vehicles for therapeutic gene products to neoplastic foci. The stem cells with tumor tropic potential are selected based on the stem cells exhibiting CXCR4 receptors or an affinity for the chemokine SDF-1. The stem cells may additionally exhibit markers characteristic of astrocytic progenitors. The stem cells may be administered as part of a treatment regimen including the chemokine SDF-1.11-06-2008
20090304640Transfection of Collagen-Producing Cells - A method is provided for introducing at least one polynucleotide of interest into an intervertebral disc cell, wherein the polynucleotide of interest is transfected with a lipid-based delivery agent. Also provided are methods for introducing polynucleotides encoding one or more telomerase catalytic subunits into collagen-producing cells and methods for increasing extracellular matrix formation in collagen-producing cells.12-10-2009
20130089528COMPOSITIONS AND METHODS FOR PRESERVING INSULIN-PRODUCING CELLS AND INSULIN PRODUCTION AND TREATING DIABETES - Nuclear Transport Modifiers such as cSN50 and cSN50.1, afford in vivo islet protection following a 2-day course of intense treatment in autoimmune diabetes-prone, non-obese diabetic (NOD) mice, a widely used model of Type 1 diabetes (T1D), which resulted in a diabetes-free state for one year without apparent toxicity and the need to use insulin. cSN50 precipitously reduces the accumulation of islet-destructive autoreactive lymphocytes while enhancing activation-induced cell death of T and B lymphocytes derived from NOD mice. cSN50 attenuated pro-inflammatory cytokine and chemokine production in immune cells in this model of human T1D. cSN50 also provides cytoprotection of beta cells, therefore preserving residual insulin-producing capacity. Because intracellular delivery of a Nuclear Transport Modifier peptide such as cSN50 and cSN50.1 can result in lowering of blood glucose levels and may reducing insulin resistance, the compositions, methods and cells described herein can also be used for treating Type 2 diabetes (T2D).04-11-2013
20130089527METHODS OF EXPANDING MYELOID CELL POPULATIONS AND USES THEREOF - The present disclosure relates to a method of expanding myeloid progenitor cells by culturing an initial population of cells in a medium comprising a mixture of cytokines and growth factors that promote growth and expansion of the myeloid progenitor cells. The expanded cell population provides a source of cells as therapeutic treatments for neutropenia and/or thrombocytopenia arising in patients subjected to myeloablative therapy and hematopoietic stem cell transplantation.04-11-2013
20130089529AGENT FOR OSTEOGENESIS USING SUBSTANCE-P AND PREPARATION PROCESS THEREOF - The present invention relates to an agent for osteogenesis containing as an active ingredient mesenchymal stem cells (MSCs) that have been mobilized from bone marrow into blood by administration of Substance-P; and a process of preparing the agent.04-11-2013
20130089526Methods for Using Synthetic Triterpenoids in the Treatment of Bone or Cartilage Diseases or Conditions - The present invention features the use of a synthetic triterpenoid to induce gene expression and differentiation of stem or progenitor cells in the treatment of bone/cartilage diseases or conditions.04-11-2013
20090117085MNTF DIFFERENTIATION AND GROWTH OF STEM CELLS - The present invention provides methods for inducing differentiation of an embryonic stem cell into a motor neuron using a motoneuronotrophic factor (MNTF) or its peptide analogues. The present invention further provides a method for isolating a population of stem cell derived motor neurons and a population of cells comprising the differentiated neural cells. Additionally, the present invention is directed to a method of enhancing the survival of the differentiated neural cells in long term cell cultures. Finally, the present invention provides compositions containing MNTF or its peptide analogs for therapeutic use in conjunction with stem cells.05-07-2009
20090191160Methods of producing pluripotent stem-like cells - The instant invention provides methods and compositions for the production and use of pluripotent stem-like cells from somatic cells, e.g., fibroblasts.07-30-2009
20130052167Methods and Apparatus for Creating Particle Derivatives of HDL with Reduced Lipid Content - The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.02-28-2013
20130052168METHODS AND COMPOSITIONS FOR TISSUE REGENERATION - A kit is disclosed that includes a first component comprising alginate, wherein the first component is comprised in a first sterile vial, and a second component comprising cells comprising keratinocytes or fibroblasts, or mixtures thereof, that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGFβ, angiopoietin, EGF, IL-Iβ, IL-6, IL-8, TGFα, and TNFα, wherein the cells are allogeneic and mitotically inactive, a buffered solution, and human serum albumin or a cryoprotectant, wherein the second component is comprised in a second sterile vial.02-28-2013
20090169520Compounds, Pharmaceutical Compositions and Therapeutic Methods of Preventing and Treating Diseases and Disorders Associated With Amyloid Fibril Formation - Compounds, pharmaceutical compositions and methods for prevention and/or reversal of amyloid fibril formation and treating amyloid-related disorders are provided. Also provided a method of limiting and/or reducing inflammation.07-02-2009
20130052166MATERIALS AND METHODS FOR MINIMALLY-INVASIVE ADMINISTRATION OF A CELL-CONTAINING FLOWABLE COMPOSITION - The disclosed invention is based on the discovery that a cell-based therapy can be used to treat, ameliorate, manage and/or reduce the progression of clinical sequelae associated with vascular interventions or cardiovascular diseases, particularly occlusive thrombosis, restenosis, intimal hyperplasia, inflammation and vasodilation. The invention further benefits from the additional discovery that a heretofore undescribed implantable flowable composition is capable of sustaining a confluent population of sufficiently viable cells which can be effectively administered via a minimally-invasive surgical procedure without diminishing the clinical effectiveness or the viability of the cells. The disclosed invention can be used to treat vasculature as well as non-vascular tubular structures such as a fallopian tube.02-28-2013
20100135964TISSUE GRAFTING METHOD - The tissue grafting method relates to a tissue graft material, a method of preparing the material, and a method of using the material. The tissue graft material is made from the tunica serosa of the small intestine of a warm-blooded vertebrate, which has been delaminated from the tunica muscularis, tunica submucosa, and the tunica mucosa of the intestinal tissue. The tissue graft material may be perforated by discrete punctures. The tissue graft material is dehydrated by air drying or vacuum drying, sterilized with ethylene oxide, and stored in a hermetically sealed enclosure at room temperature until needed, having an indefinite storage life. When needed, the tissue graft material is rehydrated, cut to match the size of the wound, and applied to the wound. The graft may be overlaid with nylon mesh, or bandaged with an elastic tubular dressing.06-03-2010
20110002894COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING HEART TISSUE DEGENERATION AND USES THEREOF - The present invention provides compositions useful for cardiac therapy comprising a cyclin-associated agent. The present invention also provides kits for use in delivering a cyclin-associated agent to cardiac cells in a subject, comprising the composition of the present invention and a catheter. The present invention additionally provides a methods for enhancing cardiac function; promoting regeneration of cardiac tissue; inducing endogenous myocardial regeneration; and preventing or treating heart failure in a subject in need thereof by augmenting cyclin in cells.01-06-2011
20110002892MODULAR APTAMAR-REGULATED RIBOZYMES - An extensible RNA-based framework for engineering ligand-controlled gene regulatory systems, called ribozyme switches, that exhibit tunable regulation, design modularity, and target specificity is provided. These switch platforms typically contain a sensor domain, comprised of an aptamer sequence, and an actuator domain, comprised of a hammerhead ribozyme sequence. A variety of modes of standardized information transmission between these domains can be employed, and this application demonstrates a mechanism that allows for the reliable and modular assembly of functioning synthetic hammerhead ribozyme switches and regulation of ribozyme activity in response to various effectors. In some embodiments aptamer-regulated cis-acting hammerhead ribozymes are provided.01-06-2011
20090304648Mast Cell Stabilizers to Prevent or Treat Laminitis - Provided herein are mast cell stabilizers used to prevent, treat, or mitigate severity of laminitis. Mast cell stabilizers can be combined with antihistamines and other medicaments to prevent, treat, or mitigate severity of laminitis.12-10-2009
20090304643Methods of Preparing and Characterizing Mesenchymal Stem Cell Aggregates and Uses Thereof - The invention provides compositions and methods for preparing and characterizing multipotential mesenchymal stem cell aggregates. The invention further provides methods for using stem cell aggregates of the invention.12-10-2009
20090304642METHODS OF SPECIFYING MESODERMAL, ENDODERMAL AND MESOENDODERMAL CELL FATES - We disclose a method for producing a mesodermal or a endodermal cell from a pluripotent stem cell, the method comprising activating a Wnt signalling pathway in the pluripotent stem cell. In some embodiments, the pluripotent stem cell is in a substantially 2 dimensional configuration, such as a monolayer, for at least a portion of the time when the Wnt signalling pathway is activated.12-10-2009
20090304641Methods and Compositions for Regulating Gene Expression - In certain embodiments, the disclosure relates to compositions and methods relating to a translation-based gene regulation system that functions in mammalian cells. In certain specific embodiments, the disclosure relates to methods of regulating gene expression via modulating translational termination.12-10-2009
20090304639Method for preparing an organ for transplantation - The present invention provides a means for achieving generation of a complex organ such as kidney and the like through the use of hMSCs to generate the human organ. The method for preparing a desired organ for transplantation to human by transplanting an isolated human mesenchymal stem cell to the embryo of a pregnant mammal host to induce differentiation of the mesenchymal stem cell is a method wherein the mesenchymal stem cell is transplanted into the embryo at a corresponding site for differentiation into the desired organ in the host at a transplantation time when the host is still at an immunologically tolerant stage.12-10-2009
20090304644SYSTEMS AND METHODS FOR MANIPULATION OF REGENERATIVE CELLS SEPARATED AND CONCENTRATED FROM ADIPOSE TISSUE - The invention provides methods for manipulating regenerative cells from adipose tissue. Specifically, it provides methods for enrichment of desired cells and enhancement of their therapeutic effects.12-10-2009
20090041732Survivin Peptides As Cancer Vaccines - Provided are compositions and methods for treating survivin expressing cancers. The compositions contain peptide survivin peptide mimics with improved MHC-I binding characteristics. The method involves administering a survivin peptide mimic with improved MHC-I binding characteristics to an individual to effect inhibition of the growth of survivin expressing cancer cells in the individual.02-12-2009
20090041731Treatment for Diabetes - Methods and compositions for treating diabetes mellitus in a patient in need thereof are provided. The methods include administering to a patient a composition providing a gastrin/CCK receptor ligand, e.g., a gastrin, and/or an epidermal growth factor (EGF) receptor ligand, e.g., TGF-α, in an amount sufficient to effect differentiation of pancreatic islet precursor cells to mature insulin-secreting cells. The composition can be administered systemically or expressed in situ by cells transgenically supplemented with one or both of a gastrin/CCK receptor ligand gene, e.g., a preprogastrin peptide precursor gene and an EGF receptor ligand gene, e.g., a TGF-α gene. The methods also include transplanting into a patient cultured pancreatic islets in which mature insulin-secreting beta cells are proliferated by exposure to a gastrin/CCK receptor ligand and an EGF receptor ligand.02-12-2009
20090041729Process for Decellularizing Soft-Tissue Engineered Medical Implants, and Decellularized Soft-Tissue Medical Implants Produced - The invention provides methodologies and apparatus for producing acellular soft-tissue implants, both in small quantities and in commercializable quantities. Such soft-tissue implants include vascular graft substitutes. An acellular graft is produced by subjecting the tissue sample to an induced pressure mediated flow of an extracting solution, followed by inducing a pressure mediated flow of a treating solution, then washing the treated tissue to produce the acellular graft. The acellular grafts produced are uniform and non-immunogenic. The inventive method allows for the production of multiple decellularized soft tissue implants, where processing time is significantly less than prior art processes and the number of implants produced per day is increased over prior art processes. In clinical use, the decellularized grafts produced exhibit significantly improved in long-term durability and function.02-12-2009
20130071362HUMAN PLACENTAL COLLAGEN COMPOSITIONS, AND METHODS OF MAKING AND USING THE SAME - The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal.03-21-2013
20130071364Amnion-derived cells, methods of making and uses thereof - The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies.03-21-2013
20130071363Amnion-derived cells, methods of making and uses thereof - The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies.03-21-2013
20130071357IDENTIFICATION, PROLIFERATION IN SITU, HARVESTING, SEPARATION, AND TRANSPLANTATION OF ADULT-DERIVED REGENERATIVE PLURIPOTENT TRANSITIONAL BLASTOMERE-LIKE STEM CELLS AND METHODS OF TREATMENT THEREOF - Non-embryonic transitional blastomere-like stem cells are disclosed. Most preferably, such cells are obtained from the blood after induction by a plant-based compound to proliferate and reverse diapadese into the vasculature or from various tissues of postnatal mammals or humans (using tissue biopsied from the mammal or human), are in the range of 3-5 microns, have a normal karyotype, and do not spontaneously differentiate in situ (in vivo) or in serum-free medium without differentiation inhibitors. These non-embryonic transitional blastomere-like stem cells typically express CD66e, CEA-CAM-1, CD10, SSEA (SSEA-1, SSEA-3, and SSEA-4), telomerase, Sonic hedgehog, but do not typically express Nanog, Nanos, BCl-2 or CXCR-4. Such transitional blastomere-like pluripotent stem cells can be differentiated into epiblast-like stem cells, ectodermal, mesodermal, and endodermal tissues, but NOT placental tissues or germ cells. Moreover, when implanted into a mammal or human, such cells will not be teratogenic.03-21-2013
20130071361METHODS OF TREATMENT OF HEMOPHILIA - The present invention provides methods of treating hemophilia in a subject, the methods comprising transplanting a therapeutically effective amount of bone marrow, cord blood, cord blood or bone marrow fraction expressing Factor VIII, mononuclear cells, or mesenchymal stromal cells from a donor to the subject with hemophilia. The present invention also provides compositions for treating hemophilia.03-21-2013
20130071359METHODS AND COMPOSITIONS FOR BONE AND CARTILAGE REPAIR - Biologically active extract of 03-21-2013
20130071360Brown Fat Cell Compositions and Methods - Methods of developing and using cell lines, such as stem cell lines, for therapeutic or cosmetic use. In one embodiment the cell lines are used to treat a wide range of degenerative and metabolic disorders including, but not limited to, obesity, diabetes, hypertension, and cardiac deficiency. Also described are methods of using such cell lines to screen for compounds that play a role in regulating a variety of processes.03-21-2013
20130071358ALLOGENEIC MICROVASCULAR TISSUE FOR SOFT TISSUE TREATMENTS - Disclosed are products and methods for treating soft tissue injuries. The provided methods include the production of processed or cryopreserved microvascular tissue. Also provided are products and methods of using processed or cryopreserved microvascular tissue for the treatment of soft tissue injuries.03-21-2013
20130164265SKIN CARE COMPOSITIONS - This invention provides compositions and methods of manufacturing such compositions that employ GRAS compounds which can act to promote the generation of stem, epidermal or other skin cells in the epidermis, activation of collagen synthesis, activation of hyaluronic acid synthesis, enhanced skin hydration, and dermal healing by stimulating stem cell and fibroblast migration to sites of needed repair. These compositions and methods are useful for rejuvenating the skin and for treating some skin-related aging or other dermal damaging conditions, including wrinkle reduction and treatment of minor dermal wounds.06-27-2013
201301642663-DIMENSIONAL SCAFFOLDS FOR IMPROVED DIFFERENTIATION OF PLURIPOTENT STEM CELLS TO HEPATOCYTES - The present invention relates to the use of 3-dimensional (3D) synthetic or animal-derived bioscaffolds as substrates for the improved growth and differentiation of hPS (Human pluripotent stem cells); these scaffolds being adapted for use in conjunction with existing cell culture lab plastic-ware. More specifically, it relates to the seeding of these scaffolds, either alone or in conjunction with various biologic matrix coatings, with hPS cells for the improved differentiation of said hPS cells into hepatocyte or hepatocyte-like cell types. The invention also relates to the seeding of partially-differentiated hepatocyte progenitors onto scaffolds for further differentiation into more mature hepatocyte-cell types.06-27-2013
20090092587LAMININS, DERIVATIVES, AND COMPOSITIONS INCLUDING SAME AND METHODS FOR THEIR THERAPEUTIC USE - In various embodiments, the present disclosure provides a method of treating a subject using laminin or a composition that includes laminin. In one embodiment, the method is used to enhance muscle regeneration, maintenance, or repair in a subject. In another embodiment, the method is used to promote wound healing. The method, in yet another embodiment, is used to prevent or reduce muscle damage or injury. In specific implementations of these methods, the laminin or composition that includes laminin is administered in a therapeutically effective amount. In some implementations, the laminin is a complete laminin protein. In other implementations, the laminin is a laminin fragment, a laminin derivative, or a laminin analogue.04-09-2009
20090092586DIFFERENTIATION OF NON-EMBRYONIC STEM CELLS TO CELLS HAVING A PANCREATIC PHENOTYPE - The invention provides methods for differentiating non-embryonic multipotent stem cells along the pancreatic lineage. The present invention further provides non-embryonic multipotent stem cells and progeny derived therefrom to provide pancreatic cells to a subject.04-09-2009
20130058905Angiohematopoietic Progenitor Cells - A purified human cell population of subsets of angiohematopoietic progenitor cells, wherein the population is at least 94% pure and wherein the cells are selected with cell markers selected from the group of KDR, APLNR, VE-cadherin, PDGFRα, CD31, CD235a, CD73, CD43, and CD41a.03-07-2013
20130058904Method and system for treatment of biological tissue - A composition for reconstruction, replacement or repair of damaged or diseased biological tissue comprising an extracellular matrix (ECM) composition that includes an ECM scaffold component derived from a mammalian source and at least one additional bioactive component selected from the group consisting of a statin and a chitin derivative.03-07-2013
20130058906PROCESS, TUBE AND DEVICE FOR THE PREPARATION OF WOUND HEALANT COMPOSITION - The present invention is related to the field of tissue regeneration. It concerns more particularly new processes, tubes and devices for thrombin, platelet concentrate and wound healant preparations, alone or in combination with cell extracts, cell compositions and uses thereof.03-07-2013
20130058907METHOD AND SYSTEM FOR THE PRODUCTION OF CELLS AND CELL PRODUCTS AND APPLICATIONS THEREOF - A cell culture system for the production of cells and cell derived products includes a reusable instrumentation base device incorporating hardware to support cell culture growth. A disposable cultureware module including a cell growth chamber is removably attachable to the instrumentation base device. The base device includes microprocessor control and a pump for circulating cell culture medium through the cell growth chamber. The cultureware module is removably attached to the instrumentation base device. Cells are introduced into the cell growth chamber and a source of medium is fluidly attached to the cultureware module. Operating parameters are programmed into the microprocessor control. The pump is operated to circulate the medium through the cell growth chamber to grow cells or cell products therein. The grown cells or cell products are harvested from the cell growth chamber and the cultureware module is then disposed.03-07-2013
20130058902DENDRITIC CELL SUBSETS FOR GENERATING INDUCED TOLEROGENIC DENDRITIC CELLS AND RELATED COMPOSITIONS AND METHODS - Disclosed are induced tolerogenic dendritic cells (itDCs) produced from dendritic cell subsets that possess a desired physiological characteristic, as well as related compositions and methods.03-07-2013
20130058903Stem-Cell Material and Method of Use - Provided herein are mesenchymal stem cells which have been modified by the introduction of polynucleotides encoding for a mammalian Cdk1 protein. These cells do not sense in culture and are non-tumorigenic thereby providing an ongoing source of cells as well as conditioned medium. The conditioned medium from these cells can be used for tissue repair. Also provided is a method of modifying mesenchymal stem cells which can be continuously propagated in culture and are non-tumorigenic.03-07-2013
20130058900Method for facilitating the production of differentiated cell types and tissues from embryonic and adult pluripotent and multipotent cells - The invention is concerned with producing differentiated cells, tissues and organs from pluripotent and mutlipotent cells. The methods of the invention are particularly useful for producing differentiated cells from pluripotent cells wherein communication between the cells of more than one embryonic germ layer or more than one organ system are required for development along a specific cell lineage. The invention methods are effected by in vivo or in vitro culturing of embryonic and developing or developed allogeneic or xenogeneic cells.03-07-2013
20130058901TRANSPLANTABLE GRAFT-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS AND METHODS OF USE - Disclosed are transplantable graft-specific induced tolerogenic dendritic cells (itDCs), as well as related compositions and methods.03-07-2013
20110014164EFFICIENT INDUCTION OF PLURIPOTENT STEM CELLS USING SMALL MOLECULE COMPOUNDS - The disclosure features a method of producing an induced pluripotent stem cell a somatic cell. The method includes contacting a somatic cell with a DNA methyl transferase inhibitor or a histone deacetylase (HDAC) inhibitor, or a combination thereof, to produce a pluripotent stem cell.01-20-2011
20110014162Preserved Compositions of Activated NK Cells and Methods of Using the Same - Disclosed herein are activated NK cells that exhibit durable and prolonged activity in the absence of the activating agent and retain their activated state after preservation. Methods of administrating the NK cells to a patient do not require co-administration of the activating agent, and thus, pharmaceutical compositions comprising the NK cells may remain substantially free of the activating agent.01-20-2011
20110014161Cardiac Tissue-Derived Cells - The present invention is directed to methods and compositions for repairing damaged myocardium using human cardiac tissue-derived cells. In particular, the present invention provides methods and compositions for repairing damaged myocardium using expanded human cardiac tissue-derived cells that do not express telomerase.01-20-2011
20110014159METHOD FOR OBTAINING CHARACTERIZED MUSCLE-DERIVED CELL POPULATIONS AND USES - A method for obtaining cell populations derived from the muscular tissue and their use for preparing cell therapy products includes culturing cells previously removed by biopsy from skeletal muscular tissues, identifying the different types of cells present at different stages of culture, selecting the culture stage on the basis of the required cell population and collecting the selected culture stage for preparing a cell therapy product. The invention also concerns cell populations derived from muscular tissue obtained by implementing the method whereof the dominant cell type is CD34+, CD15+ or CD56+ or Class 1+HLA, or comprises a doubly negative CD56−/CD15− cell type or may comprise more minority CD10+, Stro-1+ and CD 117+ cell types.01-20-2011
20120189590COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS - The specification discloses compositions and methods for treating a soft tissue defect of an individual.07-26-2012
20090280094Treatment of Ischemic Diseases Using Erythropoietin - Disclosed is a method for stimulating revascularization in a subject comprising the steps of: 11-12-2009
20090269314HUMAN CARDIOVASCULAR PROGENITOR CELLS - The present invention provides populations of human cardiovascular progenitor cells, methods of making such cells, and methods of using the cells for production of populations of cardiovascular colonies and populations of cardiomyocytes. Methods of cardiomyocytes replacement therapy are also provided.10-29-2009
20090269312Methods, Systems, and Apparati for Cellular Therapeutic Agent Preparation and Delivery - Methods and devices for the preparation of a biological pharmaceutical composition outside of a classified environment, such as Biological Safety Cabinet type environment, are described. In one aspect of the present technology, a method is provided to prepare a biological pharmaceutical composition preferably in an area next to a patient's bedside or at a facility's pharmacy. The method comprises transferring an appropriate amount of a diluent from a diluent component into a mixing receptacle using a transfer device, connecting a pooling harness between a biological pharmaceutical component and the mixing receptacle, transferring a biological pharmaceutical composition through the pooling harness to the mixing receptacle, mixing the diluent and the biological pharmaceutical composition to form a biological pharmaceutical composition mixture and administering the biological pharmaceutical composition mixture to a patient for either flat based or weight based dosing needs.10-29-2009
20090269311Method for treating multiple system atrophy - The present invention provides a method for treating multiple system atrophy, comprising administering a therapeutically effective amount of mesenchymal stem cells (MSCs) to a human in need thereof. Preferably, the administering is performed by an intra-arterial injection of said MSCs and one or more intravenous injections of said MSCs.10-29-2009
20090269309Retinoic acid stimulates differentiation of pancreatic progenitor cells into insulin producing cells - The invention relates to a method of forming pancreatic hormone-producing endocrine cells in vitro, wherein pancreatic stem cells are treated with one or more retinoids and/or retinoic acid in vitro and cultured. Especially the dorsal pancreatic bud is used and to the cells obtained by the method. Further, it relates to the use of the pancreatic hormone-producing endocrine cells, for the production of a pharmaceutical composition for transplantation and/or treatment of type 1 and type 2 diabetes. It also relates to a method for treatment of type 1 and type 2 diabetes by administrating the hormone-producing endocrine cells to individuals in need thereof. The invention also regards the use of one or more retinoids and/or retinoic acid for the differentiation, in vitro of pancreatic stem cells into pancreatic hormone-producing endocrine cells, such as glucagon producing cells, and in particular, insulin producing β-cells.10-29-2009
20120225041METHODS AND COMPOSITIONS FOR TREATING TISSUE USING SILK PROTEINS - Compositions for forming a self-reinforcing composite biomatrix, methods of manufacture and use therefore are herein disclosed. Kits including delivery devices suitable for delivering the compositions are also disclosed. In some embodiments, the composition can include at least three components. In one embodiment, a first component can include a first functionalized polymer, a second component can include a second functionalized polymer and a third component can include silk protein or constituents thereof. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition can include a biologic encapsulated, suspended, disposed within or loaded into a biodegradable carrier. In some embodiments, the composition(s) of the present invention can be delivered by a dual lumen injection device to a treatment area in situ, in vivo, as well as ex vivo applications.09-06-2012
20120225040METHODS AND COMPOSITIONS FOR TREATING TISSUE USING SILK PROTEINS - Compositions for forming a self-reinforcing composite biomatrix, methods of manufacture and use therefore are herein disclosed. Kits including delivery devices suitable for delivering the compositions are also disclosed. In some embodiments, the composition can include at least three components. In one embodiment, a first component can include a first functionalized polymer, a second component can include a second functionalized polymer and a third component can include silk protein or constituents thereof. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition can include a biologic encapsulated, suspended, disposed within or loaded into a biodegradable carrier. In some embodiments, the composition(s) of the present invention can be delivered by a dual lumen injection device to a treatment area in situ, in vivo, as well as ex vivo applications.09-06-2012
20120225039TISSUE ENGINEERED CARTILAGE, METHOD OF MAKING SAME, THERAPEUTIC AND COSMETIC SURGICAL APPLICATIONS USING SAME - Cartilage has been constructed using biodegradable electrospun polymeric scaffolds seeded with chondrocytes or adult mesenchymal stem cells. More particularly engineered cartilage has been prepared where the cartilage has a biodegradable and biocompatible nanofibrous polymer support prepared by electrospinning and a plurality of chondocytes or mesenchymal stem cells dispersed in the pores of the support. The tissue engineered cartilages of the invention possess compressive strength properties similar to natural cartilage. Methods of preparing engineered tissues, including tissue engineered cartilages, are provided in which an electrospun nanofibrous polymer support is provided, the support is treated with a cell solution and the polymer-cell mixture cultured in a rotating bioreactor to generate the cartilage. The invention provides for the use of the tissue engineered cartilages in the treatment of cartilage degenerative diseases, reconstructive surgery, and cosmetic surgery.09-06-2012
20120225038MYELOID-DERIVED SUPPRESSOR CELLS GENERATED IN VITRO - A population of myeloid-derived suppressor cells and the culture procedure to obtain these in vitro starting with bone marrow cells of mice, other animals and human beings, in the presence of specific cytokine combinations used to determine concentrations, is provided.09-06-2012
20130064800Tissue-Engineered Endothelial and Epithelial Implants Differentially and Synergistically Regulate Tissue Repair - Endothelial implants restore vascular homeostasis after injury without reconstituting vascular architecture. Endothelial cells line the vascular epithelium and underlying vasa vasorum precluding distinction between cellular controls. Unlike blood vessels, the airway epithelium is highly differentiated and distinct from endothelial cells that line the bronchial vasa allowing investigation of the differential control tissue engineered cells may provide in airways and blood vessels. Through airway injury and cell culture models, tissue engineered implants of the bronchial epithelium and endothelium were found to promote synergistic repair of the airway through biochemical regulation of the airway microenvironment. While epithelial cells modulate local tissue composition and reaction, endothelial cells preserve the epithelium; together their relative impact was enhanced suggesting both cell types act synergistically for airway repair.03-14-2013
20130064801Cellular Compositions and Methods of Making and Using Them - The invention relates to cellular compositions comprising hematopoietic cells with the potential or increased potential to form non-hematopoietic cells; methods for producing such cellular compositions; methods for differentiation of cells of cellular compositions of the invention into cells that exhibit morphological, physiological, functional, and/or immunological features of non-hematopoietic cells; and uses of the cellular compositions. The invention also relates to a method for the expansion of hematopoietic stem and progenitor cells.03-14-2013
20130064799METHODS FOR PROMOTING CELL REPROGRAMMING - The present invention is based on the seminal discovery that several kinases play important roles in barrier pathways in somatic cell reprogramming. The present invention provides that modulating expression or activity of these kinases can significantly promote or enhance cell reprogramming efficiency. Key kinases are identified and key regulation networks involving such kinases are also identified that may be advantageously targeted to significantly increase reprogramming efficiency as well as direct differentiation of induced pluripotent stem (iPS) cells.03-14-2013
20130064798METHODS AND COMPOSITIONS FOR TREATING CONGESTIVE HEART FAILURE - Compositions and methods for treating congestive heart failure are provided herein.03-14-2013
20110206645TREATMENT OF BONE-RELATED CANCERS USING PLACENTAL STEM CELLS - Provided herein are methods of suppression of proliferation and growth of cells of bone-related cancers, e.g., multiple myeloma or chondrosarcoma cells, using placental cells, e.g., the placental stem cells described herein, and populations of such placental cells. Also provided herein are methods of treating individuals having cells of a bone-related cancer.08-25-2011
20130064797COMPOSITION FOR MUCOSALLY DELIVERING FRUIT CELL CULTURES AND/OR PREPARATIONS DERIVED THEREFROM AND METHODS OF USING SAME - A pharmaceutical or nutraceutical composition comprising a cell line callus culture of grape berry cells grown in vitro, whereby the cell line callus culture of grape berry cells is derived from one or more of grape-berry cross section, grape-berry skin, grape-berry flesh, grape seed, grape embryo of seeded or seedless cultivars or grape seed coat.03-14-2013
20100124547COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF FACTOR VII GENES - The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a Factor VII gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of a Factor VII gene using said pharmaceutical composition; and methods for inhibiting the expression of Factor VII in a cell.05-20-2010
20090246180HYPOXIA INDUCING FACTORS AND USES THEREOF FOR INDUCING ANGIOGENESIS AND IMPROVING MUSCULAR FUNCTIONS - This invention provides HIF-3α nucleic acid and sequences. Also provided are methods for using HIF-3α nucleic acids, proteins, fragments, antibodies, probes, and cells, to characterize HIF-3α, modulate HIF-3α cellular levels, induce angiogenesis, improve muscular function, and treat coronary and cardiac diseases in mammals.10-01-2009
20090238803HUMAN CORD BLOOD DERIVED UNRESTRICTED SOMATIC STEM CELLS (USSC) - A composition in human cord and placental blood which comprises unrestricted somatic stem cells is described here which can be amplified in vitro to large quantities sufficient for medical applications as regenerative medicines. Initiation and maintenance as well as ex vivo expansion protocols of such stem cells from cord blood is described.09-24-2009
20090238802Intraperitoneal Delivery Of Genetically Engineered Mesenchymal Stem Cells - A method of expressing at least one protein in an animal by intraperitoneal administration of mesenchymal stem cells genetically engineered with at least one polynucleotide encoding the at least one protein. The method may be employed in treating lysosomal storage disorders, such as Fabry Disease, or arthritic disorders, or hemophilia, for example.09-24-2009
20090238801AMNION-DERIVED STEM CELLS AND USES THEREOF - The present invention relates to stem cells obtained from the amnion and their methods of obtaining and culturing. The present invention further relates to compositions comprising amnion-derived stems cells (ADSCs) and to methods of using ADSCs.09-24-2009
20090238800ISOLATION AND THERAPEUTIC APPLICATION OF ADULT RETINAL STEM CELLS COLLECTED FROM EXTRA-RETINAL TISSUES - The present invention is directed to an adult retinal cell line isolated from extra-retinal ocular tissue, and methods of isolating adult retinal cells from extra-retinal ocular tissue. The present invention is further directed to adult retinal stem cells isolated from vestigial tissue dissected from the eye of a donor mammal suffering from persistent fetal vasculature. The present invention is further directed to a culture medium for growing or maintaining retinal stem cells, and methods of maintaining adult retinal cells in culture. The present invention is further directed to methods of treating a treating an eye with retinal dystrophy using retinal stem cells, and an eye with glaucomatous injury with retinal stem cells. The present invention is further directed to kits for harvesting extra-retinal ocular tissue comprising a sterile container and a harvesting solution, wherein the kit allows the survival of the tissue until later dissociation of cells from the tissue.09-24-2009
20090238798Nucleotide Sequences Encoding Insecticidal Proteins - The present invention provides nucleotide sequences encoding an insecticidal protein exhibiting lepidopteran inhibitory activity, as well as a novel insecticidal protein referred to herein as a Cry1A.105 insecticide, transgenic plants expressing the insecticide, and methods for detecting the presence of the nucleotide sequences or the insecticide in a biological sample.09-24-2009
20090238799Conditionally-Immortalised Pancreatic Cells - Conditionally immortalized pancreatic cells are produced which remain immortal in the presence of 4-hydroxytamoxifen (4-OHT) but express normal pancreatic cell markers when 4-OHT is not present. The cells therefore permit cell lines to be constructed to produce cells useful for transplantation or in screening assays.09-24-2009
20090232783Method for Regulating Production of Hemoglobin Beta Chains - A method is described for repressing production of β-globin protein and increasing production of γ-globin protein in a human cell utilizing a ferritin-H protein, a vector encoding ferritin-H, or an exogenous ferritin-H inducer.09-17-2009
20090232782Method for treating brain ischemic injury through transplantation of human umbilical mesenchymal stem cells - A method for treating or preventing an ischemic brain injury or neurological damage due to ischemia in a subject includes transplanting a therapeutically effective amount of human umbilical mesenchymal stem cells (HUMSCs) obtained from Wharton's Jelly to the ischemic areas of the brain injury or the neurological damage of the subject. Recovery from neurological behavior deficits also is improved according by the method.09-17-2009
20090232781Treatment of liver diseases through transplantation of human umbilical mesenchymal stem cells - A method for treating liver diseases or liver damage, including but not limited to liver fibrosis, and/or aiding recovery from liver diseases, including but not limited to liver fibrosis, or liver damage in a subject, includes transplanting human umbilical mesenchymal stem cells (HUMSCs) obtained from Wharton's Jelly to the area of liver disease or damage of the subject.09-17-2009
20090232780COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION - This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation.09-17-2009
20090232779OLIGODENDROCYTES DERIVED FROM HUMAN EMBRYONIC STEM CELLS FOR REMYELINATION AND TREATMENT OF SPINAL CORD INJURY - This invention provides populations of neural cells bearing markers of glial cells, such as oligodendrocytes and their precursors. The populations are generated by differentiating pluripotent stem cells such as human embryonic stem cells under conditions that promote enrichment of cells with the desired phenotype or functional capability. Various combinations of differentiation factors and mitogens can be used to produce cell populations bearing markers of oligodendrocyte precursor cells. Upon further differentiation form complex processes characteristic of mature oligodendrocytes. The cells are capable of forming myelin sheaths, and can be used therapeutically improve function of the central nervous system.09-17-2009
20090232776USE OF IMMUNOMODULATORY COMPOUNDS FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH ENDOTHELIAL DYSFUNCTION - Methods of treating, preventing or managing endothelial dysfunction and other disorders are disclosed. The methods encompass the administration of an immunomodulatory compound provided herein. Further described are methods of treatment using the immunomodulatory compounds in combination with a second active agent. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods provided herein are also disclosed.09-17-2009
20090232775Compounds and methods for increasing neurogenesis - The invention is directed to methods of promoting neurogenesis by contacting neuronal tissue with neurogenesis modulating agents. Novel methods for treating neurological disorders using neurogenesis modulating agents are disclosed.09-17-2009
20090232774Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance - The present invention provides a method of treating a disease in a subject in need thereof via non-syngeneic graft administration without or with reduced concomitant graft rejection. The method comprises administering to the subject a therapeutically effective graft being non-syngeneic with the subject, and a dose of tolerogenic cells being non-syngeneic with both the subject and the graft for preventing or reducing graft rejection in the subject, thereby treating the disease in the subject09-17-2009
20090232772HUMAN CORNEAL ENDOTHELIAL CELL-DERIVED PRECURSOR CELLS, CELLULAR AGGREGATES, METHODS FOR MANUFACTURING THE SAME, AND METHODS FOR TRANSPLANTING PRECURSOR CELLS AND CELLULAR AGGREGATES - Providing is cellular aggregates derived from corneal endothelial cells that, when transplanted, readily adhere to the parenchyma of cornea and function in a manner equivalent to corneal endothelial cells, and a method of transplantation of the cellular aggregates. Cellular aggregates derived from corneal endothelial cells. The cellular aggregates derived from corneal endothelial cells is prepared by culturing human corneal endothelial cells in a medium containing fetal bovine serum, growth factor and glucose; and then float culturing the cells obtained in a medium containing growth factor. A method of transplantation into the anterior chamber the cellular aggregate or the cellular aggregate prepared by the above method, comprising inserting a tube into the parenchyma of cornea, introducing the cellular aggregate into the anterior chamber through the inserted tube, and causing the cellular aggregate that has been introduced to adhere to Descemet's membrane by assuming in a downward-facing position.09-17-2009
20090232771Method of controlling cell functions - The present invention provides methods of screening genes associated with cell regeneration, growth and differentiation and regulators for cell regeneration, growth or differentiation; regulators for cell regeneration, growth or differentiation; and so on. More specifically, the present invention provides methods of screening genes associated with cell regeneration, growth and differentiation, which comprises the step of quantitatively analyzing expression levels of multiple genes collectively in a cell having a regeneration, differentiation or growth capability to thereby identify the genes associated with the regeneration, growth or differentiation of the cell; methods of screening genes associated with cell regeneration, growth and differentiation, which comprises the step of quantitatively analyzing expression levels of multiple genes collectively in a cell having a regeneration, differentiation or growth capability to thereby identify one or more genes that show higher expression levels in the cell or are specific in expression as compared to the other cells; and, the step of contacting at least one candidate substance capable of regulating the functions of the identified genes or their gene products with the cell and comparing changes before and after the contact; and so on.09-17-2009
20090232777Expansion and Differentiation of Mesenchymal Stem Cells - A cell culture system for expanding and differentiating mammalian mesenchymal stem cells to chondrocytes is provided. Said cell culture system comprises a subpopulation of isolated MSC selected for their expression of integrin alpha 10, as well as additives promoting expansion and differentiation to chondrocytes. Methods and uses of said expanded and differentiated cells with a chondrogen phenotype are also provided, as well as compositions comprising said expanded and differentiated chondrocyte cells.09-17-2009
20090232773Method for Distinguishing Mesenchymal Stem Cell Using Molecular Marker and Use Thereof - Disclosed is a method for distinguishing a mesenchymal stem cell comprising, using at least one gene selected from the genes having the nucleotide sequences indicated by the accession numbers shown in Table 1 as a distinguish marker, detecting the difference in expression of the distinguish marker between a mesenchymal stem cell and a connective tissue cell to distinguish the mesenchymal stem cell from the connective tissue cell. This method enables to distinguish an undifferentiated mesenchymal stem cell from other connective tissue cell such as fibroblasts, osteoblasts, chondrocytes and adipose cells with good accuracy. A mesenchymal stem cell given by this method or a composition comprising the mesenchymal stem sell can be used as a therapeutic for use in the regenerative medicine.09-17-2009
20120195862BIOMECHANICAL INDUCTION OF HEMATOPOIESIS - The present invention provides methods and compositions for increasing the hematopoietic potential of a population of hematopoietic progenitor cells, vascular cells, and or hemogenic endothelium, by exposing the cells to at least one external biomechanical stimulus. More specifically, the application of shear stress to hematopoietic progenitor cells or endothelial cells stimulates hematopoiesis, with or without concurrent application of other extrinsic modulators of hematopoiesis.08-02-2012
20090047261Composition For Treatment Of Articular Cartilage Damage - Disclosed is a composition for the treatment of cartilage or bone damage or loss or defect. The composition comprises mesenchymal stem cells separated from umbilical cord blood and/or mesenchymal stem cells proliferated and/or differentiated. The composition also comprise chondrocytes and/or chondroblasts, or osteocytes and/or osteoblasts, differentiated from the mesenchymal stem cells separated from the umbilical cord blood.02-19-2009
20090047258COMPOSITIONS AND METHODS FOR REVERSING AGE-RELATED CHANGES IN EXTRACELLULAR MATRIX PROTEINS - The invention is directed to compositions and methods for reversing age-related changes in extracellular matrix proteins, particularly the collagen framework of basement membranes of various organs. The invention has particular application to age-related changes that impair Retinal Pigment Epithelium (RPE) cell repopulation of human Bruch's membrane.02-19-2009
20120114618Mesenchymal Stem Cells Producing Inhibitory RNA for Disease Modification - Compositions and methods for delivering a siRNA, dsRNA, or miRNA polynucleotide into a target cell comprising contacting the target cell with a mesenchymal stem cell, which mesenchymal stem cell comprises an exogenous DNA sequence expressing the siRNA or dsRNA polynucleotide, thereby delivering the siRNA, dsRNA, or miRNA polynucleotide to the target cell through a cellular protrusion or a microvesicle.05-10-2012
20120114617PEPTIDE PROMOTING CELL ADHESION AND MIGRATION - Synthetic peptide including the sequence KKLRIKSKEK (SEQ ID 1) or a sequence of identical size, in which the K residue (in position 1) and the R residue (in position 4) are conserved, the sequence being able to bind to the syndecan-1 receptor.05-10-2012
20120114616OLFACTORY STEM CELLS AND USES THEREOF - Some aspects of this invention are based, at least in part, on the discoveries (i) pluripotent stem cell populations can be obtained from olfactory mucosa, (ii) that various regions of the olfactory mucosa contain pluripotent stem cells, (iii) that cells from these olfactory mucosa derived stem cell populations can be maintained in cultures containing EGF and/or bFGF, (iv) that cells from these olfactory mucosa derived stem cell populations are able to form neurospheres, and/or (v) that cells from these olfactory mucosa derived stem cell populations can differentiate into various lineages, including mesenchymal and neuronal lineages.05-10-2012
20120114615HYDROLYTICALLY DEGRADABLE POLYSACCHARIDE HYDROGELS - Provided are polysaccharide compositions capable of controllable hydrolytic degradation and suitable for controlled release of therapeutic agents. Also provided are methods for synthesizing such compositions and a variety of applications in which the compositions may be used.05-10-2012
20120114614METHODS AND COMPOSITIONS FOR LONG TERM HEMATOPOIETIC REPOPULATION - Methods for isolating a CD13305-10-2012
20120114613DEFINITIVE ENDODERM CELL POPULATIONS - The present invention provides cell populations that are enriched for mesendoderm and mesoderm, and cell populations that are enriched for endoderm. The cell populations of the invention are useful for generating cells for cell replacement therapy.05-10-2012
20090010899Methods related to surgery - The invention is directed to methods related to surgery, for example gastrointestinal surgery. In particular, the invention is methods of treating fistulae, promoting accelerated healing of anastomoses and preventing failure of anastomoses. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), cell lysates derived therefrom, and cell products derived therefrom, each alone or in combination.01-08-2009
20090010898Method for treating a mammal having damaged articular cartilage tissue - A method for treating a mammal having damaged articular cartilage tissue includes harvesting a tissue sample from the mammal, growing articular cartilage cells from the tissue sample, and transplanting the articular cartilage cells into the damaged tissue. Growing the articular cartilage cells from the tissue sample can be accomplished by breaking the tissue sample into fragments, placing the fragments into a culture vessel, inducing at least some of the fragments to adhere to the culture vessel, and supplying the fragments with nutrients so that articular cartilage cells contained therein divide and grow.01-08-2009
20090010897Muscle derived cells for the treatment of cardiac pathologies and methods of making and using the same - The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration for dermatological conditions, gastroesophageal reflux, vesico-ureteral reflux, urinary incontinence, fecal incontinence, heart failure, and myocardial infarction.01-08-2009
20090010896METHODS AND COMPOSITIONS FOR OPTIMIZED EXPANSION AND IMPLANTATION OF MESENCHYMAL STEM CELLS - Compositions and methods are provided for the optimized expansion and implantation of mesenchymal stem cells into a patient in need thereof. Autologous mesenchymal stem cells (MSCs) to a patient in need of MSCs are harvested, expanded within novel growth parameters under the influence of autologous growth factors located on the patient's platelets.01-08-2009
20090304645In vitro engineered, regenerated urinary tract tissue compositions and methods for producing same - A method for providing a urinary tract tissue graft composition includes providing a tissue culture frame and a segment of small intestinal submucosa and positioning the segment of small intestinal submucosa in the tissue culture frame such that the segment of small intestinal submucosa is suspended and held in a taut position by the tissue culture frame. Smooth muscle and urothelial cells are isolated from a tissue specimen of a subject and cultured, and then seeded upon the segment of small intestinal submucosa, thereby forming a urinary tract tissue graft. A tissue culture frame in which such a urinary tract tissue graft may be formed is also disclosed.12-10-2009
20100086523METHOD FOR GENERATING PLURIPOTENT STEM CELLS - The present invention relates to a method for generating pluripotent stem cells and to pluripotent stem cells generated from human testis.04-08-2010
20080311089Augmentation and Repair of Vocal Cord Tissue Defects - The present invention provides a method for corrective surgery in a human subject of a vocal cord defect being amenable to rectification by the augmentation of tissue subjacent to the vocal cord defect comprising the steps of: 12-18-2008
20080305087Device and Method Using Integrated Neuronal Cells and an Electronic Device - The present invention provides a device of integrated neuronal cells interfaced with an electronic device and a method of producing the same.12-11-2008
20080305085Compositions And Methods For Stem Cell Expansion - The present invention features methods and compositions that are useful for promoting stem cell survival and expansion. In addition, the invention also provides compositions and methods for the treatment of neoplasia.12-11-2008
20120237488LSC AND HSC SIGNATURES FOR PREDICTING SURVIVAL OF PATIENTS HAVING HEMATOLOGICAL CANCER - A method for determining prognosis in a subject having a hematological cancer comprising: a) determining an expression profile by measuring the gene expression levels of a set of genes selected from a leukemic stem cell (LSC) gene signature marker set or an hematopoietic stem cell (HSC) gene signature marker set, in a sample from a subject; and b) classifying the subject as having a good prognosis or a poor prognosis based on the expression profile; wherein a good prognosis predicts an increased likelihood of survival within a predetermined period after initial diagnosis and poor prognosis predicts a decreased likelihood of survival within the predetermined period after initial diagnosis.09-20-2012
20120237486MESENCHYMAL STEM CELL AND THE METHOD OF USE THEREOF - Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells.09-20-2012
20120237485Trabecular Meshwork Stem Cells - Provided herein are isolated populations of multipotent stem cells capable of differentiating into trabecular meshwork (TM) cells, methods of obtaining an isolated population of TM cells, and isolated populations of TM cells obtained therefrom. Compositions, kits, and devices comprising the isolated populations of multipotent stem cells or TM cells are also provided herein. Further provided are methods of using the compositions, kits, and devices for decreasing intraocular pressure in an eye, increasing cell density in a trabecular meshwork of an eye, increasing outflow of aqueous humor from an eye, or treating or preventing a medical condition in a subject.09-20-2012
20120237484Generation of Functional Basal Forebrain Cholinergic Neurons From Stem Cells - The present invention provides method, compositions, and systems for generating basal forebrain cholinergic neurons (BFCNs) using FGF8, SHH, LXH8, GBX1, or vectors encoding these ligands, as well as using such BFCNs to treat neurological disorders such as Alzheimer's disease.09-20-2012
20130164267ADIPOSE TISSUE-DERIVED STEM CELLS FOR VETERINARY USE - The invention provides for compositions and methods for making and using adipose-derived stem cells for treating non-human mammals for various medical conditions. In particular, the invention provides methods and compositions useful for repair of bone fractures, and for treatment of “dry eye” conditions, acute renal failure, and chronic renal failure in non-human mammals.06-27-2013
20130164268REGULATION OF GLYPICAN 4 ACTIVITY TO MODULATE THE FATE OF STEM CELLS AND USES THEREOF - The present invention thus relates to stem cells or progenitor cells wherein the expression and/or activity of a member of the glypican family is reduced or abolished for use for the treatment of a pathological condition selected from the group consisting of a degenerative disease, a cardiac disorder, a metabolic disease and an injury by stem cell-based therapy.06-27-2013
20130164269CELL CULTURE SYSTEM FOR BIOREACTOR SCALE-UP OF CELLS - The present invention relates to growing stem cells, for e.g., MSCs, in large-scale under GMP-compliance, using media and reagents that satisfy GMP requirements, while maintaining stemness, for effective downstream therapeutic use, which include but are not limited to, stem cell therapy, production of products, such as beneficial factors, recombinant proteins, etc. obtained from such stem cells.06-27-2013
20090004157MATURE TYPE-1 POLARIZED DENDRITIC CELLS WITH ENHANCED IL-12 PRODUCTION AND METHODS OF SERUM-FREE PRODUCTION AND USE - The present invention discloses novel dendritic cell maturation-inducing cytokine cocktails, and methods for inducting type-1 polarized dendritic cells in serum-free conditions which enhance the desirable properties of DC1s generated in serum-supplemented cultures. The invention further discloses methods and systems using IFNγ and other ligands of the IFNγ receptor, in combination with IFNα (or other type I interferons), poly I:C, and other IFNα (and IFNβ) inducers to enhance the IL-12-producing properties of dendritic cells. More specifically, the present invention discloses type-1 polarized dendritic cells that have a unique combination of a fully-mature status and an elevated, instead of “exhausted”, ability to produce IL-12p70. allows for the generation of fully-mature DC1s in serum-free AIM-V medium. The invention discloses systems that use the foregoing products and methods to facilitate the clinical application of DC1-based vaccines and the identification of novel factors involved in the induction of Th1 and CTL responses by DC1.01-01-2009
20090016998NOVEL METHOD OF PRENATAL ADMINISTRATION OF MAMMALIAN UMBILICAL CORD STEM CELLS FOR THE INTRAUTERINE TREATMENT OF MAMMALIAN LYSOSOMAL STORAGE DISEASES - A method of treating a fetus or embryo suspected of having a congenital condition that involves an abnormal or missing protein, the method has the steps of a. providing a plurality of human umbilical cord blood in a form suitable for intravenous administration; a b. administering the human umbilical cord blood cells to a mother carrying a fetus of embryo suspected of having said congenital condition. Such congenital conditions include Sanfilippo's syndrome, Hunter's syndrome, Hurler's syndrome, Tay-Sachs disease, Gaucher's disease, von Gierke's disease, Pompes disease, Cori disease, Andersen disease, McArdle's disease, Hers disease, Tauri's disease or Type IX glycogen storage disease.01-15-2009
20100034780TUMOR ANTIGEN PEPTIDE DERIVED FROM AMACR - The present invention relates to a peptide which comprises a partial peptide derived from AMACR and is capable of binding to an HLA antigen and is recognized by a CTL, and a pharmaceutical composition comprising the peptide and a pharmaceutically acceptable carrier, and the like.02-11-2010
20090232778Methods and Compositions for Hair Growth - Methods and compositions for identifying and isolating dermal papilla cells are described. DP cells can be identified based on corin expression. Isolated DP cells can be used, e.g., to modulate hair growth.09-17-2009
20090098092Composite Bone Material and Method of Making and Using Same - Bone composite implants and the method of constructing bone composite implants are disclosed which may be used in the repair, replacement, and/or augmentation of various portions of animal or human skeletal systems. Furthermore, the bone composite implants of the present invention may be considered load-bearing implants which are incorporated into the skeletal structure of the patient.04-16-2009
20100178277METHODS AND COMPOSITIONS FOR STIMULATING CELLS - The invention provides compositions and methods for treating, preventing, delaying the onset, and/or delaying the development of a disease or condition for which the activation, differentiation, and/or proliferation of one or more cell types is beneficial. These compositions and methods include, for example, a hydrogenated pyrido[4,3-b]indole such as dimebon and/or a cell that has been incubated with a hydrogenated pyrido[4,3-b]indole such as dimebon. In some embodiments, the compositions and methods also include a growth factor and/or an anti-cell death compound. The invention also provides methods of activating a cell, promoting the differentiation of a cell, and/or promoting the proliferation of a cell by incubating the cell with one or more hydrogenated pyrido[4,3-b]indoles or pharmaceutically acceptable salts thereof. In some embodiments, the cell is also incubated with one or more growth factors and/or anti-cell death compounds.07-15-2010
20120121553SELECTION AND PROPAGATION OF PROGENITOR CELLS - A population of progenitor cells and methods for obtaining and culturing the progenitor cells, that are useful in fields including regenerative medicine (tissue regeneration), transplantation, and cancer research.05-17-2012
20120315254METHODS AND COMPOSITIONS FOR ENHANCING FAT GRAFT SURVIVAL - A method of enhancing fat cell survival in a subject in need thereof is disclosed. The method comprising (a) implanting a population of fat cells into the subject; and (b) administering Erythropoietin to the subject, thereby enhancing fat cell survival in the subject.12-13-2012
20110236356METHODS OF ISOLATING AND USING STEM CELLS - Methods of isolating and using stem cells from neural crest, e.g. periodontal ligament, isolated stem cell and therapeutic cell cultures, and therapeutic applications for a variety of conditions. The cells and cell cultures are especially useful for autologous administration.09-29-2011
20120148540PROLIFERATED CELL LINES AND USES THEREOF - The subject invention pertains to tumor cell lines useful for increasing the proliferation potential of any human or animal cell in culture, thereby providing immortalized or continuous cell lines and cultures. The invention also concerns proliferation factors, and compositions containing the factors, which are capable of increasing the proliferation potential of any human or other animal cell in culture. The subject invention further pertains to a method for proliferating cells in culture by contacting cells with the proliferation factors. The proliferated cells can range in plasticity and can include, for example, blast cells, fertilized ova, non-fertilized gametes, embryonic stem cells, adult stem cells, precursor or progenitor cells, and highly specialized cells. Optionally, the cells can be induced to cease proliferation. The proliferated cells of the subject invention are useful for cell therapy, cell/gene therapy, biological production of molecules, and as in vitro models for research, toxicity testing, and drug development.06-14-2012
20090246178CD56 POSITIVE HUMAN ADULT PANCREATIC ENDOCRINE PROGENITOR CELLS - The invention relates to the discovery of a selective cell surface marker that permits the selection of a unique subset of pancreatic stems cells having a high propensity to differentiate into insulin producing cells or into insulin producing cell aggregates.10-01-2009
20110123497GRAFT COMPOSITION FOR NEURAL TISSUE REGENERATION, METHOD OF PRODUCTION AND USES THEREOF - The present invention provides a biocompatible, biodegradable graft composition for regeneration of neural tissue, comprising the following components: a) a gel scaffold formed from an isolated platelet containing fluid and an activating agent comprising calcium chloride, with or without thrombin, b) a nerve growth factor selected from BDNF, NGF, retinoic acid and combinations thereof, and c) a culture of at least 50,000 progenitor stem cells; the method of production and the uses thereof.05-26-2011
20100129331DISACCHRIDES FOR THE TREATMENT OF TENDONS, LIGAMENTS, AND BONES - The present invention relates to the use of a series of disaccharides, as well as of compositions containing them, for the preparation of a medicament for the treatment or prevention of a tendon, ligament or bone disease, disorder or injury. The present invention also relates to the new compositions comprising a disaccharide in combination with inulin polysulphate, a glycosamino-glycan, a growth factor or cells. The glycosaminoglycan is preferably chondroitin sulphate or hyaluronic acid and the growth fact is IFG-1.05-27-2010
20100143313HOMOGENEOUS DIFFERENTIATION OF HEPATOCYTE-LIKE CELLS FROM EMBRYONIC STEM CELLS - One of the major hurdles of cellular therapies for the treatment of liver failure is the low availability of functional human hepatocytes. Although embryonic stem (ES) cells represent a potential cell source for therapy, current methods for differentiation result in mixed cell populations or low yields of the cells of interest. The present invention provides for a rapid, direct differentiation method that yields a homogeneous population of endoderm-like cells with 95% purity. In one embodiment, mouse ES cells cultured on top of collagen-sandwiched hepatocytes differentiate and proliferate into a uniform and homogeneous cell population of endoderm-like cells. The endoderm-like cell population was positive for Foxa2, Sox17 and AFP, and could further differentiate into hepatocyte-like cells that demonstrate hepatic morphology, functionality, and gene and protein expression. Incorporating the hepatocyte-like cells into a bioartificial liver device to treat fulminant hepatic failure improved animal survival, thereby underscoring the therapeutic potential of these cells.06-10-2010
20110280842METHODS OF REPROGRAMMING CELLS - The present invention provides methods of reprogramming cells, for example, directly reprogramming a somatic cell of a first cell type into a somatic cell of a second cell type, are described herein. In particular, the present invention generally relates to methods for reprogramming a cell of an endoderm origin to a cell having pancreatic β-cell characteristics. The present invention also relates to an isolated population comprising reprogrammed cells, compositions and their use in the treatment of diabetes mellitus. In particular, the present invention relates to reprogramming a cell of an endoderm origin to a cell having pancreatic β-cell characteristics by increasing the protein expression of at least one transcription factor selected from Pdx1, Ngn3 or MafA in the cell of endoderm origin to reprogram the cell of an endoderm cell to a cell which exhibits at least one or at least two characteristics of an endogenous pancreatic β-cell.11-17-2011
20110280843TREATMENT OF DISEASES AND DISORDERS USING PLACENTAL STEM CELLS - Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.11-17-2011
20110280841Electroprocessing in Drug Delivery and Cell Encapsulation - The invention is directed to novel compositions comprising an electroprocessed material and a substance, their formation and use. The electroprocessed material can, for example, be one or more natural materials, one or more synthetic materials, or a combination thereof. The substance can be one or more therapeutic or cosmetic substances or other compounds, molecules, cells, vesicles. The compositions can be used in substance delivery, including drug delivery within an organism by, for example, releasing substances or containing cells that release substances. The compositions can be used for other purposes, such as prostheses or similar implants.11-17-2011
20120189592METHODS FOR PROMOTING HEMATOPOIETIC RECONSTITUTION - The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E07-26-2012
20120189589COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS - The specification discloses compositions and methods for treating a soft tissue defect of an individual.07-26-2012
20120189587CELL SHEET FOR TISSUE REPAIR AND BIO-ARTIFICIAL TISSUE ENGINEERING, METHOD OF PRODUCING THE SAME AND METHOD OF USING THE SAME - Disclosed is a cell sheet for tissue repair and bio-artificial tissue engineering. The cell sheet comprises treated stem cell embedded in its self-secreted extracellular matrix (ECM) and formed a cell sheet. The cell sheet is formed by isolating the stem cell, expanding the stem cell and treating the stem cell with biological factors or factors leading to the production of biological factors, to induce its differentiation, production of extracellular matrix and formation of a cell sheet in vitro. The cell sheet is used as a bioactive material or as an acellular material for the promotion of tissue repairs or used to form a bio-artificial organ for tissue replacement. The cell sheet of the present invention eliminates the need to use scaffolds for cell delivery. The cell sheet facilitates in vivo cell transplantation and provides some tensile mechanical strength for bearing early mechanical load during tissue repair.07-26-2012
20120189586Human Placental Derived Extracellular Matrix and Uses Therof - The invention provides a composition for use in tissue augmentation of a human. More specifically, the composition comprises collagen extracted from human placenta and a bulking agent. Furthermore, the invention discloses methods of augmenting soft tissue comprising the use of the compositions described herein.07-26-2012
20100247492METHODS FOR THE DETECTION OF CIRCULATING TUMOR CELLS - The present invention provides methods for revealing, detecting, and analyzing circulating tumor cells in the blood of a subject. Revealing detectable circulating tumor cells allows for early stage detection and diagnosis in addition to long term prognosis in subjects with cancer. Additionally, enrichment allows for robust detection and clinically meaningful analysis of low volume samples for use in clinical settings as well as innovative methods for the treatment of cancers.09-30-2010
20110020291USE OF STEM CELLS FOR WOUND HEALING - Cells, compositions, and methods of cell therapy for administering a therapeutically effective amount of stem cells or cell concentrate to achieve accelerated wound healing of normal and chronic wounds, while minimizing the formation of scar tissue.01-27-2011
20090123437METHODS FOR COLLECTING AND USING PLACENTA CORD BLOOD STEM CELLS - An innovative method of collecting cord blood stem cells from an isolated mammalian non-exsanguinated or partially exsanguinated placenta by placental perfusion is described and also an easy method for safe long duration cold storage of the placenta. Placental perfusion can include perfusing the isolated placenta with a pulsatile flow of perfusion solution, for example, using a pulsatile or peristaltic pump or device. The stem cells can then be isolated from the perfusate. Significantly increased amounts of CD133+ stem cells can be collected from the perfusate. The perfusion solution can include an anticoagulant. The isolated mammalian placenta need not be treated with an anticoagulant prior to perfusing. The isolated placenta can be free from an anticoagulant prior to perfusing.05-14-2009
20090269319ARPE-19 as a Platform Cell Line for Encapsulated Cell-Based Delivery - ARPE-19 cells were evaluated as a platform cell line for encapsulated and unencapsulated cell-based delivery technology. ARPE-19 cells were found to be hardy (the cell line is viable under stringent conditions, such as in central nervous system or intra-ocular environment); can be genetically modified to secrete the protein of choice; have a long life span; are of human origin; have good in vivo device viability; deliver efficacious quantity of growth factor; trigger no or low level host immune reaction, and are non-tumorigenic.10-29-2009
20100021438KIDNEY DERIVED STEM CELLS AND METHODS FOR THEIR ISOLATION, DIFFERENTIATION AND USE - The invention relates generally to methods for isolation and culture of kidney stem cells, cells isolated by the methods, and therapeutic uses for those cells.01-28-2010
20090202496METHOD FOR REGENERATING AN IMMUNE SYSTEM - An isolated and purified cell line of hematopoeitic stem cells (HSC) that are incapable of expressing the CCR5 receptor on the cell surface (“the CCR5Δ32 cells” are used to regenerate the immune system in a subject in need thereof and especially to treat a subject infected with human immunodeficiency virus (HIV). The method is carried out by transplanting CCR5Δ32 into the recipient subject. Because mature immune cells derived from CCR5Δ32 cells cannot express functional CCR5 receptors, they will be resistant to infection by HIV and other pathogens that use the CCR5 receptor to infect cells. An embodiment of the invention includes administration of a nutritional regimen to the patient that optimizes conditions for CCR5Δ32 cell transplantation. Another embodiment of the invention includes co-transplanting mesenchymal cells along with the HSC in order to enhance the growth and development of the transplanted HSC.08-13-2009
20100196327METHODS FOR DIAGNOSING BIOLOGICAL SAMPLES CONTAINING STEM CELLS - The present invention relates to a method for diagnosing the compatibility of a biological sample containing stem cells from a donor with the immune system of a recipient. Furthermore, the present invention relates to a method for determining the quality of a stem cell preparation based on the inventive method, as well as methods of diagnosing an immune disorder affecting stem cell recognition. The present invention further relates to a method for producing an improved stem cell preparation, and an apparatus that is equipped for performing the method according to the invention. The invention can be used in the field of stem cell-based transplantation and respective diseases. The invention also includes a method for testing the efficacy of donor immune cells as treatments for disease such as cancer in a host patient. A method for testing the immune response of a patient to recall antigens is also disclosed.08-05-2010
20110171180BIOENGINEERED SKIN SUBSTITUTES - A bioengineered skin substitute was developed that contains a microfabricated basal lamina analog that recapitulates the native microenvironment found at the dermal-epidermal junction (DEJ).07-14-2011
20090324555Neural Stem Cells - Subject of the invention is a method for generating neural stem cells in vitro, wherein dental progenitor cells are isolated from soft tissue of tooth or wisdom tooth and cultivated until they form primary spheres which are then dissociated into single cells. These single cells are cultivated until they form spheroids and the spheroid-forming cells are separated to obtain neural stem cells.12-31-2009
20100034786Use of PI3K M-TOR and Akt Inhibitors to Induce FOXP3 Expression and Generate Regulatory T Cells - The invention relates to a method of inducing Foxp3 expression in a T cell comprising (i) stimulating a T cell (ii) inhibiting signalling via PBK alpha or PBK delta or m-TOR or Akt in said T cell, wherein said inhibition is commenced 10 to 22 hours after the stimulation of (i). The invention also relates to certain uses of PBK inhibitors, PBK inhibitors for particular uses, and kits.02-11-2010
20090022693METHOD FORISOLATING STEM CELLS FROM CRYOPRESERVED DENTAL TISSUE - The invention relates to a method for isolation of multipotent stem cells from dental tissue in which the stem cells are extracted from a tissue structure and then cultured. The invention also relates to stem cells isolated by means of the method according to the invention as well as bone cells and nerve cells produced by means of the method according to the invention. The invention also relates to a method for producing a bank of stem cells in which the cells are stored by means of the method according to the invention. According to the present invention, the cells of a pad-like soft tissue that can be localized beneath the papilla directly on the apical side of an extracted immature tooth are cryopreserved in the tissue structure such that the tissue structure is disintegrated to extract the stem cells only after thawing. These results show that stem cells/progenitor cells can be isolated even after cryopreservation of the source tissue and these stem cells/progenitor cells respond to osteogenic stimulation. In addition, the response of cells after cryopreservation turns out to be stronger than that without cryopreservation.01-22-2009
20100266558METHOD AND ASSAY FOR GLYCOSYLATION PATTERN DETECTION RELATED TO CELL STATE OF STEM CELLS - A method and assay for characterizing populations of stem cells according to their glycosylation pattern, particularly for distinguishing between stem cell populations, for example with regard to state of differentiation.10-21-2010
20100266555MICRO RNAS AS MARKERS OF THE FUNCTIONAL STATE OF A DENDRITIC CELL - The present invention relates to the use of specified micro RNAs as markers of the functional state of a dendritic cell. In one aspect the invention relates to a method for producing a quality-controlled therapeutic composition comprising dendritic cells. In another aspect the invention relates to a method of in vitro screening of immunomodulatory compounds.10-21-2010
20100266552TREATMENT OF CHRONIC LUNG DISEASE - A method of cellular therapy for a lung disease or condition in a subject is disclosed, wherein the method involves the administration of multipotent epithelial stem cells derived from amnion tissue (AECs). In a particular application, the method is used for the treatment of lung diseases and conditions such as chronic lung diseases including chronic obstructive pulmonary disease (COPD), acute lung conditions such as acute respiratory distress syndrome (ARDS), and ventilator associated lung injury (VALI).10-21-2010
20090155225USES AND ISOLATION OF VERY SMALL OF EMBRYONIC-LIKE (VSEL) STEM CELLS - The presently disclosed subject matter provides populations of stem cells that are purified from bone marrow, peripheral blood, and/or other sources. Also provided are methods of using the stem cells for treating tissue and/or organ damage in a subject.06-18-2009
20110052550Therapeutic Uses of Allogeneic Myeloid Progenitor Cells - Myeloid function is enhanced by transplantation or infusion of allogeneic myeloid progenitor cells, including CMP, GMP, MEP and MKP cell subsets. Myeloid progenitors ameliorate sequelae of anemia and thrombocytopenia, and can prevent or treat gastrointestinal mucositis associated with chemotherapy, radiotherapy, and the like. The transplantation or infusion may be performed in the absence of HLA typing, and the cells may be mismatched at one or more Class I HLA loci. The transplantation may provide for treatment of ongoing disease, or prevention of disease in high risk patients.03-03-2011
20100119490Therapeutic Use of CD31 Expressing Cells - As described below, the present invention features compositions and methods related to the isolation, culture and therapeutic use of CD31-expressing cells.05-13-2010
20080299092Cosmetic preparation and method for preparing the same - The present invention relates to the use of dedifferentiated plant cells in cosmetic preparations for protecting of stem cells against intrinsic and extrinsic stress factors, in particular for promoting proliferation of stem cells and for protecting them against apoptosis. In particular, the invention relates to the use of dedifferentiated plant cells from fruits of 12-04-2008
20100284976COMPOSITIONS FOR THE PREPARATION OF MATURE DENDRITIC CELLS - The invention relates to a method for in vitro maturation of at least one immature dendritic cell, comprising stimulating said immature dendritic cell with TNFα, IL-1β, IFNγ, a TLR7/8 agonist and prostaglandin E2 (PG). Furthermore, the invention relates to a composition comprising said factors as well as to mature dendritic cells produced by the method of the invention.11-11-2010
20120189583PLACENTAL OR UMBILICAL CORD TISSUE COMPOSITIONS - The present invention encompasses compositions, including solutions, gels, and pastes, manufactured from amniotic membrane, umbilical cord membrane, or both. The present invention also encompasses methods of making such compositions, and methods of using the compositions to treat conditions of the eye.07-26-2012
20110300111GENERATION OF INDUCED PLURIPOTENT STEM CELLS WITHOUT THE USE OF VIRAL VECTORS - Presented herein, generally, are methods for generating reprogrammed mammalian cells, e.g., induced pluripotent stem cells, from differentiated mammalian cells without the use of viral or plasmid vectors. In one aspect, the methods involve contacting a differentiated cell with transducible polypeptides comprising a reprogramming factor polypeptide linked to a cell penetration peptide so that a reprogrammed mammalian cell that exhibits at least one characteristic of pluripotency is generated. Also presented herein are methods for cardiac differentiation of a mammalian cell without the use of viral or plasmid vectors. In one aspect, such methods involve contacting a mammalian cell exhibiting at least one characteristic of pluripotency with a transducible polypeptide, so that cardiac differentiation of the cell occurs.12-08-2011
20100034787COMPOSITION AND METHODS FOR PROMOTING HAIR GROWTH - The present disclosure provides compositions and methods for promoting the growth of hair for cosmetic purposes as well as for treating disorders of hair growth. The compositions are conditioned media obtained from a three dimensional tissue that produces a combination of cellular factors effective to induce, promote, or enhance hair growth.02-11-2010
20110286977G6PC2-Encoded Beta Cell Surface Tags - The invention relates to G6PC2-encoded beta cell surface markers, methods of identifying and obtaining a culture cells comprising fully differentiated beta cells. Also contemplated is a method of sorting such cells, isolated cells and compositions thereof.11-24-2011
20110200563CALCIUM-MEDIATED EFFECTS OF CORAL AND METHODS OF USE THEREOF - This invention is directed to coral scaffolds seeded with precursor cells in culture in the presence of a chelator and uses thereof in inducing or enhancing bone and/or cartilage formation in a subject, and kits related thereto. This invention is also directed to use of cadherin-upregulating coral for treating cancer or inhibiting cancer progression. This invention is also directed to use of aragonite or calcite-producing species for in vivo calcium release, and its application to the treatment of skin diseases, disorders or conditions.08-18-2011
20090202500Pharmaceuticals That Promote Functional Regeneration of Damaged Tissues - The present inventors revealed the following for the first time in the world: 08-13-2009
20110008300Cryopreservation of Adipose Tissue for the Isolation of Mesenchymal Stem Cells - The present invention relates to a method and composition for the cryopreservation of adipose tissue with the intention to use this tissue in the culturing of stem and/or progenitor cells. The method uses a specific cryoprotection medium to prevent damage of the original tissue during the cryopreservation while still maintaining a high viability of the stem and/or progenitor cells obtained from the cryopreserved adipose tissue. Furthermore the cryoprotection medium of the present invention does not contain any kind of xenogeneic sera, a critical factor since it is the intention of that the cryopreserved tissue is used for obtaining stem and/or progenitor cells that can be used in medicine. The cryoprotection medium is characterized in that it is a solution of physiological water comprising glycerol and sucrose and/or trehalose and optionally serum albumin.01-13-2011
20110286976BI-SPECIFIC FUSION PROTEINS - Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.11-24-2011
20110286975SYSTEMS AND METHODS FOR MAGNETIC GUIDANCE AND PATTERNING OF MATERIALS - Systems and methods generally useful in medicine, cellular biology, nanotechnology, and cell culturing are discussed. In particular, at least in some embodiments, systems and methods for magnetic guidance and patterning of cells and materials are discussed. Some specific applications of these systems and methods may include levitated culturing of cells away from a surface, making and manipulating patterns of levitated cells, and patterning culturing of cells on a surface. Specifically, a method of culturing cells is presented. The method may comprise providing a plurality of cells, providing a magnetic field, and levitating at least some of the plurality of cells in the magnetic field, wherein the plurality of cells comprise magnetic nanoparticles. The method may also comprise maintaining the levitation for a time sufficient to permit cell growth to form an assembly.11-24-2011
20110286974Method for treating diabetes and other glucose regulation disorders using stem cells - Various embodiments of the invention provide methods of treating diabetes and other glucose regulation disorders. In one embodiment, the method comprises removing L-cells from a donor, obtaining stem cells from a patient, and culturing the L-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived L-cells (SCDLC). An amount of the SCDLC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food. In another embodiment, the method comprises removing K-cells from a donor, obtaining stem cells from a patient, and culturing the K-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived K-cells (SCDKC). An amount of the SCDKC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food.11-24-2011
20110286973METHODS FOR INTRODUCING HETEROLOGOUS CELLS INTO FISH - The invention provides methods of introducing heterologous cells into fish. After introduction cells remain viable, and in some instances proliferate, for sufficient time to conduct a variety of analyses on the heterologous cells or the fish or both. Such methods are useful for screening potential drugs for toxicity toward introduced cells or for capacity to stimulate differentiation and/or proliferation of introduced cells. Such methods are also useful for diagnosing the presence of small quantities of cancerous cells or pathogens in patient tissue samples. Such methods are also useful for culturing cells for subsequent use in cell or tissue engineering.11-24-2011
20120230961MESENCHYMAL STEM CELL AND THE METHOD OF USE THEREOF - Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells.09-13-2012
20120230960PHARMACEUTICAL KITS COMPRISING MESENCHYMAL STEM CELLS - A method of treating a natural soft skeletal tissue injury in a patient the method comprising administering to the patient a composition of mesenchymal stem cells in liquid suspension enriched compared to the natural source of said cells, or tenocytes derived therefrom. The method is particularly suited to the regeneration of tendons in competitive mammals, such as the superficial digital flexor tendon of the horse.09-13-2012
20110293584Tissue Regeneration - The present invention relates to a method of treating a tissue defect in a human or animal body comprising the steps of implanting into said body an unseeded scaffold; allowing or effecting a wound healing response at the site of said defect; allowing said scaffold to be vascularized until a substantially sufficient fluid flow through said scaffold is assured for the transport of nutrients and/or waste products, and seeding said vascularised scaffold with a suitable population of tissue-regenerating cells.12-01-2011
20110293574Hematopoietic stem cell growth factor - The present invention relates, in general, to stem cells and, in particular, to a hematopoietic stem cell (HSC) growth factor and to methods of using same.12-01-2011
20100183568METHOD FOR PRODUCTION OF HEPATIC-LOBULE-LIKE CELL CLUSTER FROM ADIPOSE-TISSUE-DERIVED CELL - Disclosed are: a method for producing a hepatic-lobule-like cell mass from an adipose-tissue-derived cell, which is characterized by culturing the adipose-tissue-derived cell; a hepatic-lobule-like cell mass produced by the method; a method for the screening of a substance capable of promoting or inhibiting the formation of a hepatic-lobule-like cell mass, which is characterized by culturing an adipose-tissue-derived cell to produce the hepatic-lobule-like cell mass, wherein a candidate substance is added to a culture medium; and a kit for use in the screening method.07-22-2010
20130216502Methods of Treating Intestinal Injury Using Heparin Binding Epidermal Growth Factor and Stem Cells - The invention provides for methods of treating, abating and reducing the risk for intestinal injury by administering a combination heparin binding epidermal growth factor (HB-EGF) and stem cells, such as mesenchymal stem cells or intestinal stem cells, in an amount effective to reduce the onset or severity of intestinal injury. The invention also provides for methods of promoting engraftment of stem cells, such as mesenchymal stem cells or intestinal stem cells, within the intestine of a patient suffering from intestinal injury.08-22-2013
20110293583METHODS FOR CELL EXPANSION AND USES OF CELLS AND CONDITIONED MEDIA PRODUCED THEREBY FOR THERAPY - Methods for treating a subject suffering from a compromised endogenous hematopoietic system are described that comprise administering to the subject a therapeutically effective amount of adherent stromal cells. Methods of preparing adherent stromal cells and pharmaceutical compositions comprising the cells are also described.12-01-2011
20110293581BONE-REGENERATING COMPOSITION CONTAINING ANGIOGENIN - The present invention relates to a bone-regenerating composition containing angiogenin and to a bone-generating scaffold comprising the composition. Angiogenin has a superior ability to induce initial angiogenesis and bone regeneration as compared to the platelet rich plasma (PRP) which is used as a conventional element for stimulating bone regeneration, thus improving the speed of bone regeneration12-01-2011
20110293580GYNOGENETIC OR ANDROGENETIC PRODUCTION OF PLURIPOTENT CELLS AND CELL LINES, AND USE THEREOF TO PRODUCE DIFFERENTIATED CELLS AND TISSUES - Methods for obtaining pluripotent (embryonic stem) cells from parthenogenetic embryos, especially primates, are provided. These cells are useful for producing differentiated cells, tissues and organs, especially human and non-human primate cells, tissues and organs.12-01-2011
20110293576MESENCHYMAL STROMAL CELL POPULATIONS AND METHODS OF ISOLATING AND USING SAME - The invention relates to mesenchymal stromal cells produced by culturing the cells in platelet lysate supplemented media and methods of using these cells to treat neurological and kidney associated disorders.12-01-2011
20110293572INCREASING THE PLASTICITY OF STEM CELLS - The invention relates to methods of culturing non-embryonic cells to increase their plasticity and their potential to differentiate into multi-lineage cell types.12-01-2011
20110293577Therapeutic Methods Using Adipose Tissue-Derived Cell Suspensions Comprising Adipocytes - Provided herein is a use of an adipose tissue-derived cell suspension which comprises adipocytes for the preparation of a pharmaceutical composition for use in the treatment of an inflammatory disorder, a cartilage or bone disorder and/or the alleviation of pain associated with an inflammatory disorder in a mammalian subject. Also provided herein is a method of treating an inflammatory disorder, a cartilage or bone disorder or alleviating pain associated with an inflammatory disorder in a mammalian subject, comprising administering to the subject a pharmaceutical composition which comprises: (i) an adipose tissue-derived cell suspension which comprises adipocytes; or (ii) a cell-free extract which is prepared from an adipose tissue-derived cell suspension, wherein the adipose tissue-derived cell suspension comprises adipocytes, together with a pharmaceutically-acceptable carrier or diluent.12-01-2011
20110293575PHOTOCHEMICAL INTERNALISATION OF KINASE INHIBITORS - The present invention relates to a method for enhancing the activity of kinase inhibitors in target cells, and more specifically for enhancing the activity of tyrosine kinase inhibitors (TKIs), said method comprising contacting a cell with a kinase inhibitor and a photosensitizing agent and irradiating said cell with light of a wavelength effective to activate the photosensitizing agent, and to the use of this method for enhancing the effects of kinase inhibitors or kinase inhibitor-based drugs in particular to achieve cell death, for example, in cancer treatment and other diseases or conditions in which kinase inhibitors, such as TKIs, have a beneficial effect.12-01-2011
20110293573METHOD AND APPARATUS FOR CULTURING TISSUE - A method for culturing microtissue is provided. The method includes steps of: (a) forming a pattern microarray on a hydrophobic film; (b) adhering the hydrophobic film to a carrier; (c) disposing a plurality of cells on the hydrophobic film for culturing depending on the pattern microarray, and forming a plurality of hair follicle microtissues.12-01-2011
20100028310Composition for Transplantation Comprising Adipose Stem Cells or Adipocytes - The present invention relates to a composition for transplantation in a physiologically compatible buffer solution comprising, (a) a transplant-cell selected among an adipose stem cell, an adipocyte, adipose tissues (fat tissue) and a mixture thereof; and (b) a semi-solid substance derived from a living body or a biodegradable substance selected among a hyaluronic acid, collagen, elastin, thrombin, chondroitin sulfate, albumin and a mixture thereof. 02-04-2010
20100166719Hair growth method - A method of enabling effective hair growth and furthermore, inducing hair growth closely similar to the natural hair state in the case of transplanting dermal papillae or cultured dermal papilla cells into the skin to regenerate the hair, characterized by comprising transplanting a composition containing the following components into an epidermis defect site: (a) dermal papillae or dermal papilla cells, (b) an epidermal tissue or epidermal cells and/or (c) a tissue constituting hair follicles or cells thereof.07-01-2010
20090269315METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS - Cells present in processed lipoaspirate tissue are used to treat patients, including patients with cardiovascular conditions, diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in processed lipoaspirate are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic cardiovascular benefit.10-29-2009
20090104161METHOD FOR ACTIVATION TREATMENT OF ANTIGEN-PRESENTING CELL - Activated antigen-presenting cells that can induce immunocytes including disease antigen-specific CD8+ CTLs and/or γδ T cells efficiently in vivo and/or in vitro, a medical composition comprising the activated antigen-presenting cells, a treatment and prevention method using the activated antigen-presenting cells, and an induction method of immunocytes including disease antigen-specific CTLs and/or γδ T cells induced using the activated antigen-presenting cell, immunocytes induced by the above-noted method, a medical composition comprising the immunocytes, and a treatment and prevention method using the immunocytes are provided. By co-pulsing antigen-presenting cells with bisphosphonate in addition to the pulse with a disease antigen, the ratio of disease antigen-specific CD8+ CTLs and/or γδ T cells and the number of the disease antigen-specific CD8+ CTLs and the γδ T cells can be increased, compared with the case where the co-pulse with bisphosphonate is not carried out.04-23-2009
20090104160Mobilization of Stem Cells After Trauma and Methods Therefor - Methods are presented in which release of stem cells from skeletal muscle is quantitated and correlated with severity of a disease or trauma, a future treatment option, prognosis, and/or anticipated time to recovery. Most preferably, the stem cell is a BLSC and/or an ELSC, and the stem cell isolation for the cell count is performed using sedimentation or filtration as principal separation step, thereby avoiding commonly used complicated, expensive, and time-consuming processes such as antibody-based separation and fluorescence-activated cell sorting.04-23-2009
20110300112METHODS FOR ENHANCING YIELD OF STEM CELL CULTURES AND ENHANCING STEM CELL THERAPY - The present application relates to methods and compositions for the generation of therapeutic cells having reduced incidence of karyotypic abnormalities. In several embodiments cardiac stem cells are cultured in an antioxidant-supplemented media that reduces levels of reactive oxygen species, but does not down regulate DNA repair mechanisms. In several embodiments, physiological oxygen concentrations are used during culture in order to increase the proliferation of stem cells, decrease the senescence of the cells, decrease genomic instability, and/or augment the functionality of such cells for cellular therapies.12-08-2011
20110081326DIFFERENTIATION OF MESENCHYMAL STEM CELLS INTO FIBROBLASTS, COMPOSITIONS COMPRISING MESENCHYMAL STEM CELL-DERIVED FIBROBLASTS, AND METHODS OF USING THE SAME - Methods and compositions are provided for the differentiation and characterization of mammalian fibroblast from mesenchymal stem cells. The methods of the invention provide a means to obtain mesenchymal stem cell-derived fibroblast populations, e.g., seeded on a scaffold, which may be used in wound healing.04-07-2011
20080233087Methods for identifying, isolating, and utilizing endocrine progenitor cells from adult human pancreata - The presence of the cell surface marker CD133 or the presence of a glycosylated form of the prominin-1 gene product on adult pancreatic cells is used to identify pancreatic endocrine progenitor cells, and useful in methods of isolation and enrichment. Isolated pancreatic endocrine progenitor cells can be used for cell based therapy for insulin-dependent diabetes and pancreatectomy patients.09-25-2008
20090148422METHODS OF PROLIFERATING STEM CELLS - The invention relates to methods of proliferating stem cells. More particularly, the invention relates to the use of glycosaminoglycans or proteoglycans to promote the growth of stem cells in ex vivo culture, while preserving their multipotentiality.06-11-2009
20100040584METHODS FOR PROMOTING NEOVASCULARIZATION - The success of tissue engineering and therapeutic neovascularization depends on the development of a microvascular network. The present invention provides methods for promoting neovascularization in tissue engineering constructs, tissue repair, and wound healing comprising endothelial and mesenchymal progenitor cells.02-18-2010
20100272695CELL COMPOSITIONS DERIVED FROM DEDIFFERENTIATED REPROGRAMMED CELLS - Methods and cell culture compositions, in particular, pancreatic cell culture methods and compositions, derived from dedifferentiated human reprogrammed pluripotent stem cells, such as, induced pluripotent stem (iPS) cells.10-28-2010
20090041733METHODS FOR CELL MOBILIZATION USING IN VIVO TREATMENT WITH HYALURONAN (HA) - The use of forms of hyaluronic acid having a molecular weight less than about 750,000 daltons selected from the group consisting of hyaluronic acid and pharmaceutically acceptable salts thereof is provided for the same purposes known for using recombinant GM-CSF or G-CSF.02-12-2009
20080213231Pluripotent Stem Cell Cloned From Single Cell Derived From Skeletal Muscle Tissue - Techniques are provided which can isolate pluripotent stem cells at high purity capable of differentiation into at least a myocardial cell to regenerate the cardiac muscle. The pluripotent stem cells at high purity capable of differentiation into at least a myocardial cell to regenerate the cardiac muscle can be isolated through the following steps: (i) collecting a skeletal muscle tissue from a mammal and enzymatically treating the obtained skeletal muscle tissue to prepare a skeletal muscle tissue-derived cell; (ii) culturing the obtained skeletal muscle tissue-derived cell in a culture medium containing an epidermal growth factor and a fibroblast growth factor; (iii) selecting and separating a colony that is floating in the culture medium.09-04-2008
20100015107Expression elements - The invention relates to genetic elements capable of improving the levels of expression of operably-linked transcription units. In particular, said genetic elements are derived from the 5′ untranslated regions of ribosomal protein genes and may comprise a CpG island. Also provided are vectors and host cells comprising said genetic elements and methods of use to obtain high levels of recombinant gene expression.01-21-2010
20100233139METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER - Methods of treating patients for conditions such as breast augmentation, soft tissue defects, and urinary incontinence, are described. The methods include removing adipose tissue from a patient, processing a portion of the adipose tissue to obtain a substantially isolated population of cells comprising disaggregated adipose-derived stem cells, mixing the concentrated population of adipose-derived cells comprising disaggregated adipose-derived cells with a portion of unprocessed, intact, non-disaggregated adipose tissue to form a composition, and administering the composition to the patient from which the adipose tissue was removed.09-16-2010
20120189594METHODS FOR PROMOTING HSC SELF-RENEWAL - The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E07-26-2012
20120189591COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS - The specification discloses compositions and methods for treating a soft tissue defect of an individual.07-26-2012
20120189585METHOD AND COMPOSITION FOR RESTORATION OF AGE-RELATED TISSUE LOSS IN THE FACE OR SELECTED AREAS OF THE BODY - This application relates to stem cell compositions and methods for restoring age-related tissue loss in the face and other selected areas of the body. In a first embodiment, a composition includes stem cells and hyaluronic acid as a carrier wherein the stem cells are peripheral blood stem cells, bone marrow-derived blood stem cells, or mesenchymal stem cells.07-26-2012
20120189584GENIPIN CROSS-LINKED FIBRIN GELS - The invention provides a genipin cross-linked fibrin gel. The ratio of genipin to fibrin in the gel ranges from about 0.1:1 to about 10:1 (genipin:fibrin). The gel can be hydrogel. Also provided is method for repairing tissue defects by administering the gel to site of tissue defect.07-26-2012
20110217269METHOD OF FOSTERING THE HEALING OF SKIN WOUNDS USING CELLS OF THE ROOT SHEATH, COMPOSITION AND PREPARATION METHOD - The present invention relates to a method for promoting the healing of skin wounds or the re-establishment of the function of the skin and/or its skin appendices of a second skin area, comprising the step of: applying cells obtained from hair root sheaths of a first skin area of a donor onto a second skin area of a host. It further relates to cells, a preparation, the use of cells as well as a method for preparing a preparation.09-08-2011
20110217271TREATMENT OF DISEASES OR DISORDERS USING PLACENTAL STEM CELLS - The present invention provides a method of extracting and recovering embryonic-like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta. A placenta is treated to remove residual umbilical cord blood by perfusing an exsanguinated placenta, preferably with an anticoagulant solution, to flush out residual cells. The residual cells and perfusion liquid from the exsanguinated placenta are collected, and the embryonic-like stem cells are separated from the residual cells and perfusion liquid. The invention also provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate endogenous cells, including, but not limited to, embryonic-like stem cells. The invention also provides methods for propagation of exogenous cells in a placental bioreactor and collecting the propagated exogenous cells and bioactive molecules therefrom.09-08-2011
20110217270METHODS FOR TREATING TUMORS AND CANCEROUS TISSUES - The invention disclosed herein relates generally to immunotherapy and, more specifically, to therapeutic methods for treating tumors and cancerous tissues by first inducing necrosis or apoptosis (e.g., cryotherapy, chemotherapy, radiation therapy, ultrasound therapy, or a combination thereof applied against at least a portion of the tumor or cancerous tissue), and then delivering one or more se doses of antigen presenting cells (e.g., autologous dendritic cells) intratumorally or proximate to the tumor or cancerous tissue, but only after a selected period of time sufficient for the bioavailability of liberated cancer-specific antigens (monitored over the selected period of time) resulting from the necrosis or apoptosis to be at or near a maximum value. The present invention provides an alternative strategy to the ex vivo loading of target antigen to antigen presenting cells such as, for example, enriched autologous dendritic cells for purposes of enhancing an immune response.09-08-2011
20090280095CELL CULTURE OF KERATINOCYTES UNDER NON-DIFFERENTIATING CONDITIONS - The present invention relates to a cell culture medium comprising (a) an inhibitor of bone morphogenetic protein-4 (BMP-4) and (b) an inhibitor of pigment epithelium-derived factor (PEDF, also known as SerpinF1). In one embodiment, the inhibitors are antibodies against BMP-4 and PEDF, respectively. The medium allows to culture keratinocytes under non-differentiating conditions. The invention also relates to corresponding methods and kits. As the media and methods disclosed allow for an improved manufacture of keratinocytes, the invention also relates to the treatment of skin wounds and to the manufacture of corresponding medicaments. This will be of advantage for treatment e.g. of burns, ulcers, etc., in which transplantation of keratinocytes or skin is required.11-12-2009
20090169527MATERIALS FROM BONE MARROW STROMAL CELLS FOR USE IN FORMING BLOOD VESSELS AND PRODUCING ANGIOGENIC AND TROPHIC FACTORS - A therapeutic for use in inducing angiogenesis and vasculogenesis, the therapeutic including angiogenesis and vasculogenesis inducing factors isolated from stem cells in conjunction with a pharmaceutically acceptable cell therapy. A method of amplifying the production of angiogenesis and vasculogenesis inducing factors secreted by exposing stem cells to and co-culturing the stem cells with a compound for increasing the production of angiogenesis and vasculogenesis inducing factors. Angiogenesis and vasculogenesis inducing factors isolated and purified from stem cells for use in a therapy. A process for obtaining the angiogenesis and vasculogenesis inducing factors as set forth above, the process including the steps of isolating and purifying human mesenchymal stem cells from tissue prior to differentiation and then culture expanding the mesenchymal stem cells to produce a tool for neurological and musculoskeletal therapy. Isolated and culture expanded mesenchymal stem cells under the influence of a requisite compound, that are capable of differentiating and producing a desired cell phenotype needed for tissue repair.07-02-2009
20090130064DIFFERENTIATION OF STEM CELLS AND STABILIZATION OF PHENOTYPICAL PROPERTIES OF PRIMARY CELLS - Methods of inducing differentiation of stem cells and stem cells obtained are disclosed. A method for stabilizing the phenotype of isolated primary cells in vitro is disclosed. In both methods, a central role is played by histone deacetylase inhibitors.05-21-2009
20090130067Cell Population Having Immunoregulatory Activity, Method for Isolation and Uses - The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (IFN-γ) by expressing indolamine-2,3-dioxygenase (IDO) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues.05-21-2009
20100111909Dedifferentiation of Adult Mammalian Cardiomyocytes into Cardiac Stem Cells - Dedifferentiation is a mechanism whereby specialized cells regain properties of their ancestors, including, in the extreme, stemness. We found that highly-purified cardiomyocytes isolated from adult mammalian hearts dedifferentiated rapidly when cultured in mitogen-rich medium. Such myocytes reentered the cell cycle and proliferated, expressing stem cell surface markers such as c-kit and early cardiac transcription factors including GATA and NKx2.5. These myocyte-derived cells (MDC) were capable of re-differentiating into myocytes and endothelial cells. Contrary to prevailing dogma, cardiomyocyte dedifferentiation yields proliferative cells expressing stem cell markers and capable of multilineage differentiation. Cardiomyocyte dedifferentiation is a potential source of endogenous stem cells in the adult heart.05-06-2010
20090186006PLACENTAL VASCULAR LOBULE STEM CELLS - The present invention provides isolated populations of stem and progenitor cells from fetal vascular lobules of the placenta. The isolated populations of stem and progenitor cells of the invention express the markers CD144, CD105, and/or CD31 and lack expression of the hematopoietic-lineage marker CD45. Under specific conditions, cells of the invention may function as endothelial precursors and may provide therapeutic preparations, for example, in the treatment of ischemia.07-23-2009
20090317367METHODS OF PRODUCING PREADIPOCYTES AND INCREASING THE PROLIFERATION OF ADULT ADIPOSE STEM/PROGENITOR CELLS - The present invention describes preadipocytes and methods of differentiating macrophages into preadipocytes by co-culturing adipocytes and resident adipose tissue macrophages. Also described are methods of increasing the proliferative rate of adipose adult stem/progenitor cells.12-24-2009
20090148416ANGIOGENICALLY INDUCED TRANSPLANTS AND METHODS FOR THEIR USE AND MANUFACTURE - Angiogenically induced transplants and methods for their use and manufacture are disclosed. The angiogenic potential of the transplants is increased by contacting the transplants with donor mesenchymal cells such as hair follicle dermal papilla stem cells. Methods for treating disorders and diseases, such as disorders of the skin and angiopathies, are also disclosed.06-11-2009
20100166715T-140 PEPTIDE ANALOGS HAVING CXCR4 SUPER-AGONIST ACTIVITY FOR BONE MARROW RECOVERY - The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful for providing improved bone marrow transplantation and in the treatment of other conditions wherein bone marrow depletion or suppression is involved.07-01-2010
20100111907Methods and compositions for gene inactivation - Disclosed herein are methods and compositions for inactivating CCR-5 genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs, such as adenovirus (Ad) vectors, and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided.05-06-2010
20090324560METHOD FOR PREPARATION OF CARTILAGE CELL - Chondrocytes are prepared from perichondrocytes.12-31-2009
20090148421COMPOSITIONS COMPRISING VASCULAR AND MYOCYTE PROGENITOR CELLS AND METHODS OF THEIR USE - The invention provides compositions of adult cardiac vascular progenitor cells (VPCs) and adult cardiac myocyte progenitor cells (MPCs) useful for the treatment of various cardiac conditions. The invention also encompasses methods of generating a biological bypass, repairing damaged myocardium, and treating or preventing hypertensive cardiomyopathy and heart failure with the compositions of the invention. Methods of isolating the cardiac progenitor cells are also disclosed.06-11-2009
20090148418Skeletal Site-Specific Characterization of Orofacial and Illiac Crest Human Bone Marrow Stromal Cells in Same Individuals - The present invention relates to methods and compositions useful for the detection, enrichment, and use of orofacial-derived bone marrow stromal cells. In one aspect, the invention relates to the use of characteristics specific to orofacial-derived bone marrow stromal cells to distinguish orofacial-derived bone marrow stromal cells from other cells.06-11-2009
20090148419USE OF ADIPOSE TISSUE DERIVED MESENCHYMAL STEM CELLS FOR THE TREATMENT OF GRAFT VERSUS HOST DISEASE - The present invention relates to the use of a particular type of adipose tissue derived mesenchymal stem cells (AD-MSCs), which exert immunosuppressive properties, in the manufacture of a pharmaceutical composition for the prevention and treatment of the graft-versus-host disease (GVHD) produced after allogeneic hematopoietic stem cell transplantation.06-11-2009
20090148415Treatment for Chronic Myocardial Infarct - A method of treating chronic post-myocardial infarction including helical needle transendocardial delivery of autologous bone marrow (ABM) mononuclear cells around regions of hypo or akinesia in chronic post-myocardial infarction (MI) patients. The treatment is safe and improves ejection fraction (EF).06-11-2009
20090148420STEM CELLS - Stem cells obtained through in vitro culture with heparan sulphate are described.06-11-2009
20090148417CARBON NANOTUBES SERVING AS STEM CELL SCAFFOLD - The present invention relates to a scaffold for transplanting a stem cell comprising a carbon nanotube without cytotoxicity, and a composition for stem cell therapy comprising (a) a stem cell; and (b) a carbon nanotube serving as a stem cell scaffold without cytotoxicity. The scaffold for transplanting stem cells comprising carbon nanotubes show excellent effects without cytotoxicity on networking between differentiated stem cells and tissues present in transplantation sites, thereby showing significant cell therapy efficacy.06-11-2009
20090053182ENDOMETRIAL STEM CELLS AND METHODS OF MAKING AND USING SAME - The invention provides pluripotent stem cells and methods for making and using pluripotent stem cells. Pluripotent stem cells, among other things, can differentiate into various cell lineages in vitro, ex vivo and in vivo. Pluripotent stem cells, among other things, can also be used to produce conditioned medium.02-26-2009
20090148423ENDOTHELIAL PROGENITOR CELLS AND METHODS OF USE THEREOF - Endothelial progenitor cells immunoreactive for VEGFR-2 or Tie-2, and CD45 are provided. Optionally the cell is immunoreactive with CD14. The cells are capable of differentiating in vivo into an endothelial cell or a smooth muscle cells. The cultures integrate well after transplantation into adult vasculature.06-11-2009
20110171183Markers of Induced Pluripotent Stem Cells - The disclosure relates to the expression of podocalyxin-like protein (PODXL) on the surface of induced pluripotent stem cells and particularly, although not exclusively, to the use of PODXL as a marker of induced pluripotent stem cells.07-14-2011
20110171179Method for Regulating Production of Hemoglobin Beta Chains - A method is described for repressing production of β-globin protein and increasing production of γ-globin protein in a human cell utilizing a ferritin-H protein, a vector encoding ferritin-H, or an exogenous ferritin-H inducer.07-14-2011
20110020293Use of Stem Cells to Reduce Leukocyte Extravasation - The invention is generally directed to reducing inflammation by means of cells that secrete factors that reduce leukocyte extravasation. Specifically, the invention is directed to methods using cells that secrete factors that downregulate the expression of cellular adhesion molecules in vascular endothelial cells. Downregulating expression of cellular adhesion molecules reduces leukocyte adhesion to the endothelial cells such that extravasation is reduced. The end result is a reduction of inflammation. The cells are non-embryonic non-germ cells that have pluripotent characteristics. These may include expression of pluripotential markers and broad differentiation potential.01-27-2011
20080317718Cell Differentiation Of Adipose-Derived Precursors Cells - The present invention provides a simple method for controlled differentiation of adipose-derived precursor cells. A method is provided for preparing a differentiated cell. The method comprises A) obtaining a mixture by mixing a) an adipose-derived precursor cell and b) a differentiated cell corresponding to a desired site; and B) culturing the mixture under sufficient conditions which allow the adipose-derived precursor cell to differentiate. The present invention also provides a composition for cell implantation comprising a) an adipose-derived precursor cell and b) a differentiated cell corresponding to a desired site.12-25-2008
20090142305PEGYLATED FIBRINOGEN-BASED BIOMATRIX - The invention involves methods and materials related to fibrin-based biomatrices.06-04-2009
20110262405APPARATUS, SYSTEM, AND METHOD FOR HARVESTING IMPROVED BONE GRAFT MATERIAL WITH REAMER-IRRIGATOR-ASPIRATOR (RIA) DEVICE - The present invention provides for the harvesting of specific materials in multiple stages of filtration of bone graft materials from a Reamer-Irrigator-Aspirator (RIA) Device, specifics of interconnected stages, related filtration materials, and techniques. The harvesting process collects large material in a first stage, and other materials of a limited geometric size in at least a second stage of filtration. Such material captured in the second stage may contain plasma, cellular elements including stem cells as well as growth factors and other particulate matter of a specific geometrically limited size, using various filtration approaches including centrifugation in some embodiments. Further embodiments of the invention provide for an improved tubing interface and management approach to ease use in the operating room. Filtration materials may include collagen based filters and may allow direct implant of small scale and larger scale matter in specific portions within the collagen itself.10-27-2011
20110171182METHODS FOR CELL EXPANSION AND USES OF CELLS AND CONDITIONED MEDIA PRODUCED THEREBY FOR THERAPY - Methods for treating a subject suffering from a compromised endogenous hematopoietic system are described that comprise administering to the subject a therapeutically effective amount of adherent stromal cells. Methods of preparing adherent stromal cells and pharmaceutical compositions comprising the cells are also described.07-14-2011
20080267924AUTOLOGOUS LYMPH NODE TRANSFER IN COMBINATION WITH VEGF-C OR VEGF-D GROWTH FACTOR THERAPY TO TREAT SECONDARY LYMPHEDEMA AND TO IMPROVE RECONSTRUCTIVE SURGERY - The present invention provides materials and methods for repairing tissue and using vascular endothelial growth factor C (VEGF-C) genes and/or proteins. Methods and materials related to the use of VEGF-C for the reduction of edema and improvement of skin perfusion is provided. Also provided is are materials and methods for using VEGF-C before, during, and after reconstructive surgery.10-30-2008
20100040587CELLS FOR THERAPY OF THE HEART, METHOD OF OBTAINING A CELL PREPARATION, AND CELL PREPARATION - Fibroblast-like cells obtained from heart muscle biopsies, which are CD90 negative, CD105 positive, CD117 negative and/or CD166 positive as well as cell preparations of such cells for therapy of heart diseases, as well as a method for providing the latter. The cells are characterized by a good cultivability in cell culture. Furthermore a method for obtaining the cells and cell preparations according to the invention are disclosed.02-18-2010
20100119494METHODS AND COMPOSITIONS RELATED TO MODULATING THE EXTRACELLULAR STEM CELL ENVIRONMENT - This invention relates, in part, to methods and compositions that modulate the stem cell environment. More specifically, the invention relates, in part, to methods and compositions for modulating stem cell differentiation. Therefore, methods and compositions are provided for modulating glycosaminoglycan moieties, e.g., heparan sulfate glycosaminoglycan (HSGAG) moieties, in the microenvironment of stem cells. Methods and compositions for promoting or inhibiting embryonic stem cell differentiation (e.g., differentiation into endothelial cells) are also provided. This invention also relates, therefore, in part, to cell populations (e.g., endothelial cell populations or impoverished endothelial cell populations) that can be produced with the methods and compositions provided. Furthermore, the invention relates, in part, to tissues, and uses thereof, formed by the methods and compositions provided. Moreover, the invention also relates, in part, to methods of treatment using the methods and compositions provided.05-13-2010
20100119493Telencephalic Glial-Restricted Cell Populations and Related Compositions and Methods - Provided herein are telencephalic glial-restricted precursor cell populations and related compositions. Related compositions include, but are not limited to, any cell or cell population derived from a population of telencephalic glial-restricted precursor cells. Further provided are methods of using and producing telencephalic glial-restricted precursor cell populations and related compounds.05-13-2010
20120141437Cardiac Muscle Regeneration Using Mesenchymal Stem Cells - Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.06-07-2012
20120141438CARDIAC MUSCLE REPAIR OR REGENERATION USING BONE MARROW-DERIVED STEM CELLS - Disclosed are compositions and methods for repairing and/or regenerating cardiac tissue by administering adult bone marrow-derived stem cells to an individual. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.06-07-2012
20100266557NOVEL PEPTIDE-BASED SCAFFOLDS FOR CARTILAGE REGENERATION AND METHODS FOR THEIR USE - Disclosed herein are novel peptide amphiphile molecules and compositions composed of a peptide sequence that non-covalently binds the growth factor TGF-β1. Also disclosed are methods of using these peptide amphiphiles to create a gel scaffold in situ that enhances articular cartilage regeneration when used in combination with microfracture. Significant improvement in tissue quality and overall O'Driscoll histological scores were observed in rabbits with full thickness articular cartilage defects treated with the TGF-binding peptide amphiphile. The gel can further serve as a delivery vehicle for recombinant TGF-β1 protein growth factor. Scaffolds that localize and retain chondrogenic growth factors may synergistically enhance cartilage repair when combined with microfracture, by inducing bone marrow mesenchymal stem cells into chondrogenic differentiation. This invention represents a promising new biomimetic approach to enhance current techniques of articular cartilage regeneration in the clinical setting.10-21-2010
20080248000Stem Cells, Method For Their Purification, Identification, and Use - Herein is described a new population of circulating CD14+cells, with a low density surface expression of CD34 and endowed with stem capacity, a method for their purification and identification, and their therapeutic use.10-09-2008
20120189593METHODS FOR PROMOTING HSC ENGRAFTMENT - The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E07-26-2012
20120189588Compositions and Methods for Implantation of Processed Adipose Tissue and Processed Adipose Tissue Products - The invention provides compositions and methods for the preparation of processed adipose tissue. The invention further provides methods of use of the processed adipose tissue.07-26-2012
20080292600TREATMENT OF GRAFT-VERSUS-HOST DISEASE - This present application describes a therapeutic agent for treating acute or chronic graft-versus-host disease using clonal marrow stem cells (cMSCs) as active ingredient.11-27-2008
20090311222TRANSPLANTATION OF NEURAL CELLS - Restoration or increase of inhibitory interneuron function in vivo is achieved by transplantation of MGE cells into the brain. Compositions containing MGE cells are provided as are uses to treat various diseases characterised by abnormal inhibitory interneuron function or in cases where increase inhibition may ameliorate neural circuits that are abnormally activated.12-17-2009
20090311223TREATMENT OF ERECTILE DYSFUNCTION BY STEM CELL THERAPY - Methods, cells and compositions of matter are provided for treatment of erectile dysfunction using stem cell therapy. In particular, various stem cells are modified or administered freshly isolated in order to induce smooth muscle regeneration, neural regeneration, and restoration of endothelial function. In some embodiments endogenous stem cells are mobilized or activated to achieve therapeutic benefit. In other embodiments compositions derived from stem cells are utilized for treatment of erectile dysfunction.12-17-2009
20100266559STABILIZED, STERILIZED COLLAGEN SCAFFOLDS WITH ACTIVE ADJUNCTS ATTACHED - Bioimplants and methods of making the bioimplants are provided. The bioimplants comprise biological tissues having conjugated thereto adjunct molecules. The biological tissues are sterilized with a chemical sterilizing agent, such as a water soluble carbodiimide. The processes of making the bioimplants include a process in which an adjunct molecule is conjugated to a biological tissue during the sterilization process.10-21-2010
20090214489PEPTIDES AND COMPOUNDS THAT BIND TO A RECEPTOR - Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.08-27-2009
20120308535Pharmaceutical Composition Containing Expanded Adult Stem Cells and Methods of Using Same for Treatment - A method for the expansion of adult stem cells from blood, particularly but not only peripheral blood, involves removing adult stem cells from blood of a mammal, immediately expanding the stem cells via in-vitro treatment with MCSF (Macrophage Colony Stimulating Factor) at a concentration of about 8-15 nM, and purifying the expanded stem cells. Compositions and methods of using the expanded adult stem cells are also described.12-06-2012
20100119495HUMAN SKIN EQUIVALENTS EXPRESSING EXOGENOUS POLYPEPTIDES - The present invention relates generally to compositions for wound closure. More specifically, the present invention provides human skin equivalents engineered to express exogenous polypeptides (e.g., antimicrobial polypeptides and keratinocyte growth factor 2) and compositions and methods for making human skin equivalents engineered to express exogenous polypeptides. In addition, the present invention provides methods for treatment of wounds with human skin equivalents engineered to express exogenous polypeptides.05-13-2010
20100119492Method and device for activating stem cells - Invention embodiments described herein include methods and devices for stimulating mesenchymal stem cells in a stem cell source to differentiate into osteoblasts capable of forming bone. Devices and methods described include exposing a stem cell source, such as bone marrow aspirate, adipose tissue and/or purified allogenic stem cells, to an active agent, in a manner effective to form activated stem cells.05-13-2010
20100119489Stimulation of Pancreatic Beta Cell Proliferation - This invention provides a polypeptide, TMEM27, and secreted forms thereof, nucleic acids and constructs encoding the same, and cells comprising the same. The TMEM27 protein is expressed in hormone positive cells at early stages of pancreas development and pancreatic β-cells in the mature pancreas, whose expression promotes pancreatic β-cell replication and increased islet mass. Applications of the protein in diagnostics and therapeutics are described.05-13-2010
20100135966AGENTS FOR TREATING FLAVIVIRIDAE INFECTIONS - The invention relates to agents for the treatment, therapy and inhibition of Flaviviridae virus infections, which agents comprise proteasome inhibitors as the active component. The agents which are used for inhibiting the release, maturation and replication of Flaviviridae comprise, as the active component in pharmaceutical preparations, substance classes which share the common property of inhibiting the 26S proteasome in cells. These substance classes include, in particular, proteasome inhibitors which affect the activities of the ubiquitin/proteasome pathway, in particular the enzymic activities of the 26S and the 20S proteasome complex. The application of the invention lies in the antiviral therapy of Flaviviridae infections, especially in preventing the establishment and maintenance of a chronic hepatitis C virus infection and a hepatopathogenesis which is associated therewith.06-03-2010
20090087415Treatment of cardiovascular disorders using the cell differentiation signaling protein Nell1 - It has been identified in accordance with the present invention that Nell1 is essential for normal cardiovascular development by promoting proper formation of the heart and blood vessels. The present invention therefore provides therapeutic methods for treating cardiovascular disorders by employing a Nell1 protein or nucleic acid molecule.04-02-2009
20120269777COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS - The specification discloses compositions and methods for treating a soft tissue defect of an individual.10-25-2012
20100080778STEM CELL EXPANSION ENHANCING FACTOR AND METHOD OF USE - The present invention relates to a stem cell expansion factor, and to a method for enhancing hematopoietic stem cell expansion by direct delivery of a protein in the cell and which protein is able to cross cell membrane. The method comprises directly delivering in a HSC an amino acid sequence having the activity of a peptide encoded by a Hoxb4 nucleotide sequence. Once delivered, the amino acid sequence is functionally active in the hematopoietic stem cell and enhances expansion thereof. The amino acid sequence may is a HOXB4 or HOXA4 protein.04-01-2010
20100080780PLURIPOTENT AUTOLOGOUS STEM CELLS FROM ORAL MUCOSA AND METHODS OF USE - The present invention provides a new readily accessible source of adult somatic stem cells from the gastrointestinal tract in general and oral mucosa in particular, methods for isolating pluripotent stem cells from oral mucosa, cells derived therefrom and uses thereof.04-01-2010
20120294837METHODS OF ISOLATING AND CULTURING MESENCHYMAL STEM CELLS - Provided herein is a relatively pure population of mesenchymal stem cells (MSCs) expressing the Notch 2 receptor (Notch 2+ a MSCs). Also provided is a method of isolating from a subject a population of Notch 2+ MSCs and a method of culturing the population of Notch 2+ MSCs. Also provided is a method of treating a subject with a disorder associated with a deficiency or defect in cells of mesenchymal lineage comprising administering a population of Notch 2+ MSCs to the subject.11-22-2012
20120269775Adipose Stromal Stem Cells For Tissue And Vascular Modification - Methods are provided for promoting angiogenesis in a mammal, such methods including the administration of therapeutic quantity of adipose-derived stromal cells to a mammal such that therapeutic angiogenesis occurs.10-25-2012
20120269776PRODUCTIONS OF ARTIFICIAL TISSUES BY MEANS OF TISSUE ENGINEERING USING AGAROSE-FIBRIN BIOMATERIALS - The present invention is encompassed in the field of biomedicine and more specifically tissue engineering. It relates specifically to an in vitro method for preparing an artificial tissue, to the artificial tissue obtainable by said method and to the use of this artificial tissue to partially or completely increase, restore or replace the functional activity of a damaged tissue or organ.10-25-2012
20120269774ALLOGENEIC STEM CELL TRANSPLANTS IN NON-CONDITIONED RECIPIENTS - Methods, cells, and compositions of matter are disclosed for performing stem cell transplants in patients that have not been previously immunosuppressed. Specific disclosed are methods of matching, methods of treating the stem cell graft, and use of engraftment-assisting cells and agents.10-25-2012
20090162326METHOD FOR ISOLATING STEM CELLS AND STEM CELLS DERIVED FROM A PAD-LIKE TISSUE OF TEETH - The invention relates to a method for isolating non-embryonic stem cells from a tissue that is located in immediate vicinity of immature, developing teeth or wisdom teeth. The invention further relates to non-embryonic stem cells derived from said tissue. The method according to the invention utilises a living soft tissue residing underneath the dental papilla 12 in immediate vicinity of the apical side of a developing tooth, which is clearly distinguished from other tooth tissue, such as dental papilla 12 or follicle. The pad-like tissue 16 can only be detected in a defined, specific developmental stage in an early phase of root formation. That is, identifying and separating the pad-like tissue 16 is only possible from the appearance of the bony alveolar fundus to the end of the formation of the root of the tooth.06-25-2009
20100098669USE OF ADIPOSE TISSUE-DERIVED STROMAL STEM CELLS IN TREATING FISTULA - Provided herein are novel methods and compositions utilizing adipose tissue-derived stromal stem cells for treating fistulae.04-22-2010
20100098670Autologous dental pulp stem cell-based bone graft substitute - The invention features methods and compositions for promoting the growth and differentiation of dental pulp stem cells and the use of the differentiated cells for the treatment of orthopedic conditions.04-22-2010
20100098673BONE GRAFT COMPOSITES AND METHODS OF TREATING BONE DEFECTS - Bone graft compositions comprising demineralized bone matrix, calcium phosphate, collagen and bioinductive cellular solution. Methods to repair and heal defective and missing bone using the bone graft compositions are also described.04-22-2010
20100098671 COMPOSITION FOR PREVENTION OR TREATMENT OF BONE MARROW DAMAGE - Disclosed herein are a composition for prevention or treatment of bone marrow damage comprising Substance-P as an active ingredient; a use of Substance-P for the preparation of a medicament for prevention or treatment of bone marrow damage; a method for prevention or treatment of bone marrow damage comprising administering a therapeutically effective amount of Substance-P to a mammal; an anticancer supplement comprising Substance-P as an active ingredient; a use of Substance-P for the preparation of an anticancer supplement; and a method for prevention or treatment of cancer comprising administering a therapeutically effective amount of Substance-P as an anticancer supplement to a mammal.04-22-2010
20120107282NEURAL STEM CELL COMPOSITION CAPABLE OF TREATING CANCER AND METHOD OF TREATMENT - Disclosed is a method of treatment of an individual suffering from primary brain tumors (glioma and medulloblastoma) and brain metastases of extracranial cancers using human stem cells encoding therapeutic genes. The method includes giving the individual a clinically acceptable therapeutic reagent by intravascular injection of a pharmaceutical composition. The pharmaceutical composition includes neural stem cells (NSCs) genetically engineered to express a suicide gene (cytosine deaminase) and a cytokine gene (IFN-β) and a pharmaceutical carrier suitable for injection. The NSCs migrate selectively to tumor site in the brain, target tumor cells, kill tumor cells, inhibit tumor growth and thus treat the tumor.05-03-2012
20120107281COMPOSITIONS AND METHODS FOR MODIFYING CELL SURFACE GLYCANS - Methods and compositions for modifying glycans (e.g., glycans expressed on the surface of live cells or cell particles) are provided herein.05-03-2012
20090142308Methods for treating autoimmune disease by inducing autoantigen-specific regulatory CD4+ T cells - Described herein are methods and compositions for the treatment and monitoring the progress of autoimmune diseases. In some embodiments, the methods include the stimulation of regulatory T cells specific to autoantigens associated with the autoimmune disease. A specific embodiment relates to diabetes mellitus, and the prevention or delay of loss of residual β-cell mass, providing a longer remission period and delaying the onset of diabetes related, progressive, complications through immunotherapeutic induction of regulatory T cells specific for human insulin B chain. In addition, the methods described herein can be used to predict whether a subject, e.g., a subject with ongoing anti-insulin autoimmunity, will progress to T1DM, and to evaluate a subject's response to a therapeutic intervention.06-04-2009
20090263363Compositions and Methods For Treating Bone Formation Disorders - The present invention relates to compositions and methods for the detecting, treating, and empirically investigating disorders associated with bone formation (e.g., osteoporosis). In particular, the present invention provides compositions and methods for using maspin and targets of maspin in the diagnosis, treatment, and empirical investigation of disorders associated with bone formation (e.g., osteoporosis).10-22-2009
20090263361HUMAN TROPHOBLAST STEM CELLS AND USE THEREOF - Existence of human trophoblast stem (hTS) cells has been suspected but unproved. The isolation of hTS cells is reported in the early stage of chorionic villi by expressions of FGF4, FGFR-2, Oct4, Thy-1, and stage-specific embryonic antigens distributed in different compartments of the cell. hTS cells are able to derive into specific cell phenotypes of the three primitive embryonic layers, produce chimeric reactions in mice, and retain a normal karyotype and telomere length. In hTS cells, Oct4 and fgfr-2 expressions can be knockdown by bFGF. These facts suggest that differentiation of the hTS cells play an important role in implantation and placentation. hTS cells could be apply to human cell differentiation and for gene and cell-based therapies.10-22-2009
20090263359Particulate Delivery Vehicles for Embryoid Bodies - The present invention provides a vehicle for delivering various chemicals, compositions and proteins to stem cells and embryoid bodies. The vehicle may be biocompatible and biodegradable polymer microparticles. Typically the particles will contain at least a growth factor for delivery to the embryoid bodies, and generally the growth factor induces differentiation of the cells in the embryoid body along a specific lineage. The present invention also provides methods for directing differentiation of the cells in the embryoid body.10-22-2009
20090263358METHOD FOR TREATING MULTIPLE MYELOMA - The present invention relates to methods for the treatment of multiple myeloma. More particularly, the present invention relates to a method for inducing apoptosis in myeloma cells by administration of a K121-like antibody.10-22-2009
20090104163Immunomodulatory Properties of Multipotent Adult Progenitor Cells and Uses Thereof - Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.04-23-2009
20090047260KERATIN BIOMATERIALS FOR CELL CULTURE AND METHODS OF USE - Provided herein are cell culture substrates and microcarriers that include a keratin, e.g., in porous particulate form. The substrate may be provided in or further includes a liquid carrier and/or viable cells. The keratin may be alpha kerateines, gamma kerateines, and combinations thereof, and may be in the form of a meta keratin. In some embodiments, the keratin is acidic or basic. Methods of administering cultured cells are also provided, including administering the cell culture substrates or microcarriers to a subject in need thereof. Kits are further provided, and may include a suitable container; a plurality of cell culture substrates or microcarriers as described herein packaged into said container; and optionally, instructions for use.02-19-2009
20090047257Novel cell populations and uses thereof - The invention provides, among other things, novel cell populations of CD13302-19-2009
20090047259Methods of Using the Calcineurin A Variant CnA-beta 1 - The present invention relates to an inhibitor or activator of the calcineurin subunit Aβ1 isoform (CnAβ1) and the production of a medicament for the treatment of skeletal muscle injury or degeneration or cancer in a subject. CnAβ1 is constitutively active, cyclosporin-insensitive, highly expressed in proliferating myoblasts and human tumors, where it inhibits FoxO transcription factors independently of its phosphatase activity. The CnAβ1 isoform is a candidate for interventional strategies in muscle wasting, and a target for cancer treatment.02-19-2009
20090202499Human Telomerase Reverse Transcriptase Peptides - Tumor antigens can be categorized as tumor type specific or common. Telomerase reverse transcriptase (TRT) is the first bona fide common tumor antigen. While several 9mer peptides of the human TRT (hTRT) have been identified for HLA-A2, the most prevalent (˜50%) HLA type in humans, little information exists on peptides for the remaining HLA types. As described herein, a multi-step approach was taken to select and characterize a panel of HLA-B79mer peptides as candidate immunogens. Specifically, several of algorithm based predictions, in vivo immunization of HLA-B7 transgenic mice, in vitro immunization of human blood lymphocytes, in vivo processing and supertype binding were employed to identify HLA-B7-restricted epitopes in hTRT. A correlation between in vivo immunogenicity and actual HLA-B7 binding avidity was found for the seven predicted peptides. Furthermore, endogenous processing was found to correlate with in vitro immunogenicity in human PBMC and HLA-B7 supertype binding.08-13-2009
20110200565VIRUS CLEARANCE OF NEOPLASTIC CELLS FROM MIXED CELLULAR COMPOSITIONS - The present invention relates to a method for removing neoplastic cells from a mixed cellular composition, which is outside of a living organism, by using a virus which selectively infect and kill neoplastic cell. A variety of viruses can be used in this method to remove neoplastic cells for different purposes, for example, to purge hematopoietic stem cells prior to transplantation. Also provided are compositions prepared according to this method, and kits comprising a combination of viruses which are useful in this invention.08-18-2011
20110200566Compositions and Methods for the Treatment of Vitiligo - Compositions and methods for darkening skin and treating vitiligo are provided.08-18-2011
20090142307Shape-Based Approach for Scaffoldless Tissue Engineering - Methods for forming tissue engineered constructs without the use of scaffolds and associated methods of use in tissue replacement. One example of a method may comprise providing a shaped hydrogel negative mold; seeding the mold with cells; allowing the cells to self-assemble in the mold to form a tissue engineered construct.06-04-2009
20090142309Hydroxyphenyl cross-linked macromolecular network and applications thereof - A dihydroxyphenyl cross-linked macromolecular network is provided that is useful in artificial tissue and tissue engineering applications, particularly to provide a synthetic macromolecular network for a wide variety of tissue types. In particular, artificial or synthetic cartilage, vocal cord material, vitreous material, soft tissue material and mitral valve material are described. In an embodiment, the network is composed of tyramine-substituted and cross-linked hyaluronan molecules, wherein cross-linking is achieved via peroxidase-mediated dityramine-linkages that can be performed in vivo. The dityramine bonds provide a stable, coherent hyaluronan-based hydrogel with desired physical properties.06-04-2009
20090291067Composition for treating cancer comprising adult stem cell culture or its fraction - The present invention provides a pharmaceutical composition for treating cancer, comprising a culture of adult stem cells or a fraction of the culture as an active ingredient. The culture of adult stem cells and its fraction, especially a specific fraction of adult stem cell culture, inhibit proliferation of a variety of cancer such as melanoma, pancreatic cancer, breast cancer, hepatic cancer, gastric cancer, colon cancer, lung cancer, and cervical cancer, thereby having excellent cancer-treating activity. The composition according to the present invention includes, not stem cells, but a complex of active proteins secreted from the stem cells, and thus both pharmaceutical problems in formulation and individual variation, which usually occurred when using stem cells, can be minimized. And also, side effects caused by direct administration of cells into the human bodies can be thoroughly prevented.11-26-2009
20080206209MYELINATION OF CONGENITALLY DYSMYELINATED FOREBRAINS USING OLIGODENDROCYTE PROGENITOR CELLS - One form of the present invention is directed to a method of remyelinating demyelinated axons by treating the demyelinated axons with oligodendrocyte progenitor cells under conditions which permit remyelination of the axons. Another aspect of the present invention relates to a method of treating a subject having a condition mediated by a loss of myelin or a loss of oligodendrocytes by administering to the subject oligodendrocyte progenitor cells under conditions effective to treat the condition mediated by a loss of myelin or a loss of oligodendrocytes. A further aspect of the present invention relates to an in vitro method of identifying and separating oligodendrocyte progenitor cells from a mixed population containing other mammalian brain or spinal cord cell types. This further aspect of the present invention involves removing neurons and neuronal progenitor cells from the mixed population to produce a treated mixed population. Oligodendrocyte progenitor cells are then separated from the treated mixed population to form an enriched population of oligodendrocyte progenitor cells.08-28-2008
20080206207Intracoronary Device And Method Of Use Thereof - Engraftment of therapeutic cells and agents to a target site in an organism is enhanced by mechanical, chemical and biological methods and systems.08-28-2008
20080206208EXTRAMEDULLARY ADIPOSE TISSUE CELLS AND USE THEREOF FOR REGENERATING HEMATOPOIETIC AND MUSCULAR TISSUES - The invention concerns cells derived from the cellular fraction of the vascular stroma of the extramedullary adipose tissue, methods for preparing them and their use in regeneration of hematopoietic lines and cardiac and skeletal muscular tissues, in particular for treating genetic or acquired hemopathies, myopathies and cardiomypathies.08-28-2008
20090110669METHODS FOR IMPROVING CELL LINE ACTIVITY IN IMMUNOISOLATION DEVICES - Methods for maintaining and improving the secretory activity of cells housed in immunoisolation devices.04-30-2009
20090274668Combined Regulation of Neural Cell Production - This invention relates to a method of selectively producing neural cells, including neurons or glial cells, in vitro or in vivo. Also provided are methods of treating or ameliorating neurodegenerative disease or medical conditions by producing neural cells. Thus, a combination of factors is used to achieve two steps: increasing the number of neural stem cells and instructing the neural stem cells to selectively become neurons or glial cells.11-05-2009
20090274663Materials and Methods Relating to Cell Based Therapies - The invention provides a novel multipotent cell population of adult origin that can be used to treat ageing and disease, particularly by transplantation to site of cellular damage.11-05-2009
20130216508HUMAN LUNG STEM CELLS AND USES THEREOF - Embodiments of the invention relate to human stem cells and their therapeutic use in the treatment and/or prevention of lung diseases. Provided herein are compositions comprising c-kit positive human lung stem cells and methods of preparing and using c-kit positive human lung stem cells for the treatment and/or prevention of lung diseases.08-22-2013
20090104162Attenuated reoviruses for selection of cell populations - The present invention relates to methods for killing neoplastic cells, such as ras-activated cancerous cells, in vitro. In particular embodiments, an attenuated reovirus (e.g., a reovirus lacking a wild-type S1 gene) may be administered to a mixed cellular composition comprising cancerous cells and stem cells such as adult stem cells and/or hematopoietic stem cells; in these embodiments, the attenuated reovirus may result in killing of the cancerous cells with little or no damage to the healthy stem cells.04-23-2009
20090285786METHOD TO MODULATE HEMATOPOIETIC STEM CELL GROWTH - The present invention provides for compositions and methods for modulating hematopoietic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E2 (PGE2) and agents that stimulate the PGE2 pathway. Conversely, HSC modulators that prevent PGE2 synthesis decrease HSC numbers. HCS modulators may be used in vitro, in vivo, or ex vivo.11-19-2009
20090285785External Agent for Treatment of Skin Ulcer - [Problems] To provide a novel external agent for treatment of skin ulcer which has an excellent healing effect on intractable skin ulcer such as bedsore, diabetic skin ulcer and ischemic skin ulcer.11-19-2009
20100278788Osteogenic Differentiation Of Bone Marrow Stem Cells And Mesenchymal Stem Cells Using A Combination Of Growth Factors - The invention relates to methods for osteogenic differentiation of human bone marrow stem cells (BMSC) or mesenchymal stem cells (MSC), in particular using human plasma or serum and FGF and TGFB growth factors. The invention also provides the so-obtained cells and cell populations, as well as further products comprising such and uses thereof in bone therapy.11-04-2010
20110171181METHODS FOR MODIFYING VASCULAR VESSEL WALLS - This invention relates in one aspect to the treatment of a vascular vessel with a biomaterial. The biomaterial can be a remodelable material that strengthens and/or supports the vessel walls. Additionally the biomaterial can include a variety of naturally occurring or added bioactive agents and/or viable cellular populations.07-14-2011
20090291066 COMPOSITION AND METHOD OF TREATING FACIAL SKIN DEFECT - This invention relates to a subcutaneous deliverable composition containing an agonist of the peroxisome proliferator-activated receptor-gamma, and a method for treating facial skin defects in a mammalian subject using the subcutaneous deliverable composition.11-26-2009
20090169525METHODS OF REDUCING TRANSPLANT REJECTION AND CARDIAC ALLOGRAFT VASCULOPATHY BY IMPLANTING AUTOLOGOUS STEM CELLS - The invention provides novel methods of reducing transplant rejection and cardiac allograft vasculopathy in humans by employing the implantation of autologous progenitor cells into the transplanted donor heart. The autologous progenitor cells can be vascular progenitor cells (VPCs) and/or myocyte progenitor cells (MPCs) isolated from the recipient's explanted heart. Alternatively, bone marrow progenitor cells (BMPCs) isolated from the recipient may also be used.07-02-2009
20090269310METHOD FOR OBTAINING HUMAN SMOOTH MUSCULAR CELLS AND USES THEREOF - The invention concerns a method for obtaining in vitro a population of cells comprising essentially human smooth muscular cells expressing calponin and SM-MHC from a sample of human muscular biopsy or from human muscular biopsies differentiated in vitro into skeletal muscle cells. The invention also concerns a composition comprising the isolated smooth muscular cells obtainable by said method as therapeutic principle designed for humans. The invention further concerns the use of the isolated smooth muscular cells for preparing a therapeutic composition designed to replace smooth muscular cells. In particular, the invention concerns the use of said isolated smooth muscular cells for treating ischemia, cancer or any disease requiring revascularization of damaged tissues. Finally, the invention concerns the use of said smooth muscular cells as vector for an active principle for preparing a therapeutic composition designed for humans requiring treatment with said active principle.10-29-2009
20120121551COMPOSITIONS AND METHODS FOR IMMUNOSTIMULATORY RNA OLIGONUCLEOTIDES - The present invention provides 4-nucleotide (4mer) RNA motifs that confer immunostimulatory activity, in particular, IFN-α-inducing activity to a RNA oligonucleotide. The present invention also provides RNA oligonucleotides, including siRNA, with high or low immunostimulatory activity. The present invention further provides the use of the RNA oligonucleotides of the invention for therapeutic purposes.05-17-2012
20110200564DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE (AD) - Disclosed herein are novel methods, assays and systems for detecting an increased risk for Alzheimer's disease (AD) in a subject by identifying at least one nuclei acid polymorphism described herein in a biological sample from the subject. Levels of the genes associated with the nucleic acid polymorphism described herein are also determined for detection of higher risk for AD. Disclosed herein further provides methods for treating AD by administering to a subject in need thereof with ATXN1.08-18-2011
20100111906VOLUME MAINTAINING OSTEOINDUCTIVE/OSTEOCONDUCTIVE COMPOSITIONS - An osteoinductive/osteoconductive composition prepared from a quantity, of demineralized fibrous bone elements possessing an average surface area to volume ratio of about 100:1 to about 20:1, a quantity of mostly shaped regular non-fibrous bone elements possessing an average surface area to volume ratio of about 10:1 or less and a sufficient quantity of biocompatible fluid carrier sufficient to provide the composition as a deformable mass is provided herein. Also provided is a method of using the composition to repair a bone defect site.05-06-2010
20100111905METHODS FOR IMPROVED ENGRAFTMENT FOLLOWING STEM CELL TRANSPLANTATION - The present invention relates to methods repairing, regenerating, and reconstituting tissues by transplanting at least two stem cell populations, wherein the first and the second population of stem cells are introduced into a subject separated by a time interval of about 2 to about 24 hours. The stem cells can be derived from umbilical cord, mobilized peripheral blood, or bone marrow. The cells of at least the second population may be enriched for adult stem and progenitor cells. The methods of the invention are useful in accelerating hematopoeitic recovery in subjects following myeloablation or chemotherapy.05-06-2010
20080213229Fibrin Contained Semi-Solid Osteoblast Composition for Curing Bone Fracture and Method for Producing the Same - A method for producing the fibrin contained semi-solid osteoblast composition has developed for treating the bone fracture. The method is comprised of: isolating osteoblasts from a bone tissue and culturing/proliferating the isolated osteoblasts in Dulbecco's Modified Eagle's Medium (DMEM) or Minimum Essential Medium, Alpha Modification (α-MEM) to prepare an osteoblast suspension. Then, mixing the resulting osteoblast suspension with a coagulation factor to prepare an osteoblast therapeutic agent. Accordingly, the fibrin contained semi-solid osteoblast composition of the present invention has capability to achieve the bone grafting for performing bone union without the clinical graft rejection. It is possible to uniformly distribute the fibrin mixed semi-solid osteoblast composition into the affected area of the bone fracture via injection. Therefore, the fibrin contained semi-solid osteoblast composition is effectively and rapidly cure the bone fracture via constant injection of into the affected area.09-04-2008
20080213228Methods and Compositions for Treatment of Bone Defects with Placental Cell Populations - Provided herein are methods of using adherent placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. Also provided herein are methods of differentiating the placental stem cells. Further provided herein are methods of using the placental stem cells to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with stem cells and compositions comprising stem cells.09-04-2008
20100061962Tissue Engineered Cartilage, Method of Making Same, Therapeutic and Cosmetic Surgical Applications Using Same - Cartilage has been constructed using biodegradable electrospun polymeric scaffolds seeded with chondrocytes or adult mesenchymal stem cells. More particularly engineered cartilage has been prepared where the cartilage has a biodegradable and biocompatible nanofibrous polymer support prepared by electrospinning and a plurality of chondocytes or mesenchymal stem cells dispersed in the pores of the support. The tissue engineered cartilages of the invention possess compressive strength properties similar to natural cartilage. Methods of preparing engineered tissues, including tissue engineered cartilages, are provided in which an electrospun nanofibrous polymer support is provided, the support is treated with a cell solution and the polymer-cell mixture cultured in a rotating bioreactor to generate the cartilage. The invention provides for the use of the tissue engineered cartilages in the treatment of cartilage degenerative diseases, reconstructive surgery, and cosmetic surgery.03-11-2010
20100278785INJECTION DEVICE FOR INJECTION INTO BIOLOGICAL TISSUE AND INJECTION DEPOT - An injection device (11-04-2010
20100278783Method of Preparing Autologous Cells and Method of Use for Therapy - A method for expanding mesenchymal cells derived from autologous bone marrow in autologous culture medium which can be used in a clinical setting, and a business method for performing such expansions in the future as a service for patients. A method for expanding mesenchymal cells derived from autologous bone marrow in autologous culture medium including a diagnostic kit for the autologous cell therapy to determine whether a patient will respond to the autologous cell therapy for treatment of a disease, in which said kit comprising a system for detecting gene and protein expression comprising at least two isolated DNA molecules wherein each isolated DNA molecule detects expression of a gene that is differentially expressed in the tissue of the patient that is intended to be the source of the autologous cell therapy.11-04-2010
20100278787CARDIOMYOCYTE-LIKE CELL CLUSTERS DERIVED FROM HBS CELLS - A cluster is provided comprising cardiomyocyte-like cells, wherein the cluster has i) contracting cells, ii) cells that are electrically connected, and expresses iii) cardiac markers including Nkx.2.5, troponin and myosin, iv) markers for functional adrenergic receptors, v) markers for functional muscarinic receptors, vi) markers for functional ion-channels including hERG, Na+, Ca11-04-2010
20090041730Joint Repair Using Mesenchymal Stem Cells - A method of repairing and/or stabilizing a joint by administering mesenchymal stem cells to the joint. Such a method provides for the regeneration of cartilaginous tissue in the joint, including meniscal tissue.02-12-2009
20090169528KERATINOCYTES EXPRESSING EXOGENOUS ANGIOGENIC GROWTH FACTORS - The present invention relates to in vitro cultured skin tissue, and in particular to cultured skin tissue comprising exogenous genes encoding angiogenic growth factors. In some embodiments, the keratinocytes express exogenous angiopoietin-1 or a member of the VEGF family, preferably VEGF-A. In particularly preferred embodiments, the keratinocytes are incorporated into cultured skin tissue.07-02-2009
20090169526BMP-6 ESTROGEN RESPONSIVE ELEMENT AND METHODS OF USE THEREOF - This invention is directed to a BMP-6 ERE nucleic acid sequence, vectors, cells and compositions comprising same. This invention also provides methods for identification of estrogen agonists, antagonists and therapeutic applications of same. This invention also provides methods of treating conditions, which are associated with estrogen insufficiency or with lack of response to external estrogen or agonists thereof utilizing sequences, vectors, cells and/or compositions described herein.07-02-2009
20090169524COMPOSITES AND METHODS OF PREPARATION AND USE THEREOF - The invention provides composites, methods for their preparation, composites prepared according to the methods, and methods for using the composites.07-02-2009
20080241106Method for Preventing and Treating Diabetes Using Neurturin - The present invention relates generally to methods for preventing and/or treating pancreatic disorders, particularly those related to diabetes, by administering a neurturin protein product.10-02-2008
20080241109Method for Ex-Vivo Purging in Autologous Transplantation - The present invention concerns a new method for ex-vivo purging of cells in autologous transplantation, wherein the sample of taken cells is treated with a sufficient amount of a multimeric form of the soluble portion of FasL to kill malignant cells without substantially affecting viability of cells to be transplanted. Autologous stem cell transplantation (ASCT) following high-dose chemotherapy with or without radiotherapy has become the standard therapy for the majority of patients with large-cell lymphomas, multiple myeloma, and refractory/recidivating Hodgkin's disease. Such therapy is nowadays also contemplated for selected patients with low-grade lymphomas (chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma) and for patients with acute myeloid leukemia (AML). Current treatments for cell purging include chemotherapy and antibody cocktails. These treatments are often toxic on stem cells and not efficient in eliminating cancer cells. Thus, there is an unmet medical need for cell purging in ASCT which this project will address.10-02-2008
20080241107Methods and Compositions For Preparing Pancreatic Insulin Secreting Cells - The present invention concerns the use of transdifferentiated cells to treat pancreatic diseases. More particularly, it provides methods for the culture and transdifferentiation of human cord blood, cells into insulin-secreting cells. It also concerns the endocrine hormones, such as insulin, produced by such cultures, and the use of the transdifferentiated cells in the treatment of diabetes.10-02-2008
20110200562Chimeric Cytokine of IL-7 and Beta Chain of HGF and Methods of Use - The present invention relates to a single-chain or chimeric polypeptide comprising a cytokine and a growth factor linked by at least one amino acid residue, and wherein the chimeric polypeptide enhances the proliferation and/or differentiation of hematopoietic precursor cells. In particular the invention relates to, a chimeric polypeptide comprising the beta-chain of hepatocyte growth factor, and IL-7 linked by at least one amino acid, and wherein the chimeric polypeptide demonstrates pre-pro-B proliferation and growth stimulating activity.08-18-2011
20080233088PREPARATIVE REGIMEN FOR ENGRAFTMENT, GROWTH AND DIFFERENTIATION OF NON-HEMATOPOEITIC CELLS IN VIVO AFTER TRANSPLANTATION - The invention relates to methods of obtaining an expanded population of mammalian ex vivo cells and/or for treating a mammalian subject by (a) administering to a subject an effective amount of an agent that confers a growth disadvantage to at least a subset of endogenous cells at the site of engraftment; (b) administering to the subject an effective amount of a mitogenic stimulus for the ex vivo cells; and (c) administering the ex vivo cells to the subject, wherein the ex vivo cells engraft at the site and proliferate to a greater extent than the subset of endogenous cells, to repopulate at least a portion of the engraftment site with the ex vivo cells. The repopulated cells can be harvested for further use or be left at the engraftment site of a subject to be treated. The invention also provides methods of treating brain injury in a subject by engrafting ex vivo cells at the site of injury.09-25-2008
20100129328METHODS FOR PROMOTING HAIR GROWTH - The invention is directed to methods for promoting hair growth. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), cell lysates derived therefrom, and cell products derived therefrom, each alone or in combination.05-27-2010
20100129329METHODS FOR USING ALDHbr CELLS TO SUPPLEMENT STEM CELL TRANSPLANTATION - The present invention relates to methods repairing, regenerating, and reconstituting tissues by transplanting at least two stem cell populations, wherein the first and the second population of stem cells are introduced into a subject separated by a time interval of about 2 to about 24 hours. The first population comprises stem cells derived from umbilical cord. The second population comprises ALDHbr cells. These ALDHbr cells can be administered to a patient immediately after isolation or can be primed in culture using a combination of cytokines for about 2 to about 7 days prior to transplantation. The methods of the invention are useful in accelerating time to neutrophil and/or platelet engraftment and immune reconstitution following myeloablative therapy.05-27-2010
20110268708ADIPOSE TISSUE-DERIVED STEM CELLS FOR VETERINARY USE - The invention provides for compositions and methods for making and using adipose-derived stem cells for treating non-human mammals for various medical conditions.11-03-2011
20110268706PREPARATION METHOD OF POROUS HYALURONIC ACID SPONGE FOR CELL DELIVERY SYSTEM - Provided is a preparation method of a porous hyaluronic acid sponge comprising the steps of: dissolving hyaluronic acid in an aqueous sodium hydroxide solution; adding an epoxy-based crosslinking agent to the resultant aqueous sodium hydroxide solution in which hyaluronic acid is dissolved and homogenizing the hyaluronic acid solution; hydrogelating the homogenized hyaluronic acid solution; washing the hydrogelated hyaluronic acid hydrogel with ultrapure water; swelling the washed hyaluronic acid hydrogel to attain porosity; and freeze-drying the hyaluronic acid hydrogel to obtain a porous hyaluronic acid sponge.11-03-2011
20120294836HIGH YIELD METHOD AND APPARATUS FOR VOLUME REDUCTION AND WASHING OF THERAPEUTIC CELLS USING TANGENTIAL FLOW FILTRATION - The present invention provides processes for aseptically processing live mammalian cells in an aqueous medium to produce a cell suspension having a cell density of at least about 10 million cells/mL and cell viability of at least about 90%. These methods comprise a step of reducing the volume of the medium using a tangential flow filter (TFF) having a pore size of greater than 0.1 micron, during which step the trans-membrane pressure (TMP) is maintained at less than about 3 psi and the shear rate is maintained at less than about 4000 sec11-22-2012
20090047256Biodegradable Elastomers - The present inventions in various aspects provide elastic biodegradable polymers. In various embodiments, the polymers are formed by the reaction of a multifunctional alcohol or ether and a difunctional or higher order acid to form a pre-polymer, which is cross-linked to form the elastic biodegradable polymer. In preferred embodiments, the cross-linking is performed by functionalization of one or more OR groups on the pre-polymer backbone with vinyl, followed by photopolymerization to form the elastic biodegradable polymer composition or material. Preferably, acrylate is used to add one or more vinyls to the backbone of the pre-polymer to form an acrylated pre-polymer. In various embodiments, acrylated pre-polymers are co-polymerized with one or more acrylated co-polymers.02-19-2009
20080274089Inflammation - This invention provides adult neural stem cell (aNSC) materials and methods for treating central nervous system disorders.11-06-2008
20080274087BRAIN TISSUE DAMAGE THERAPIES - A cultured pluripotent animal cell that is CD13+, CD90+, and CD117−. Also disclosed are methods for making the cell and methods of treating a brain tissue damage and increasing the expression level of a neuraltrophic factor in a subject.11-06-2008
20080286245PREPARATION OF REGULATORY T CELLS USING ICAM-1 CO-STIMULATION - A method for generating a purified regulatory T cell composition having a CD411-20-2008
20080286243Method For Isolation of a Hair Follicle Stem Cell and a Composition For Hair Reproduction - The present invention relates to a method for isolating hair follicle stem cells and a composition for inducing hair growth. More specifically, relates to a method for isolating hair follicle stem cells showing a positive immunological response to CD34, by chemically degrading hair follicle-containing scalp tissue and then culturing the degraded tissue in a serum-containing medium and a serum-free medium, as well as a composition for inducing hair growth, which contains, as an active ingredient, CD34-positive hair follicle stem cells isolated by the method. The hair follicle-derived stem cells, which are obtained according to the disclosed method, are classified as autologous adult stem cells, have self-renewal capability, the ability to differentiate into adult hair follicle cells and the ability to induce hair growth, and can be used as a novel cell therapeutic agent against hair loss. In addition, the present invention relates to a method for culturing hair follicle cells, which has high yield compared to that of the prior art, as well as a method for identifying hair follicle stem cells.11-20-2008
20080286241Transplantation of Differentiated Immature Adipocytes and Biodegradable Scaffold for Tissue Augmentation - Provided is a technology involving differentiating preadipocytes, derived from human adipose tissues, into adipocytes and transplanting the differentiated adipocytes in conjunction with a biodegradable scaffold into the body. According to the present invention, when immature adipocytes having a cell diameter of 20 to 40 μm, obtained by differentiation of adipose tissue-derived preadipocytes into adipose tissues, are used in conjunction with a scaffold in autologous or allogeneic transplantation, maturation of adipocytes at the target transplantation site leads to a gradual increase in the volume of adipocytes. Therefore, the adipocyte-scaffold composition according to the present invention can be utilized as an effective body volume replacement and can treat various disorders due to defects of soft tissues or aesthetic defects in appearance.11-20-2008
20120141429Method for stimulating osteogenesis - Nanostructures such as nanowires, nanosprings, nanorods, and nanoparticles, when maintained in contact with a source of bone cells, enhance the proliferation of the bone cells and integration bone into the nanostructures. The nanostructures may or may not be coated with a metal or metal oxide coating and preferably are textured. Such coated or non-coated nanostructures may be utilized on the surface of bone implants to enhance osseointegration of the implants.06-07-2012
20080292599Chondrogenic Compositions and Methods of Use - The invention provides a method of treatment joint and disk disease comprising administering to the subject in need thereof a novel composition comprising a substantially purified plurality of cells enhanced with at least one bioactive factor capable of causing at least a portion of the plurality of cells to express an increased amount of at least one chondrogenic marker.11-27-2008
20080292597Umbilical Cord Stem Cell Composition & Method of Treating Neurological Diseases - A neurological disease is treated by administering to a patient a therapeutically effective amount of a composition including human umbilical cord stem cells. The composition may include growth factors mixed with the stem cells immediately prior to being administered. A specific pre and post transplantation protocol provides optimal methods for obtaining favorable clinical results.11-27-2008
20100183560Angiogenesis-modulating compositions and uses - Hedgehog agonists and antagonists can be used to regulate angiogenesis, and have utility in treating tissue repair and cancer, and to prevent angiogenesis driven pathologies.07-22-2010
20100034779COMPOSITIONS AND METHODS FOR PRODUCING PLURIPOTENT CELLS FROM ADULT TESTIS - The present application describes a method of producing embryonic stem cell (ESC)-like cells derived from adult mammalian testis. Furthermore, the application describes to a method of producing embryoid bodies from ESC-like cells as well as a method of producing a tissue and/or a differentiated cell from the ESC-like cell or the embryoid body. In addition, an ESC-like cell, an embryoid body and/or differentiated cell and/or tissue obtainable by said methods and pharmaceutical preparations containing the same are provided. Finally, the application describes to the use of these products for medical treatments and the preparation of pharmaceutical compositions for medical treatments.02-11-2010
20100034782Methods of Using Anti-Thymocyte Globulin and Related Agents - Uses for anti-thymocyte globulin (ATG, e.g., Thymoglobulin®) and related compositions are described. In one aspect, ATG and, optionally, TGF-beta are used for in vitro generation of regulatory T cells, which are useful for cell therapy of immune-mediated conditions. In another aspect, ATG is directly administered to a subject at a low dose (e.g., less than 1 mg/kg per day) to treat an immune-mediated condition. The immune-mediated conditions include, for example, transplant rejection, graft-versus-host disease, and autoimmune diseases.02-11-2010
20080311087Human Umbilical Tissue-Derived Cell Compositions for the Treatment of Incontinence - Compositions for the treatment of incontinence are disclosed. More particularly, compositions of human umbilical tissue-derived cells and a carrier are disclosed. The compositions are useful in the treatment urinary and fecal incontinence.12-18-2008
20080311086Use of Keratinocyte Composition for the Treatment of Restenosis - Methods for treating and/or preventing restenosis in a subject by local administration to the subject of a composition that includes keratinocytes is disclosed. Administration is preferably by way of a catheter having an inflatable balloon, such as a double or dumbbell-shaped balloon.12-18-2008
20080311085Method for treating an animal having damaged tissue structure - A method for treating an animal having damaged tissue structure includes harvesting a tissue sample from a subject harvesting a tissue sample from the animal, growing tendon-like cells from the tissue sample, and transplanting the tendon-like cells into the damaged tissue structure. Growing the tendon-like cells from the tissue sample can be accomplished by breaking the tissue sample into fragments, placing the fragments into a culture vessel, inducing at least some of the fragments to adhere to the culture vessel, and supplying the fragments with nutrients so that tendon-like cells contained therein divide and grow.12-18-2008
20080311088Method of Treating Lung Diseases Using Cells Separated Or Proliferated From Umbilical Cord Blood - There is provided a method of treating lung diseases including administering cells separated or proliferated from umbilical cord blood to a patient suffering from such diseases.12-18-2008
20120294834REGENERATION OF, REESTABLISHING FUNCTION IN AND REPLACING MICROVASCULATURE IN ORGANS AND TISSUES - The invention provides compositions and methods involving the use of endothelial progenitor cells (EPC) to re-generate and/or reestablish a functioning microvasculature in damaged or ischemic organs and tissue. The invention also provides compositions and methods using EPC for replacing lost function in organ and tissue that is damaged, ischemic, or scarred. Such compositions and methods may find utility in, for instance, organs or tissues that have been damaged due to lack of vasculature.11-22-2012
20080292598CHIMERIC TRANSPLANT - Compositions comprising amniotic fluid stem cells which are derived from non-identical donor sources. Donors may be non-identical siblings, non-identical twins, and/or donors which are unrelated by a familial relationship. Also disclosed are methods for making such amniotic stem cell compositions, and methods for their use, such as therapeutic stem cell transplantation.11-27-2008
20090191166SCREENING AND THERAPY FOR LYMPHATIC DISORDERS INVOLVING THE FLT4 RECEPTOR TYROSINE KINASE (VEGFR-3) - The present invention provides materials and methods for screening for and treating hereditary lymphedema in human subjects.07-30-2009
20090004150Method for Expanding Postembryonic Stem and Progenitor Cells from Umbilical Cord Blood and Immunotherapeutic Agent - Method for obtaining and expanding postembryonic hematopoietic stem cells from umbilical cord blood while avoiding unwanted differentiation. Initial cells from umbilical cord blood are proliferated and multiplied ex vivo in a stroma-free medium and in the presence of a regio-modified glycan or glycosaminoglycan. The regio-modified glycan or glycosaminoglycan, e.g. a heparin derivative, is N-desulfated, and N-reacetylated or N-reacylated, in essence, on C2 atoms. The heparin derivative advantageously comprises less than 5 percent of C3-O-sulfate, at least 60 percent C2-O-sulfate, and it is preferably added in a quantity of 15 to 50 mg/L to the medium in order to stop an unwanted differentiation. The stem cells generated in this manner can differentiate, after expansion, into myeloma cells and lymphatic cells, and they can be used as an immunotherapeutic agent against many diseases.01-01-2009
20100266553METHOD FOR ISOLATING AND CULTURING ADULT STEM CELLS DERIVED FROM HUMAN AMNIOTIC EPITHELIUM - The present invention relates to a method for isolating and culturing adult stem cells derived from human amniotic membrane in high yield, and more particularly to a method for obtaining a large amount of adult stem cells, the method comprising obtaining amniotic epithelial cells from human amniotic tissue in high yield by treatment with dithiothreitol (DTT) and a low concentration of trypsin and culturing the amniotic epithelial cells in a medium containing a Rho-associated kinase inhibitor. The human amniotic epithelial cell-derived stem cells are easily extracted compared to existing therapeutic stem cells such as umbilical cord blood stem cells and bone marrow stem cells, the yield and proliferation thereof are significantly increased by DTT treatment, the addition of the ROCK inhibitor or the replacement of medium. Thus, the method can be used to efficiently prepare adult stem cells.10-21-2010
20080206205Cd34(+) Cells And Their Methods Of Use08-28-2008
20080206204Human parthenogenetic stem cells - The invention provides a method for establishing pluripotent cell lines from human parthenotes, the uses of said cell lines for producing differentiated cells or tissues and for therapeutic applications especially in regenerative medicine.08-28-2008
20120269787SYSTEMIC, ALLOGENIC STEM CELL THERAPIES FOR TREATMENT OF DISEASES IN EQUINES - A method for treating preselected diseases comprising the steps of providing a therapeutic dose of a mesenchymal stem cell composition, the mesenchymal stem cell composition comprising mesenchymal stem cells harvested from at least one tissue selected from the group consisting of placental tissue, bone marrow, dental tissue, testicle tissue, and dermal tissue; and systemically administering the mesenchymal stem cell composition to the patient suffering from a preselected disease or diseased state through an intravenous injection.10-25-2012
20080267922SLITRKS AS MARKERS FOR STEM AND PROGENITOR CELLS AND METHODS OF USE THEREOF - The present invention relates to slitrk proteins as markers of stem and progenitor cells, including embryonic stem cells and hematopoietic stem and progenitor cells, and also as a marker of leukemia and lymphoma cells, and of endothelial cells. The invention provides, inter alia, methods for purifying slitrk-positive cells, methods for detecting slitrk-positive cells, purified preparations of slitrk-positive cells, therapeutic compositions containing purified slitrk-positive cells, methods for targeting therapeutic agents to slitrk-positive cells, and methods of treatment, including but not limited to, methods of administering slitrk-positive cells to subjects in need thereof.10-30-2008
20120269784CARDIAC MUSCLE REPAIR OR REGENERATION USING BONE MARROW-DERIVED STEM CELLS - Disclosed are compositions and methods for method of treating a subject having reduced cardiac function or cardiac disease by administering adult bone marrow-derived stem cells to an individual. In some embodiments, the subject is a myocardial infarction patient or congestive heart failure patient. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.10-25-2012
20090155227Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease - Acute and chronic heart disease is treated using a rational, multi-tier approach. A patient is pretreated with growth factor proteins or gene therapy, followed by the administration of adult stem cells. The progress of treatment is continuously monitored by echo-cardiogram with growth factor treatment and/or stem cell administration adjusted according to the results of the echo-cardiogram or clinical status of the patient. Heart disease is also treated by a method that comprises administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.06-18-2009
20090155224Dimethyl amino ethyl ether psoralens and methods for their production and use - Water-soluble dimethyl amino ethyl ether psoralens useful in the treatment of proliferative skin disorders, microbial infections and diseases, disorders of the blood and bone marrow of mammals and in microbiocidal compositions for sterilization of blood and blood products and surgical implants and inhibition of microbial growth in industrial applications are provided.06-18-2009
20090155219METHODS FOR DAMAGING CELLS USING EFFECTOR FUNCTIONS OF ANTI-GFRA1 ANTIBODIES - The present invention relates to the use of cytoxicity based on the effector function of anti-GFRA1 antibodies. Specifically, the present invention provides methods and pharmaceutical compositions that comprise an anti-GFRA1 antibody as an active ingredient for damaging GFRA1-expressing cells using antibody effector function. Since GFRA1 is strongly expressed in breast, gastric, liver, renal or lung cancer cells, the present invention is useful in breast, gastric, liver, renal or lung cancer therapies.06-18-2009
20090098093GENERATION OF INNER EAR CELLS - Methods for generating cells of the inner ear, e.g., hair cells and supporting cells, from stem cells, e.g., mesenchymal stem cells, are provided, as well as compositions including the inner ear cells. Methods for the therapeutic use of the inner ear cells for the treatment of hearing loss are also described.04-16-2009
20090098090VITRO IMMUNIZATION - The present invention relates generally to a method of generating lymphocytes specific for particular antigens. More particularly, the present invention provides a method for generating antigen-reactive T- cells and even more particularly cytotoxic (CD8+) T-cells in 10 vitro specific for antigens such as peptide antigens. The method of the present invention enables in vitro T-cell priming for particular antigens such as antigens on cancer cells, pathogenic cells, viruses or cells infected with viruses. The present invention is useful in identifying particularly immunogenic antigens for immunotherapy. Furthermore, as a consequence, the present invention is useful in avoiding the need for expensive and time 15 consuming clinical trials. The present invention further provides a method for the treatment or prophylaxis of a disease or condition in a subject by generating T-cells reactive to an antigenic molecule and administering an effective amount of antigen-reactive T-cells to the subject or other compatible host. Furthermore, the present invention permits the generation of dendritic cell/T-cell populations for use in cellular immunotherapy.04-16-2009
20100143312TREATMENT OF DISEASES, DISORDERS OR CONDITIONS OF THE LUNG USING PLACENTAL CELLS - Provided herein are compositions and methods of treatment of individuals having a disease, disorder or condition of the lung, comprising administering a therapeutically-effective amount of placental cells, e.g., placental stem cells.06-10-2010
20090053181Modulation of Cells - The present invention is directed to methods which can be used to test agents for their ability 02-26-2009
20110206647Modulation of Angiogenesis - The invention provides methods for treating pathological conditions that can be improved by providing angiogenesis. The invention is generally directed to provide angiogenesis by administering cells that express and/or secrete one or more pro-angiogenic factors. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to express and/or secrete one or more pro-angiogenic factors. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired levels of expression and/or secretion of one or more pro-angiogenic factors.08-25-2011
20110206643Automated Cell Therapy System - A method for automated cell processing is provided, including receiving at least one tissue containing a multiplicity of cells belonging to multiple cell types, and automatically increasing both the proportion of cells of at least one of said multiple cell types as compared with at least another of said multiple cell types and the absolute number of cells of said at least one of said multiple cell types. Other embodiments are also described.08-25-2011
20090123432Novel population of hepatocytes derived via definitive endoderm (DE-hep) from human blastocysts derived stem cells - The present invention relates to a novel hepatocyte-like cell progenitor and/or a novel hepatocyte-like cell derived via definitive endoderm from human blastocyst-derived stem (hBS) cells, to a method for the preparation of such cells and to the potential use of such cells in e.g. pharmaceutical drug discovery and development, toxicity testing, cell therapy and medical treatment.05-14-2009
20100129330ADIPOCYTIC DIFFERENTIATED ADIPOSE DERIVED ADULT STEM CELLS AND USES THEREOF - The present invention is differentiated adipose tissue-derived stromal cells that exhibit the improved properties of increased extracellular matrix proteins and/or a lower amount of lipid than a mature isolated adipocyte. Methods for the expansion and differentiation of these cells are also provided. The cells of the invention are used for the treatment, repair, correction and/or regeneration of soft tissue cosmetic defects.05-27-2010
20110268709Generation of Histocompatible Tissues Using Nuclear Transplantation - Tissues produced by culture of cells produced by nuclear transfer on a matrix derived from nuclear transfer embryos or embryos and pluripotent cells provided by other methods are provided. These tissues are useful for cell therapy.11-03-2011
20090162329COMPOSITIONS COMPRISING HDAC INHIBITORS AND METHODS OF THEIR USE IN RESTORING STEM CELL FUNCTION AND PREVENTING HEART FAILURE - The invention provides compositions of histone deacetylase (HDAC) inhibitors and progenitor cells useful for treating heart failure in a subject. The invention also provides methods of restoring progenitor cell function to aged progenitor cells and methods for enhancing progenitor cell proliferation and/or differentiation using HDAC inhibitors.06-25-2009
20120141432USE OF CATALYTIC ANTIOXIDANT TO PRESERVE STEM CELL PHENOTYPE AND CONTROL CELL DIFFERENTIATION - Methods are disclosed herein for maintaining stem cells in an undifferentiated state in vitro. The methods include contacting the stem cells with an effective amount of a catalytic antioxidant. Also disclosed are methods for the increasing the number of stem cells in vitro while maintaining the stem cells in an undifferentiated state. The methods include contacting the stem cells with an effective amount of a catalytic antioxidant and an effective amount of one or more growth factors that promotes the expansion of the stem cells.06-07-2012
20110217273Composition for Preventing or Treating AIDS Containing Plant Stem Cell Line Derived from Cambium of Panax Ginseng Including Wild Ginseng or Ginseng as Active Ingredient - The present invention relates to a composition for preventing or treating acquired immunodeficiency syndrome (AIDS), comprising one or more of the following: a homogenous cell line, and a lysate, an extract and a culture thereof as an active ingredient. The homogenous cell line, the lysate, the extract and the culture thereof, which are derived from a natural product, minimize adverse side effects of prior therapeutic agents and safe for the human body. Further, they effectively increase the count of T cells such as CD4+ T cells and decrease the number of HIVs, thereby preventing opportunistic infection, dysneuria, and neoplasia caused by immune incompetence, and ultimately the risk of death. Therefore, they are useful in preventing and treating AIDS, and relieving symptoms of AIDS.09-08-2011
20090136460USE OF ADENOSINE RECEPTOR LIGANDS TO PROMOTE CELL ADHESION IN CELL-BASED THERAPIES - Intracoronary delivery of endothelial progenitor cells (EPCs) is an emerging concept for the treatment of cardiovascular disease, and enhancement of EPC adhesion to vascular endothelium should improve cell retention within targeted organs, as well as vascular development. The present inventors have shown that stimulation of adenosine receptors (AdoR) in murine embryonic EPCs (eEPCs) and cardiac endothelial cells (cECs) rapidly, within minutes, increased eEPC adhesion to cECs. eEPCs and cECs were found to predominantly express functional A05-28-2009
20090136459COMPOSITIONS FOR PREVENTING OR TREATING SKIN DEFECTS AND METHODS OF USE THEREOF - Described herein are compositions and methods that treat or prevent skin defects in a subject.05-28-2009
20090136463Schwann Cell Bridge Implants and Phosphodiesterase Inhibitors to Stimulate CNS Nerve Regeneration - The use of a composition that elevates intracellular levels of cyclic nucleotide cyclases in combination with phosphodiesterase inhibitors and cell grafts to restore function after CNS injury.05-28-2009
20090028833Proliferative Primary Human Sertoli Cell Cultures And Their Applications - Technology for the isolation and propagation of primary human Sertoli cells from normal testes tissue, including cultures of proliferative primary human Sertoli cells for research and clinical applications, and a pharmaceutical composition for cell therapy, ex vivo gene therapy, and for the reduction of autoimmune, allograft, and xenograft immune reactions.01-29-2009
20090028831STEM CELL REGULATOR, COMPOSITIONS AND METHODS OF USE - The disclosure provides methods and compositions comprising Slit2 agonists and antagonists useful for modulating hematopoietic stem cell (HSC) proliferation and growth. In some aspects, the disclosure provides methods and compositions for stimulating HSC proliferation in vivo, ex vivo, or in vitro. In other aspects, the disclosure provides methods and compositions for inhibiting HSC proliferation.01-29-2009
20090186005Methods and Compositions For Treating Motor Neuron Diseases Comprising Mesenchymal Stem Cells - Disclosed herein are a composition for treating motor neuron diseases, particularly amyotrophic lateral sclerosis (ALS), using mesenchymal stem cells, and a method for treating motor neuron diseases using the composition. The composition and treatment method can provide effective therapy for motor neuron diseases, particularly for amyotrophic lateral sclerosis (ALS).07-23-2009
20090136462TUMOR ASSOCIATED ANTIGEN PEPTIDES AND USE OF SAME AS ANTI-TUMOR VACCINES - The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.05-28-2009
20090136458Renal Carcinoma Cell Line and Uses thereof - The present invention relates to a renal carcinoma cell line capable of activating the immune system in an antigen-specific manner. According to a further aspect, the invention also includes derivatives of the cell line that maintain said activation capacity. The invention also comprises a method for targeting and activating immune system cells against cells of clear cell renal carcinoma. Said method comprises the co-incubation of isolated immune system cells (dendritic cells, CD4+, CD8+ lymphocytes etc.) with cells of the RCC BA85#21 line in accordance with the invention in a suitable culture medium, for a time sufficient to obtain antigen specific cells.05-28-2009
20090136457Methods of treating spinal cord injury and minimizing scarring - The invention is directed to methods of promoting the healing of spinal cord injury. The invention is further directed to methods of minimizing the extent of scarring following spinal cord injury. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), each alone or in combination with each other and/or other agents.05-28-2009
20090136456METHODS OF TREATING NEURODEGENERATIVE DISORDERS - The present invention provides a selected population of neural cells, including neural stem cells, neural progenitor cells, neural precursor cells, and progeny thereof, which neural cells are selected for an apoE405-28-2009
20080317720Fat-Derived Progenitor Cell and Use Thereof - An objective of the present invention is to provide methods for producing progenitor cells which show a high proliferation ability ex vivo and promote neovascularization or myocardium regeneration, by culturing pluripotent cells in a medium containing adrenomedullin (AM) and/or vascular endothelial growth factor (VEGF). Moreover, another objective of the present invention is to provide the progenitor cells and uses thereof. In order to solve the above problems, the inventors of the present application have successfully developed a novel culture technique for producing progenitor cells from adipose tissues more efficiently compared to the conventional techniques, by using adrenomedullin (AM) and/or vascular endothelial growth factor (VEGF). The progenitor cells produced by the present inventors are specialized cells having a potent proliferation ability, a revascularization ability, and a myocardium regeneration ability, and have the property of not differentiating into adipocytes even if subjected to differentiation induction into adipocytes. Therefore, the progenitor cells of the present invention can be effective pharmaceutical agents for intractable diseases in the brain, lung, liver, kidney and the like.12-25-2008
20090274666B7-H1, A NOVEL IMMUNOREGULATORY MOLECULE - The invention provides novel polypeptides useful for co-stimulating T cells, isolated nucleic acid molecules encoding them, vectors containing the nucleic acid molecules, and cells containing the vectors Also included are methods of making and using these co-stimulatory polypeptides.11-05-2009
20090028829Fusion proteins for the treatment of CNS - This disclosure relates to compositions capable of use in the treatment of spinal cord injuries and related disorders of the central nervous system (CNS), and in particular, compositions including proteoglycan degrading molecules and compositions capable of blocking and/or over coming the activity of neuronal growth inhibitory molecules, as well as fusion proteins which includes a proteoglycan degrading domain and a domain capable of blocking and or over coming the activity of neuronal growth inhibitory molecules.01-29-2009
20090186004Method For Preparing An Organ For Transplantation - The present invention provides a method for preparing an organ, particularly a kidney, for transplantation into mammals. In detail, the present invention provides a method for preparing autotransplantation of autologous organs, particularly a kidney, wherein the isolated autologous mesenchymal stem cells are transplanted into an embryo inside a pregnant mammalian host or into an embryo dissected from a pregnant mammalian host at a desired site to induce differentiation, which is then transplanted into the individual.07-23-2009
20090142311ENGINEERED INTERVERTEBRAL DISC TISSUE - Surgically implantable tissue engineered intervertebral disc tissues that effectively replicate the physicochemical properties of the corresponding in vivo tissues are provided. Methods for producing such tissues can involve culturing the intervertebral disc cells to produce cells surrounded by an extracellular matrix and culturing the cells and matrix on a semipermeable membrane to form a cohesive tissue.06-04-2009
20130216506Bioreactor for Isolation of Rare Cells and Methods of Use - The present invention relates to a bioreactor apparatus, and methods of use, for the isolation of rare blood cells, including hematopoietic stem cells and megakaryocytes. The apparatus includes a soft substrate and an anti-contractility agent, thereby providing a soft microenvironment to cultured cells. The apparatus of the invention is permissive for the survival of non-dividing cells while dividing cells are eliminated. This unique property allows for the simple isolation of rare blood cells without the use of costly equipment and antibodies.08-22-2013
20090004151Method of Three-Dimesionally Culturing Chondrocytes - It is intended to provide a method of three-dimensionally culturing normal joint chondrocytes; the production and supply of chondrocytes; and a transplantation material to be used in an injured site in a joint tissue.01-01-2009
20090252712CHIMERIC C3-LIKE RHO ANTAGONIST BONE THERAPEUTIC - Methods of treating bone disorders in a subject in need thereof by administering to said subject a therapeutically effective amount of a Rho antagonist are disclosed.10-08-2009
20090252711Stem Cells And Methods Of Making And Using Stem Cells - The invention provides a method of making a pluripotent stem cell from a cell that is not pluripotent, such as from a differentiated stem cell or a lineage-restricted stem cell. The methods comprise culturing the starting cell in the presence of one or more epigenetic altering agents, such as a histone deacetylase inhibitor and/or a DNA methyltransferase inhibitor. Pluripotent stem cells are also provided, as are methods of treating or preventing a disease, disorder, or condition in a mammal using the cells.10-08-2009
20090252710TUMOR SUPPRESSION USING HUMAN PLACENTAL PERFUSATE AND HUMAN PLACENTA-DERIVED INTERMEDIATE NATURAL KILLER CELLS - Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells.10-08-2009
20130121971COMPOSITIONS AND METHODS OF VASCULAR INJURY REPAIR - The present invention relates to pharmaceutical compositions comprising a chemotactic hematopoietic stem cell product comprising an enriched population of CD34+ cells containing a subpopulation of CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic activity, methods of preparing these compositions and use of these compositions to treat or repair vascular injury, including infarcted myocardium.05-16-2013
20130121972NATIVE WHARTON'S JELLY STEM CELLS AND THEIR PURIFICATION - Noncultured Wharton's Jelly stem cells and methods of their purification, storage and use are provided.05-16-2013
20130121973DIFFERENTIATION OF MESENCHYMAL STEM CELLS INTO FIBROBLASTS, COMPOSITIONS COMPRISING MESENCHYMAL STEM CELL-DERIVED FIBROBLASTS, AND METHODS OF USING THE SAME - Methods and compositions are provided for the differentiation and characterization of mammalian fibroblast from mesenchymal stem cells. The methods of the invention provide a means to obtain mesenchymal stem cell-derived fibroblast populations, e.g., seeded on a scaffold, which may be used in wound healing.05-16-2013
20130121974METHODS OF MAKING ENHANCED, AUTOLOGOUS FAT GRAFTS - Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.05-16-2013
20090053183Treatment of Diseases and Disorders Using Self-Renewing Colony Forming Cells Cultured and Expanded In Vitro - The present invention relates to methods and uses of cells for the prevention and treatment of a wide variety of diseases and disorders and the repair and regeneration of tissues and organs using low passage and extensively passaged in vitro cultured, self-renewing, colony forming somatic cells (CF-SC). For example, adult bone marrow-derived somatic cells (ABM-SC), or compositions produced by such cells, are useful alone or in combination with other components for treating, for example, cardiovascular, neurological, integumentary, dermatological, periodontal, and immune mediated diseases, disorders, pathologies, and injuries.02-26-2009
20110223143STEM CELL FOR THERAPEUTIC USE WHICH IS DERIVED FROM HUMAN MONOCYTE, AND METHOD FOR INDUCING SAME - The present invention relates to stem cells obtained by culturing monocytes in the presence of (i) M-CSF and (ii) at least one member selected from the group consisting of ganglioside and water-soluble plant-derived extract, thereby dedifferentiating the monocytes; a therapeutic agent for treating damaged cells, tissues or organs; a cell drug agent; a method of producing stem cells, a culture medium for dedifferentiating monocytes; a dedifferentiation inducing agent; a cell drug kit; a kit for producing dedifferentiated cells; and a pharmaceutical composition.09-15-2011
20110223139RAPID PREPARATION OF STEM CELL MATRICES FOR USE IN TISSUE AND ORGAN TREATMENT AND REPAIR - A rapid method for preparing stem cell and physiologically acceptable matrix compositions for use in tissue and organ repair is described. Compared with previous tissue engineering materials, the stem cell-matrix compositions of the present invention do not require long-term incubation or cultivation in vitro prior to use in in vivo applications. The stem cells can be from numerous sources and may be homogeneous, heterogeneous, autologous, and/or allogeneic in the matrix material. The stem cell-matrix compositions provide point of service utility for the practitioner, wherein the stem cells and matrix can be combined not long before use, thereby alleviating costly and lengthy manufacturing procedures. In addition, the stem cells offer unique structural properties to the matrix composition which improves outcome and healing after use. Use of stem cells obtained from muscle affords contractility to the matrix composition.09-15-2011
20080241111Pluripotent Stem Cell Derived from Cardiac Tissue - An object of the present invention is to provide a stem cell applicable to regenerative therapeutic method, and to provide a technique to carry out regenerative therapy using the cell. A collected cardiac tissue fragment is enzymatically treated to prepare a cell suspension. Then using the cell suspension, following steps are carried out: (1) separation of cells by the density gradient method, (2) suspension-culture in a culture medium containing fibroblast growth factor and epidermal growth factor and (3) selection and separation of cells forming a floating sphere to obtain pluripotent stem cells. Thus-obtained pluripotent stem cells are used to carry out regenerative therapy.10-02-2008
20110142806Electroactive Scaffold - A scaffold assembly and related methods of manufacturing and/or using the scaffold for stem cell culture and tissue engineering applications are disclosed which at least partially mimic a native biological environment by providing biochemical, topographical, mechanical and electrical cues by using an electroactive material. The assembly includes at least one layer of substantially aligned, electrospun polymer fiber having an operative connection for individual voltage application. A method of cell tissue engineering and/or stem cell differentiation uses the assembly seeded with a sample of cells suspended in cell culture media, incubates and applies voltage to one or more layers, and thus produces cells and/or a tissue construct. In another aspect, the invention provides a method of manufacturing the assembly including the steps of providing a first pre-electroded substrate surface; electrospinning a first substantially aligned polymer fiber layer onto the first surface; providing a second pre-electroded substrate surface; electrospinning a second substantially aligned polymer fiber layer onto the second surface; and, retaining together the layered surfaces with a clamp and/or an adhesive compound.06-16-2011
20090053180Tandem cardiac pacemaker system - This invention provides pacemaker systems comprising (1) an electronic pacemaker, and (2) a biological pacemaker, wherein the biological pacemaker comprises a cell that functionally expresses a chimeric hyperpolarization-activated, cyclic nucleotide-gated (HCN) ion channel at a level effective to induce pacemaker current in the cell. The invention also provides related biological pacemakers, atrioventricular bridges, methods of making same, and methods of treating a subject afflicted with a cardiac rhythm disorder.02-26-2009
20120070418STEM CELLS FOR MUSCULOSKELETAL TISSUE REPAIR - The stem cells that can be propagated and maintained for extended periods of time in culture in the absence of a feeder layer, and can be used to repair tissue damage. These cells are derived from fetal tissues and are able to repair different types of damage in musculoskeletal system, with significantly greater efficacy than stem cells derived from adult tissues. These cells are hypoimmunogenic and can be used for allogeneic transplantation to vertebrate hosts having disease and/or damage in musculoskeletal and other tissues. The cells can be administered by direct injection to the site in need of repair or by systemic (e.g., intravenous) administration. The stem cells of the invention are capable of migrating to the sites in need of repair, and of adopting a phenotype most appropriate to the nature of the damage, injury or disease.03-22-2012
20090081170Cardiac progenitor cells - The present invention relates to the field of progenitor cells, and in particular to the field of cardiac progenitor cells. More particularly, the present invention pertains to the identification of a population of progenitor cells in the adult mammalian heart that is capable of giving rise to significant levels of de novo cardiomyocytes with the potential to replenish injured muscle post-infarction and/or promote neovascularisation to bring about complete cardiac regeneration. Accordingly, the present invention relates to methods for generating a population of mammalian post-natal epicardium derived cells (EPDCs), populations of EPDCs so generated, and methods of using same.03-26-2009
20090081168METHOD OF FORMING A PEPTIDE-RECEPTOR COMPLEX WITH ZSIG33 - The present invention relates to a method of forming a peptide-receptor complex with zsig33 polypeptides and their receptors as well as antibodies. Methods of modulating gastric contractility, nutrient uptake, growth hormones, the secretion of digestive enzymes and hormones, and/or secretion of enzymes and/or hormones in the pancreas are also included.03-26-2009
20110142809METHOD FOR SEPARATING HIGHLY ACTIVE STEM CELLS FROM HUMAN STEM CELLS AND HIGHLY ACTIVE STEM CELLS SEPARATED THEREBY - The present invention relates to a method for separating highly active stem cells from human stem cells, the highly active stem cells separated by the method, a cell therapeutic agent containing the stem cells, and a medium for separating the highly active stem cells from stem cells containing a specific cytokine. According to the present invention, the method is useful for separating the highly efficient stem cells from mesenchymal stem cells of various origins. Further, the method is very useful in developing a cell therapeutic agent of high efficiency because the method can be applicable to stem cells of various origins which are cultured under different conditions. Senescent stem cells increased by several passage times in vitro can be effectively sorted out, so the method can be used for reactivating the stem cells.06-16-2011
20110142810CELL PREPARATION FOR BONE TISSUE REGENERATION - The present invention provides a cell preparation that can be prepared from cells collected from a patient of any age group, and that has an excellent bone tissue regenerative capacity and is effective for bone tissue regeneration. Undifferentiated osteoblasts obtained from alveolar bone, particularly those obtained by being cultured after the enzyme treatment of alveolar bone have a remarkable bone tissue regenerative capacity, and are therefore useful for a cell preparation for bone tissue regeneration.06-16-2011
20110142808Polymerized Hemoglobin Media and Its Use in Isolation and Transplantation of Islet Cells - Solutions and suspensions comprising polymerized hemoglobin derived from human blood are disclosed. The solutions and suspensions may comprise cell culture medium, an enzyme (such as a protease), and/or a buffer. Processes of preparing the solutions and suspensions are also disclosed. The solutions and suspensions may be employed in methods of isolating mammalian cells, such as pancreatic islets, methods of preserving mammalian tissue and organs, methods of aiding the recovery of mammalian cells following their isolation, methods of maintaining mammalian cells, methods of propagating mammalian cells, and methods of treating a mammal with diabetes.06-16-2011
20110142807Mesenchymal Stem Cells and Uses Therefor - Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting would healing, and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.06-16-2011
20110142805METHOD OF RENAL REPAIR AND REGENERATION AND THE TREATMENT OF DIABETIC NEPHROPATHY - We have disclosed methods for treating chronic kidney disease. More specifically, we have disclosed methods for treating diabetic nephropathy with human kidney derived cells.06-16-2011
20110229444Neuregulin And Cardiac Stem Cells - The present invention relates to compositions and methods for inducing cardiomyogenesis in mammalian cells, particularly embryonic stem cells in vitro and in vivo.09-22-2011
20090068154Cell Composition for Transplant - The present invention provides a cell composition for transplant comprising fibroblasts originating in buccal fat pad.03-12-2009
20090191168Pregnancy-Induced Oligodendrocyte Precursor Cell Proliferation Regulated by Prolactin - The present invention relates to a method to increase oligodendrocytes and oligodendrocyte precursor cells through administration of prolactin or a prolactin inducing agent.07-30-2009
20110229441Method and Medium for Neural Differentiation of Pluripotent Cells - The invention relates to a culture medium comprising an inhibitor of the BMP signaling pathway; and an inhibitor of the TGF/activin/nodal signaling pathway and to a method for obtaining a population of neural precursors using said culture medium.09-22-2011
20110229440Differentiation of Human Embryonic and Induced Pluripotent Stem Cells - The invention relates to culture systems, methods, and conditions that allow pluripotent undifferentiated hESCs or iPSCs to progressively and uniformly differentiate into cells of the chondrogenic lineage.09-22-2011
20090162330Method of Isolating Human Neuroepithelial Precursor Cells from Human Fetal Tissue - A method for isolating human neuroepithelial precursor cells from human fetal tissue by culturing the human fetal cells in fibroblast growth factor and chick embryo extract and immunodepleting from the cultured human fetal cells any cells expressing A2B5, NG2 and eNCAM is provided. In addition, methods for transplanting these cells into an animal are provided. Animals models transplanted with these human neuroepithelial precursor cells and methods for monitoring survival, proliferation, differentiation and migration of the cells in the animal model via detection of human specific markers are also provided.06-25-2009
20110020296METHODS FOR TREATING DISEASES AND INCREASING LONGEVITY - Diseases such as cancer, HIV/AIDS, diabetes, infectious diseases, as well as diseases related to the immune and autoimmune systems, are treated through the formation and/or enhancement of the function of organs and suborgans of human patients. An important organ for such purpose is the thymus. Enhancement may be direct or indirect and utilizes energy, enhancement compositions, and/or living organisms to enhance the cells and/or cell products produced by organs and suborgans.01-27-2011
20110020295PRE-TRANSPLANT ACCOMMODATED ORGANS RESISTANT TO ANTI-DONOR IMMUNITY - This invention includes the composition of organ grafts accommodated prior to transplantation and therefore resistant to rejection by preformed antibodies. Accommodation is achieved within the donor animal by administration of sub-lethal levels of accommodation inducing factors derived from animals sensitized to the donor.01-27-2011
20120301444Amnion-derived cell compositions, methods of making and uses thereof - The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies.11-29-2012
20090004153MUSCLE DERIVED CELLS FOR THE TREATMENT OF URINARY TRACT PATHOLOGIES AND METHODS OF MAKING AND USING SAME - The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration for urinary incontinence and other urinary tract pathologies.01-01-2009
20090004154Method for treating a mammal having damaged pancreatic tissue - A method for treating a mammal having damaged pancreatic tissue includes harvesting a tissue sample from the mammal, growing pancreatic cells from the tissue sample, and transplanting the pancreatic cells into the damaged tissue. Growing the pancreatic cells from the tissue sample can be accomplished by breaking the tissue sample into fragments, placing the fragments into a culture vessel, inducing at least some of the fragments to adhere to the culture vessel, and supplying the fragments with nutrients so that pancreatic cells contained therein divide and grow.01-01-2009
20090004161Methods for treating pustular conditions of the skin - The invention is directed to methods for treating pustular conditions of the skin, for example, acne. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), cell lysates derived therefrom, and cell products derived therefrom, each alone or in combination.01-01-2009
20090004158Methods of controlling proliferation and differentiation of stem and progenitor cells - A method of ex-vivo expanding a population of stem cells, while at the same time inhibiting differentiation of the stem cells. The method comprises ex-vivo providing the stem cells with conditions for cell proliferation and with at least one copper chelator in an amount and for a time period for permitting the stem cells to proliferate and, at the same time, for reducing a capacity of the stem cells to differentiate01-01-2009
20090004156POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNalpha17 GENE - The present invention relates to new polynucleotides derived from the nucleotide sequence of the IFNα-17 gene comprising new SNPs, and new polypeptides derived from the natural wild-type IFNα-17 protein comprising at least one mutation caused by at least one SNP of the invention, as well as their therapeutic uses.01-01-2009
20090004155Method for treating a mammal having damaged myocardium tissue - A method for treating a mammal having damaged myocardium tissue includes harvesting a tissue sample from the mammal, growing myocardium cells from the tissue sample, and transplanting the myocardium cells into the damaged tissue. Growing the myocardium cells from the tissue sample can be accomplished by breaking the tissue sample into fragments, placing the fragments into a culture vessel, inducing at least some of the fragments to adhere to the culture vessel, and supplying the fragments with nutrients so that myocardium cells contained therein divide and grow.01-01-2009
20090202501Chimeric NK receptor and methods for treating cancer - The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are further provided.08-13-2009
20090004160Mass Producing Method of Growth Factor Using Adipose Derived Adult Stem Cells - The present invention relates to a method for producing large amounts of human growth factors from human adipose-derived stem cells. More specifically, the invention provides a method capable of synthesizing human growth factors in significantly large amounts by culturing adipose-derived stem cells extracted from human adipose cells in suitable media and conditions. Also, stem cell culture media produced according to the method of the invention, and human growth factors isolated from the culture media, can be advantageously used as raw materials for drugs and cosmetics.01-01-2009
20090004159Polymerized Hemoglobin Media and Its Use in Isolation and Transplantation of Islet Cells - Solutions and suspensions comprising polymerized hemoglobin derived from human blood are disclosed. The solutions and suspensions may comprise cell culture medium, an enzyme (such as a protease), and/or a buffer. Processes of preparing the solutions and suspensions are also disclosed. The solutions and suspensions may be employed in methods of isolating mammalian cells, such as pancreatic islets, methods of preserving mammalian tissue and organs, methods of aiding the recovery of mammalian cells following their isolation, methods of maintaining mammalian cells, methods of propagating mammalian cells, and methods of treating a mammal with diabetes.01-01-2009
20090208463MESENCHYMAL STEM CELLS AND USES THEREFOR - Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting wound healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.08-20-2009
20090208468SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE - The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating an immune-mediated disorder, such as, but not limited to, an autoimmune disease, by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide. Also disclosed are methods of suppressing an immune response in a subject by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.08-20-2009
20090208465METHOD OF TREATING NEURAL DEFECTS - The present invention provides a therapeutic agent for a nerve injury and a method for treating a nerve injury. One aspect of the invention is the method for treating a nerve injury by administering to a patient with a nerve injury a therapeutic agent for a nerve injury containing a differentiated cell-derived pluripotent cell obtained by forced expression of reprogramming genes such as a combination of the Oct3/4 gene, Sox2 gene, Klf4, and c-myc gene. in a differentiated cell; or cells obtained by inducing the aforementioned differentiated cell-derived pluripotent cells to differentiate into an embryoid body or a neurosphere.08-20-2009
20090208466INK-JET PRINTING OF TISSUES - A method of forming an array of viable cells is carried out by ink-jet printing a cellular composition containing said cells on a substrate. At least two different types of viable mammalian cells are printed on the substrate, the at least two different types of viable mammalian cells selected to together form a tissue. In some embodiments at least three or four different viable mammalian cells are printed on the substrate, the cells selected to together form a tissue. In some embodiments one of the viable mammalian cell types is a stem cell. In some embodiments the method further comprises printing at least one support compound on the substrate, the support compound selected to form a tissue together with said cells. In some embodiments the method further comprises printing at least one growth factor on the substrate, the growth factor selected to cause the cells to form a tissue.08-20-2009
20090220465METHODS AND COMPOSITIONS FOR MODULATION OF STEM CELL AGING - Methods are described for promoting or maintaining self-renewal of a stem cell expressing or expected to express p1609-03-2009
20090220464MESENCHYMAL STEM CELLS AND USES THEREFOR - Methods of treating autoimmune diseases, allergic responses, cancer, inflammatory diseases, or fibrosis in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.09-03-2009
20090220462STEM CELLS - The present invention relates, in general, to stem cells and, in particular, to a method of expanding stem cells by inhibiting aldehyde dehydrogenase (ALDH). The invention further relates to methods of identifying compounds suitable for use in effecting expansion of stem cells.09-03-2009
20090214490HUMAN EMBRYONIC STEM CELL METHODS AND PODXL EXPRESSION - A method of identifying an undifferentiated human embryonic stem cell in a sample which may contain such cells, the method comprising identifying the cell or cells within the sample that express podocalyxin-like protein (PODXL) on their surface. A method of isolating an undifferentiated human embryonic stem cell from a sample containing such cells, the method comprising isolating the cell or cells within the sample that express PODXL on their surface. Typically, the methods use an antibody which binds to PODXL. Undifferentiated human embryonic stem cells isolated by the method may be useful in cell therapy. Also, in particular, compositions of cells differentiated from a human embryonic stem cell but which composition has been depleted of undifferentiated human embryonic stem cells are provided which are useful in cell therapy.08-27-2009
20090214484STEM CELL THERAPY FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS - The invention provides a method for treating CNS disorders by administering a neural stem cell composition and a mesenchymal stem cell composition on opposing sides of the blood brain barrier. The neural stem cell composition is administered to the central nervous system, while the mesenchymal stem cell composition is administered to the circulatory system, such as by intravenous injection. The method finds use in the treatment of degenerative GNS disorders, as well as traumatic CNS disorders such as stroke and spinal cord injury.08-27-2009
20100003223METHOD FOR THE PRODUCTION OF MULTICOMPONENT STEM CELLS, RELATIVE KITS AND USES IN THE MEDICAL FIELD - The invention relates to a method for the production of multipotent stem cells starting from highly differentiated adult somatic cells of mammals or their precursors comprising the demethylating treatment phase of highly differentiated cells with 5′ Aza 2′ cytidine and relative kits and uses in the medical field.01-07-2010
20100003222METHODS FOR BONE REGENERATION USING ENDOTHELIAL PROGENITOR CELL PREPARATIONS - The present invention relates in general to orthopedics and to a method for promoting repair of large bone defects, in particular non-union or delayed union fractures. Specifically the invention concerns the use of endothelial progenitor cell preparations for bone repair.01-07-2010
20090098094SKELETAL MUSCLE AUGMENTATION UTILIZING MUSCLE-DERIVED PROGENITOR COMPOSITIONS, AND TREATMENTS THEREOF - The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. The invention also relates to novel uses of muscle-derived progenitor cells for the treatment of cosmetic or functional conditions, including, but not limited to skeletal muscle weakness, muscular dystrophy, muscle atrophy, spasticity, myoclonus and myalgia. The invention also relates to the novel use of MDCs for the increase of skeletal muscle mass in athletes or other organisms in need of greater than average skeletal muscle mass.04-16-2009
20090257987Method of generating dopamine-secreting cells - Methods of generating cells which secrete dopamine are disclosed. One method comprises incubating mesenchymal stem cells in a culture medium comprising brain derived neurotrophic factor (BDNF), wherein the culture medium comprises no more than 0.1 μM retinoic acid (RA). Another method comprises incubating mesenchymal stem cells in a culture medium comprising glial-derived neurotrophic factor GDNF, transforming growth factor β3 (TGFβ3) and retinoic acid (RA). Cells generated by the above-described methods are also disclosed as well as uses thereof.10-15-2009
20090081169METHOD FOR OSTEOGENIC DIFFERENTIATION OF BONE MARROW STEM CELLS (BMSC) AND USES THEREOF - Methods for obtaining osteoprogenitors, osteoblasts or osteoblast phenotype cells, as well as cell populations including such cells, from human bone marrow stem cells in vitro or ex vivo are disclosed. Bone marrow stem cells are contacted with human serum or plasma and a growth factor or a biologically active variant or derivative thereof. In addition, osteoprogenitor, osteoblast or osteoblast phenotype cell types and cell populations are provided. The cell populations may include additional cell types, such as endothelial cells or progenitors. The osteoprogenitors, osteoblasts or osteoblast phenotype cells may be used in therapy, particularly bone therapy.03-26-2009
20120141435USE OF OLIVE LEAF EXTRACTS IN A PHARMACEUTICAL COMPOSITION FOR INDUCING ANGIOGENESIS AND VASCULOGENESIS - The invention relates to the use of olive leaf extracts for producing a pharmaceutical composition capable of inducing angiogenesis and vascularization. In general, the composition can be used for therapeutic applications in order to promote the differentiation of stem cells into endothelial progenitor cells (EPCs) and/or mature endothelial cells, as well as to induce the vessel formation from said endothelial cells. The vascularization-inducing angiogenic composition of the invention is intended for, inter alia, cardiovascular disease, ischemic processes in general, ulcers, and wound healing in both human and veterinary medicine.06-07-2012
20090117087METHODS AND COMPOSITIONS FOR PRINTING BIOLOGICALLY COMPATIBLE NANOTUBE COMPOSITES OF AUTOLOGOUS TISSUE - A method of carrying out an autologous tissue implant in a subject in need thereof is carried out by: (a) forming an autologous tissue implant from autologous cells collected from a subject (e.g., by ink-jet printing, the autologous cells and the scaffold, separately or together), and then (b) implanting the autologous tissue implant in said subject.05-07-2009
20100015099Materials and methods relating to treatment of injury and disease to the central nervous system - The application provides materials and methods for promoting myelination of neuronal axons in the CNS. These derive from the findings first that the molecules Nogo and Caspr interact with one another during establishment and maintenance of the axoglial junction, and secondly that the molecules F3 and NB-3 are capable of promoting oligodendrocyte maturation via interaction with Notch. The materials and methods provided may be used in the treatment of CNS damage, in particular the treatment of spinal cord injury, multiple sclerosis, epilepsy and stroke.01-21-2010
20100150880Isolated mesenchymal cell population and method for isolating and using same - The present invention provides a novel isolated mesenchymal cell population of highly purified osteoprogenitors (HipOPs) that can be used in the formation of bone tissue and methods for isolating and using same.06-17-2010
20100150881Compositions and Methods for Use of Scar Tissue in Repair of Weight Bearing Surfaces - Compositions and methods are provided for weight bearing surface, i.e., intervertebral disc (‘disc’), between spinous processes and articular cartilage, repair. Compositions include fibrosis inducing agents for facilitating fibrosis in or on the site in need of repair in order to form fibrotic connective tissue. In addition, methods are provided for distracting the appropriate disc space during treatment of a disc in need of repair, and in particular treatment of the disc in need of repair with a fibrosis inducing agent.06-17-2010
20120195860LATENT NEURAL STEM CELL POPULATION - The present invention relates to a latent neural stem cell population which is capable of activation by membrane depolarization of a neural cell population, isolation and culture of same, and uses thereof.08-02-2012
20090136461Neuronal differentiation method of adult stem cells using small molecules - The present invention relates to a neuronal differentiation method of adult stem cells using small molecules, more particularly to a method for inducing differentiation of adult stem cells into nerve cells using small molecules, which enables effective differentiation into nerve cells and, thus, is useful in treating intractable CNS disorders such as Parkinson's disease, dementia, Alzheimer's disease and spinal cord injury.05-28-2009
20090130068Oral Tissue Regeneration and Repair - A method for treating an oral condition of a subject by grafting cultured tissue constructs to the oral tissue. The cultured tissue constructs comprise cultured cells and endogenously produced extracellular matrix components without the requirement of exogenous matrix components or network support or scaffold members. Some tissue constructs of the invention are comprised of multiple cell layers or more than one cell type. The tissue constructs of the invention have morphological features and functions similar to tissues their cells are derived and their strength makes them easily handleable. Preferred cultured tissue constructs of the invention comprise cells derived from human tissue.05-21-2009
20090117088CELLULAR INTERVENTION TO TREAT DAMAGED MYOCARDIUM - A system and method for treating damage myocardial tissue includes delivering replacement cells to the myocardium of a patient and electrically stimulating the spinal column of the patient to affect a cellular environment within the myocardium.05-07-2009
20090257986EPIDERMAL AND DERMAL EQUIVALENTS - The present invention relates to the treatment of skin defects by organotypically-cultured autologous keratinocytes isolated from the outer root sheath of anagen or growing hair. Methods for primary, as well as subsequent organotypic cultures (i.e., epidermal equivalents) in fully-defined media supplemented by autologous human serum and substances isolated form blood components, with minimal allogeneic biological supplements, are disclosed herein. Techniques to prepare epidermal equivalents for transplantation by use of a biocompatible glue are also disclosed herein.10-15-2009
20100266556METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND - An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy useful for treatment of various hematopoietic disorders is provided.10-21-2010
20100266554METHODS AND COMPOSITION FOR TREATING NEURAL DEGENERATION - Disclosed herein are methods and compositions for the use of marrow adherent stem cells and their descendents; e.g., bone marrow-derived neural regenerating cells; in the treatment of various neurodegenerative disorders. In certain embodiments, bone marrow-derived neural regenerating cells transplanted to sites of neural degeneration stimulate growth and/or survival of host neurons.10-21-2010
20100015101NOVEL TUMOR ANTIGEN PEPTIDES - The invention relates to novel tumor antigen proteins and peptides derived therefrom and use of the same in the filed of cancer immunity. Specifically, the inventions relates to a peptide which comprises a partial peptide derived from Lengsin, BJ-TSA-9, C20orf42, BUB1, C10orf3 or HIFPH3 and is capable of binding to an HLA antigen and is recognized by a CTL, and a pharmaceutical composition comprising the peptide and a pharmaceutically acceptable carrier.01-21-2010
20100015100DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS - The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides an improved method for the formation of pancreatic endoderm, pancreatic hormone expressing cells and pancreatic hormone secreting cells. The present invention also provides methods to promote the differentiation of pluripotent stem cells without the use of a feeder cell layer.01-21-2010
20100015104GENERATION OF ADIPOSE TISSUE AND ADIPOCYTES - The invention provides novel methods by which adipose tissue, preadipocytes, and adipocytes can be generated for research purposes, and methods for identifying cell populations that can proliferate and differentiate into adipocytes in vivo. The invention further provides a means for the in vivo derivation of “designer” or “customized” adipose tissue, preadipocytes, and adipocytes. Also provided are methods for identifying agents that affect adipocytes and adipose tissue, as well as the agents themselves. In particular, the present invention allows for creation of tissues and cells that can be used to screen for agents useful for treating human disorders associated with adipose tissue, including obesity, metabolic syndrome, and diabetes.01-21-2010
20100015103Cell culture method and application thereof - The invention relates to a cell culture method, particularly to a co-culture method for human mesenchymal stem cells and target animal cells, in order to solve the problem that animal cells are not easy to survive alone upon culturing. The invention also provides a method for using a stem cell conditioned medium to culture animal cells. The invention also provides a method to induce the transformation of human fetal islet-like cell clusters from human stem cells and its application thereof.01-21-2010
20100150877Osteopontin for the Prediction and Treatment of Cardiovascular Diseases - Osteopontin for the prediction and treatment of cardiovascular diseases The present invention relates to the use of endothelial progenitor cells (EPCs) and osteopontin for the treatment of cardiovascular diseases or complications. The invention also relates to the use of EPC osteopontin levels as a marker of the risk of the development of these cardiovascular complications. In particular, the invention provides compositions and methods based on osteopontin and the genes encoding osteopontin.06-17-2010
20100150883STEM CELLS TREATED BY IN VITRO FUCOSYLATION AND METHODS OF USE - A method of in vitro fucosylation of selectin ligands on cord blood-derived hematopoietic stem cells for bone marrow transplantation is disclosed. In this method, an effective amount of an α1,3-fucosyltransferase, e.g., α1,3-fucosyltransferase VI, is used in vitro to treat cord blood-derived hematopoietic stem cells to convert non-functional PSGL-1 or other ligands on the cell surface into functional forms that bind selectins, especially P-selectin or E-selectin. The treated cells have enhanced effectiveness in reconstituting bone marrow in patients in need of such therapy.06-17-2010
20100150882HUCBC TREATMENT OF AMYLOID ASSOCIATED DISEASE - Administration of human umbilical cord blood cells (HUCBC) or HUCBC-derived plasma is used to treat amyloid-based diseases, such as Alzheimer's disease, Huntington's disease, cerebral amyloid antigopathy, and type-II diabetes. Modulating inflammatory reactions by infusing HUCBC resulted in a marked reduction of amyloid plaques and immune-associated cellular damage. HUCBC infusion also significantly reduced cerebral amyloid angiopathy in mice models. These effects were associated with suppression of the CD40-CD40L interaction and a reduction in surface expressed CD-40 was observed on immune cells. Further, Aβ phagocytic activity was increased and soluble and insoluble Aβ protein levels were modulated by treatment. HUCBC-infused sera also significantly increased phagocytosis of Aβ06-17-2010
20100172882COMPOSITIONS AND METHODS FOR TARGETED INACTIVATION OF HIV CELL SURFACE RECEPTORS - Compositions for targeted mutagenesis of cell surface receptors for HIV and methods of their use are provided herein. The compositions include triplex-forming molecules that bind to duplex DNA in a sequence specific manner at target sites to form triple-stranded structures. The triplex-forming molecules can be triplex-forming oligonucleotides (TFOs) or peptide nucleic acids (PNAs). The triplex-forming molecules are useful to induce site-specific homologous recombination in mammalian cells when used in combination with donor oligonucleotides. The triplex-forming molecules target sites within or adjacent to genes that encodes cell surface receptors for human immunodeficiency virus (HIV). This binding stimulates homologous recombination of a donor oligonucleotide to cause mutations in HIV cell surface receptor genes that result in one or more deficiencies in the ability of the encoded receptor to bind to HIV and allow its transport into the cell. Methods for ex vivo and in vivo prophylaxis and therapy of HIV infection using the disclosed compositions are also provided.07-08-2010
20120141430Tissue Regeneration Membrane - The present invention relates to a membrane comprising at least one positively charged, synthetic, hydrophobic polymer, at least one hydrophilic polymer and at least one plasticizer; wherein said membrane is flexible and is capable of supporting at least one of cell adherence, cell proliferation or cell differentiation. The invention further relates to use of a membrane of the invention in the preparation of an implantable devices including cell delivery systems, cell growing surfaces and scaffolds. The invention further provides methods for promoting tissue regeneration in a defected tissue region applying membranes of the invention.06-07-2012
20120141436COMPOSITIONS AND METHODS FOR PROMOTING BETA CELL MATURITY - Compositions and methods for providing an enriched population of mature, glucose-responsive insulin secreting cells, and for modulating insulin expression, activity and secretion in a subject.06-07-2012
20100183569POROUS COMPOSITE MATERIAL, PREPARATION PROCESS THEREOF AND USE TO REALIZE TISSUE ENGINEERING DEVICES - The present invention refers to a porous composite material, wherein at least one interdispersed biopolymer is present, with a calcium-phosphate mineral component comprising from 50 w/% to 95 w/% of α-tricalcium phosphate (α-TCP, α-Ca07-22-2010
20100183562SUB -POPULATION OF HEMATOPOIETIC STEM CELLS THAT EXPRESS THE CRISP-1 PROTEIN - The subject of the present invention is a sub-population of isolated hematopoietic stem cells that express the CRISP-1 gene and produce the CRISP-1 protein on the cytoplasmic membrane of the cell, their isolation and their application in the therapeutic/diagnostic/prognostic field.07-22-2010
20080311084Mapc Engraftment in the Hematopoietic System - The present invention relates to MAPCs and progeny derived therefrom to provide lymphohematopoietic cells in a tissue of the lymphohematopoietic system of a subject.12-18-2008
20100260723IMPLANTABLE SYSTEM FOR AN INTERVERTEBRAL DISC AND INTERVERTEBRAL DISC IMPLANT - The present invention relates to an implantable system comprising a biologically acceptable bag comprising a cell carrier medium and a multi-component system, the use of such an implantable system for implanting into an intervertebral disc for the treatment of an annulus fibrosus and/or nucleus pulposus defect and/or for preventing an annulus fibrosus and/or nucleus pulposus defect, and an intervertebral disc implant.10-14-2010
20100260729Corn Event PV-ZMIR13 (MON863) Plants and Compositions and Methods for Detection Thereof - The present invention provides compositions and methods for detecting the presence of the corn event MON863 DNA inserted into the corn genome from the transformation of the recombinant construct containing a Cry3Bb gene and of genomic sequences flanking the insertion site. The present invention also provides the corn event MON863 plants, progeny and seeds thereof that contain the corn event MON863 DNA.10-14-2010
20090117086Preparation of replicating macrophages and use in diagnosis and therapy - Provided are methods for replicating macrophages in vitro and cell culture compositions comprising replicating macrophages. Also provided are methods for preparing replicating Kupffer cells from human liver. Further provided are methods for enhancing or extending immune function in an individual suffering from a deficiency relating to a reduced number of functional macrophages in a tissue or organ by administering a therapeutically effective amount of a replicating macrophages obtained by the methods of the invention.05-07-2009
20090117083IMMUNOMODULATORY ALKALOIDS - Immunotherapy comprises administration of an alkaloid at a dose sufficient to induce IL-2 production in dendritic cells in a patient. The alkaloid induces the production of IL-2 in dendritic cells. The alkaloids need not be naturally occurring, and may be synthetic analogues or derivatives of naturally occurring counterparts. Such analogues or derivatives are preferably pharmaceutically acceptable analogues, salts, isomers or derivatives as herein defined. However, preferred alkaloids are phytochemicals. Such phytochemicals may be isolated from natural sources or synthesised in vitro. Particularly preferred are alkaloids is selected from piperidine alkaloids; pyrrolin alkaloids; pyrrolidine alkaloids; pyrolizidine alkaloids: indolizidine alkaloids and nortropane alkaloids.05-07-2009
20100189696LITHIUM STIMULATION OF CORD BLOOD STEM CELL PROLIFERATION AND GROWTH FACTOR PRODUCTION - The present invention provides methods for expanding human umbilical cord blood stem cells and methods for stimulating growth factor production by cord blood stem cells using an in vitro cell culture system comprising a lithium salt. The present invention also provides in vivo methods for enhancing the survival and growth of transplanted cord blood stem cells by treating the cells with a lithium salt prior to transplantation. In vivo methods for reducing rejection of transplanted cord blood stem cells by administering a lithium salt after transplantation are also provided.07-29-2010
20100260724METHOD FOR MEASURING THE PLASMINE ACTIVITY OF MICROPARTICLES PRESENT IN A SAMPLE OF A BIOLOGICAL FLUID AND USE THEREOF - The invention relates to a method for measuring the plasmine activity of microparticles, in particular circulating microparticles, in a sample of a biological fluid, particularly a biological fluid in a flow situation, wherein said method can be used as a diagnosis method or a method for following a treatment.10-14-2010
20110177040Cytokine Induction Of Selectin Ligands On Cells - Methods and compositions for treating cells with cytokines are provided herein.07-21-2011
20100183571TREATMENT OF MULTIPLE SCLEROSIS USING PLACENTAL STEM CELLS - The present invention provides methods of immunomodulation using placental stem cells and placental stem cell populations. The invention also provides methods of producing and selecting placental cells and cell populations on the basis of immunomodulation, and compositions comprising such cells and cell populations.07-22-2010
20100183563DENTINOGENESIS PROMOTER AND DENTINOGENIC PULP-CAPPING MATERIAL - The present invention provides a dentinogenesis inducer and dentinogenesis pulp-capping material, which are effectively used for formation (regeneration) of dentin. The present invention also provides a method of producing odontoblasts useful for dental regenerative therapy and the application of the obtained odontoblasts. The dentinogenesis inducer and the dentinogenesis pulp-capping material of the present invention are both characterized by the use of an HMG-CoA reductase inhibitor as an active ingredient. Additionally, odontoblasts can be produced by culturing cells capable of differentiating into odontoblasts in the presence of the HMG-CoA reductase inhibitor.07-22-2010
20100260721Enrichment of Cells - The present invention relates to methods of isolating and enriching mesenchymal stem cells (MSCs) comprising treating a tissue sample comprising cells and extracellular matrix with an amount of a collagenase that is sufficient to free MSCs from the extracellular matrix in a liquid medium and then isolating a fraction of the medium containing MSCs. The isolated MSCs can be isolated in surprisingly large numbers such that the fraction can have immediate use in a number of clinical contexts. This represents an advance of prior art techniques that either require the pooling of large volumes of sample tissues from different sources or require MSCs to be expanded in culture. The invention therefore further concerns the clinical use of cells isolated according to the methods of the first aspect of the invention.10-14-2010
20100260730SHIP-Deficiency to Increase Megakaryocyte Progenitor Production - The invention concerns a method for increasing megakaryocyte and megakaryocyte progenitor numbers in vitro or in vivo by suppressing SH2-containing inositol-5-phosphatase (SHIP) function in megakaryocytes or megakaryocyte progenitors expressing the SHIP gene. SHIP function can be suppressed by administering an interfering RNA, or other SHIP inhibitor, to the megakaryocytes or megakaryocyte progenitors in vitro or in vivo.10-14-2010
20100260722Material for ameliorating skin tissue and method for producing the same - A material for ameliorating skin tissue provided by the invention comprises, as a main component, a culture obtained by culturing cells or tissue fragments derived from human or other mammalian alveolar mucosa. Typically, 50% or more of the cells contained in the culture are fibroblasts, and having a high growth rate and a high productivity in vascular endothelial cell growth factor (VEDF) and/or keratinocyte growth factor (KGF).10-14-2010
20100260727METHOD TO AMPLIFY CARDIAC STEM CELLS IN VITRO AND IN VIVO - Compositions comprising stem cells delivered into infarcted myocardium by endocardial injection, engraft and differentiate into myocytes, endothelial cells, and vascular smooth muscle, and do so without the requirement for survival enhancing modification. These cells engraft whether injected acutely (days) or late (months) after myocardial infarction, and the efficiency of engraftment correlates with the functional recovery of the heart. The stem cells also recruit endogenous cardiac precursor cells, reconstitute myocardial stem cell niches, and enhance endogenous cell differentiation into myocytes.10-14-2010
20100260725Materials and Methods for Treating Allergic and Inflammatory Conditions - The subject invention provides for the utilization of bone-marrow derived stem cells in the treatment of allergic and inflammatory diseases. In one embodiment, the invention provides for treatment of asthma. Bone-marrow derived stem cells can be used for decreasing inflammation and alter the course of immune response in the lung.10-14-2010
20100260728METHODS OF PRODUCING PANCREATIC HORMONES - Disclosed herein are methods of producing pancreatic hormone-expressing cells by first differentiating pluripotent cells in cell culture so as to produce endodermal cells, the endodermal cells being competent to further differentiate into hormone-expressing cells capable of secreting at least one pancreatic hormone in response to a physiological signal, and then, transplanting the cultured endodermal cells into an organism, such as an organism in need of an endocrine cell therapy.10-14-2010
20100260726Methods for Producing a Non Human Model for Aortic Aneurysm - The present invention relates to methods for producing a non human animal model for aortic aneurysm which could provide insight into the diagnosis and treatment of said disease. Furthermore, the present invention relates to methods and compositions for the treatment or the prevention of aneurysm in a subject in need thereof.10-14-2010
20100189697CARDIAC-SPECIFIC PROGENITOR CELLS - This document provides methods and materials related to treating cardiovascular tissue (e.g., heart tissue or vascular tissue). For example, stem cells (e.g., CXCR4+/Flk-1+ stem cells), compositions containing stem cells, methods for obtaining stem cells, and methods for repairing cardiovascular tissue are provided.07-29-2010
20100183561Biological therapeutic compositions and methods thereof - Novel uses of Platelet Rich Plasma (PRP) for infection prevention, bone repair and transmyocardial vascularization is disclosed. The present disclosure is directed to methods for preparing concentrated mesenchymal or haematopoietic stem cells, and autologous platelet-rich plasma (PRP) from the blood utilizing the Magallen® System. The stem cells and/or PRP may be combined with secondary biological agents such as antibiotics, fibrinogen and thrombin, and appropriately used in variety of medical conditions, such as, cardiovascular, thoracic, transplantation, head and neck, oral, gastrointestinal, orthopedic, neurosurgical, and plastic surgery.07-22-2010
20080299088Uses of Notch Receptors, Notch Ligands, and Notch Modulators in Methods Related to Metabolic Diseases - Disclosed are methods for identifying and isolating a precursor cell. Also, disclosed are methods of increasing insulin synthesis from a pancreatic β-cell. Further, disclosed are methods of improving pancreatic β-cell function. Still further, disclosed are methods of preventing or delaying the onset of a metabolic disease, methods of treating or preventing a metabolic disease in a subject, and to compositions for treating or preventing a metabolic disease in a subject in need of such treatment or prevention.12-04-2008
20100189700CULTURE FOR EXPANDING STEM CELLS EX-VIVO - The present invention relates to a culture including a growth medium and a combination of cytokines consisting of i) interleukin-6 (IL6); ii) flt3-ligand (FLT3); iii) stem cell factor (SCF) and iv) thrombopoi-etin (TPO); the use of the culture for expanding. ex vivo stem cells and/or parental cells and cells differentiated therefrom, and the use of said cells obtainable from said expansion.07-29-2010
20100166711METHOD FOR TREATING SKIN WOUNDS - The present invention relates to a method for treating a skin wound in an individual, comprising applying to the skin wound of the individual a therapeutically effective quantity of gingival fibroblasts.07-01-2010
20100015102Composition for treatment of cartilage disease - The present invention provides a composition for regenerating cartilage or treating a cartilage disease containing a monovalent metal salt of alginic acid for which the endotoxin level thereof has been lowered to an extent that does not substantially induce inflammation or fever. As a result, it is possible to provide a composition for regenerating cartilage that improves cartilage regenerative action and ease of application to a cartilage injury lesion, and a composition for treating a cartilage disease, which has the effects of protecting cartilage from mechanical irritation, inhibiting degenerative changes in cartilage caused by wear and inflammation, repairing a cartilage injury lesion, and inhibiting inflammation and pain of joint tissue.01-21-2010
20100150878DERMAL MICRO-ORGANS, METHODS AND APPARATUSES FOR PRODUCING AND USING THE SAME - Embodiments of the present invention provide Dermal Micro-organs (DMOs), methods and apparatuses for producing the same. Some embodiments of the invention provide a DMO including a plurality of dermal components, which substantially retain the micro-architecture and three dimensional structure of the dermal tissue from which they are derived, having dimensions selected so as to allow passive diffusion of adequate nutrients and gases to cells of the DMO and diffusion of cellular waste out of the cells so as to minimize cellular toxicity and concomitant death due to insufficient nutrition and accumulation of waste in the DMO. Some embodiments of the invention provide methods and apparatuses for harvesting the DMO. An apparatus for harvesting the DMO may include, according to some exemplary embodiments, a support configuration to support a skin-related tissue structure from which the DMO is to be harvested, and a cutting tool able to separate the DMO from the skin-related tissue structure. Other embodiments are described and claimed.06-17-2010
20100233143Parthenogenic Activation of Human Oocytes for the Production of Human Embryonic Stem Cells - Methods of producing human stem cells are disclosed for parthenogenetically activating human oocytes by manipulation of O09-16-2010
20100226896METHOD FOR INTRATHECAL ADMINISTRATION OF AUTOLOGOUS STEM CELLS IN PREMATURE INFANTS - The invention provides a method of treating a premature infant at a statistical risk of sustaining an intraventricular hemorrhage. The method, or therapeutic protocol, can include at least one or more of the following steps: identifying premature infants at a statistical risk of having an intraventricular hemorrhage, collecting umbilical cord blood from the identified premature infant, separating totipotential stem cells (e.g., having the ability to proliferate and differentiate as neural stem cells) from the collected cord blood, storing the separated stem cells, establishing evidence of an intraventricular hemorrhage (preferably prior to Grade III/IV if possible) in the premature infant, and intrathecally administering the autologous cord blood derived stem cells to the premature infant.09-09-2010
20100226894Mobilization of a complete cells mixture with embryonic like stem cells from the peripheral blood - Disclosed is a method to recover a mixture cell population consisting of a complete profile of progenitor cells including embryonic like stem cells (a “complete progenitor cell mixture” or CPM) from the peripheral blood of an individual by administering to that individual a combination of at least one or more from the category of growth factors and hormones combining with at least one or more from the category of cell fusion inhibitor compounds, and then recovering peripheral blood progenitor cells from said individual. The hormones and growth factors group should include hGH (human growth hormone) with or without erythropoietin (EPO), but specifically without either G-CSF or GM-CSF. The cell fusion inhibitor group should include a CXCR4 antagonist. Also disclosed is a method for using or preserving such a complete progenitor cells mixture (CPM) for the treatment of diseases.09-09-2010
20100239541TRANSPLANTATION OF HUMAN NEURAL CELLS FOR TREATMENT OF NEURODEGENERATIVE CONDITIONS - A method of treating neurodegenerative conditions is provided. Neural stem cells may be implanted at and/or remote from a region of neuron degeneration. The methods can include isolating neural stem cells from regions where specific types of neurons corresponding to the neurons to be replaced are generated. The methods can include isolating neural stem cells secreting growth factors affecting the growth and/or regeneration of specific types of neuron. In this invention, we disclose a method of treating such disorders, including several neurodegenerative disorders arising from the lack of cells that produce particular neurotransmitters in neural circuitry by transplanting exogenously cultured and expanded neural progenitors which, upon transplantation into a neural tissue, differentiate into neurons capable of integrating and producing neurotransmitters in sufficient quantities and in a sufficient manner to overcome the symptoms associated with the neurodegeneration.09-23-2010
20100226893High Retention Cell Injectate - The present disclosure generally relates to high retention cell injectates, methods of producing the high retention cell injectates and further to methods of treating diseases or conditions by administering the cell injectates to patients in need thereof. To allow for cell rentention into a provided hyaluronic acid solution, the present disclosure provides pretreatment of cells with one or more substances that increases the number of CD44 receptors on their surfaces. Cells expressing CD44 ligands show increase in binding to hyaluronic acid. The pretreated cells are thus incorporated into hyaluronic acid.09-09-2010
20100226895NEURAL SCAFFOLDS - Disclosed herein are compositions and methods useful for preparing neural scaffolds. The scaffolds comprise tissue taken from the spinal cord and/or dura mater of vertebrate and can be processed to form gels or sheets. Methods of treating patient with CNS injury are also presented.09-09-2010
20100233131SELENIUM DEDIFFERENTIATED CELL, PREPARATION METHOD AND USAGE THEREOF - Provided are a cell therapeutic composition containing selenium, a method of dedifferentiating selenium-treated cells, a cell therapeutic composition containing cells dedifferentiated from the selenium-treated cells by the same method, and a cell therapeutic composition containing cells redifferentiated from the dedifferentiated cells.09-16-2010
20120195861METHODS AND COMPOSITIONS FOR PRODUCING GERM CELLS FROM PERIPHERAL BLOOD DERIVED GERMLINE STEM CELLS - Described herein are the use of peripheral blood derived germline stem cells and their progenitors, methods of isolation thereof, and methods of use thereof.08-02-2012
20100233130Method and Apparatus for Maintenance and Expansion of Hematopoietic Stem Cells From Mononuclear Cells - A method of expanding/maintaining undifferentiated hematopoietic stem cells by obtaining unselected mononuclear cells; and seeding the mononuclear cells into a stationary phase plug-flow bioreactor in which a three dimensional mesenchymal/stromal cell culture has been pre-established, thereby expanding/maintaining undifferentiated hematopoietic stem cells.09-16-2010
20100239540Peptide Linked Cell Matrix Materials for Stem Cells and Methods of Using the Same - Biostructures that comprises modified alginates entrapping one or more stem cells are discloses. The modified alginates comprise at least one alginate chain section to which is bonded by covalent bonding at least one cell attachment peptide. Pluralities of stem cells are also disclosed. Methods of preventing death of stem cells and cells differentiated there from are disclosed. Methods of preparing a plurality of stem cells are disclosed. Methods of treating an individual who has a degenerative disease, such as a neurological disorder, or injury involving nerve damage by administering stem cells to said individual are disclosed.09-23-2010
20110059055TREATING MYELIN DISEASES WITH OPTIMIZED CELL PREPARATIONS - The disclosure relates to oligodendrocyte-biased glial progenitor cells and methods of making, isolating, and using such cells.03-10-2011
20110059054ENHANCED DENDRITIC CELLS FOR CANCER IMMUNOTHERAPY - Described herein are methods of cancer immunotherapy, particularly methods of preparing a population of enhanced dendritic cells and methods of treating cancer using the enhanced dendritic cells.03-10-2011
20110059053METHOD OF TREATING BIOCELLS - A method of treating biocells includes the steps of: a. providing biocells; b. applying at least one stressor to the biocells sufficient to cause nonlethal and reparable cell wall damage to the biocells, thereby putting the biocells in a catabolic state during which catabolic metabolic functions predominate over anabolic metabolic functions; and c. obtaining at least one product produced by the biocells during the catabolic state. In another embodiment, the method includes the steps of: a. providing biocells that are mammalian cells; b. applying at least one stressor to the biocells sufficient to cause nonlethal and reparable cell wall damage to the biocells, the reparable cell wall damage comprising openings that allow increased passage of materials through the cells walls; and c. inserting foreign DNA through the openings into the biocells.03-10-2011
20110059051Molecular Control of Brown Fat Differentiation and Engergy Expenditure - The invention provides methods and compositions for inducing brown fat cell differentiation through modulation of Prdm 16 activity or expression. Also provided are methods for preventing or treating obesity or an obesity related disorder in a subject through stimulation of Prdm 16 expression or activity. Further provided are methods for identifying compounds that are capable of modulating Prdm 16 expression or activity.03-10-2011
20110059050METHODS AND COMPOSITIONS RELATING TO STEM CELL TRANSPLANTATION - The invention relates to methods and compositions for stem cell transplantation. Aspects of the invention relate to administering hematopoietic stem cells and mesemchymal cells to a patient.03-10-2011
20090220463Pharmaceutical Composition For Treating Vascular-Related Diseases Comprising Peptide - Disclosed is a composition for treating vascular diseases by acting on abnormal angiogenesis by means of secretion of angiopoietins.09-03-2009
20100239544METHODS OF TREATMENT USING ELECTROMAGNETIC FIELD STIMULATED STEM CELLS - Methods of modifying stem cells and compositions of modified stem cells, in particular mesenchymal stem cells, using electric or electromagnetic fields. In various embodiments, the present invention's methods are for the treatment of a human or other mammal subject in need thereof, comprising providing an in vitro culture comprising mesenchymal stem cells, administering an electric stimulation to the in vitro culture, and implanting the mesenchymal stem cells into the subject. Methods also include treatment of a human or other mammal subject, comprising implanting mesenchymal stem cells into the subject, and administering an electric stimulation to the mesenchymal stem cells in situ. Other embodiments include methods of administering electric stimulation in conjunction with growth factors to stem cells.09-23-2010
20130216503Methods for Generating Cardiomyocytes - The present disclosure provides method of generating cardiomyocytes from post-natal fibroblasts. The present disclosure further provides cells and compositions for use in generating cardiomyocytes.08-22-2013
20130216504CCN3 AND CCN3 PEPTIDES AND ANALOGS THEREOF FOR THERAPEUTEC USES - The present invention provides a method for treating a human patient with a pathology by administering to the subject an effective amount of an agent selected from the group of: native full-length CCN3 proteins; analog CCN3 full-length proteins with native cysteine residues substituted by a replacement amino acid; CCNp native peptide fragments having from about 12 to about 20 amino acids; analog CCNp peptide fragments with native cysteine residues substituted with a replacement amino acid; and combinations thereof.08-22-2013
20130216505METHODS AND COMPOSITIONS FOR THE CLINICAL DERIVATION OF AN ALLOGENIC CELL AND THERAPEUTIC USES - Various cells, stem cells, and stem cell components, including associated methods of generating and using such cells are provided. In one aspect, for example, an isolated cell that is capable of self-renewal and culture expansion and is obtained from a subepithelial layer of a mammalian umbilical cord tissue. Such an isolated cell expresses at least three cell markers selected from CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and does not express at least three cell markers selected from CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR.08-22-2013
20130216507METHODS FOR PROMOTING HSC ENGRAFTMENT - The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E08-22-2013
20100303772METHOD AND SYSTEM FOR DIRECTING A LOCALIZED BIOLOGICAL RESPONSE TO AN IMPLANT - The invention provides methods for directing a localized biological response of a mammalian body to an implant disposed within the body. In one embodiment, a delivery system is positioned outside the body and adjacent to the implant within the body. The delivery system comprises a first tissue response modifier effective for directing a localized biological response of the body to the implant. The tissue response modifier is nonsurgically delivered from the delivery system into the body in a quantity effective to direct the localized biological response of the body to the implant. The invention also provides an implant system for long-term use comprising an implant and nonsurgical means for delivering a tissue response modifier through the epidermis of the body, the tissue response modifier effective for directing a localized biological response of the body to the implant.12-02-2010
20100254953CELL GROWTH METHOD AND PHARMACEUTICAL PREPARATION FOR TISSUE REPAIR AND REGENERATION - The present invention relates to a method for growing, rapidly and massively ex vivo, cells collected from a living subject to provide a safe and effective pharmaceutical preparation for biological tissue repair/regeneration. Specifically, the present invention relates to a method for growing cells in a sample collected from a living subject by culturing the cells in a medium containing allogeneic (including autogenic) serum. Preferably the allogeneic serum has been determined as being negative for a serum tumor marker and/or an infectious factors, and the amount of the anticoagulant (e.g., heparin, a heparin derivative, or a salt thereof) added to the collected sample is less than 5 U/mL with respect to the volume of the sample or the amount of the anticoagulant in the medium at the start of culture is less than 0.5 U/mL. The present invention further relates to use of the method.10-07-2010
20100239539Methods for promoting differentiation and differentiation efficiency - The invention is directed to methods for promoting differentiation of stem cells to hematopoietic cell lineages. The invention is further directed to increasing the differentiation efficiency of hematopoietic stem/progenitor cells. Such methods utilize novel compositions, including but not limited to, Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as Amnion-derived Cellular Cytokine Solution or ACCS), each alone or in combination with each other or other agents.09-23-2010
20100254955SURGICAL DEVICE FOR SKIN THERAPY OR TESTING - A device, and method of making the device, capable of therapeutic treatment and/or for in vitro testing of human skin. The device may be used on skin wounds for burned, injured, or diseased skin, and provides structures and functions as in normal uninjured skin, such as barrier function, which is a definitive property of normal skin. The device contains cultured dermal and epidermal cells on a biocompatible, biodegradable reticulated matrix. All or part of the cells may be autologous, from the recipient of the cultured skin device, which advantageously eliminates concerns of tissue compatibility. The cells may also be modified genetically to provide one or more factors to facilitate healing of the engrafted skin replacement, such as an angiogenic factor to stimulate growth of blood vessels. The inventive device is easy to handle and manipulate for surgical transplant, can be made into large sheets to minimize the number of grafts required to cover a large surface area to be treated, and can be produced within the time frame to treat a burned individual requiring a skin graft.10-07-2010
20100254952Isolated myeloid-like cell populations and methods of treatment therewith - The present invention provides a method of rebuilding and stabilizing functional vasculature in hypoxic retinal tissue comprising contacting the hypoxic retinal tissue with an effective amount of cells from an isolated myeloid-like cell population comprising a majority of cells that express CD44 antigen, CD11b antigen, and hypoxia inducible factor 1α (HIF-1α). The isolated myeloid-like bone marrow cells optionally can be transfected with a gene encoding a therapeutically useful peptide, for delivering the gene to the retina.10-07-2010
20100254954Human Bone Stem Cells From Amniotic Mesenchymal Cell Layer - A bone stem cell which may be supplied stably and which is free from the problem about the compatibility in transplantation is disclosed. The bone stem cell according to the present invention is separated from human amniotic mesenchymal cell layer. The bone stem cell may be used for osteogenesis in a bone defect or the like.10-07-2010
20120141431METHODS FOR IDENTIFYING, ISOLATING, AND UTILIZING ENDOCRINE PROGENITOR CELLS FROM ADULT HUMAN PANCREAS - The presence of the cell surface marker CD133 or the presence of a glycosylated form of the prominin-06-07-2012
20100209396Method of Enhancing Proliferation and/or Hematopoietic Differentiation of Stem Cells - The present invention provides methods for inducing differentiation of a stem cell, such as an embryonic stem cell, into a hematopoietic stem cell, by expressing a cdx gene and/or a hox gene. The method is useful for generating expanded populations of hematopoietic stem cells (HSCs) and thus mature blood cell lineages. This is desirable where a mammal has suffered a decrease in hematopoietic or mature blood cells as a consequence of disease, radiation or chemotherapy.08-19-2010
20100209399BRAIN-DERIVED STEM CELLS FOR REPAIR OF MUSCULOSKELETAL SYSTEM IN VERTEBRATE SUBJECTS - The stem cells that can be propagated and maintained for extended periods of time in culture in the absence of a feeder layer, and can be used to repair tissue damage. These cells are derived from fetal tissues and are able to repair different types of damage in musculoskeletal system, with significantly greater efficacy than stem cells derived from adult tissues. These cells are hypoimmunogenic and can be used for allogeneic transplantation to vertebrate hosts having disease and/or damage in musculoskeletal and other tissues. The cells can be administered by direct injection to the site in need of repair or by systemic (e.g., intravenous) administration. The stem cells of the invention are capable of migrating to the sites in need of repair, and of adopting a phenotype most appropriate to the nature of the damage, injury or disease.08-19-2010
20090028834Methods and compositions for stimulating the proliferation or differentiation of stem cells with substance P or an analog thereof - Compositions and methods are provided for stimulating cell proliferation and differentiation with substance P or a substance P analog. In one embodiment, the methods provide for stimulating or promoting stem cell differentiation by contacting a stem cell with substance P or a substance P analog. In another embodiment, the methods provide for administering to subject an effective amount of substance P or a substance P analog to treat an illness, disease or disorder.01-29-2009
20100239538COMPOSITIONS COMPRISING VASCULAR AND MYOCYTE PROGENITOR CELLS AND METHODS OF THEIR USE - The invention provides compositions of adult cardiac vascular progenitor cells (VPCs) and adult cardiac myocyte progenitor cells (MPCs) useful for the treatment of various cardiac conditions. The invention also encompasses methods of generating a biological bypass, repairing damaged myocardium, and treating or preventing hypertensive cardiomyopathy and heart failure with the compositions of the invention. Methods of isolating the cardiac progenitor cells are also disclosed.09-23-2010
20100021439METHODS AND COMPOSITIONS FOR TREATING INTERVERTEBRAL DISC DEGENERATION - A fluid matrix comprising cross-linked remodelable collagen from a donor vertebrate animal is useful for regenerating hydrodynamic function in damaged intervertebral discs in vivo. The matrix may be injectable and may comprise cells and a plurality of purified cell growth factors. The matrix promotes cell growth and elaboration of proteoglycans to facilitate regeneration of native tissues. The collagen in the matrix may be cross-linked using photooxidative catalysis and visible light, and purified cell growth factors are preferably at least partly bone-derived.01-28-2010
20100303767METHODS FOR COMPACT AGGREGATION OF DERMAL CELLS - The invention provides for a method for aggregating dermal papilla cells or dermal sheath cells or a combination thereof, the method comprising: growing dermal papilla cells or dermal sheath cells or a combination thereof in suspension culture; and contacting the culture with an effective amount of an enzyme, wherein a substrate of the enzyme is an extracellular matrix molecule in the suspension culture, so as to aggregate dermal papilla cells or dermal sheath cells. The culture may be a hanging drop culture and the enzyme may be a hyaluronidase.12-02-2010
20100209404ENHANCED METHOD FOR PRODUCING STEM-LIKE CELLS FROM SOMATIC CELLS - The instant invention provides methods and compositions for the production and use of pluripotent stem-like cells from low passage somatic cells, e.g., fibroblasts.08-19-2010
20100135963USE OF PAX4 IN PANCREATIC CELL PROLIFERATION - The present invention relates to an in vitro method for the generation and isolation of pancreatic β-cells, comprising the steps of (a) contacting an adult cell derived from mammalian pancreatic islets or an explant culture of adult pancreatic islets with functional, wild-type Pax4; and (b) detecting and isolating; from said adult cell or explant culture, β-cells that proliferate in response to the contact with Pax4. Furthermore, the use of functional; wild-type Pax4 for the preparation of a pharmaceutical composition for transplantation and/or tissue replacement is described.06-03-2010
20100203021PROVISION OF NEW CARDIOMYOCYTE PROGENITOR CELLS AND CARDIOMYOCYTES DERIVED THEREFROM - The present invention relates to cardiomyocyte progenitor cells (CMPCs), to methods for their isolation and to the use of this CMPCs for the provision of cardiomyocytes, by way of differentiating the obtained CMPCs with a demethylating agent. The present invention also relates to pharmaceuticals compositions comprising cardiomyocytes for use in a cardiomyocyte replacement therapy and/or for the treatment in myocardial infarctation or for ameliorating the effects of myocardial infarctation.08-12-2010
20100129327METHOD OF TREATING HEARING LOSS - The present invention relates to a method of generating cochlear hair cell-like cells in the inner ear of a subject. Preferably, the subject is human and is suffering from sensorineural hearing loss. The invention also relates to a method of generating cochlear hair cell-like cells in vitro and use of the cochlear hair cell-like cells for treating or preventing sensorineural hair loss in a subject.05-27-2010
20120141439BIOARTIFICAL LUNG - Presented is an airway organ bioreactor apparatus, and methods of use thereof, as well as bioartificial airway organs produced using the methods, and methods of treating subjects using the bioartificial airway organs.06-07-2012
20120141433Vaporized Stem Cell Derivatives for Topical and Other Therapeutic Uses - The invention provides compositions of vaporized stem cell derivatives and methods for their use and manufacture in the treatment of skin conditions and other therapeutic applications. Stem cell derivatives comprising vaporized stem cells, stem cell factors and/or stem cell microvesicles are disclosed and contemplated as being within the scope of the invention. The invention finds use in medical, rejuvenative and cosmetic applications.06-07-2012
20120141434Methods for Selecting Expanded Stem Cell Populations - A method and criteria are provided for selecting expanded hematopoietic stem cell populations for allogenic transplantation, the selected cell populations having high probability of engraftment and positive clinical outcome.06-07-2012
20120141428MUSCLE-DERIVED CELLS (MDCS) FOR TREATING MUSCLE- OR BONE-RELATED INJURY OR DYSFUNCTION - The present invention provides muscle-derived cells, preferably myoblasts and muscle-derived stem cells, genetically engineered to contain and express one or more heterologous genes or functional segments of such genes, for delivery of the encoded gene products at or near sites of musculoskeletal, bone, ligament, meniscus, cartilage or genitourinary disease, injury, defect, or dysfunction. Ex vivo myoblast mediated gene delivery of human inducible nitric oxide synthase, and the resulting production of nitric oxide at and around the site of injury, are particularly provided by the invention as a treatment for lower genitourinary tract dysfunctions. Ex vivo gene transfer for the musculoskeletal system includes genes encoding acidic fibroblast growth factor, basic fibroblast growth factor, epidermal growth factor, insulin-like growth factor, platelet derived growth factor, transforming growth factor-1, transforming growth factor-a, nerve growth factor and interleukin-1 receptor antagonist protein (IRAP), bone morphogenetic protein (BMPs), cartilage derived morphogenetic protein (CDMPs), vascular endothelial growth factor (VEGF), and sonic hedgehog proteins.06-07-2012
20090280093COMPOSITIONS AND POPULATIONS OF CELLS OBTAINED FROM THE UMBILICAL CORD AND METHODS OF PRODUCING THE SAME - The present invention relates to populations and compositions of stem and progenitor cells derived from the umbilical cord, and methods of obtaining the same. In some embodiments, one or more entire umbilical cords or sections thereof are subjected to a process where a cell population is derived without prior removal of any blood vessel. The population may be derived using mechanical and chemical means. The presently disclosed process may be applied to a single umbilical cord or to a plurality of umbilical cords, for example, as a batch process. Optionally, this process includes removing some or all cord blood before deriving the population. In some embodiments, presently disclosed cell populations include mesenchymal stem cells derived from Wharton's jelly and endothelial progenitor cells derived from a wall of a blood vessel of an umbilical cord. Optionally, the cell population includes stem cells derived from cord blood. The presently disclosed cell populations and compositions may be banked and/or used in a number of clinical or other applications. Exemplary applications include but are not limited to applications related to regenerative medicine, for screening compounds, for research, and for gene therapy.11-12-2009
20090074732Scaffold for Cell Growth and Differentiation - The present invention provides a devitalized mammalian parenchymatous tissue composition which includes an interstitial structure which can serve as a scaffold for tissue repair or regeneration. The devitalized mammalian parenchymatous tissue composition can further include the basement membrane of the tissue.03-19-2009
20090074730NOVEL STEM CELLS, NUCLEOTIDE SEQUENCES AND PROTEINS THEREFROM - The present invention provides novel stem cells, nucleotide sequences and proteins therefrom. More specifically, the present invention provides Pax7+/Myf5− stem cells and methods for identifying and isolating them. Also provided is a MEGF10 nucleotide sequence and protein.03-19-2009
20090074731METHOD OF ISOLATION AND USE OF CELLS DERIVED FROM FIRST TRIMESTER UMBILICAL CORD TISSUE - A method of isolating a pluripotent cell from human umbilical cord is described herein. The method involves collecting a sample of umbilical cord from fetal tissue obtained at less than 20 weeks of gestation, for example a first trimester umbilical cord. The sample is treated to obtain isolated umbilical cord cells, after which the isolated umbilical cord cells are incubated. Stem cells obtained in this way can be differentiated for use in therapeutic applications.03-19-2009
20090074728Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase - The present invention relates to the use of tissue non-specific alkaline phosphatase (TNAP) as a marker for identifying and/or isolating adult multipotential cells. The present invention also relates to cell populations enriched by methods of the present invention and therapeutic uses of these cells.03-19-2009
20090074727METHOD OF TREATING SOLID TUMOR - The present invention provides a method of immune/gene combination therapy that has an effect of suppressing growth of an intractable solid tumor and is useful for treatment of such a tumor, and a therapeutic composition used for said method.03-19-2009
20120034194Somatic Stem Cells - A population of somatic stem cells and a method of preparing same. Also disclosed are two subpopulations thereof and their various uses.02-09-2012
20090257988METHODS AND COMPOSITIONS FOR ACCELERATING THE GENERATION OF REGULATORY T CELLS EX VIVO - The present invention is directed to generating regulatory T cells by treating a cell culture that includes non-regulatory T cells with a regulatory composition. The invention encompasses methods utilizing a regulatory composition that includes agents that prevent methylation of the locus for the FOXP3 transcription factor, agents that accelerate differentiation of T cells into suppressor cells, and agents that are histone deacetylase inhibitors. The invention also encompasses compositions of regulatory T cells generated by culturing non-regulatory T cells with a regulatory composition as well as the use of such regulatory T cells in the treatment of autoimmune diseases and aberrant immune responses.10-15-2009
20100221231Skin replacement compositions and methods - The invention is directed to methods of making novel skin replacement compositions. The invention is further directed to the novel skin replacement compositions. The invention is also directed to methods for treating wounds, in particular burns and chronic, non-healing wounds, with such novel skin replacement compositions.09-02-2010
20090274665Stem Cells For Treating Lung Diseases - The invention is compositions and methods for treating lung diseases and conditions using mesenchymal stem cells. The preferred stem cells are those derived from a human umbilical cord, or from bone marrow.11-05-2009
20120195863METHODS AND APPARATUS FOR ENHANCED RECOVERY OF CELLS AND OF CELL-ENRICHED MATRIX FROM TISSUE SAMPLES - This document describes methods and an apparatus for recovery of a cell-enriched matrix and cells (e.g., regenerative cells) from a tissue sample. In some embodiments, at least two rounds of acceleration and deceleration are performed.08-02-2012
20090324561Cells exhibiting neuronal progenitor cell characteristics and methods of making them - Disclosed are cells exhibiting neuronal progenitor cell characteristics, and methods of making them from marrow adherent stem cells by regulating cellular pathways in the marrow adherent stem cells that are associated with glial transdifferentiation of the marrow adherent stem cells.12-31-2009
20090202497USE OF GLP-1, GLP-1 DERIVATIVES OR GLP-1 FRAGMENTS FOR SKIN REGENERATION, STIMULATION OF HAIR GROWTH, OR TREATMENT OF DIABETES - The present invention relates to the use of GLP-I, GLP-I derivatives or GLP-I fragments for skin regeneration or hair growth in mammals. As used for skin regeneration, GLP-I, GLP-I derivatives or GLP-I fragments can be applied to dermal wounds including burns, lacerations, cuts and scrapes. As used for hair growth, GLP-I, GLP-I derivatives or GLP-I fragments can be applied to humans suffering from alopecia, or baldness. GLP-I, GLP-I derivatives or GLP-I fragments can also be used to stimulate hair growth in animals raised for their pelts. GLP-I, GLP-I derivatives or GLP-I fragments can also be used in the redifferentiation of endothelial or skin cells into insulin producing cells, as a treatment for patients suffering from diabetes.08-13-2009
20110027238Mesenchymal Stem Cells and Uses Therefor - Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.02-03-2011
20090162325CELL IMPLANTATION TO PREVENT AND/OR TREAT AUTOIMMUNE DISEASE - The present invention is directed to the prevention or treatment of autoimmune diseases, and in particular, of type I diabetes, by administering a therapeutically effective amount of an implantable composition comprising living choroid plexus cells.06-25-2009
20090110668SUBPOPULATIONS OF BONE MARROW-DERIVED ADHERENT STEM CELLS AND METHODS OF USE THEREFOR - The presently disclosed subject matter provides an isolated subpopulation of bone marrow-derived adherent stem cells that are purified from bone marrow-derived adherent cells. Also provided are methods for isolating the subpopulation of bone marrow-derived adherent stem cells from bone marrow-derived adherent cells and for using the isolated subpopulation of bone marrow-derived adherent stem cells for treating tissue and/or organ damage in a subject.04-30-2009
20090130065Multipotent adult stem cells - Isolated human multipotent adult stem cell and isolated populations of cells that include human multipotent adult stem cells are disclosed. Human hair-follicle derived multipotent adult stem cells and methods of preparing isolated populations of cells that include human multipotent adult stem cells are disclosed. Isolated human hair-follicle derived multipotent adult stem cell that can differentiate in culture into a neuronal cell, a glial cell, a melanocyte cell, a muscle cell, an osteocyte, a chondrocyte, and a lymphocyte. Isolated human hair-follicle derived multipotent adult stem cell that can grow in cell culture in spheres are disclosed. Human pancreas derived multipotent adult stem cells, human liver derived multipotent adult stem cells, human kidney derived multipotent adult stem cells, human heart derived multipotent adult stem cells, human neural derived multipotent adult stem cells and methods of preparing isolated populations of cells that include such human multipotent adult stem cells are disclosed. Method of treating an individual who has diabetes, cardiac muscle damage, muscle damage and disease, neurodegenerative disease or nerve damage or injury, bone loss, damage and/or disease, cartilage loss, damage and/or disease, hair loss and immune disorders, are disclosed.05-21-2009
20080292601TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH IL-10 EXPRESSING CELLS - This present application describes a therapeutic agent for treating acute or chronic graft-versus-host disease using clonal marrow stem cells (cMSCs) as active ingredient.11-27-2008
20100021434Isolated Oligodendrocyte-Like Cells and Populations Comprising Same for the Treatment of CNS Diseases - Isolated human cells and populations thereof are provided comprising at least one oligodendrocyte phenotype and at least one mesenchymal stem cell phenotype, wherein the mesenchymal stem cell phenotype is not an oligodendrocyte phenotype. Methods of generating and using same are also provided.01-28-2010
20080267921Cardiac Stem Cells - Human cardiac stem cells can be isolated from endomyocardial biopsies. Such cells mediate cardiac regeneration and improve heart function in a mouse infarct model. The cells can be used for autologous, allogeneic, syngeneic, or xenogeneic therapeutic applications in patients. The stem cells can be genetically modified to enhance their therapeutic activity.10-30-2008
20100297087PLURIPOTENT STEM CELLS CHARACTERIZED BY EXPRESSION OF GERMLINE SPECIFIC GENES - The present invention relates to pluripotent or multipotent somatic stem cells characterized by the expression of the germline specific gene, DAZL. The somatic stem cells expressing the DAZL marker are further characterized by expression of additional markers and absence of expression of certain blood markers. In particular, the present invention discloses therapeutic and diagnostic uses, other than the germ cell potential use, of the DAZL pluripotent or multipotent stem cells isolated from adult or peripheral somatic sources such as peripheral blood, bone marrow or umbilical cord blood.11-25-2010
20090110667DETECTION AND TREATMENT OF AUTOIMMUNE DISORDERS - Disclosed herein are methods of treatment of autoimmune diseases such as systemic lupus erythematosus (SLE) as well as clinical assays for detection of autoimmune disease activity in patients utilizing the involving a PD1 ligand.04-30-2009
20110243900SOFT TISSUE AND BONE AUGMENTATION AND BULKING UTILIZING MUSCLE-DERIVED PROGENITOR CELLS, COMPOSITIONS AND TREATMENTS THEREOF - The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration for dermatological conditions, gastroesophageal reflux, vesico-ureteral reflux, urinary incontinence, fecal incontinence, heart failure, and myocardial infarction.10-06-2011
20130129692PLURIPOTENT CELLS - Pluripotent cells that are immunopositive for both the neural progenitor marker nestin and a pluripotent cell marker are provided. The cells exhibit rapid doubling times and can be maintained in vitro for extended periods. Also provided are cell cultures containing the pluripotent cells, a method of transplanting human pluripotent cells to a host, and a method of reducing seizure activity in a subject. These pluripotent cells, when transplanted into the ventricle of a host animal, migrate to the site of damage and adopt a suitably corrective phenotype, resulting in both structural and functional restoration.05-23-2013
20110129448METHODS TO MOBILIZE PROGENITOR/STEM CELLS - Methods to elevate progenitor and stem cell counts in animal subjects using compounds which bind to the chemokine receptor CXCR4 are disclosed. Preferred embodiments of such compounds are of the formula06-02-2011
20110117061Ex Vivo Expansion of Human Hematopoietic Stem Cells - Methods and kits for expanding the number of hematopoietic stem cells are provided. The methods comprise incubating cells in medium comprising isolated IGFBP-2 and an angiopoietin-like protein (Angptl). Expanded HSCs are provided as well as culture media and kits for the expansion of human HSCs in a defined medium. Methods of administering expanded human HSCs to and individual are provided as well as methods of treating an individual by administering certain growth factors and cytokines.05-19-2011
20110117062Methods For Producing Enriched Populations of Human Retinal Pigment Epithelium Cells - This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.05-19-2011
20100303768Isolated lineage negative hematopoietic stem cells and methods of treatment therewith - Isolated, mammalian, adult bone marrow-derived, lineage negative hematopoietic stem cell populations (Lin12-02-2010
20100303770METHODS FOR CULTURING DERMAL CELLS FOR TREATMENT OF SKIN INJURIES SUCH AS BURNS - The present invention relates to novel methods of growing or otherwise producing unpassaged or minimally-passaged dermal cells from a small biopsy specimen for treating skin injuries significantly larger than the biopsy.12-02-2010
20100303773TSP-1, TSP-2, IL-17BR AND HB-EGF ASSOCIATED WITH STEM CELL ACTIVITY AND USE THEREOF - Thrombospondin 1 (TSP-1), TSP-2, interleukin 17B receptor (IL-17BR) and heparin-binding epidermal growth factor-like growth factor (HB-EGF) associated with stem cell activity and use thereof.12-02-2010
20110123500METHODS OF ISOLATING NON-SENESCENT CARDIAC STEM CELLS AND USES THEREOF - The invention describes the isolation and methods of use of a non-senescent pool of adult cardiac stem cells. In particular, a subset of adult cardiac stem cells with superior regenerative capacity is disclosed. Such cells were found to have immortal DNA. Compositions comprising the non-senescent stem cells are also described. In addition, the present invention provides methods for repairing aged myocardium or damaged myocardium using the isolated non-senescent adult cardiac stem cells.05-26-2011
20110123498MESENCHYMAL STROMAL CELL POPULATIONS AND METHODS OF USING SAME - The invention relates to mesenchymal stromal cells produced by culturing the cells in platelet lysate supplemented media and methods of using these cells to treat neurological and kidney associated disorders.05-26-2011
20120269783COMPOSITION CONTAINING AUTOLOGOUS MONONUCLEAR CELLS AND PIG COLLAGEN SCAFFOLD IN PASTE FORM AND ITS USE IN THE PREPARATION OF A MEDICAMENT FOR SURGICAL TREATMENT - Composition including autologous mononuclear cells supported on scaffold chosen from the group including lyophilized scaffold or pre-constituted scaffold in the form of membrane or tissue, with possible addition of platelet gel, as well as use of said composition for the preparation of medicaments for surgical treatments.10-25-2012
20100303766CELL POPULATION WITH ENHANCED TRANSPLANTATION ACTIVITY - A cell having excellent migration ability and engraftment ability to tissues is required for the restoration and the like of damaged tissues making use of a hematopoietic stem cell transplantation or a stem cell transplantation. By the present invention, a cell population having excellent migration ability and engraftment ability to tissues, a pharmaceutical preparation comprising said cell and a transplantation method of said cell are provided. The cell of the present invention is useful for hematopoietic stem cell transplantation and restoration of damaged tissues using stem cell transplantation and the like.12-02-2010
20100303771GABA NEURON PROGENITOR CELL MARKER 65B13 - The present inventors identified a selective marker 65B13 for GABA neuron progenitor cells of the spinal dorsal horn and cerebellum, and successfully isolated GABA neuron progenitor cells using antibodies that bind to a protein encoded by the gene. 65B13 was demonstrated to be useful as a marker to isolate GABA-producing neuron progenitor cells in the spinal dorsal horn and cerebellum. GABA neuron progenitor cells can be efficiently identified or isolated by using the identified marker as an indicator.12-02-2010
20090169522MESENCHYMAL STEM CELLS EXPRESSING TNF-A RECEPTOR - Mesenchymal stem cells which express TNF-α receptor Type I in an amount of at least 13 pg/1007-02-2009
20130136721Compositions and Methods of Generating a Differentiated Mesodermal Cell - The invention features a culture system, culture system components and culture methods that are useful for the rapid and reliable generation of differentiated mesodermal cells, including cardiac myocytes, from stem cells, such as human embryonic stem cells and human induced pluripotent stem cells differentiated mesodermal cells, including differentiated cardiac myocytes.05-30-2013
20130136722Methods of Ex Vivo Expansion of Blood Progenitor Cells, and Generation of Composite Grafts - This invention provides methods and compositions of hematopoietic progenitor cells and hematopoietic stem cells, particularly methods for expanding populations of these cells types from biological sources.05-30-2013
20130136723CONNECTIVE TISSUE REPAIR - The invention concerns a homogenous population of human stem cells isolated from the full depth of human cartilage tissue and/or isolated from aged human cartilage; and uses thereof.05-30-2013
20090214493Cardiac Muscle Regeneration Using Mesenchymal Stem Cells - Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectable or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.08-27-2009
20090214492ISOLATED STROMAL CELLS FOR USE IN THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM - Methods of treating a human patient having a disease, disorder or condition of the central nervous system are disclosed. The methods include obtaining a bone marrow sample from a human donor, isolating stromal cells from the bone marrow sample, and administering the isolated stromal cells to the central nervous system of the human patient, wherein the presence of the isolated stromal cells in the brain effects treatment of the disease, disorder or condition. Stromal cells which are isolated may be cultured in vitro, they may be genetically engineered to produce therapeutic compounds, and/or they may be pre-differentiated prior to administration into the central nervous system.08-27-2009
20090214491Method Of Using Mitotically Inactivated Stem Cells For Damaged Tissue Repair - The present invention is directed to the use of mitotically and/or lethally inactivated stem cells for the repair of damaged organs and/or tissues. Stem cells are mitotically and/or lethally inactivated and transplanted into damaged tissue. Any form of ex vivo inactivation of stem cells may be used such that the stem cells cannot undergo mitosis or cell division before in vivo application. Mitotically and/or lethally inactivated stem may be used to ameliorate numerous disease, injury, traumatic, ischemic, aging, and/or degenerative conditions in different types of organs and/or tissues.08-27-2009
20090214488METHODS AND COMPOSITIONS FOR TREATING BASEMENT MEMBRANE DISORDERS - The invention features methods and compositions for the treatment of basement membrane diseases and disorders, such as Alport's syndrome.08-27-2009
20090214487USE OF MESENCHYMAL STEM CELLS FOR TREATING GENETIC DISEASES AND DISORDERS - A method of treating a genetic disease or disorder such as, for example, cystic fibrosis, Wilson's disease, amyotrophic lateral sclerosis, or polycystic kidney disease, in an animal comprising administering to said animal mesenchymal stem cells in an amount effective to treat the genetic disease or disorder in the animal.08-27-2009
20090214485STEM CELL THERAPY FOR THE TREATMENT OF DIABETIC RETINOPATHY AND DIABETIC OPTIC NEUROPATHY - The invention comprises methods and stem cell compositions for the treatment of diabetic retinopathy and other degenerative diseases of the eye. The invention is practiced in two stages with the first stage comprising the administration of neural stem cells to the eye, and the second stage comprising the administration of mesenchymal cells intravenously.08-27-2009
20090214483Progenitor Cells and Uses Thereof - Methods for preparing progenitor cells are described where epithelial cells are induced to undergo epithelial-mesenchymal transition as a result of exposure to an inducing agent or introduction of a gene therein that induces epithelial-mesenchymal transition. Progenitor cells resulting therefrom have use in cell-based therapies, among other utilities.08-27-2009
20100322906Method for Obtaining Pancreatic Endocrine Cells From Adipose Tissue-Origin Cells - A method of obtaining pancreatic endocrine cells from cells originating in an adipose tissue characterized by comprising culturing the adipose tissue-origin cells; the pancreatic endocrine cells that can be obtained thereby; a method of treating or preventing a disease caused by the hypofunction in pancreatic endocrine cells wherein the above-described pancreatic endocrine cells are used; a method of screening a substance capable of promoting or inhibiting the differentiation into pancreatic endocrine cells characterized by comprising adding a candidate substance to a medium in the course of culturing adipose tissue-origin cells to obtain the pancreatic endocrine cells; and so on.12-23-2010
20110110899Combined Chemical and Genetic Approaches for Generation of Induced Pluripotent Stem Cells - The present invention provides for identification and use of small molecules to induce pluripotency in mammalian cells as well as other methods of inducing pluripotency.05-12-2011
20110110901METHODS OF LONG-TERM CULTURE OF EUKARYOTIC CELLS AND USES THEREOF - An immortalizing protein complex, comprises an internalizing molecule, a transforming polypeptide and an endosome releasing molecule; all molecule and/or polypeptides being operatively linked to one or more of the other polypeptides, and optionally one or more of a nuclear internalizing molecule and a telomere extending molecule. A method of producing immortalized cells or extending the life of primary cells, comprises contacting the immortalizing protein complex of the invention with a target cell under conditions and for a period of time effective for the protein complex to be internalized and the transforming polypeptide released, and allowing for the transforming polypeptide to extend the life of the cell and/or overcome cell arrest. Also provided are an immortalizing polynucleotide encoding the protein complex, a hybrid vector carrying an expression vector and the polynucleotide, a cell transformed with the hybrid vector, a cell expressing the protein complex, and a cell immortalization kit that comprises the protein complex and/or a polynucleotide encoding the protein and/or a hybrid expression vector carrying the polynucleotide, and instructions for its(their) use to practice the method for immortalizing cells. Cells and tissue transplants comprising the cell(s), and various uses for the immortalized cells and tissue thereof are also provided.05-12-2011
20110110897Adult Human Cardiac-Derived Progenitor Cells - The present invention is based, in part, on the discovery that cardiac progenitor cells are present in and can be isolated from adult human heart. Accordingly, a cell of the present invention comprises a human adult cardiac-derived progenitor cell capable of differentiating into a cardiac myocyte where said cell is isolated according to the expression of specific biomarkers, identified elsewhere herein. The present invention also includes methods of use of an adult cardiac-derived progenitor cell in the treatment of heart disease.05-12-2011
20090214481TREATMENT OF ISCHEMIA USING STEM CELLS - The invention features a method for treating or preventing ischemia in a mammal by administering unrestricted somatic stem cells (USSCs) to the mammal.08-27-2009
20090214480Novel cancer antigen peptide and the use thereof - Novel peptides useful as a therapeutic and/or prophylactic agent of cancers, as well as medical uses thereof, are described. Each of these peptides have a consecutive amino acid sequence within a specific region of YKL-40 antigen expressing on the cell surface of brain tumor cells, that is, within the region aa10-19, aa49-61, aa74-83, aa96-117, aa152-161, aa177-185, aa202-211, aa246-261 or aa326-354, which peptide has an immunity-inducing activity. These peptides are useful for therapy and/or prevention of cancers when administered to a living body, and are useful for inducing T cells which exert cytotoxic activity against cancer cells when used to stimulate the T cells in vitro.08-27-2009
20110212064THERAPEUTIC PRODUCTS COMPRISING VITALIZED PLACENTAL DISPERSIONS - This invention provides a fluid therapeutic placental product comprising placental cells and a placental dispersion comprising placental factors. The placental cells and the placental dispersion are derived from placental tissue. A placental tissue can optionally be an amnion, chorion, or a trophoblast-depleted chorion. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.09-01-2011
20110212062COMPOSITIONS AND METHODS USING STEM CELLS IN CUTANEOUS WOUND HEALING - Provided herein are compositions and methods using stem/progenitor cells in a therapeutic approach for treatment of or promotion of healing of acute and chronic wounds.09-01-2011
20110008297OXYSTEROLS FOR ACTIVATION OF HEDGEHOG SIGNALING, OSTEOINDUCTION, ANTIADIPOGENESIS, AND WNT SIGNALING - Synthetic oxysterols can be made and can be used for the treatment of bone disorders, obesity, cardiovascular disorders, and neurological disorders.01-13-2011
20110008301HUMAN ADIPOSE DERIVED INSULIN MAKING MESENCHYMAL STEM CELLS FOR TREATING DIABETES MELLITUS - The invention provides a novel therapeutic composition comprising of insulin producing mesenchymal stem cells obtained from human adipose tissue along with Hematopoietic stem cells for the treatment of diabetic patients especially insulinopenic patients. The invention also describes a simple and efficient process for the isolation, proliferation and differentiation of insulin producing mesenchymall stem cells from human adipose tissue. Unfiltered extract of adipose tissue is used in the process with a medium totally free from xenogenic material; the serial passages of the cells are avoided in the process.01-13-2011
20110008299TREATMENT OF PELVIC FLOOR DISORDERS WITH AN ADIPOSE-DERIVED CELL COMPOSITION - A method for treating a pelvic floor disease comprises removing adipose tissue from a patient, processing a first portion of the adipose tissue to obtain a heterogeneous mixture of cells that includes adipose-derived stem cells, combining the heterogeneous mixture of cells with a second, unprocessed portion of the adipose tissue in a ratio of from approximately 1:1 to 1:4 to produce a cell composition, wherein the second portion of the adipose tissue is structured to provide a natural scaffold, and administering the cell composition to the patient to treat a pelvic floor disease.01-13-2011
20090068156TREATMENT OF MUSCULAR DYSTROPHY WITH CORD BLOOD CELLS - The invention features methods for treating a patient suffering from muscular dystrophy by administration of umbilical cord blood cells, e.g., by IV infusion.03-12-2009
20090068153CELL COMPOSITION FOR TISSUE REGENERATION - A method of extracting human progenitor cells from perivascular tissue of human umbilical cord. The extracted cells are then co-cultured with hematopoetic stem cells and are useful to grow and repair human tissues including bone. Also included are related methods and compositions related thereto.03-12-2009
20090068152GENE TRANSFER FOR REGULATING SMOOTH MUSCLE TONE - The invention provides methods of regulating smooth muscle tone in a subject, comprising the introduction, into smooth muscle cells of the subject, of a DNA sequence encoding a potassium channel protein involved in the regulation of smooth muscle tone, and expression of the DNA sequence in a sufficient number of smooth muscle cells of the subject to regulate smooth muscle tone in the subject. The invention provides methods of gene transfer for treating erectile dysfunction, bladder dysfunction, and other smooth muscle disorders.03-12-2009
20110008296MUSCLE-DERIVED CELLS HAVING DIFFERENTIATION CAPACITIES - The present application relates to cell populations having differentiation capacities, which are obtainable by isolation from a muscle tissue, more particularly from a skeletal and/or cardiac muscle tissue, preferably from endomysial and/or cardiac tissue, more preferably from endomysial tissue. The cell populations of the invention comprise ALDH-positive cells, and notably have myogenic and/or adipogenic and/or osteogenic differentiation capacities.01-13-2011
20110014160DDR1-Mediated Cell Purification of Pancreatic Endocrine Cells Through Their Progenitors - The invention relates to a method of identifying, obtaining and/or quantifying a culture of pancreatic cells selected from the group consisting of ductal/endocrine progenitor cells, endocrine progenitor cells, early endocrine cells, and fully differentiated endocrine cells. Also contemplated is a method of expanding the numbers of such cells as well as sorting such cells. The invention further relates to a selective cell surface marker, DDR1, that permits the selection of a unique subset of cells with pancreatic endocrine progenitor phenotype. Furthermore, the invention relates to isolated cells selected from such cells and compositions thereof.01-20-2011
20110008298METHOD OF DERIVING PROGENITOR CELL LINE - We disclose a method comprising: (a) providing an embryonic stem (ES) cell; and (b) establishing a progenitor cell line from the embryonic stem cell; in which the progenitor cell line is selected based on its ability to self-renew. Preferably, the method selects against somatic cells based on their inability to self-renew. Preferably, the progenitor cell line is derived or established in the absence of co-culture, preferably in the absence of feeder cells, which preferably selects against embryonic stem cells. Optionally, the method comprises (d) deriving a differentiated cell from the progenitor cell line.01-13-2011
20110014158COMPOSITIONS AND METHODS OF USING CHONDROITINASE ABCI MUTANTS - The present invention relates to protein and nucleic acid mutants of chondroitinase ABCI. Such chondroitinase ABCI mutant enzymes exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.01-20-2011
20130149287Corticogenesis of Human Pluripotent Cells - This invention relates to in vitro methods for the induction of corticogenesis in human pluripotent cells, such as iPS cells, by culturing the cells under conditions which stimulate retinoid signalling and inhibit TGFβ superfamily signalling. This may be useful in production of cortical neurons, in particular patient-specific cortical neurons; the modelling of juvenile and adult-onset neurological diseases; and the development of therapeutics.06-13-2013
20100183566METHOD FOR EFFICIENT TRANSFER OF HUMAN BLASTOCYST-DERIVED STEM CELLS (hBS CELLS) FROM A FEEDER-SUPPORTED TO A FEEDER-FREE CULTURE SYSTEM - Technology is provided for the transfer of human blastocyst-derived stem cells (hBS cells) to a feeder-free culture system and propagation of the cells in such a feeder-free culture system, the method comprising the following steps of (a) transferring the blastocyst-derived stem cells from feeder to feeder free culture by mechanical treatment, (b) culturing the blastocyst-derived stem cells under feeder cell free growth conditions in a suitable growth medium and/or on a suitable support substrate, and (c) optionally passaging the blastocyst derived stem cell line every 3-10 days by enzymatic and/or mechanical treatment. The application of hBS cells cultured under a feeder-free condition in medicine (e.g., myocardial regeneration) and screening and toxicity testing also is provided.07-22-2010
20110110898Bioactive removal of hypertrophic scars - An embodiment of the invention includes methods for the long-term augmentation and/or repair of skin defects (scars, skin laxness, skin thinning, and skin augmentation), cellulite, breast tissue, wounds and burns, urological and gastroesophageal sphincter structures, hernias, periodontal disease and disorders, tendon and ligament tears and baldness, by the injection or direct surgical placement/implantation of autologous cultured cells and/or cultured cell-produced extracellular matrix that is derived from connective tissue, dermis, fascia, lamina propria, stroma, adipose tissue, muscle, tendon, ligament or the hair follicle. The corrective application is done on tissue proximal or within the area of the defect. The method involves retrieving viable cells from the subject, a neonate or human fetus. Alternatively, the corrective application involves the cells placed in a matrix, preferably comprised of autologous extracellular matrix constituents as a three-dimensional structure or as a suspension, prior to placement into a position with respect to the subject's defect. In a further embodiment, the preferable autologous extracellular matrix constituents are collected from culture and placed in a position with respect to the subject's defect.05-12-2011
20090035284DERIVATION OF NEURAL STEM CELLS FROM EMBRYONIC STEM CELLS AND METHODS OF USE THEREOF - Provided is a method for the derivation of neural stem cells (NSCs) from embryonic stem cells (ESCs) and the use of the NSCs for treatment of various neural disorders. The NSCs that are derived from the ESCs are tissue-specific multipotent NSCs with a stable growth rate, unlimited self-renewal capacity, and a predictable differentiation profile. Being both non-tumorigenic and engraftable, the NSCs of the present invention have utility in repopulation stroke-damaged tissue. The NSCs of the present invention may be differentiated to produce tyrosine-hydroxylase expressing neurons, which may be used as a source of dopaminergic neurons for subjects suffering from a condition characterized by dopaminergic dysfunction, such as Parkinson's disease.02-05-2009
20090035283Composition and Method for Inhibition of Melanin Synthesis - The present invention provides a whitening cosmetic composition comprising a stem cell, a culture medium thereof or a protein isolated from the culture medium and a method of whitening a skin which comprises administering to the skin an therapeutically effective amount of a stem cell, a culture medium thereof or a protein isolated from the culture medium.02-05-2009
20110027234METHODS FOR IDENTIFICATION AND SELECTION OF HUMAN EMBRYONIC STEM CELL DERIVED CELLS - A nucleic acid construct is disclosed, the nucleic acid comprising a polynucleotide comprising a nucleic acid sequence encoding a detectable expression product, the nucleic acid sequence being operably linked to a human tissue specific promoter. A method of lineage tracing of human stem cells and isolated human embryonic stem cell comprising the nucleic acid construct are also disclosed.02-03-2011
20110033428METHOD FOR ISOLATING SMOOTH MUSCLE STEM CELLS - This invention relates to a method for isolating smooth muscle stem cells derived from mammalian smooth muscle comprising bringing mammalian smooth muscle cells into contact with a fluorescence-labeled anti-CD45 antibody, anti-CD34 antibody, and anti-CD49f antibody, and isolating cells that would not bind to the anti-CD45 antibody but would bind to the anti-CD34 antibody and the anti-CD49f antibody.02-10-2011
20110033426USE OF MODIFIED CELLS FOR THE TREATMENT OF MULTIPLE SCLEROSIS - The present invention describes blood cells chemically coupled with immunodominant myelin peptides and their use in the treatment of Multiple Sclerosis.02-10-2011
20110033427Expansion Of Renewable Stem Cell Populations - Ex vivo and in vivo methods of expansion of renewable stem cells, expanded populations of renewable stem cells and their uses.02-10-2011
20100135969METHOD OF TREATING CANCER USING PLATELET RELEASATE - Platelets are concentrated from the blood of a patient. The platelets are treated by a method such as ultrasound or agitation to obtain platelet releasate. This releasate as a whole or a component thereof is formulated into an injectable formulation which is administered to the same patient the platelets were extracted from in order to treat the patient's cancer.06-03-2010
20110110900NOVEL ADULT PROGENITOR CELL - The invention relates to the isolation and use of a novel progenitor cell population from the lamina propria of the oral mucosa. The novel progenitor cell population is highly proliferative and can be differentiated into a range of cell lineages. Further, these novel progenitor cells possess immunomodulatory activity and so can be used in the allogeneic transfer of tissue or to help combat immune disorders.05-12-2011
20090162328IN VIVO ASSAY AND MOLECULAR MARKERS FOR TESTING THE PHENOTYPIC STABILITY OF CELL POPULATIONS AND SELECTED CELL POPULATIONS FOR AUTOLOGOUS TRANSPLANTATION - An in vivo assay to measure anchorage-independent growth and phenotypic stability of a certain cell population comprising subcutaneous or intramuscular injection in a mammal of a cell suspension of articular chondrocytes in an iso-osmotic liquid, the same suspension comprising articular chondrocytes in an amount equivalent to at least 1×1006-25-2009
20110117065COMPOSITIONS AND METHODS FOR USING CELLS TO TREAT HEART TISSUE - This document relates to compositions containing cardiogenic factors, to methods to obtain cells by culturing initial cells in the presence of such factors; and methods of administering the obtained cells to heart tissue.05-19-2011
20110044954Methods of producing germ-like cells and related therapies - The present invention relates to methods of producing germ-like cells (GLCs) from embryonic stem cells and induced pluripotent stem cells, GLCs produced by such methods, gametes derived from such GLCs, pharmaceutical compositions and kits containing such GLCs, screens that use GLCs to identify agents useful in enhancing mammalian reproductive health, and methods of treatment that use GLCs to enhance mammalian reproductive health.02-24-2011
20120134966EMBRYONIC STEM CELL SPECIFIC MICRORNAS PROMOTE INDUCED PLURIPOTENCY - The methods of the present application describe that introduction of physiologically relevant miRNAs can enhance or modulate somatic cell reprogramming, generating induced pluripotent stem cells (iPS cells). These miRNAs did not further enhance reprogramming in the presence of cMyc. Furthermore, unlike previously described methods of generating iPS cells, such as through the introduction of genetic elements using viruses, the methods of the present invention reduce the risk of activating oncogenes in the iPS cells. The methods of the invention generate iPS cells that can be free of genetic modifications and thus have greater potential for use as therapeutic agents than those generated by existing methods.05-31-2012
20120034191EXTRACELLULAR MATRIX COMPOSITIONS FOR TISSUE REGENERATION - The invention is compositions of extracellular matrix that comprise mammalian extracellular matrix from two or more tissue sources in a mammal. The invention also includes methods of using these compositions to regenerate tissue or generate new tissue at sites of defects or wounds in mammals.02-09-2012
20110243903USE OF A ROCK INHIBITOR TO SUSTAIN PRIMARY HUMAN KERATINOCYTES IN A PROLIFERATIVE STATE - Disclosed herein is the finding that treatment with a ROCK inhibitor increases proliferation and induces immortalization of primary keratinocytes. Accordingly, provided is a method of immortalizing primary keratinocytes by exposure to a ROCK inhibitor. Also provided are immortalized primary keratinocytes produced by the described method, as well as organotypic tissue equivalents and cell cultures comprising the immortalized primary keratinocytes. Furthermore, ROCK inhibitor-treated cells show a greatly increased ability to support viral DNA replication of both “low risk” and “high risk” HPV genomes, indicating that ROCK inhibitors will be useful for studying the life cycles of a wide range of HPVs.10-06-2011
20110212069Modulation of Microglia Activation - The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component. The invention is generally directed to reducing inflammation by administering cells that modulate microglia activation. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to modulate microglia activation. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired levels of potency to modulate microglia activation.09-01-2011
20090324557METHOD TO INDUCE AND EXPAND THERAPEUTIC ALLOANTIGEN-SPECIFIC HUMAN REGULATORY T CELLS IN LARGE-SCALE - Methods for inducing, expanding, and/or generating alloantigen-specific regulatory T cells. Alloantigen-specific regulatory T cells can be induced, expanded, and/or generated from naive CD412-31-2009
20110142804NANOFIBER SCAFFOLD - The invention is directed to a device and method to prevent migration of Human Mesenchymal Stem Cells (hMSCs) from a delivery site while allowing communication between the stem cells and native cardiomyocytes. The device is characterized by scaffold pore size, fiber diameter and biomaterial selection. The invention includes a two part polyurethane scaffold that prevents migration of stem cells, allows gap junction formation through pores and is packaged for minimally invasive delivery.06-16-2011
20100239543PLURIPOTENT EMBRYONIC-LIKE STEM CELLS, COMPOSITIONS, METHODS AND USES THEREOF - The present invention relates to pluripotent stem cells, particularly to pluripotent embryonic-like stem cells. The invention further relates to methods of purifying pluripotent embryonic-like stem cells and to compositions, cultures and clones thereof. The present invention also relates to a method of transplanting the pluripotent stem cells of the present invention in a mammalian host, such as human, comprising introducing the stem cells, into the host. The invention further relates to methods of in vivo administration of a protein or gene of interest comprising transfecting a pluripotent stem cell with a construct comprising DNA which encodes a protein of interest and then introducing the stem cell into the host where the protein or gene of interest is expressed. The present also relates to methods of producing mesodermal, endodermal or ectodermal lineage-committed cells by culturing or transplantation of the pluripotent stem cells of the present invention.09-23-2010
20110212061Mesoderm and Definitive Endoderm Cell Populations - The present invention provides cell populations that are enriched for mesendoderm and mesoderm, and cell populations that are enriched for endoderm. The cell populations of the invention are useful for generating cells for cell replacement therapy. The present invention further provides a method of generating hepatocytes, cell populations enriched for hepatocytes, and a method of hepatocyte replacement therapy.09-01-2011
20110212068METHODS AND COMPOSITIONS FOR TREATING CONGESTIVE HEART FAILURE - Compositions and methods for treating congestive heart failure are provided herein.09-01-2011
20110212065METHODS OF MANUFACTURE OF THERAPEUTIC PRODUCTS COMPRISING VITALIZED PLACENTAL DISPERSIONS - This invention provides a fluid therapeutic placental product comprising placental cells and a placental dispersion comprising placental factors. The placental cells and the placental dispersion are derived from placental tissue. A placental tissue can optionally be an amnion, chorion, or a trophoblast-depleted chorion. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.09-01-2011
20100080777COMPOSITION CONTAINING AUTOLOGOUS MONONUCLEAR CELLS AND PIG COLLAGEN SCAFFOLD IN PASTE FORM AND ITS USE IN THE PREPARATION OF A MEDICAMENT FOR SURGICAL TREATMENT - Composition including autologous mononuclear cells supported on scaffold chosen from the group including lyophilized scaffold or pre-constituted scaffold in the form of membrane or tissue, with possible addition of platelet gel, as well as use of said composition for the preparation of medicaments for surgical treatments.04-01-2010
20100008891Production of Pluripotent Cells Through Inhibition of Bright/Arid3a Function - The present invention involves the identification of Bright/ARID3a as involved in the regulation of pluripotency in cells, and the targeting of that function for the regulation of pluripotency. Thus, methods of de-differentiating cells into pluripotent cells are provided, as well as methods for re-differentiating such cells in a controlled fashion.01-14-2010
20110091429Methods for Enhancing Stem Cell Engraftment During Transplantation - The present invention relates to the fields of hematopoietic stem cell transplantation and molecular biology. More specifically, methods for improving engraftment efficiency in stem cell transplants by improving stem cell homing to bone marrow are provided.04-21-2011
20090004152METHODS OF PRODUCING PANCREATIC HORMONES - Disclosed herein are methods of producing pancreatic hormone-expressing cells by first differentiating pluripotent cells in cell culture so as to produce endodermal cells, the endodermal cells being competent to further differentiate into hormone-expressing cells capable of secreting at least one pancreatic hormone in response to a physiological signal, and then, transplanting the cultured endodermal cells into an organism, such as an organism in need of an endocrine cell therapy.01-01-2009
20090220461Metastasis inhibition preparations and methods - Disclosed are compositions and pharmaceutical preparations suitable for inhibiting metastasis of a malignant cancer in an animal. Methods for inhibiting and/or eliminating metastasis in an animal are also provided. In some embodiments, the preparations and compositions comprise a whole cell tumor preparation comprising tumor tissue cells and tumor connective tissue stroma. The disclosure also provides methods for preparing the preparations and pharmaceutical preparations. Inhibition of metastasis of malignant prostate cancer to the lung is shown in vivo.09-03-2009
20090257989Intraperitoneal Delivery Of Genetically Engineered Mesenchymal Stem Cells - A method of expressing at least one protein in an animal by intraperitoneal administration of mesenchymal stem cells genetically engineered with at least one polynucleotide encoding the at least one protein. The method may be employed in treating lysosomal storage disorders, such as Fabry Disease, or arthritic disorders, or hemophilia, for example.10-15-2009
20090246181THERAPEUTIC COMPOSITION FOR ATOPIC DERMATITIS - A novel type of therapeutic agent, human mesenchymal stem cells, and a composition containing the same for the treatment of atopic dermatitis is disclosed. A method for the treatment of atopic dermatitis in patient is also disclosed.10-01-2009
20100015106Method and compositions for inhibiting tumorigenesis - The present invention discloses methods of producing neuronal cells from stem cells, particularly from adult brain stem cells. The use of such neuronal cells in the treatment and/or prevention of neurological diseases, conditions and/or injuries is also disclosed. In addition, the present invention provides a novel source of neuronal cells for use as a laboratory tool.01-21-2010
20100008890MAPC Therapeutics Without Adjunctive Immunosuppressive Treatment - The invention relates to the treatment of various injuries, disorders, dysfunctions, diseases, and the like with MAPCs, without the need for adjunctive immunosuppressive treatment.01-14-2010
20100015105METHOD OF TREATING SCHIZOPHRENIA - A method of treating schizophrenia in a subject in need thereof is provided. The method comprising, administering to the subject a therapeutically effective amount of cells expressing at least one exogenous polypeptide forming a connexin channel and/or a hyperpolarizing ion channel, thereby treating the schizophrenia in the subject.01-21-2010
20100034784USE OF FUSED NICOTINAMIDES TO PROMOTE NEUROGENESIS - The present invention provides a group of compounds found to increase the number of neurons derived from stem cells for use as a therapeutic agent in neurological conditions or diseases. In one embodiment of the present invention, the compounds are used to detect the mechanism by which the number of neurons is increased.02-11-2010
20100034781Oxysterol Compounds and the Hedgehog Pathway - This invention relates, for example, to synthetic oxysterols. Also described are methods for using the compounds, including treating subjects in need thereof, and pharmaceutical compositions and kits for implementing methods of the invention.02-11-2010
20100034778STEM CELLS - The present invention relates, in general, to stem cells and, in particular, to a method of expanding human stem cells using a retinoic acid receptor modulator.02-11-2010
20100034785Differentiation of Pluripotent Cells into Primary Germ Layer Progenitors - This invention relates to the culture of pluripotent cells in a fully humanised chemically defined medium. Cells may be cultured over a prolonged period of time without losing their pluripotent status or may be controllably induced to differentiate into progenitor cells of the three primary germ layers by the addition of differentiation factors, for example differentiation factors which modulate one or more of the Activin/Nodal, FGF, Wnt or BMP signalling pathways.02-11-2010
20100055079Method of Harvesting, Isolating, and Culturing Neural Stem Cells and Related Methods of Treating a Patient - The present invention provides a method of producing purified neural stem cells, comprising harvesting fluid containing neural stem cells from cerebrospinal fluid surrounding the spinal cord of an individual, isolating the neural stem cells from the fluid, culturing the neural stem cells in a culture medium effective to induce proliferation of the neural stem cells and purifying the cultured neural stem cells. Also provided is a method of treating a patient afflicted with a neurological condition, in which the purified neural stem cells are administered autologously into the same individual or heterologously to a patient other than the individual. Administration of the purified neural stem cells results in the purified neural stem cells propagating in the site of the brain region afflicted with the neurological condition.03-04-2010
20090035285Compositions and Methods for Enrichment of Neural Stem Cells Using Ceramide Analogs - The present invention provides compositions and methods for human neural cell production. More particularly, the present invention provides cellular differentiation methods employing amphiphilic lipid compounds, preferably ceramide analogs of the β-hydroxyalkylamine type and optionally employing an essentially serum free MEDII conditioned medium for the generation of human neural cells from pluripotent human cells. The methods alternatively comprise modulating apoptosis by modifying the levels of PAR-4, with or without the presence of amphiphilic lipid compounds and optionally employing MEDII conditioned medium. The methods alternatively encompass modulating apoptosis by modulating the intracellular concentration of endogenous lipid second messengers, such as ceramide.02-05-2009
20120244130CELL PREPARATION FOR ERECTILE DYSFUNCTION OR SENSORY DISORDERS OF THE LOWER URINARY TRACT CONTAINING ADIPOSE TISSUE DERIVED MESENCHYMAL STEM CELLS - An object is to provide a novel medical use of adipose tissue-derived mesenchymal stem cells. It was discovered that adipose tissue-derived mesenchymal stem cells (ASC) promote improvement of erectile dysfunction and recovery of the urge to urinate (improvement of sensory disorders of the lower urinary tract). On the basis of the discovery, a cell preparation containing adipose tissue-derived mesenchymal stem cells, which is effective to erectile dysfunction or sensory disorders of the lower urinary tract, is provided. In one embodiment, adipose tissue-derived mesenchymal stem cells and body fat are used in combination.09-27-2012
20100055075METHODS OF TREATING ISCHEMIC SPASTITICY - The invention relates generally to methods of treating spasticity, rigidity, or muscular hyperactivity conditions by introducing a portion of an expanded population of neural stem cells into an area of a recipient spinal cord.03-04-2010
20100068191PURIFIED MESENCHYMAL STEM CELL COMPOSITIONS AND METHODS OF PURIFYING MESENCHYMAL STEM CELL COMPOSITIONS - One or more purified mesenchymal stem cell pharmaceutical compositions and methods of manufacture utilizing centrifugal filtration are disclosed. Threshold limits for intravenous administration of mesenchymal stem cell pharmaceutical compositions comprising residual animal products are also disclosed.03-18-2010
20100055077METHODS FOR INCREASING AND MOBILIZING HEMATOPOIETIC STEM CELLS - A method is provided for increasing the number of hematopoietic stem cells in the bone marrow, increasing the mobilization of these cells to migrate from the bone marrow to the bloodstream and elsewhere, and increasing the number of differentiating hematopoietic stem cells in the bloodstream.03-04-2010
20100055074Light as a Replacement for Mitogenic Factors on Progenitor Cells - The present invention generally relates to a method of using light treatment supporting specific cell types in a subject. Specifically, the present invention relates to methods for stimulating the proliferation, migration, differentiation and survival of cell using specific parameter of lights. These methods are particularly useful in the cellular regeneration and replacement in a tissue injury, such as CNS or PNS injury, and in transplantation of organs, tissues and cells.03-04-2010
20100061965RESPIRATORY SYNCYTIAL VIRUS RENDERS DENDRITIC CELLS TOLEROGENIC - The present invention includes compositions, methods and systems for inducing immune tolerance using antigen presenting cells by infecting isolated antigen presenting cells with an effective amount of respiratory syncytial virus (RSV) or portions thereof sufficient to infect the antigen presenting cells and contacting CD403-11-2010
20110086008COMPOSITION AND METHOD FOR THE REPAIR AND REGENERATION OF CARTILAGE AND OTHER TISSUES - The present invention relates to a new method for repairing human or animal tissues such as cartilage, meniscus, ligament, tendon, bone, skin, cornea, periodontal tissues, abscesses, resected tumors, and ulcers. The method comprises the step of introducing into the tissue a temperature-dependent polymer gel composition such that the composition adhere to the tissue and promote support for cell proliferation for repairing the tissue. Other than a polymer, the composition preferably comprises a blood component such as whole blood, processed blood, venous blood, arterial blood, blood from bone, blood from bone-marrow, bone marrow, umbilical cord blood, placenta blood, erythrocytes, leukocytes, monocytes, platelets, fibrinogen, thrombin and platelet rich plasma. The present invention also relates to a new composition to be used with the method of the present invention.04-14-2011
20090028830Preparation of multipotent stem cells and the use thereof - The invention relates to a method for the enriched induction of multipotent stem cells, named P-stem cells, from CD1401-29-2009
20110177042Method for Dedifferentiating Melanocytes - The present invention features a method for producing a dedifferentiated melanocyte. The method involves contacting a melanocyte with an agent that activates Notch1 and selecting for a dedifferentiated melanocyte which exhibits a premelanoma stem cell-like state. Agents for activating Notch1 and methods for using the cells and agents are also provided.07-21-2011
20110177041MATERIAL FOR TREATMENT OF CEREBRAL INFARCTION AND BRAIN TISSUE REGENERATION METHOD - Disclosed is a therapeutic material for cerebral infarction, which can recover a vascular disorder in an area affected by cerebral infarction to improve the brain function. The therapeutic material for cerebral infarction includes a dental pulp stem cell comprising at least one member selected from a CD105-positive cell, an SP cell, a CD24-positive cell, a CD133-positive cell, a CD271-positive cell and a CD150-positive cell. The therapeutic material may additionally include a protein secreted from a dental pulp cell. A transplanted dental pulp stem cell cannot be differentiated directly into a neural progenitor cell or a neurocyte, but is involved indirectly in the promotion of differentiation to eliminate an area affected by cerebral infarction, thereby recovering the affected area into a normal area.07-21-2011
20110177038Inhibition of Tumor Growth via Peroxiredoxin 3 - Deregulated expression of the c-Myc transcription factor is found in a wide variety of human tumors. Because of this significant role in oncogenesis, considerable effort has been devoted to elucidating the molecular program initiated by deregulated c-myc expression. The primary transforming activity of Myc is thought to arise through transcriptional regulation of numerous target genes. Thus far, Myc target genes involved in mitochondrial function have not been characterized in depth. Here, we describe a nuclear c-Myc target gene, PRDX3, which encodes a mitochondrial protein of the peroxiredoxin gene family. Expression of PRDX3 is induced by the mycER system and is reduced in c-myc−/− cells. Chromatin immunoprecipitation analysis spanning the entire PRDX3 genomic sequence reveals that Myc binds preferentially to a 930-bp region surrounding exon 1. We show that PRDX3 is required for Myc-mediated proliferation, transformation, and apoptosis after glucose withdrawal. Results using mitochondria-specific fluorescent probes demonstrate that PRDX3 is essential for maintaining mitochondrial mass and membrane potential in transformed rat and human cells. These data provide evidence that PRDX3 is a c-Myc target gene that is required to maintain normal mitochondrial function.07-21-2011
20100061963Methods of Improving Stem Cell Homing and Engraftment - A method of enhancing cell engraftment potential is provided. The method comprising ex-vivo or in-vitro subjecting a population of cells to an amount of nicotinamide for a period of time sufficient to effect the population of cells, thereby enhancing cell engraftment potential.03-11-2010
20100061966Cardiac Stem Cells - Human cardiac stem cells can be isolated from endomyocardial biopsies. Such cells mediate cardiac regeneration and improve heart function in a mouse infarct model. The cells can be used for autologous, allogeneic, syngeneic, or xenogeneic therapeutic applications in patients. The stem cells can be genetically modified to enhance their therapeutic activity.03-11-2010
20110081321OMENTUM AS A SOURCE OF STROMAL/STEM CELLS AND MEDICAL TREATMENTS USING STROMAL/STEM CELLS - Methods for generating and using omentum cells, and particularly stromal cells and/or omentum stem cells, in medical treatments such as tissue repair and regeneration to facilitate healing from traumatic injury to an abdominal organ, and immune modulation treatments such as suppression of immune responses and inflammation and prevention of tissue fibrosis. According to one aspect, a medical procedure is performed on a patient that involves harvesting omental tissue from the patient, and then transferring the omental tissue to an organ of the patient. At least a portion of the harvested omental tissue may be activated prior to transferring the omental tissue to the organ. Alternatively, the transferred omental tissue may comprise non-lymphoid cells isolated from the omentum tissue and obtained by homogenizing at least a portion of the harvested omental tissue. The invention also encompasses a medical procedure comprising the transfer of omental stem cells to a patient, and a procedure comprising in vitro activation of omental stem cells by T cells to enhance immunomodulatory functions of the omental stem cells.04-07-2011
20110150842Derivation of Embryonic Stem Cells - This present invention provides novel methods for deriving embryonic stem cells, those cells and cell lines, and the use of the cells for therapeutic and research purposes without the destruction of the embryo. It also relates to novel methods of establishing and storing an autologous stem cell line prior to implantation of an embryo, e.g., in conjunction with reproductive therapies such as IVF.06-23-2011
20110250179METHODS FOR TREATMENT AND DIAGNOSIS OF CANCER - The present invention relates to methods for the treatment of cancer based on the induction of the choline kinase beta (hereinafter ChoKβ) activity as well as to methods for the design of personalized therapies and for determining the response of an agent capable of inducing choline kinase beta (hereinafter ChoKβ) for the treatment of cancer as well as to methods for determining the prognosis of a patient based on the determination of the ChoKβ expression levels as well as based on the determination of the relationship between the ChoKβ and ChoKα expression levels. Finally, the invention relates to methods for determining the response of a patient who suffers from cancer to ChoKα-inhibiting agents based on the determination of the PEMT and/or ChoKβ expression levels.10-13-2011
20110086007EPIDERMAL STIMULATION TO ENHANCE HAIR FOLLICLE FORMATION - The present invention features a method for improving the efficiency of hair formation by follicular cell implantation. The method includes the use of epidermal stimulation (ES) to stimulate keratinocytes in a subject's skin in order to make them more receptive to hair inductive signals originating from implanted follicular cells (e.g. dermal papilla cells, dermal sheath cells, and/or outer root sheath cells).04-14-2011
20110086009Cell line for the production of prostacyclin and uses thereof - Provided herein are methods for producing a biomolecule by converting or engineering a plurality of cells, e.g., mammalian cells, having an endogenous precursor of a biomolecule to cells transfected to contain a nucleic acid that stably overexpresses a hybrid enzyme effective to metabolized the precursor to the biomolecule in the cell, e.g., prostacyclin produced from arachidonic acid. Also provided are methods of treating a pathophysiological condition associated with at least a decrease in the biomolecule or treating a vascular disease by administering the engineered, stably transfected mammalian cells to a subject where production of the biomolecule treats the condition or vascular disease. Further provided are the recombinant hybrid enzymes and the engineered cell lines and pharmaceutical compositions thereof, the nucleic acids encoding the hybrid enzymes, and vectors comprising the nucleic acids.04-14-2011
20110081324COLLAGEN PEPTIDE CONJUGATES AND USES THEREFOR - Described herein are conjugates of collagen peptides and metal binding agents and compositions resulting therefrom, useful in various tissue engineering and regeneration applications, in cell culture, cell adhesion, cosmetic surgery, construction of artificial skin substitutes, management of severe burns and burn surgery, reconstruction of bone and a wide variety of dental, orthopedic and surgical purposes, as drug delivery vehicles and in delivering populations of cells to a site of disease or injury.04-07-2011
20110081322ELASTIN PRODUCING FIBROBLAST FORMULATIONS AND METHODS OF USING THE SAME - The present invention describes therapeutic compositions comprising fibroblasts that have been stimulated to increase expression of extracellular matrix components or elastin, or to produce enhanced elastogenesis or the appearance thereof at a site of administration. The therapeutic fibroblast formulations can be prepared using a variety of elastogenic agents, including digests of mammalian elastin, chemically digested plant extracts comprising elastin-like peptides, and synthetic elastogenic peptides. The invention further comprises cosmetic and pharmaceutical treatment methods using the therapeutic fibroblast compositions of the invention.04-07-2011
20110070204MEDIUM FOR HANDLING AND STORING BIOLOGICAL TISSUES OF THE MUSCULOSKELETAL SYSTEM OUTSIDE AN ORGANISM - The present disclosure relates to a medium for handling, including storing, cultivating, coating, impregnating and/or preserving musculoskeletal tissues such as bone, cartilage, tendon, muscle, nerve, ligament, blood vessel, skin, fascia, bursa and joint capsule tissue or cells, wherein the medium is an aqueous solution comprising hyaluronan and a first saccharide, polyol, or combination thereof. Further disclosed are methods of handling musculoskeletal tissue or cells or preserving the viability of these tissues or cells using this medium as well as the preserved tissues or cells.03-24-2011
20110076254POROUS SCAFFOLDS FOR STEM CELL RENEWAL - A method for expanding a population of stem cells using a porous scaffold, a porous scaffold populated with renewed stem cells, methods of administering stem cells using the porous scaffold and cells collected from the porous scaffold, and methods for tissue engineering and treating a condition treatable by administration of stem cells using the porous scaffold and cells collected from the porous scaffold.03-31-2011
20110070203MESENDODERM AND MESODERM CELL POPULATIONS - The present invention provides cell populations that are enriched for mesendoderm and mesoderm, and cell populations that are enriched for endoderm. The cell populations of the invention are useful for generating cells for cell replacement therapy.03-24-2011
20110070205MULTIPOTENT STEM CELLS AND USES THEREOF - The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD4903-24-2011
20110070207THERAPEUTIC COMPOSITION FOR ATOPIC DERMATITIS - A novel type of therapeutic agent, human mesenchymal stem cells, and a composition containing the same for the treatment of atopic dermatitis is disclosed. A method for the treatment of atopic dermatitis in patient is also disclosed.03-24-2011
20110070202Targeted delivery to the brain of magnetically labeled stem cells - Provided herein is a method of targeting stem cells to a specific region of the central nervous system of an individual in need of such treatment, comprising the steps of administering stem cells containing a superparamagnetic nanoparticles to said individual; and applying an external source of a magnetic field to the exterior of said individual's brain so as to advance and maneuver said stem cells. Also provided is a composition for targeting cells to a specific region of the central nervous system of an individual in need of such treatment, comprising stem cells containing a superparamagnetic nanoparticles.03-24-2011
20110070206METHODS OF APPLYING PHYSICAL STIMULI TO CELLS - We describe herein methods for applying physical stimuli to cells, including mesenchymal stem cells, in culture or in vivo. These methods can be applied in, and are expected to benefit subjects in, a great variety of circumstances that arise in the context of, for example, traumatic injury (including that induced by surgical procedures), wound healing (of the skin and other tissues), cancer therapies (e.g., chemotherapy or radiation therapy), tissue transplantation (e.g., bone marrow transplantation), and aging. More generally, the present methods apply where patients would benefit from an increase in the number of cells (e.g., stem cells) within a given tissue and, ex vivo, where it is desirable to increase the proliferation of cells (e.g., stem cells) for scientific study, inclusion in devices bearing cells (e.g., polymer or hydrogel-based implants), and administration to patients.03-24-2011
20110070201Mucosal or enteral administration of biologically active macromolecules - A method of systemically delivering a biologically active, recombinant biomolecule, in a biologically active form, to a subject in need thereof. , the method comprising, enterally or mucosally administering to the subject a therapeutically effective amount of plant cells expressing an exogenous biologically active recombinant biomolecule, thereby systemically delivering the biologically active recombinant biomolecule, in a biologically active form, to the subject.03-24-2011
20120201789GENERATION OF CHOROID PLEXUS EPITHELIAL CELLS FROM HUMAN EMBRYONIC STEM CELLS - Choroid plexus epithelial cells are generated in a culture medium using embryonic stem cells and adding an effective amount of bone morphogenetic protein and/or other members of the transforming growth factor beta (TGF-beta) superfamily. Generation of such choroid plexus epithelial cells are confirmed using a combination of genetic markers, antibodies, histology inspection, functional assays, and integration into the endogenous choroid plexus in mice.08-09-2012
20120201787TREATMENT OF SPINAL CORD INJURY AND TRAUMATIC BRAIN INJURY USING AMNION DERIVED ADHERENT CELLS - Provided herein are methods of treating spinal cord and traumatic brain injuries using cells from amnion, and populations of such cells, referred to herein as “amnion derived adherent cells” (“AMDACs”).08-09-2012
20120201786METHODS FOR THE USE OF STEM CELLS AND STEM CELL FACTORS IN THE TREATMENT OF SKIN CONDITIONS - The invention provides a method for treating a skin condition in a patient through the administration of stem cells, stem cell factors or a combination thereof. The invention finds use in medical (i.e. healing) and cosmetic applications. Disclosed herein are methods for making and using compositions of stem cells and stem cell factors, and methods for their use in the treatment of skin conditions.08-09-2012
20110150848Cell Suspension Preparation Technique and Device - The present invention provides for methods and devices suitable for producing a transplantable cellular suspension of living tissue suitable for grafting to a patient. In applying the method and/or in using the device, donor tissue is harvested, subjected to a cell dissociation treatment, cells suitable for grafting back to a patient are collected and dispersed in a solution that is suitable for immediate dispersion over the recipient graft site.06-23-2011
20110150843METHOD FOR THE THERAPEUTIC CORRECTION OF HEMOPHILIA A BY TRANSPLANTING BONE MARROW CELLS - The transdifferentiation of bone marrow cells (BMCs) into hepatocytes can be used for the development of cellular medicine for degenerative and genetic diseases. Since the liver is the primary site of factor VIII (FVIII) synthesis, the partial replacement of mutated liver cells by healthy cells in hemophilia A (HA) could manage the severity of the bleeding disorder. The use of BMCs could be used as a therapy for the bleeding phenotype of hemophilia A and other related disorders.06-23-2011
20100310524Compositions Suitable for Treatment of Spinal Disease, Disorder or Condition - The invention relates to the use of viral inactivated-plasma cryoprecipitate concentrate (VIPCC) comprising a suitable fibronectin/fibrinogen ratio for treating a spine disease, disorder or condition such as intervertebral disc degeneration.12-09-2010
20100310526COSMETIC METHOD FOR INCREASING THE PIGMENTATION OF SKIN USING MELANOCYTE PRECURSOR CELLS - The present invention proposes a cosmetic method for increasing the pigmentation of skin with the steps application of melanocyte precursor cells from root sheaths collected from a first area of skin of a donor to a second area of skin of a recipient. Furthermore, the use of melanocyte precursor cells for increasing the pigmentation of skin as well as a method for producing a suspension having precursor cells from the root sheath is proposed.12-09-2010
20100310531PEPTIDE-COATED CELL LOCALIZATION TO DISEASED OR DAMAGED TISSUES AND METHODS RELATED THERETO - Embodiments of the present invention are directed to a coated cell comprising a therapeutic cell and a plurality of targeting complexes coating the therapeutic cell and each of said targeting complexes comprising a homing molecule, a lipid moiety, and a spacer having from about 1 to about 10 amino acids and covalently linking the homing molecule to the lipid moiety and wherein the lipid moiety is non-covalently attached to the therapeutic cell. In some embodiments, the therapeutic cell is a stem cell. Embodiments of the invention are directed to methods of coating a therapeutic cell. Embodiments of the invention are directed to methods of treating diseases of the vasculature.12-09-2010
20100310527LIPOSOME MEDIATED DELIVERY OF LINEAGE DETERMINING FACTORS - Methods and compositions are provided for lineage predetermination of cellular transplants including through liposome mediated transfection with aqueous protein extracts from populations of differentiated mammalian cells, or cellular fractions thereof, wherein the differentiated mammalian cells are enriched in one or more of adipocytes, chondrocytes, endothelial cells, hepatocytes, cardiomyocytes, smooth muscle cells, skeletal muscle cells, cardiac pacemaker cells, Schwann cells, pancreatic islet cells, hematopoietic cells, myeloblasts, neurons, and osteoblasts.12-09-2010
20100310528Vector System for Site-Specific Integration - The integration system comprises at least one vector capable of expressing at least one exogenous gene, the vector comprising a coding sequence for an attP gene region and a coding sequence for at least one therapeutic molecule and an integrase. The integration system has an application in bacterial metabolic engineering and in gene therapy.12-09-2010
20100310525WNT PATHWAY STIMULATION IN REPROGRAMMING SOMATIC CELLS - The invention provides compositions and methods of use in reprogramming somatic cells. Compositions and methods of the invention are of use, e.g., for generating or modulating (e.g., enhancing) generation of induced pluripotent stem cells by reprogramming somatic cells. The reprogrammed somatic cells are useful for a number of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a pluripotent state and/or enhances the speed and/or efficiency of reprogramming. Certain of the compositions and methods relate to modulating the Wnt pathway.12-09-2010
20100055078METHODS OF MAKING A TRANSPLANTABLE BONE REPAIR SYSTEM USING MULTIPOTENT STEM CELLS - Methods are provided herein for making a biocompatible transplantable bone repair device. In some examples, the method includes culturing multipotent stem cells with a first medium containing a fibroblast growth factor (FGF), such as fibroblast growth factor-2 (FGF-2), in the substantial absence of dexamethasone, seeding a biologically compatible substrate including extracellular matrix (ECM) with the multipotent stem cells cultured with FGF, and inducing the cells to differentiate to osteoblast cells by culturing with a second medium containing a differentiation factor (such as bone morphogenetic protein, such as bone morphogenetic protein-2 (BMP-2)), in the substantial absence of dexamethasone. Also provided are methods for treating a bone defect by surgically implanting the biocompatible transplantable bone repair device at the site of a bone defect.03-04-2010
20100297088Methods for Culturing Minimally-Passaged Fibroblasts and Uses Thereof - The present invention relates to novel methods of growing at least 100 million minimally-passaged fibroblasts from a small biopsy specimen. The invention includes methods wherein a small biopsy specimen is seeded directly into a large tissue culture flask, and passaged no more than three times.11-25-2010
20110256110AMNIOTIC FLUID CELLS AND USES THEREOF - The present invention relates generally to amniotic fluid derived renal progenitor cells positive for CD24 and OB-cadherin and subpopulations thereof, as well as methods of isolating and uses thereof. The invention is further directed to preventing and treating kidney damage with a population of amniotic fluid derived c-kit positive stem cells.10-20-2011
20110212067Methods for Purifying Cells Derived from Pluripotent Stem Cells - The present invention is directed to methods to differentiate pluripotent stem cells. In particular, the present invention provides methods of characterization of cells differentiated into cells expressing markers characteristic of the pancreatic endocrine lineage utilizing unique surface markers. The present invention also provides methods to enrich or sort cells expressing markers characteristic of the pancreatic endocrine lineage. The present invention also provides methods to deplete cells that may contaminate populations of cells expressing markers characteristic of the pancreatic endocrine lineage formed by the methods of the present invention, thereby reducing the incidence of tumor formation in vivo following transplantation.09-01-2011
20120034196GENE ENCODING A MULTIDRUG RESISTANCE HUMAN P-GLYCOPROTEIN HOMOLOGUE ON CHROMOSOME 7P15-21 AND USES THEREOF (FRANK) - The invention relates to an MDR family P-glycoprotein located on human chromosome 7p15-21, polynucleotide sequences encoding this P-glycoprotein and fragments thereof. This gene is utilized in methods for assessing cancer cell susceptibility to therapies directed against multidrug resistance, and for the design of diagnostic and therapeutic methods relating to cancer multidrug resistance. The invention also relates to methods for determining whether a test compound may inhibit multidrug resistance.02-09-2012
20120034195PLACENTAL STEM CELLS DERIVE FROM POST-PARTUM MANMALIAN PLACENTA, AND USES AND METHODS OF TREATMENT USING SAID CELLS - The present invention provides compositions and methods of using placental stem cells that originate from a post-partum placenta with conventional cord blood compositions or other stem or progenitor cells. The placental stem cells can be used alone or in a mixture with other stem cell populations. In accordance with the present invention, the placental stem cells may be mixed with other stem cell populations, including but not limited to, umbilical cord blood, fetal and neonatal hematopoietic stem cells and progenitor cells, human stem cells and progenitor cells derived from bone marrow. The placental stem cells and the mixed populations of placental stem cells and stem cells have a multitude of uses and applications, including but not limited to, therapeutic uses for transplantation and treatment and prevention of disease, and diagnostic and research uses.02-09-2012
20120034192COMPOSITIONS AND METHODS FOR ENHANCING CELL REPROGRAMMING - The invention provides compositions and methods of use to enhance reprogramming of mammalian cells. Certain compositions and methods of the invention are of use to enhance generation of induced pluripotent stem cells by reprogramming somatic cells. Certain compositions and methods of the invention are of use to enhance reprogramming of pluripotent mammalian cells to a differentiated cell type. Certain compositions and methods of the invention are of use to enhance reprogramming of differentiated mammalian cells of a first cell type to differentiated mammalian cells of a second differentiated cell type. The reprogrammed somatic cells are useful for a number of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that enhances or contributes to reprogramming mammalian cells. Certain of the inventive compositions and methods relate to inhibiting histone methylation.02-09-2012
20100189695IRAK-1 AS REGULATOR OF DISEASES AND DISORDERS - The present invention provides methods and compositions for treatment of diseases and disorders. More specifically, the invention for the first time shows a link between IRAK-1 and phosphorylation of proteins involved in cardiovascular disease, diabetes, neurodegeneration, and associated diseases and disorders and complications. Typically, the diseases and disorders involve an inflammatory component. Assays for bioactive substances affecting IRAK-1 regulated progression of inflammation and diseases and disorders involving inflammation are also disclosed.07-29-2010
20110212066METHOD OF FOSTERING THE RESTORATION OF A BODY FUNCTION USING CELLS OF THE ROOT SHEATH, COMPOSITION AND PREPARATION METHOD - The present invention proposes a method for promoting the re-establishment of at least one function of the skin of a second skin area or of another area or part or tissue, comprising applying cells obtained from hair root sheaths of a first skin area of a donor onto a second skin area or another area or part or another tissue of a host. Furthermore, cells, a preparation, the use of cells and a method for preparing a preparation are proposed.09-01-2011
20110212063METHODS OF MANUFACTURE OF IMMUNOCOMPATIBLE CHORIONIC MEMBRANE PRODUCTS - Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.09-01-2011
20100098672USE OF MESENCHYMAL STEM CELLS FOR TREATING GENETIC DISEASES AND DISORDERS - A method of treating a genetic disease or disorder such as, for example, cystic fibrosis, Wilson's disease, amyotrophic lateral sclerosis, or polycystic kidney disease, in an animal comprising administering to said animal mesenchymal stem cells in an amount effective to treat the genetic disease or disorder in the animal.04-22-2010
20110250185TUMOR SUPPRESSION USING PLACENTAL STEM CELLS - The present invention provides methods of suppression of tumor cell proliferation and tumor growth using placental stem cells and placental stem cell populations. The invention also provides methods of producing and selecting placental cells and cell populations on the basis of tumor suppression, and compositions comprising such cells and cell populations.10-13-2011
20110250183Combination Therapy for Treatment of Patients with Neurological Disorders and Cerebral Infarction - The present invention provides compositions and methods for treating stroke patients using TCM and a Western medicament used for the treatment of stroke patients.10-13-2011
20110250181HUMAN LYSOSOMAL PROTEINS FROM PLANT CELL CULTURE - A device, system and method for producing glycosylated proteins in plant culture, particularly proteins having a high mannose glycosylation, while targeting such proteins with an ER signal and/or by-passing the Golgi. The invention further relates to vectors and methods for expression and production of enzymatically active high mannose lysosomal enzymes using transgenic plant root, particularly carrot cells. More particularly, the invention relates to host cells, particularly transgenic suspended carrot cells, vectors and methods for high yield expression and production of biologically active high mannose Glucocerebrosidase (GCD). The invention further provides for compositions and methods for the treatment of lysosomal storage diseases.10-13-2011
20110250182ANGIOGENESIS USING PLACENTAL STEM CELLS - Provided herein are methods of treating individuals having diseases or disorders of the circulatory system, using placental cells, e.g., the placental stem cells and placental multipotent cells (PDACs) described herein, and populations of such placental cells. The invention also provides methods of angiogenesis using such cells or populations of cells comprising such cells.10-13-2011
20110250180CCN3 PEPTIDES AND ANALOGS THEREOF FOR THERAPEUTIC USE - The present invention provides a CCN3 peptide for treating a subject in need thereof having an amino acid sequence identified as CCNp37, CCNp38 (human), CCNp38 (mouse), a cysteine-substituted CCNp37, cysteine-substituted CCNp38 (human) or a cysteine-substituted CCNp38 (mouse).10-13-2011
20110158962DENTAL PULP MARROW SIMILAR CELLS (DPMSC) AND METHODS OF ISOLATING AND USING - The invention provides for isolated population of pulp marrow similar cells (DPMSCs) and methods for isolating and using these cells. The population of DPMSCs are highly homogenous for CD1O, CD29, CD13, CD44, CD49a, CD49d, CD59, CD73, CDw90, CD105, Oct-4 Isoform A and B, Nanog, Sox-2, and SSEA-4.06-30-2011
20110158955METHOD FOR PRODUCING CELLS HAVING CHARACTERISTIC OF HEMATOPOIETIC STEM CELLS/PROGENITOR CELLS - Provided are a new method of producing cells having characteristics of hematopoietic stem/progenitor cells, for use in hematopoietic stem cell transplantation, and hematopoietic stem/progenitor cell-like cells produced by the method. Provided in particular are a method of producing hematopoietic stem/progenitor cell-like cells retaining differentiation pluripotency and self-replication potential, comprising (1) a step for providing a mammalian pro-B cell or progenitor cell thereof, and (2) a step for culturing the cell (1) above under conditions for induction of differentiation into B cells, wherein the function and/or expression of the transcription factor E2A is suppressed at least at the stage of pre-pro-B cells or pro-B cells in the process (2) above; a hematopoietic stem/progenitor cell-like cell produced by the method; and an immunotherapeutic agent comprising the hematopoietic stem/progenitor cell-like cell, and the like.06-30-2011
20090022697System for the Implantation of Cardiac Staminal Cells with the "Ciuro? Method" - The system is composed of two inseparable parts that both make up one Device: I) A container for collecting staminal cells and for their growth factors which is the same as the portcat system with sylicon button to enable the entrance of the Huber needle through a hole. 01-22-2009
20090022698Composition For Treatment Of Articular Cartilage Damage - Disclosed is a composition for the treatment of cartilage or bone damage or loss or defect. The composition comprises mesenchymal stem cells separated from umbilical cord blood and/or mesenchymal stem cells proliferated and/or differentiated. The composition also comprise chondrocytes and/or chondroblasts, or osteocytes and/or osteoblasts, differentiated from the mesenchymal stem cells separated from the umbilical cord blood.01-22-2009
20090022692THERAPEUTIC AGENT FOR HEART DISEASE USING MAP KINASE TNNI3K - An object to be achieved by the present invention is to provide a therapeutic means for heart disease such as myocardial ischemia or myocardial infarction. The present invention provides a therapeutic agent for heart disease which comprises a myocardial progenitor cell expressing MAP kinase TNNI3K at a high level as an active ingredient.01-22-2009
20100003224Combination Therapy - Methods to mobilize progenitor and/or stem cells from the bone marrow to the bloodstream by administering a combination of at least one CXCR4 inhibitor and at least one VLA-4 inhibitor are described. The combinations may also be used to treat multiple myeloma.01-07-2010
20080248002ANTI-ANGIOGENIC CELLULAR AGENT FOR CANCER THERAPY - The invention provides cytokine induced killer (CIK) cell populations and methods of using CIK cells to treat cellular proliferative disorders. CIK cells generated in vitro include both bulk cultures and clones. Individual CIK cell clones display distinct but overlapping lytic specificities for tumor cells and endothelial cells in vitro. When injected in vivo, bulk CIK cell cultures selectively attack tumor tissue. CIK cells can be used to treat a variety of cellular proliferative disorders, including early and late stage cancers as well as hematopoietic cell and solid tissue tumors.10-09-2008
20080248001METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS - Methods for the treatment of a cell proliferation disorder in a subject, involving: 10-09-2008
20080248006Process For Ex Vivo Formation of Mammalian Bone And Uses Thereof - The present invention concerns methods for the ex vivo formation of mammalian bone and subsequent uses of the bone. A critical and distinguishing feature of the present invention are defined tissue culture conditions and factors resulting in the formation of bone cell spheroids. The invention also provides for methods of implanting into subjects the ex vivo formed bone. Also described are methods for genetically altering the bone cell spheroids to affect bone formation, identification of candidate modulators of bone formation, and identification of genes involved in bone formation.10-09-2008
20110150847METHOD OF THREE-DIMENSIONALLY CULTURING CHONDROCYTES - It is intended to provide a method of three-dimensionally culturing normal joint chondrocytes; the production and supply of chondrocytes; and a transplantation material to be used in an injured site in a joint tissue.06-23-2011
20090324558Transdiscal administration of cycline compounds - The present invention relates to administering a doxycycline compound into a diseased intervertebral disc.12-31-2009
20090324556Mutated immunogenic peptides derived from R9M, polynucleotides coding for same and therapeutic uses thereof - The invention concerns the optimization of the wild R9M peptide and the use of the resulting peptides for therapeutic vaccination and/or preventive vaccination against leukaemia in humans. More particularly, the invention concerns mutated immunogenic peptides derived from the human TEL/AML1 fusion protein comprising the wild R9M peptide sequence Arg-Ile-Ala-Glu-Czs-Ile-Leu-Gly-Met. The invention also concerns polynucleotides coding for the mutated R9M immunogenic peptides, cellular expression vectors comprising nucleic acid sequences expressing the mutated R9M immunogenic peptides and polyclonal or monoclonal antibodies capable of being fixed on at least one of said peptides/polynucleotides. The invention further concerns the use of said peptides, polynucleotides and/or antibodies for preparing vaccines, anti-tumoral medicines and compositions and for in vitro and in vivo stimulation of the immune response in humans.12-31-2009
20090317366METHOD FOR TREATING PROGRESSIVE NEURODEGENERATIVE DISORDERS - A method for treating a progressive neurodegenerative disorder with bone marrow stem cells and a G-CSF receptor agonist.12-24-2009
20090317365SYSTEMS AND METHODS FOR MAKING HEPATOCYTES FROM EXTRAHEPATIC SOMATIC STEM CELLS AND USE THEREOF - A method for making hepatocytes from extrahepatic somatic stem cells comprises: a) culturing somatic stem cells in a medium comprising hepatic growth factor to cause the stem cells to differentiate toward hepatocytes; b) culturing cells from a) in a medium comprising HGF and oncostatin M to facilitate the cell differentiation toward hepatocytes; and c) culturing cells from b) in a medium comprising oncostatin M to cause the differentiated cells to mature into hepatocytes, thereby producing a cell population that has morphological features of hepatocytes and at least four of the following characteristics: i) antibody-detectable expression of albumin; ii) real-time reverse transcriptase-polymerase chain reaction-detectable expression of α-fetoprotein, HNF-1α, HNF-3β, HNF-4, HNF-6, α1-antitrypsin, alkaline phosphatase, tryptophan 2,3-dioxygenase, tyrosine aminotransferase, cytochrome P450 family 2 subfamily E polypeptide 1, glutamine synthetase, and/or low density lipoprotein receptor; iii) urea secretion; iv) cytochrome p450 enzyme activity; v) glycogen storage; and vi) low density lipoprotein uptake.12-24-2009
20110150845METHODS AND COMPOSITIONS FOR MODULATING IMMUNOLOGICAL TOLERANCE - The invention provides compositions and methods for modulating immune responses using mesenchymal stem cells. The invention further provides methods for inducing tolerance to self antigens using mesenchymal stem cells.06-23-2011
20110150846COMPOSITIONS AND METHODS FOR TISSUE FILLING AND REGENERATION - Injectable compositions are provided which include both a living cellular component and a filler component conducive to cell growth. The compositions are capable of providing both immediate tissue filling and long term tissue regeneration.06-23-2011
20110150844COMPOSITIONS AND METHODS FOR CONTROLLING PROLIFERATION AND DIFFERENTIATION OF CELLS - Methods and compositions for modulating cell differentiation, proliferation and morphology in vitro or in vivo are described. The methods include modifying the extracellular nanoenvironment of stem cells with a self-assembling peptide nanofiber scaffold. The extracellular nanoenvironment can be modified by changing the percentage of self-assembling peptides used to form the nanofiber scaffold, the concentration of cells in the nanofiber scaffold, the pH, or the amounts of serum. Modulating the extracellular nanoenvironment of cells in nanofiber scaffold allows for increased targeting of cell placement and therapeutic delivery, amplified by cell encapsulation and implantation.06-23-2011
20090280096PANCREATIC ENDOCRINE PROGENITOR CELLS DERIVED FROM PLURIPOTENT STEM CELLS - The invention provides pluripotent cells modified to overexpress Pdx1 and Ngn3. Pluripotent cells include embryonic stem cells and induced pluripotent stem cells. Methods of producing pancreatic endocrine progenitor cells from ES cells or from iPS cells by forced expression of Pdx1 and Ngn3 are provided. Pancreatic endocrine progenitor cells are useful for drug discovery and cell replacement therapy.11-12-2009
20090274664Method of culturing vascular smooth muscle cells, culture device and medical material obtained by the culture - There is provided a method for culturing vascular smooth muscle cells while maintaining their normal function, and a culture device and regenerative medical material for the same. The method takes advantage of vascular smooth muscle cell recognition of elastin as an extracellular matrix. The invention provides a method for culturing vascular smooth muscle cells on elastin, a culture device having elastin anchored on the cell-growing surface, a culture device wherein the cell-growing surface is composed of an elastin molded article, and medical materials obtained by culturing vascular smooth muscle cells using such culture devices.11-05-2009
20090257985METHODS OF REGULATING EXPRESSION OF GENES OR OF GENE PRODUCTS USING SUBSTITUTED TETRACYCLINE COMPOUNDS - The present invention relates, at least in part, to the use of substituted tetracycline compounds for regulation of expression of nucleic acids operably linked to a tetracycline operator system. The invention pertains to compounds used in a regulatory system which utilizes components of the Tet repressor/operator/inducer system of prokaryotes to regulate gene expression in cells. Use of certain substituted tetracycline compounds, as featured in the methods of the invention, result in improved dose-response results when compared to those for e.g., tetracycline and doxycycline. Certain methods of the invention thus allow for enhanced control of the Tet repressor/operator/inducer system in regulating gene expression in cells.10-15-2009
20110256109CHONDROGENIC PROGENITOR CELLS, PROTOCOL FOR DERIVATION OF CELLS AND USES THEREOF - The present invention provides an isolated population of chondrocyte precursor cells wherein 1% or less of the cells express Oct4, Nanog and/or TRA-1-60, 7% or less of the cells express no collagen II, collagen X, CD105 or Stro-1 and 85% or more of the cells express CBFA1, methods for preparing such cells and uses of chondrocyte cells derived from said precursor cells.10-20-2011
20120201791METHODS OF TREATING DISEASES OR CONDITIONS USING MESENCHYMAL STEM CELLS - The present invention provides a method of treating or preventing a disease or condition in a patient comprising intravenously administering a therapeutically effective amount of mesenchymal stem cells to the patient, wherein the disease or condition is osteoarthritis, rheumatoid arthritis, multiple sclerosis, stroke, ulcerative colitis, psoriasis, Hashimoto's thyroiditis, atopic dermatitis, allergic rhinitis, chronic obstructive pulmonary disease with bronchial asthma or hearing loss.08-09-2012
20120201790PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME - An isolated polynucleotide functional as a promoter in eukaryotic cells is disclosed. The isolated polynucleotide includes an endothelial specific enhancer element as detailed herein. Further disclosed is a method of expressing a nucleic acid sequence of interest in endothelial cells.08-09-2012
20080311083Methods of Modulating Beta Cell Function - Methods of modulating pancreatic function by modulating MCH signaling in a β cell.12-18-2008
20090010895Isolated cells and populations comprising same for the treatment of CNS diseases - An isolated human cell and populations thereof is provided comprising at least one astrocytic phenotype and at least one mesenchymal stem cell phenotype, wherein the mesenchymal stem cell phenotype is not an astrocytic phenotype.01-08-2009
20090098091Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis - The present disclosure teaches analogs of human chemokines and methods of using them in the prevention, treatment, and ameliorization of diseases that can benefit from therapeutic angiogenesis. The teachings are generally directed to compositions comprising SDF-1 mimetics, as well as methods that include the use of SDF-1 mimetics to induce neo-vessel formation. The disclosure also teaches articles of manufacture that can be useful in practicing the methods taught herein.04-16-2009
20080279830SPONGY EPITHELIAL CELL SCAFFOLD FOR VASCULARIZING WOUNDS - The present invention provides isolated apoptotic epithelial scaffolds. The scaffolds find use in promoting re-vascularization of wounded tissues. The present invention also provides isolated or ex vivo tri-layered cell sorted tissues comprised of a bottom layer comprised of an apoptotic epithelial scaffold, a middle layer comprised of mesenchymal cells, and a top layer comprised of non-differentiated epithelial cells. The invention further provides in vitro methods for generating isolated or ex vivo tri-layered cell sorted tissues by exposing cultured mixtures of epithelial and mesenchymal cells to an inflammatory cytokine. Further provided are methods of promoting wound healing and re-vascularization of wounds by contacting wounded tissue with the apoptotic epithelial scaffolds of the invention.11-13-2008
20080279829Phenyl-(4-Phenyl-Pyrimidin-2-Yl)-Amines For Enhancing Immunotolerance - The use of a phenyl-(4-phenyl-pyrimidin-2-yl)-amine for the preparation of a medicament for enhancing immunotolerance in a mammal; and uses, methods, processes and pharmaceutical combinations and compositions comprising such phenyl-(4-phenyl-pyrimidin-2-yl)-amine.11-13-2008
20080279825CARTILAGE MATERIAL - Cartilage materials such as cartilage fluff and a cartilage composition comprising a particulate material are disclosed. These are suitable for stimulating chondrogenesis and/or producing cartilage regeneration. Also disclosed are processes for their preparation. Methods for regenerating articular cartilage are also disclosed, which involve, for example, placing the cartilage fluff or cartilage composition into a cartilage defect.11-13-2008
20080279826Method for Expanding Cd4+ Cd25+ T Regulator Cells - A method for generating/expanding in vitro a CD411-13-2008
20110158960ISOLATION OF PRECURSOR CELLS AND THEIR USE FOR TISSUE REPAIR - Cartilage-derived morphogenetic protein CDMP-1 or a transforming growth factor β having at least 80% homology with CDMP-1, or a factor co-expressed and/or co-detectable therewith, is used as a marker of skeletal precursor cells from any part of a mammalian body.06-30-2011
20080213227Mesenchymal stem cells and uses therefor - Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.09-04-2008
20080286244Bio-Artificial Materials with Tuneable Properties - This invention relates to methods for preparing biomaterials by applying multiple cycles of tensile loading to compacted collagen gels in order to fuse the collagen fibrils together within the compacted gels. This produces a biomaterial with improved material properties. Biomaterials produced by such methods may be useful, for example, as tissue equivalent implants, in the repair and/or replacement of damaged tissue in an individual.11-20-2008
20080267926METHODS OF PRODUCING PANCREATIC HORMONES - Disclosed herein are methods of producing pancreatic hormone-expressing cells by first differentiating pluripotent cells in cell culture so as to produce endodermal cells, the endodermal cells being competent to further differentiate into hormone-expressing cells capable of secreting at least one pancreatic hormone in response to a physiological signal, and then, transplanting the cultured endodermal cells into an organism, such as an organism in need of an endocrine cell therapy.10-30-2008
20080267927Methods for improving cell therapy and tissue regeneration in patients with cardiovascular diseases by means of shockwaves - Improving cell therapy and tissue regeneration in a patient suffering from a cardiovascular or a neurological disease by treating a tissue of the patient with shock waves and/or applying to the patient a therapeutically effective amount of stem cells and/or progenitor cells. Such treatment increases expression of chemoattractants, pro-angiogenic factors, and pro-survival factors. The chemoattractants can be, for example, vascular endothelial growth factor (VEGF) or stromal cell derived factor 1 (SDF-1). For example, the treated tissue can be located in the patient's heart or in a skeletal muscle of the patient, and the shock waves can be extracorporeal shock waves (ESW) or intracorporeal shock waves. The cardiovascular disease can have an ischemic or non-ischemic etiology. For example, the cardiovascular disease can be a myocardial infarction, ischemic cardiomyopathy, or a dilatative cardiomyopathy. For example, the neurological disease can be a peripheral neuropathy or neuropathic pain.10-30-2008
20080267925Cell Therapy: A Method And A Composition For Treating Diabetes - A method of obtaining beta-islet cells from pancreases of rabbits and a composition for transplantation (xenografts or xenotransplants) of beta-islet cells isolated and cultured from rabbit pancreases to promote natural insulin production among people with diabetes.10-30-2008
20080219955Method of Producing Purified Neural Stem Cells and Related Methods of Treating a Patient - The present invention provides a method of producing purified neural stem cells, comprising harvesting fluid containing neural stem cells from cerebrospinal fluid surrounding the spinal cord of an individual, isolating the neural stem cells from the fluid, culturing the neural stem cells in a culture medium effective to induce proliferation of the neural stem cells and purifying the cultured neural stem cells. Also provided is a method of treating a patient afflicted with a neurological condition, in which the purified neural stem cells are administered autologously into the same individual or heterologously to a patient other than the individual. Administration of the purified neural stem cells results in the purified neural stem cells propagating in the site of the brain region afflicted with the neurological condition.09-11-2008
20080219958METHOD FOR INDUCING AN ANTI-TUMOR AND ANTI-CACHEXIA IMMUNE RESPONSE IN MAMMALS - The invention relates to inducing an immune response toward tumor associated antigens and in particular to the administration of high molecular weight isolates of autologous urine either alone, with adjuvants, or with antigen presenting cells. The antigen presenting cells have been cocultured with isolates of autologous urine. The invention can also be used to treat cachexia in cancer or AIDS patients.09-11-2008
20080219956HLA HOMOZYGOUS CELLS AND METHODS OF USE THEREOF - The present invention provides methods of generating a mammalian cell that is homozygous at a locus of interest, as well as cells made by the method. The present invention further provides methods of using the cells.09-11-2008
20080219957Method of Deriving Mesenchymal Stem Cells - We disclose a method comprising: (a) providing an embryonic stem (ES) cell; and (b) establishing a progenitor cell line from the embryonic stem cell; in which the progenitor cell line is selected based on its ability to self-renew. Preferably, the method selects against somatic cells based on their inability to self-renew. Preferably, the progenitor cell line is derived or established in the absence of co-culture, preferably in the absence of feeder cells, which preferably selects against embryonic stem cells. Optionally, the method comprises (d) deriving a differentiated cell from the progenitor cell line.09-11-2008
20100303769Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease - Acute and chronic heart disease is treated using a rational, multi-tier approach. A patient is pretreated with growth factor proteins or gene therapy, followed by the administration of adult stem cells. The progress of treatment is continuously monitored by echo-cardiogram with growth factor treatment and/or stem cell administration adjusted according to the results of the echo-cardiogram or clinical status of the patient. Heart disease is also treated by a method that comprises administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.12-02-2010
20100303765Scaffoldless Constructs for Tissue Engineering of Articular Cartilage - A process for culturing chondrocytes to form constructs which contain higher percentages of cells that retain the chondrocytic phenotype are disclosed. The tissue engineered constructs may be formed into neocartilage-containing compositions for a variety of in vitro and in vivo purposes. Methods of treating individuals in need of articular cartilage growth by implanting a new composition are disclosed.12-02-2010
20080254001Novel bone mineralization protein expression systems, and methods of studying their intracellular signaling pathways - The present invention is directed to methods of switching a differentiation of a cell from a non-osteogenic lineage into an osteogenic lineage. The present invention is also directed to methods of generating a model system for assessing the intracellular signaling pathways of bone growth factors.10-16-2008
20080254006TREATMENT OF ALOPECIA BY MICROPORE DELIVERY OF STEM CELLS - A method of restoring hair to skin that has suffered hair loss includes optically ablating an array of spaced-apart microchannels or voids into the skin and transplanting into the voids stem cells, a scaffold and a differentiation factor for causing the stem cells to differentiate into hair follicles.10-16-2008
20080254005Stem Cell Therapy for the Treatment of Autism and Other Disorders - Disclosed are methods, compositions of matter, and cells, useful for the treatment of autism, social integrative disorders, and various cognitive abnormalities. The invention discloses, inter alia, means of inducing angiogenesis and immune modulation either in sequence or parallel in order to substantially ameliorate or reverse the progression of autism. The use of stem cells, and cells naturally possessing or endowed with angiogenic and anti-inflammatory activity are disclosed for autism either alone or in combination with various therapeutic interventions.10-16-2008
20110165129Ameliorating Nervous Systems Disorders - The present disclosure provides methods for the treatment of a mammal having a neurological condition, disease, or injury. The methods involve increasing the number of functional GABAergic interneurons at or near the site of the neurological disease, injury, or condition.07-07-2011
20100215623BONE AUGMENTATION UTILIZING MUSCLE-DERIVED PROGENITOR COMPOSITIONS IN BIOCOMPATIBLE MATRIX, AND TREATMENTS THEREOF - The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment non-soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of non-soft tissue (e.g. bone) when combined with a biocompatible matrix, preferably SIS. The invention further provides methods of using compositions comprising muscle-derived progenitor cells with a biocompatible matrix for the augmentation and bulking of mammalian, including human, bone tissues in the treatment of various functional conditions, including osteoporosis, Paget's Disease, osteogenesis imperfecta, bone fracture, osteomalacia, decrease in bone trabecular strength, decrease in bone cortical strength and decrease in bone density with old age.08-26-2010
20110165130Methods for Preparing Human Skin Substitutes from Human Pluripotent Stem Cells - The present invention relates to an ex vivo method for obtaining a population of human keratinocytes derived from human pluripotent stem cells comprising a step of co-culturing human pluripotent stem cells with cells that support ectodermal differentiation in presence of an agent that stimulates epidermal induction and a agent that stimulates terminal differentiation of keratinocytes. A further object of the invention relates to a method for preparing a human skin substitute comprising a step of providing an organotypic culture of the substantially pure homogenous population of human keratinocytes derived from human pluripotent stem cells obtained according to the method of the invention.07-07-2011
20110165131METHODS FOR TREATING DISEASES AND INCREASING LONGEVITY - Diseases such as cancer, HIV/AIDS, diabetes, infectious diseases, as well as diseases related to the immune and autoimmune systems, are treated through the formation and/or enhancement of the function of organs and suborgans of human patients. An important organ for such purpose is the thymus. Enhancement may be direct or indirect and utilizes energy, enhancement compositions, and/or living organisms to enhance the cells and/or cell products produced by organs and suborgans.07-07-2011
20110165128HOMING IN MESENCHYMAL STEM CELLS - The present invention relates to expression of CXCR4 in mesenchymal stem cells (MSCs) and homing of MSCs to sites of injury. In particular, the invention provides expanded cultures of MSCs which maintain cell surface expression of CXCR4. The MSCs are capable of homing to sites of injury and are suitable for treatment of ischemic disorders, including cardiac disorders, bone and cartilage disorders, liver disorders, inflammatory disorders, and stroke.07-07-2011
20100247494Compositions of Mesenchymal Stem Cells to Regenerate Bone - The present invention encompasses an osteogenic composition comprising mesenchymal stem cells pre-cultured in the presence of an agent that accelerates canonical Wnt signaling therein. Also, provided are osteogenic compositions incorporated into a biocompatible gel. The present invention provides methods for treating bone degeneration or injury associated with a pathophysiological condition in a mammal or for accelerating repair of a skeletal injury in a mammal by administering to the mammal or contacting the site of injury with the osteogenic composition.09-30-2010
20110020298COLLAGEN-BINDING SYNTHETIC PEPTIDOGLYCANS, PREPARATION, AND METHODS OF USE - This invention relates to collagen-binding synthetic peptidoglycans and engineered collagen matrices comprising a collagen matrix and a collagen-binding synthetic peptidoglycan where the collagen-binding synthetic peptidoglycan can be aberrant or can have amino acid homology with a portion of the amino acid sequence of a protein or a proteoglycan that regulates collagen fibrillogenesis. The invention also relates to kits, compounds, compositions, and engineered graft constructs comprising such collagen-binding synthetic peptidoglycans or engineered collagen matrices and methods for their preparation and use.01-27-2011
20110020297DNER-MEDIATED CELL PURIFICATION OF PANCREATIC ENDOCRINE PRE-PROGENITOR CELLS AND THEIR PROGENY - The invention relates to a method of identifying and obtaining a culture cells comprising cells selected from the group consisting of endocrine pre-progenitor cells, endocrine progenitor cells, early endocrine cells, and/or fully differentiated endocrine cells. Also contemplated is a method of expanding the number of such cells as well as sorting such cells. In some aspects the invention further relates to a selective cell surface marker, DNER, that permits the selection of a unique subset of cells with endocrine pre-progenitor, endocrine progenitor, early endocrine, and/or fully differentiated endocrine phenotype. In some aspects the selective cell surface marker is selected from the group consisting of DNER, DISP2, SEZ6L2, LRP1 1 and SLC30A8. Furthermore, the invention relates to isolated cells selected from such cells and compositions thereof.01-27-2011
20110020299METHOD AND COMPOSITION FOR THE REGENERATION OF TISSUE WITH THE AID OF STEM CELLS OR BONE MARROW CELLS - The invention relates to a novel polymerisable composition essentially consisting of blood or blood plasma, and also stem cells or bone-marrow cells, and to a method for tissue regeneration with the aid of such compositions. Mixtures of this type are able to polymerise under the influence of endogenous or exogenous polymerisation factors, such as thrombin, calcium ions or cell detritus, to give viscous gels, which are very advantageous for the development and differntiation of the stem cells or bone-marrow cells into tissue-specific cells. Polymers of this type, which, in particular, additionally comprise erythropoietin (EPO), or growth factors with a similar action, exhibit excellent properties on use for tissue regeneration or in the regeneration of bone defects.01-27-2011
20110020292Use of Stem Cells to Reduce Leukocyte Extravasation - The invention is generally directed to reducing inflammation by means of cells that secrete factors that reduce leukocyte extravasation. Specifically, the invention is directed to methods using cells that secrete factors that downregulate the expression of cellular adhesion molecules in leukocytes. Downregulating expression of cellular adhesion molecules reduces leukocyte adhesion to endothelial cells such that extravasation is reduced. The end result is a reduction of inflammation. The cells are non-embryonic non-germ cells that have pluripotent characteristics. These may include expression of pluripotential markers and broad differentiation potential.01-27-2011
20110027237Intraperitoneal Delivery of Genetically Engineered Mesenchymal Stem Cells - A method of expressing at least one protein in an animal by intraperitoneal administration of mesenchymal stem cells genetically engineered with at least one polynucleotide encoding the at least one protein. The method may be employed in treating lysosomal storage disorders, such as Fabry Disease, or arthritic disorders, or hemophilia, for example.02-03-2011
20110027236PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OR PREVENTION OF OSTEOARTICULAR DISEASES - A pharmaceutical composition for the acute and/or chronic treatment or prevention of osteoarticular diseases includes an adequate pharmaceutical carrier or diluent, a polysaccharide and/or a glycosaminoglycan, an anti-inflammatory agent and stem cells.02-03-2011
20100284977Expression of Anti-Nociceptive Compounds from Endogenously Regulated Promoters - Expression of anti-nociceptive compounds under the control of endogenously regulated promoters is disclosed. Methods and materials can be used to modify nociception, the process activated by detection of noxious stimuli. The activity of endogenous promoters employed is up-regulated following nociception in animal models of pain. Thus, expression of anti-nociceptive compounds, e.g., proteins, antisense RNAs or micro RNAs, under the control of these promoters can occur in an auto-regulatory, demand-driven manner. Delivery to neurons activated during pain transmission of disclosed expression cassettes containing up-regulated promoters to drive expression of anti-nociceptive compounds can be useful for pain management.11-11-2010
20100330047Mesenchymal Stem Cells Grown Under Hypoxic Conditions: Compositions, Methods and Uses Therefor - Methods of forming ex vivo cell cultures comprising differentiated mesenchymal lineage cells are disclosed. These methods comprise a) providing a cell culture comprising a plurality of mesenchymal stem cells (MSCs); b) subjecting the MSCs to hypoxic conditions; and c) subsequent to b), subjecting the MSCs to normoxic conditions. Enhanced differentiation of various mesenchymal lineage cells can be achieved for mammalian cells such as murine cells or human cells.12-30-2010
20110256108METHODS OF SELECTION OF CELLS FOR TRANSPLANTATION - A method of selecting a population of adherent cells of a placenta tissue suitable for transplantation is disclosed. The method comprising: (a) determining prior to transplantation in a candidate population of adherent cells of a placenta tissue at least one of the following parameters: (i) percentage of viable cells in the candidate population; (ii) immune phenotype of cells in the candidate population; (iii) xeno-contamination in the candidate population; (iv) sterility of the candidate population; and (v) immunosuppressive activity of cells in the candidate population; and (b) selecting or excluding the candidate population according to predetermined values of at least one of the parameters, thereby selecting a population of adherent cells of the placenta tissue suitable for transplantation.10-20-2011
20110135611METHODS FOR TREATING APOLIPOPROTEIN E4-ASSOCIATED DISORDERS - The present disclosure provides methods of reducing apoE4 fragment-mediated toxicity of interneurons, e.g, GABAergic interneurons. The present disclosure provides methods of treating apoE4-mediated neurological disorders in an apoE4-positive individual.06-09-2011
20110135610Multipotent stem cells from the extrahepatic biliary tree and methods of isolating same - The present invention relates to a multipotent stem cell, multipotent cell populations, and an enriched multipotent cell population, each found in fetal, neonatal, pediatric, and adult biliary tree tissue and up to 72 hours post mortem (although preferentially, within 10 hours post mortem) and capable of maturing into multiple endodermal tissues that include liver, biliary and pancreatic tissues. The multipotent stem/progenitor cell and cell populations are found in peribiliary glands, and progenitors descending from them are present throughout the biliary tree including in the gallbladder. High numbers of the peribiliary glands are found in the branching locations of the biliary tree such as hilum, common hepatic duct, cystic duct, common duct, common hepato-pancreatic duct and gallbladder. Related multipotent cells, multipotent cell populations and their descendent progenitors are found throughout the biliary tree including in the gall bladder, which does not have peribiliary glands. Compositions comprising same, methods of identifying and isolating same, maintaining same in culture, expanding same in culture and differentiating or lineage restricting the same in vitro or in vivo to hepatic, biliary or pancreatic fates (e.g., as hepatocytes, cholangiocytes, and/or pancreatic islet cells) are also provided. Methods of using the multipotent cells and/or multipotent cell populations are also provided.06-09-2011
20110262406COMPOSITIONS AND METHODS FOR TARGETED INACTIVATION OF HIV CELL SURFACE RECEPTORS - Compositions for targeted mutagenesis of cell surface receptors for HIV and methods of their use are provided herein. The compositions include triplex-forming molecules that displace the polypyrimidine strand of target duplex and form a triple-stranded structure and hybrid duplex in a sequence specific manner with the polypurine strand of the target duplex. The triplex-forming molecules include a mixed-sequence “tail” which increases the stringency of binding to the target duplex, improves the frequency of modification at the target site, and reduces the requirement for a polypurine:polypyrimidine stretch. Methods for using the triplex-forming molecules in combination with one or more donor oligonucleotides for targeted modification of sites within or adjacent to genes that encodes cell surface receptors for human immunodeficiency virus (HIV) are also disclosed. Methods for ex vivo and in vivo prophylaxis and therapy of HIV infection using the disclosed compositions are also provided.10-27-2011
20110262402THERAPEUTIC AND PROPHYLACTIC AGENTS FOR ARTHRITIS - Provided is a pharmaceutical composition and a method for the treatment and/or prophylaxis of arthritis, inter alia, rheumatoid arthritis. The pharmaceutical composition comprises human mesenchymal stem cells, and the method comprises administering an effective amount human mesenchymal stem cells to a patient.10-27-2011
20110076256Human Neural Stem Cell and Pharmaceutical Composition for the Treatment of Central or Peripheral Nervous System Disorders or Injuries Using Same - The present invention relates to a human neural stern cell, and to a pharmaceutical composition for the treatment of central or peripheral nervous system disorders and injuries using same. More particularly, the present invention relates to a human telencephalon-derived human neural stem cell effective in the treatment of nervous system disorders and injuries, and to a pharmaceutical composition for the treatment of nervous system disorders and injuries using same, to the use of the human neural stem cell for preparing therapeutic agents for the treatment of nervous system disorders and injuries, and to a method for treating nervous system disorders and injuries, capable of administrating an effective amount of the human neural stem cells into individuals that need the human neural stem cells. The human neural stem cell of the present invention has active effects for treating patients of neural system disorders and injuries, specifically for treating patients with a severe spinal cord injury, ischemic brain damage, epilepsy, and Alzheimer's disease, known to have no special treatment as of present and remain with permanent neurological aftereffects. Accordingly, the pharmaceutical composition containing the human neural stem cell of the present invention provides a novel method for treating neural system injuries.03-31-2011
20110076253Defined Culture Conditions of Human Embryonic Stem Cells - The present invention relates to compositions and methods for culturing stem cells, particularly embryonic stem cells. Specifically, the invention relates to a culture medium that supports proliferation of substantially undifferentiated stem cells, while maintaining potency of the cells. An an embodiment, the culture medium is defined and supports proliferation of substantially undifferentiated embryonic stem cells in essentially serum free and feeder cell free conditions. Compositions for making the medium and methods using the culture medium are also provided.03-31-2011
20100310530Cell Therapy for Brain Tissue Damage - Disclosed are methods for conditioning stems cells and using the conditioned stems cells for treating brain tissue damage.12-09-2010
20100310529EXTRACELLULAR MATRIX FROM PLURIPOTENT CELLS - Isolated extracellular matrix from marrow adherent stromal cells and their descendents, which stimulates the growth and survival of a number of different neural cell types, is provided, along with methods for preparation and uses.12-09-2010
20110052552COMPOSITIONS TO EFFECT NEURONAL GROWTH - Compositions containing neurogenic agents for inhibition of neuron death and inducing proliferation of neural cells are disclosed03-03-2011
20110052551CARDIAC MYOCYTE MORPHOGENIC COMPOSITIONS AND METHODS OF USE THEREFOR - Disclosed are methods for inducing cardiomyogenic differentiation in cells that are competent for differentiation along the cardiomyogenic lineage such as certain unfractionated bone marrow mononuclear cells (BMMNCs). In some embodiments, the methods include contacting a plurality of unfractionated, density gradient-separated BMMNCs with a cardiomyocyte differentiation-inducing amount of a Wnt11 gene product for a time and under conditions sufficient to induce cardiomyocyte differentiation in at least a subset of the BMMNCs. Also provided are methods for treating an injury to cardiac tissue in a subject using cells that have been induced to differentiate along the cardiomyogenic lineage, recombinant host cells comprising an expression vector that encodes a Wnt11 polypeptide or a functional fragment thereof, and systems for inducing cardiomyogenic differentiation in a cultured cell.03-03-2011
20110052549CELL CULTURE DEVICE TO DIFFERENTIATE STEM CELLS IN A SPECIFIC ORIENTATION - Methods and compositions for aligning cell growth is provided by this invention by contacting at least one isolated cell with a device, wherein the device comprises a plurality of continuously orientating substantially parallel structures on the surface of the device, and culturing the cell under conditions that favor division of the at least one cell into a population of cells, thereby growing the population of cells in a substantially parallel orientation.03-03-2011
20110052548CELL CULTURE MEDIA TO DIFFERENTIATE EMBRYONIC STEM CELLS INTO NEURONAL LINEAGES - This invention provides compositions for differentiating an isolated embryonic stem cell or an isolated embryoid body into neuronal progenitor cells and methods for using same.03-03-2011
20110052547RAPAMYCIN-RESISTANT T CELLS AND THERAPEUTIC USES THEREOF - Methods for generating highly enriched Th1/Tc1 and Th2/Tc2 functions are described. In particular, the generation of these functions are attained by the addition of an immune suppression drug, rapamycin or a rapamycin derivative compound. In addition to enhanced purity of T cell function, the T cells generated in rapamycin also express molecules that improve immune T cell function such as CD28 and CD62L. Such rapamycin generated functional T cell subsets may have application in the prevention or treatment of GVHD after allogeneic hematopoietic stem cell transplantation, the treatment of autoimmunity, or the therapy of infection or cancer.03-03-2011
20110052546Inhibition of SHIP to Enhance Stem Cell Harvest and Transplantation - The instant invention teaches the inhibition of SHIP expression, or function for the increased efficacy of autologous stem cell transplants. In another embodiment, interference with SHIP function can be used to temporarily expand and mobilize the hematopoietic stem cell compartment to assist with leukapheresis, to promote hematopoietic recovery after myeloablation treatments, to deplete target stem cell clones (such as leukemic clones and other tumor stem cell types), and to deplete, or damage, the repopulating ability of the endogenous hematopoietic stem cell pool in order to allow transplanted hematopoietic stem cells to better home and engraft and to promote in vivo expansion and mobilization of other organ-specific stem cell populations (e.g., mesenchymal, mammary).03-03-2011
20110052545Regeneration system, its production and use - The present invention relates to a tissue-maintaining colony-forming unit (TM-CFU), a method of preparing the same, a pharmaceutical composition comprising the TM-CFU, the use of the TM-CFU for the manufacture of a pharmaceutical composition, and a method of determining the effect of at least one stimulus on the TM-CFU or a cellular subpopulation thereof.03-03-2011
20120148547COMBINATION OF VITAMIN E AND BETA-GLYCOSPHINGOLIPIDS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING HEPATIC DISORDERS - The present invention relates to combined compositions comprising a combination of at least one natural or synthetic beta-glycolipid and at least one tocopherol (vitamin E). The invention further provides methods and kits using said combined compositions for treating and preventing hepatic disorders, specifically, liver insult cause by hepatotoxic drugs or caused by any one of infectious, metabolic, toxic, immune, or perfusion or blood flow related hepatic injury.06-14-2012
20120148546PERICYTE PROGENITOR CELLS AND METHODS OF GENERATING AND USING SAME - Provided are methods of isolating pericyte progenitor cells from pluripotent stem cells such as embryonic stem cells and induced pluripotent stem cells, by isolating CD105+, CD73+ and/or CD105+/CD73+ cells from embryoid bodies and optionally by enriching the cells with CD31− cells. Also provided are methods of isolating endothelial cells and co-derivation of pericyte and endothelial cells progenitor cells from embryoid bodies, and methods of differentiating same for various therapeutic applications. In addition, the invention provides an isolated pericyte progenitor cell having an expression marker signature of CD105+/CD73+CD31−/alpha SMA−/CD133−/Flk-1−.06-14-2012
20120148545CARDIAC MUSCLE REPAIR OR REGENERATION USING BONE MARROW-DERIVED STEM CELLS - Disclosed are compositions and methods for repairing and/or regenerating cardiac tissue by administering adult bone marrow-derived stem cells to an individual. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.06-14-2012
20120148544Treatment of Diseases and Disorders Using Self-Renewing Colony Forming Cells Cultured and Expanded In Vitro - The present invention relates to methods and uses of cells for the prevention and treatment of a wide variety of diseases and disorders and the repair and regeneration of tissues and organs using low passage and extensively passaged in vitro cultured, self-renewing, colony forming somatic cells (CF-SC). For example, adult bone marrow-derived somatic cells (ABM-SC), or compositions produced by such cells, are useful alone or in combination with other components for treating, for example, cardiovascular, neurological, integumentary, dermatological, periodontal, and immune mediated diseases, disorders, pathologies, and injuries.06-14-2012
20120148542MACHINE PERFUSION WITH COMPLEMENT INHIBITORS - Methods for perfusing one or more organs, tissues or the like (hereinafter “organs”) with a composition comprising at least one complement inhibitor to sustain, maintain or improve the viability of the organs before and/or during transplantation.06-14-2012
20100322908COMPOSITIONS AND METHODS FOR AUGMENTATION AND REGENERATION OF LIVING TISSUE IN A SUBJECT - The present invention provides for a composition, for augmentation and regeneration of living tissue in a subject, comprising a population of porous microparticles of a biodegradable polymer, one or more mammalian cell populations, and optionally, a biocompatible adhesive.12-23-2010
20100322907Expansion of Hematopoietic Stem Cells - Described herein are methods, compositions and kits related to manipulating hematopoietic stem cells and more particularly to methods, compositions and kits related to increasing the number of hematopoietic stem cells in vitro and in vivo. Also described are methods, compositions and kits related to making an expanded population of hematopoietic stem cells (HSCs) and methods, compositions and kits related to using the expanded population of HSCs.12-23-2010
20100068186High affinity telomerase t cell receptors - The present invention provides T cell receptors (TCRs) having the property of binding to ILAKFLHWL-HLA-A*0201 and comprising at least one TCR α chain variable domain and/or at least one TCR β chain variable domain CHARACTERISED IN THAT said TCR has a K03-18-2010
20110165132Heparan Sulphate Which Binds BMP2 - The invention relates to heparan sulphate GAGs obtained by affinity chromatography using the heparin-binding domain of BMP2. The GAGs were obtained from osteoblast extracellular matrix and from a commercially available heparan sulfate (Celsus HS).07-07-2011
20110086010Methods, Systems, and Apparati for Cellular Therapeutic Agent Preparation and Delivery - Methods and devices for the preparation of a biological pharmaceutical composition outside of a classified environment, such as Biological Safety Cabinet type environment, are described. In one aspect of the present technology, a method is provided to prepare a biological pharmaceutical composition preferably in an area next to a patient's bedside or at a facility's pharmacy. The method comprises transferring an appropriate amount of a diluent from a diluent component (04-14-2011
20110020294INDUCEMENT OF ORGANOGENETIC TOLERANCE FOR PANCREATIC XENOTRANSPLANT - Provided herein is an approach to establish organogenetic tolerance via prior transplantation of pig embryonic pancreas, thereby enabling subsequent implantation of porcine islets in a subject without the need for immune-suppression. In one aspect of the invention, porcine pancreatic primordia are implanted into a mammalian subject, and after a period of time sufficient to induce tolerance, porcine islet cells are implanted in the subject.01-27-2011
20110097310ANTI-AGING OR ANTIOXIDANT COMPOSITION CONTAINING PLANT STEM CELL LINE DERIVED FROM CAMBIUM OF PANAX GINSENG - The present invention relates to an anti-aging or antioxidant composition which contains, as an active ingredient, a plant stem cell line derived from the cambium of 04-28-2011
20110097308STEM CELLS TREATED BY IN VITRO FUCOSYLATION AND METHODS OF USE - A method of in vitro fucosylation of selectin ligands on cord blood-derived hematopoietic stem cells for bone marrow transplantation is disclosed. In this method, an effective amount of an α1,3-fucosyltransferase, e.g., α1,3-fucosyltransferase VI, is used in vitro to treat cord blood-derived hematopoietic stem cells to convert non-functional PSGL-1 or other ligands on the cell surface into functional forms that bind selectins, especially P-selectin or E-selectin. The treated cells have enhanced effectiveness in reconstituting bone marrow in patients in need of such therapy.04-28-2011
20110097309Pharmaceutical Agent for Promoting the Functional Regeneration of Damaged Tissue - The present inventors assessed the possibility that bone marrow-derived cells are mobilized to the grafted skin from nonskin tissues and contribute to skin tissue regeneration during the engraftment of grafted skin on biological tissues. As a result, the present inventors for the first time in the world demonstrated that:04-28-2011
20110104122EFFICIENT PRODUCTION AND USE OF HIGHLY CARDIOGENIC PROGENITORS AND CARDIOMYOCYTES FROM EMBRYONIC AND INDUCED PLURIPOTENT STEM CELLS - This invention relates to a method for producing cardiomyocytes and/or cardiac progenitor cells, comprising culturing an induced pluripotent stem (iPS) cell or embryonic stem (ES) cell, which has been differentiated into a mesoderm cell, in the presence of cyclosporin-A.05-05-2011
20110177039ADULT BONE MARROW CELL TRANSPLANTATION TO TESTES CREATION OF TRANSDIFFERENTIATED TESTES GERM CELLS, LEYDIG CELLS AND SERTOLI CELLS - This invention pertains to the discovery that stem cells (e.g., bone marrow stem cells) transplanted directly into a testicular environment are transdifferentiated into bona fide Sertoli cells, and/or Leydig cells, and/or and germ cells. This provides a mechanism for the treatment of male infertility and/or testosterone deficiency. Thus, in one embodiment, this invention provides a method of treating infertility or testosterone deficiency in a male mammal. The method typically involves implanting stem cells into the testes of the mammal whereby the stem cells differentiate into germ cells and/or Sertoli cells and/or Leydig cells thereby reducing infertility and/or testosterone deficiency.07-21-2011
20100183570NON-EMBRYONIC STEM CELLS AND USES THEREOF - Disclosed are novel stem cells of non-embryonic origins and the uses thereof.07-22-2010
20100166716Colony-forming unit cell of human chorion and method to obtain and use thereof - The present invention features colony-forming unit cells derived from the chorion of human placenta and describes compositions and methods for the uses of chorionic cells and their products for therapeutic purposes based upon production and release of multiple growth factors and cytokines by these cells stimulating tissue regeneration independent of engraftment, as well as differentiation into a specific cell type.07-01-2010
20100166717METHOD OF TREATING ISCHEMIC DISORDERS - A method of treating an ischemic disorders in a subject includes administering stromal cell derived factor-1 (SDF-1) to ischemic tissue of the subject in an amount effective to inhibit apoptosis of cells of the tissue.07-01-2010
20100166718LARGE SCALE PANCREATIC ISLET PURIFICATION - The present invention includes a method of isolating pancreatic islets by density centrifugation wherein the pancreatic islets are loaded in a solution comprising pancreatic islets with the density gradient and the islets are isolated by centrifuging the vessel wherein the pressure on the pancreatic islets is less than 50 Pa and wherein the pancreatic islets are isolated from the gradient, the improvement comprising creating a continuous density gradient in a vessel comprising at least 100 milliliters with a bend tube that reduces convection currents that disrupt the gradient.07-01-2010
20100166710Compositions and Methods for Inducing Neuronal Differentiation - The present invention provides compositions and methods for inducing neuronal cell differentiation.07-01-2010
20100166720GENERATION OF NEURONAL CELLS FROM PLURIPOTENT STEM CELLS - The invention relates to in vitro methods for differentiating mammalian pluripotent stem cells into cells displaying a neuronal phenotype, more particularly into cortical-type neurons including inter alia pyramidal neurons and cortical inhibitory interneurons. The invention further encompasses so-obtained neuronal cells and cell population, compositions comprising such, and further uses of said neuronal cells and cell population.07-01-2010
20100166714CARDIOVASCULAR STEM CELLS, METHODS FOR STEM CELL ISOLATION, AND USES THEREOF - The present invention relates to isolation of cardiovascular stem cells, and more particularly to cardiovascular stem cells positive for markers isll07-01-2010
20120121549INDUCED PLURIPOTENT STEM CELLS AND METHODS OF USE - The invention relates to the field of stem cells and, specially, to the reprogramming of adult somatic cells; to obtain pluripotent cells by the transfection of specific genes. Thus, the invention provides induced pluripotent stem cells (iPS) and methods of obtaining and using them.05-17-2012
20120121546Method of Producing Progenitor Cells from Differentiated Cells - The present invention provides a method of producing progenitor cells, such as cells capable of being differentiated into a plurality of different cell types, from differentiated cells. Methods of using progenitor cells in differentiation and/or tissue or organ repair and/or regeneration and/or building are also provides. Methods of using progenitor cells in treatment and prophylaxis of conditions alleviated by administering stem cells or tissue or organ derived from stem cells to a subject or by grafting stem cells or tissue or organ derived from stem cells into a subject or by transplanting stem cells or tissue or organ derived from stem cells into a subject are also provided. Also included are progenitor cells and differentiated cells and/or tissues and/or organs derived therefrom, and kits comprising same.05-17-2012
20100196334Cell Suspension Preparation Technique and Device - The present invention provides for methods and devices suitable for producing a transplantable cellular suspension of living tissue suitable for grafting to a patient. In applying the method and/or in using the device, donor tissue is harvested, subjected to a cell dissociation treatment, cells suitable for grafting back to a patient are collected and dispersed in a solution that is suitable for immediate dispersion over the recipient graft site.08-05-2010
20100196329COMPOSITION FOR TREATING ISCHEMIC LIMB DISEASE COMPRISING STEM CELLS DERIVED FROM ADIPOSE TISSUE - Disclosed herein is a cell therapeutic composition for treating ischemic limb diseases, more specifically, disclosed is a cell therapeutic composition for treating ischemic diseases, which contains adipose tissue-derived mesenchymal stem cells and sucrose or mannose as an excipient. The composition induces angiogenesis around closed blood vessels in the ischemic limb lesions, and thus is useful to treat ischemic diseases.08-05-2010
20100196330PHARMACEUTICAL COMPOSITIONS COMPRISING UNACYLATED GHRELIN AND THERAPEUTICAL USES THEREOF - The present invention relates to compositions containing unacylated ghrelin and derivatives thereof and their uses in the control of glycemia in ageing patients, GH deficient patients, diabetic patients and obese patients.08-05-2010
20100196328ISCHEMIA-INDUCED NEOVASCULARIZATION IS ENHANCED BY hCNS-SC TRANSPLANTATION - The invention provides methods for inducing or enhancing neovascularization following ischemia by transplanting an effective amount of human central nervous system stem cells. The human central nervous system stem cells can be grown as neurospheres or in adherent culture. Also provided are methods for inducing the repair of ischemic tissue in a patient and methods for treating stroke in a patient suffering therefrom.08-05-2010
20100196326METHOD AND SYSTEM FOR BIASING CELLULAR DEVELOPMENT - Compositions and methods comprising siRNA targeted to APP mRNA are advantageously used to transfect stem cells and bias the cells against differentiating into glial type neural cells. The siRNA of the invention causes RNAi-mediated silencing of the APP mRNA. The inventors have discovered that expression APP induces gliogenesis, i.e., promotes differentiation of potent cells into glial cells. The transfection of potent cells with the subject siRNA silences APP mRNA and thus increases probability of the cells to differentiate into non-glial neural cells.08-05-2010
20100068187TRANSCRIPTION FACTORS FOR DIFFERENTIATION OF ADULT HUMAN OLFACTORY PROGENITOR CELLS - A method of transplantation that includes lineage priming human progenitor cells, to form lineage primed cells and transplanting the lineage primed cells into a patient. The lineage primed cells are selected from the group consisting of oligodendrocytic lineage primed cells, dopaminergic lineage primed cells, and motoneuronal lineage primed cells, and lineage priming has an efficiency of at least 1%.03-18-2010
20100068190MESOANGIOBLAST-LIKE CELL AS WELL AS METHODS AND USES RELATING THERETO - The present invention relates to a medicament comprising a mesoangioblast-like cell obtained from a subject, a method of isolating a mesoangioblast-like cell, a method of producing a mesoderm-derived cell using a mesoangioblast-like cell, the use of a mesoangioblast-like cell for the preparation of a medicament for treating a cardiovascular disease and/or an ischemic disease and a method of converting the mesoangioblast-like cell into a pluripotent stem cell.03-18-2010
20100068188COMPOSITION FOR REGENERATION OF PERIODONTAL HARD TISSUE AND METHOD FOR REGENERATION OF PERIODONTAL HARD TISSUE - An object of the present invention is to provide technology of using a preadipocyte to restore comprehensively bone, cartilage and periodontal ligament, and cause a periodontal hard tissue to regenerate. By culturing a preadipocyte using a culture medium containing (i) at least one member selected from the group consisting of glycerophosphate and salts thereof, and (ii) at least one member selected from the group consisting of ascorbic acid, derivatives thereof and salts thereof and not containing an adrenal cortical hormone in such an amount that promotes differentiation of a preadipocyte into a periodontal hard tissue cell, differentiation of the cell into a periodontal hard tissue cell is induced efficiently. Furthermore, a scaffold is combined with the preadipocyte cultured with the above-mentioned culture medium to be transplanted into a periodontal tissue that requires regeneration.03-18-2010
20110262404Novel Mesenchymal Stem Cells and Bone-Forming Cells - The invention relates to a new type of mesenchymal stem cells (MSC) which co-express at least one mesenchymal marker, preferably at least CD105 and CD34. Also provided are bone-forming cells having an analogous phenotype. The invention also provides the cells and cell populations, as well as further products comprising such and uses thereof in bone therapy.10-27-2011
20090297485COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC AND NEURODEGENERATIVE DISORDERS - Treatment methods are disclosed for psychiatric and neurodegenerative disorders by treatment of the patient with platelet-rich plasma (PRP). PRP is administered to areas of the brain that have been identified as associated with the psychiatric or neurodegenerative disorder to replenish the dysfunctional tissue.12-03-2009
20090202495Hyaluronic Acid Derivative and Neural Stem Cells for SCI and PNT Regeneration - A biomaterial for the treatment of spinal cord or of peripheral nerve injury injury, obtainable by: a) treating a hyaluronic acid derivative with a coating solution promoting Neuronal Stem Cells adhesion, branching and differentiation; b) contacting isolated Neuronal Stem Cells with the hyaluronic acid derivative obtained from step a) and culturing and expanding the absorbed cells in the presence of growth or neurotrophic factors selected from βFGF (basic fibroblast growth factor), CNTF (ciliary neurotrophic factor), BDNF (brain derived neurotrophic factor) and GDNF (glial derived neurotrophic factor) or mixtures thereof.08-13-2009
20090202494Combined use of glp-1 agonists and gastrin for regulating blood glucose levels - The invention relates generally to novel compositions and methods comprising a gastrin compound. The compositions and methods provide beneficial effects, in particular sustained beneficial effects, in particular sustained beneficial effects, in particular sustained beneficial effects, in the treatment of diabetes.08-13-2009
20090175835COMPOSITION FOR TREATING DAMAGE OF CENTRAL OR PERIPHERAL NERVE SYSTEM - The present invention provides a composition for treating damage of central or peripheral nerve system comprising neural precursor cell derived from subcutaneous tissue; neuron obtained by differentiating the neural precursor cell; or oligodendrocyte or Schwann cell obtained by differentiating the neural precursor cell; a use of neural precursor cell derived from subcutaneous tissue, neuron obtained by differentiating the neural precursor cell, or oligodendrocyte or Schwann cell obtained by differentiating the neural precursor cell, for the manufacture of an agent for treating damage of central or peripheral nerve system; a method for treating damage of central or peripheral nerve system which comprises administrating to a mammal a therapeutically effective amount of neural precursor cell derived from subcutaneous tissue, neurons obtained by differentiating the neural precursor cell, or oligodendrocyte or Schwann cell obtained by differentiating the neural precursor cell. Further, the present invention provides a method of preparing the neural precursor cell, neurons, oligodendrocyte or Schwann cell of the present invention.07-09-2009
20090175834NEURONAL PROGENITOR CELLS AND METHODS OF DERIVATION AND PURIFICATION OF NEURONAL PROGENITOR CELLS FROM EMBRYONIC STEM CELLS - The invention provides neuronal progenitor cells, populations and cultures of cells, cell compositions and methods of producing neuronal progenitor cells. Neuronal progenitor cells can be prepared from embryonic stem cells, such as human embryonic stem cells.07-09-2009
20090175833PERICYTES FOR USE AS STEM CELLS - A method of promoting perictye differentiation by selectively culturing pericytes in an enriched environment containing a promoter specific to a type of differentiation. Isolated and purified multipotent pericytes or pericyte precursors are provided. A stem cell therapy replacement comprising isolated and purified multipotent pericytes. A treatment of disease comprising an effective amount of isolated and purified multipotent pericytes or pericyte precursors is provided.07-09-2009
20090175832Isolated Embryonic-Like Stem Cells Derived From Human Umbilical Cord Blood - The present invention is related generally to embryonic-like stem cells isolated from human umbilical cord blood, designated herein as cord blood-stem cells (CB-SC's), which display the characteristics of embryonic stem cells and hematopoietic cells. These cells have the capability of proliferation and are able to differentiate to multiple types of cells. In addition, the CB-SC display low immunogenicity and immune regulation. These cells are, therefore, suitable for use in stem cell-based therapies for the treatment of diseases such as Parkinson's disease, diabetes, spinal cord damage, multiple sclerosis, cardiovascular disease, stroke and birth defects, and for preventing, treating and/or reducing an autoimmune disease in a mammalian subject.07-09-2009
20100189694Scar Tissue Treatment System - A treatment for hypertrophic scar tissue and methods for treatment of hypertrophic scar tissues utilizing viable fibroblast cells.07-29-2010
20100189698TREATMENT OR PROPHYLAXIS OF A NEUROLOGICAL OR NEUROPSYCHIATRIC DISORDERS VIA OCULAR ADMINISTRATION - A method for the treatment and/or prophylaxis of a neurological and/or neuropsychiatric disorder associated with altered dopamine function comprising administering to the eye of a patient in need thereof an effective amount of an agent that modulates neurotransmitter production or function.07-29-2010
20100189699METHOD OF CONSTRUCTING MASSES OF MYOCARDIAL CELLS AND USE OF THE MYOCARDIAL CELL MASS - The object of the present invention is to improve the post-transplantation engraftment rate of cardiomyocytes that have been purified to such an extent that they are free from non-cardiomyocytes and any components derived from other species.07-29-2010
20110189140Compositions and Methods for Tissue Repair with Extracellular Matrices - Described herein are compositions comprising decellularized cardiac extracellular matrix and therapeutic uses thereof. Methods for treating, repairing or regenerating defective, diseased, damaged or ischemic cells, tissues or organs in a subject, preferably a human, using a decellularized cardiac extracellular matrix of the invention are provided. Methods of preparing cardiomyocyte culture surfaces and culturing cells with absorbed decellularized cardiac extracellular matrix are provided.08-04-2011
20110189138REPAIR AND/OR RECONSTITUTION OF INVERTEBRAL DISCS - This invention relates to a method for repair and reconstitution of invertebral discs in a subject which involves administration of STRO-108-04-2011
20110189137METHOD FOR GENERATION AND REGULATION OF IPS CELLS AND COMPOSITIONS THEREOF - The present invention provides methods for generating induced pluripotent stem (iPS) cells having an increased efficiency of induction as compared with conventional methods. The method includes treating a somatic cell with a nuclear reprogramming factor in combination with an agent that alters microRNA levels or activity in the cell and/or a p21 inhibitor. The invention further provides iPS cells generated by such methods, as well as clinical and research uses for such iPS cells.08-04-2011
20110189136USES AND ISOLATION OF VERY SMALL EMBRYONIC-LIKE (VSEL) STEM CELLS - The presently disclosed subject matter provides populations of stem cells that are purified from bone marrow, peripheral blood, and/or other sources. Also provided are methods of using the stem cells for treating tissue and/or organ damage in a subject.08-04-2011
20110189135HUMAN STEM CELL-DERIVED NEURAL PRECURSORS FOR TREATMENT OF AUTOIMMUNE DISEASES OF THE CENTRAL NERVOUS SYSTEM - The present invention concerns the use of a population of cells comprising: (a) neural precursor cells committed to an oligodendroglial fate; (b) uncommitted neural precursor cells (c) differentiated oligodendrocytes; or (d) a combination of any one of (a) to (c) for the treatment of CNS autoimmune diseases, or for the preparation of a pharmaceutical composition for treating CNS autoimmune diseases, the population of cells being derived from human pluripotent stem cells. The invention also provides methods for obtaining such populations of cells, namely, neural precursor cells committed to an oligodendroglial fate as well as differentiated oligodendrocytes which then can be used in the treatment of CNS autoimmune diseases. A preferred autoimmune disease in the context of the present invention is multiple sclerosis where the population of cells is administered to the CNS for local treatment of the disease.08-04-2011
20110262407TREATMENT WITH ALPHA7 SELECTIVE LIGANDS - The present invention includes methods, uses, and selective alpha7 nAChR ligands for treating or preventing disease and disorders in which stimulation of neurogenesis is ameliorative; namely, wherein the recruitment of neurogenesis is therapeutic.10-27-2011
20100028309METHOD FOR DIRECTED CELL IN-GROWTH AND CONTROLLED TISSUE REGENERATION IN SPINAL SURGERY - The present invention relates to a method for directed cell in-growth and controlled tissue regeneration to prevent post-surgical or post-traumatic adhesion and fibrosis formation on the injured surface of a tissue selected from the group consisting of spinal column tissue, dura mater, and spinal nerves in a mammal, comprising the step of providing, covering and separating the tissue with a bioactive biofunctional, non-porous, microscopically multilayered collagen foil biomatrix, and to a method for treating a defect in a mammal comprising the step of providing, covering and separating said tissue with a bioactive biofunctional, non-porous, microscopically multilayered collagen foil biomatrix.02-04-2010
20100028307PLURIPOTENT STEM CELL DIFFERENTIATION - The present invention relates to the field of pluripotent stem cell differentiation. The present invention provides methods for the differentiation of pluripotent stem cells on a human feeder cell layer. In particular, the present invention provides an improved method for the differentiation of pluripotent stem cells into pancreatic endocrine cells using a human feeder cell layer.02-04-2010
20100028311USING OF SCAFFOLD COMPRISING FIBRIN FOR DELIVERY OF STEM CELLS - The invention generally relates to the field of delivery of cells to desired tissue sites, prolonged retention of the cells at the sites, and integration of cells into an area of interest for increased therapeutic effect. The invention provides, in part, compositions and methods for treating ischemia in a subject in need thereof. In some aspects, the methods of treatment comprise the administration of a fibrin scaffold or fibrin clot comprising stem cells.02-04-2010
20100028308METHODS TO MAINTAIN, IMPROVE AND RESTORE THE CARTILAGE PHENOTYPE OF CHONDROCYTES - The present invention relates to regulatory cells, which are capable of restoring, maintaining or improving the stable cartilage phenotype of expanded and passaged chondrocytes. These regulatory cells are also capable of directing precursor and stem cells into the chondrogenic lineage. An enriched population of regulatory cells can be obtained by harvesting the non-adherent cells in the culture medium of a monolayer culture of PO chondrocytes.02-04-2010
20100028305Methods for the treatment of lysosomal storage disorders - Provided herein are methods for the treatment of lysosomal storage disorders characterized by a missing or defective secreted lysosomal enzyme. Such lysosomal storage disorders include, but are not limited to neuronal ceroid lipofuscinoses. The disclosed methods involve the transplantation of human multipotent neural stem cells into the CNS of patients suffering from the lysosomal storage disorder. Also provided herein are methods of reversing or slowing the progression of neurodegeneration in patients suffering from or at risk of developing neuronal ceroid lipofuscinoses.02-04-2010
20100021441MHC MOLECULE-BINDING TUMOR-ASSOCIATED PEPTIDES - The invention relates to a tumor-associated peptide with an amino acid sequence selected from the group consisting of SEQ ID NO. 1 to SEQ ID NO. 577 from the attached sequence protocol, the peptide being capable of binding to a molecule of the human major histocompatibility complex (MHC) class I. The invention further relates to the use of the peptides for preparation of a drug and for the treatment of tumor diseases and/or adenomatous diseases. Furthermore, a pharmaceutical composition is described comprising at least one of the pepti01-28-2010
20100021442METHOD FOR PROMOTING IMMUNOTHERAPY USING AN AGENT FOR ELEVATING DENDRITIC CELL PRECURSOR LEVEL IN BLOOD - Although the fields of therapeutic applications of dendritic cells are now expanding, dendritic cell precursors exist only in a small amount in the peripheral blood and, therefore, it is still difficult to obtain them in a therapeutically useful amount even though they are proliferated in vitro. Therefore, it is a key point in performing a therapy with the use of dendritic cells in practice to elevate dendritic cell precursor level in the peripheral blood of a patient. The present invention provides an agent for elevating dendritic cell precursor level in the blood which comprises an agonist to a receptor expressed in immature dendritic cells or a functional derivative thereof as the active ingredient.01-28-2010
20100021436MULTIPOTENT ADULT STEM CELL DERIVED FROM CANINE UMBILICAL CORD BLOOD, PLACENTA AND CANINE FETUS HEART, METHOD FOR PREPARING THE SAME AND CELLULAR THERAPEUTICS CONTAINING THE SAME - The present invention relates to multipotent adult stem cells derived from canine umbilical cord blood, placental blood and blood sample from canine fetal heart, and a method for preparing the same as well as a cellular therapeutic agent containing the same, more specifically, to a multipotent adult stem cell isolated by culturing an eukaryotic cell derived from canine umbilical cord blood, placental blood and blood sample from canine fetal heart in a FBS-containing medium and a method for preparing the same. Adult stem cells according to the present invention are derived from canine umbilical cord blood, placental blood and blood sample from canine fetal heart. The adult stem cells have characteristics highly similar to human mesenchymal stem cells as well as remarkable cell growth at the initial step compared to human UCB-derived mesenchymal stem cells so that the cells are useful to treat canine incurable diseases and difficult-to-cure diseases. Furthermore, multipotent adult stem cells are effective to treat musculoskeletal diseases and neural diseases due to the ability to differentiate into osteogenic cells and neural cells.01-28-2010
20100021433Disease treatment via developing non-syngeneic graft transplantation - A method of providing a pancreatic, lymphoid/hematopietic or pulmonary organ and/or tissue function to a mammalian subject is provided. The method comprises transplanting into the subject a developing mammalian pancreatic, lymphoid/hematopietic or pulmonary organ/tissue graft, respectively, thereby generating a functional pancreatic, lymphoid/hematopietic or pulmonary organ and/or tissue, respectively, for providing the pancreatic, lymphoid/hematopietic or pulmonary organ and/or tissue function, respectively, to the subject.01-28-2010
20100021437NEURAL STEM CELLS DERIVED FROM INDUCED PLURIPOTENT STEM CELLS - The present invention provides novel populations of neural stem cells derived from induced pluripotent stem cells, and methods for making and using the same.01-28-2010
20100021440USE OF TROPOELASTIN FOR REPAIR OR RESTORATION OF TISSUE - The present invention relates to tropoelastin and to tissue repair and restoration using elastic materials. Disclosed is a process for producing an elastic material from tropoelastin including heating a solution of tropoelastin having an alkaline pH to form an elastic material from the tropoelastin in the solution. Also disclosed are elastic materials prepared according to this process and their applications.01-28-2010
20120308536METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER - Methods of treating patients for conditions such as breast augmentation, soft tissue defects, and urinary incontinence, are described. The methods include removing adipose tissue from a patient, processing a portion of the adipose tissue to obtain a substantially isolated population of cells comprising disaggregated adipose-derived stem cells, mixing the concentrated population of adipose-derived cells comprising disaggregated adipose-derived cells with a portion of unprocessed, intact, non-disaggregated adipose tissue to form a composition, and administering the composition to the patient from which the adipose tissue was removed.12-06-2012
20120308534NEURAL PROGENITOR CELL POPULATIONS - This invention provides populations of neural progenitor cells, differentiated neurons, glial cells, and astrocytes. The populations are obtained by culturing stem cell populations (such as embryonic stem cells) in a cocktail of growth conditions that initiates differentiation, and establishes the neural progenitor population. The progenitors can be further differentiated in culture into a variety of different neural phenotypes, including dopaminergic neurons. The differentiated cell populations or the neural progenitors can be generated in large quantities for use in drug screening and the treatment of neurological disorders.12-06-2012
20120308532COMPOSITION FOR THE TREATMENT OF A BONE FRACTURE - There is disclosed a composition formed by a reaction of at least one component A and at least one component B, wherein component A is selected from the group consisting of a compound comprising at least two thiol-groups and a disulfide derivative of a compound comprising at least two thiol groups, and wherein component B is a compound comprising at least two vinyl groups, for the manufacture of an implant for the treatment of a bone fracture. Advantages include that the adhesive patch formed by the composition will be solid in body fluid upon curing and will exhibit excellent mechanical strength. Advantages include that the composition is biocompatible, the material can be applied in small and inaccessible areas, the process requires less surgeon training, it solves drawback with open surgery, and it is possible to use cost effective materials and methods in the process.12-06-2012
20120308533ADIPOCYTE SHEET, THREE-DIMENSIONAL STRUCTURE THEREOF, AND METHOD FOR PRODUCING THE SAME - The present invention aims to provide an artificial tissue that can efficiently reproduce myocardial tissue function and that can be used in an actual implantation and produced by culturing. The present invention relates to a graft material for treating myocardial disease, the graft material including a cell sheet containing adipocytes.12-06-2012
20120308531Expansion of Stem Cells in Hollow Fiber Bioreactors - The invention is directed to producing large numbers of cells using hollow fiber bioreactor technology. The cells are non-embryonic stem, non-germ cells that can be characterized by one or more of the following: extended replication in culture and markers of extended replication, such as telomerase, markers of pluripotentiality, and broad differentiation potential, without being transformed.12-06-2012
20120308530Materials Composition and Methods to Control Neural Progenitor and Stem Cell Attachment, Proliferation and Guide Cell Differentiation - This invention disclosure provides culture surface compositions and methods that control the NPCs and NSCs, and/or MSCs to either largely maintain their phenotypes, or differentiate on these culture surfaces in guided lineage. The culture surface composition can be constructed to contain either OH functional groups, or —NH12-06-2012
20120308529COMPOSITIONS COMPRISING ADIPOSE STEM CELLS - The present invention relates to adipose stem cell compositions, methods for making said compositions, kits comprising said compositions and uses of said compositions in the therapy of diseases.12-06-2012
20120308528Methods and Compositions for Gene Inactivation - Disclosed herein are methods and compositions for inactivating CCR-5 genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs, such as adenovirus (Ad) vectors, and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided.12-06-2012
20120064047Use of Multipotent Adult Stem Cells in Treatment of Myocardial Infarction and Congestive Heart Failure - The invention provides isolated stem cells of non-embryonic origin that can be maintained in culture in the undifferentiated state or differentiated to form cells of multiple tissue types. Also provided are methods of isolation and culture, as well as therapeutic uses for the isolated cells in cardiac indications.03-15-2012
20120064043TISSUE ENGINEERING SCAFFOLDS AND METHODS OF USE - Provided herein are methods of producing a meniscus scaffold to remove material and increase the pore size and porosity therein. In some embodiments, methods include seeding the tissue with allogeneic or autogeneic cells. Bioscaffolds produced by the processes described herein are also provided, as are methods of treating a subject in need of a bioscaffold implant.03-15-2012
20100330049METHOD FOR GENERATING ISLET BETA CELLS FROM DEDIFFERENTIATED EXOCRINE PANCREATIC CELLS - The present invention relates to an in vitro method for generating insulin-producing beta cells from a population of mammalian cells comprising dedifferentiated exocrine pancreatic cells. The method comprises the step of culturing said dedifferentiated exocrine pancreatic cells in a culture medium in the presence of at least one agent that is able to inhibit the Notch 1 signaling pathway in said dedifferentiated exocrine pancreatic cells, and at least one ligand of the gp130 receptor and/or at least one ligand of the EGF receptor. The invention further provides a population of mammalian pancreatic cells comprising insulin-producing beta cells obtainable by the present method and uses thereof in a pharmaceutical composition for treating type 1 or type 2 diabetes.12-30-2010
20090220466VERY SMALL EMBRYONIC-LIKE (VSEL) STEM CELLS AND METHODS OF ISOLATING AND USING THE SAME - The presently disclosed subject matter provides populations of stem cells that are purified from bone marrow, peripheral blood, and/or other sources. Also provided are methods of using the stem cells for treating tissue and/or organ damage in a subject.09-03-2009
20100221230Elective Collection and Banking of Autologous Peripheral Blood Stem Cells - An elective healthcare insurance model using an individual's own peripheral blood stem cells for the individual's future healthcare uses. An individual can elect to have his or her own stem cells collected, processed and preserved, while he or she is in healthy or “pre-disease” state, for future distribution for his or her healthcare needs. The process includes methods of collection, processing, preservation and distribution of adult (including pediatric) peripheral blood stem cells during non-diseased state. The stem cells collected will contain adequate dosage amounts, for one or more transplantations immediately when needed by the individual for future healthcare treatments. The collected adult or non-neonate child peripheral blood stem cells can be aliquoted into defined dosage fractions before cryopreservation so that cells can be withdrawn from storage without the necessity of thawing all of the collected cells.09-02-2010
20090274667RETINAL PIGMENT EPITHELIAL STEM CELLS - The present invention relates to a retinal pigment epithelial stem cell isolated from a posterior region of the retinal pigment epithelium of an adult mammal. The invention also relates to a method of inducing differentiation of retinal epithelial stem and progenitor cells in vitro, wherein the cells of the invention are highly plastic, multipotential stem cells. The invention also includes methods for the treatment of retinal diseases and vision loss involving the transplantation of retinal pigment epithelial stem cells or cells differentiated from retinal pigment epithelial stem cells to the retina of a patient in need of treatment.11-05-2009
20090123434Cellular upregulation of VEGF receptor expression using nanofibrillar articles - The invention provides methods and systems for selectively upregulating the expression of a VEGF receptor in a cell using a synthetic nanofibrillar article. Exemplary embodiments relate to the upregulation of the VEGF receptor Flk-1 in endothelial cells. Cells having the selectively-upregulated VEGF receptor can be used in processes such as cell culturing, tissue engineering, cellular therapy, and drug discovery.05-14-2009
20100183564COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS - The present invention relates to compounds and compositions for expanding the number of CD34+ cells for transplantation. The invention further relates to a cell population comprising expanded hematopoietic stem cells (HSCs) and its use in autologous or allogeneic transplantation for the treatment of patients with inherited immunodeficient and autoimmune diseases and diverse hematopoietic disorders to reconstitute the hematopoietic cell lineages and immune system defense.07-22-2010
20120148548Joint Repair Using Mesenchymal Stem Cells - A method of repairing and/or stabilizing a joint by administering mesenchymal stem cells to the joint. Such a method provides for the regeneration of cartilaginous tissue in the joint, including meniscal tissue.06-14-2012
20100278782DIFFERENTIATION OF RAT LIVER EPITHELIAL CELLS INTO HEPATOCYTE-LIKE CELLS - Methods for differentiation of cells of a rat liver epithelial (RLEC) cell line to hepatocyte-like cells are disclosed. In particular, methods involve sequential exposure of the RLEC to two or more differentiation agents. Cells obtained by the method are described as well as their uses in various pharmacological, toxicological, therapeutic, diagnostic and research applications.11-04-2010
20110117066ESTABLISHED HUMAN BROWN ADIPOCYTE LINE AND METHOD FOR DIFFERENTIATION FROM AN HMADS CELL LINE - The subject matter of the invention is a functional population of human brown adipocytes, in which the expression of UCP1, CIDEA, CPT1B and Bcl2 is higher, the expression of Bax is lower and the expression of PPAR-alpha, PGC-1alpha, PGC-1beta and PRDM16 is similar compared with the corresponding expressions of a population of human white adipocytes. The invention also relates to a method for differentiation of hMADS cells into the functional population of human brown adipocytes, to a method for conversion of a population of human white adipocytes into the functional population of human brown adipocytes, and also to a method of screening for molecules capable of modulating the bodyweight in an individual.05-19-2011
20090142310METHOD OF TREATING INFLAMMATORY ARTHROPATHIES WITH SUPPRESSORS OF CPG OLIGONUCLEOTIDES - The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating inflammatory arthropathies by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.06-04-2009
20080213230Enriched stem cell and progenitor cell populations, and methods of producing and using such populations - The present invention provides a novel method to isolate and expand pure progenitor/stem cells from a primary tissue explant, which produces a population enriched in multipotent functional progenitor/stem cells free of contaminating fibroblasts and other cell types. Cardiac progenitor/stem cells isolated by this method maintain their self-renewal and clonogenic character in vitro and differentiate into normal cells in myocardium, including cardiomyocytes, endothelial cells, and smooth muscle cells, after transplantation into ischemic hearts. The present invention also includes substantially pure populations of multipotent progenitor/stem cells, e.g., cardiac progenitor/stem cells, and their use to treat and prevent diseases and injuries, including those resulting from myocardial infarction.09-04-2008
20090246179METHOD OF TREATING MYOCARDIAL INJURY - A method of treating a myocardial injury of a subject includes administering a population of at least one of mesenchymal stem cells (MSCs), multipotent adult progenitor cells (MAPCs), embryonic stem cells (ESCs), induced pluripotent stem cells (iPSs), which have down-regulated expression of disabled-2 (Dab2), to the subject.10-01-2009
20100209405SERICIN EXTRACTED SILKWORM FIBROIN FIBERS - The present invention provides a novel silk-fiber-based matrix having a wire-rope geometry for use in producing a ligament or tendon, particularly an anterior cruciate ligament, ex vivo for implantation into a recipient in need thereof. The invention further provides the novel silk-fiber-based matrix which is seeded with pluripotent cells that proliferate and differentiate on the matrix to form a ligament or tendon ex vivo. Also disclosed is a bioengineered ligament comprising the silk-fiber-based matrix seeded with pluripotent cells that proliferate and differentiate on the matrix to form the ligament or tendon. A method for producing a ligament or tendon ex vivo comprising the novel silk-fiber-based matrix is also disclosed.08-19-2010
20090104158Non-Embryonic Totipotent Blastomere-Like Stem Cells And Methods Therefor - Non-embryonic blastomere-like totipotent stem cells are disclosed. Most preferably, such cells are obtained from various tissues of postnatal mammals (e.g., using tissue biopsied from the mammal), are smaller than 1 μm, have normal karyotype, and do not spontaneously differentiate in serum-free medium without differentiation inhibitors. These non-embryonic blastomere-like totipotent stem cells typically express CD66e, CEA-CAM-1 and telomerase, but do not typically express CD10, SSEA-1, SSEA-3, and SSEA-4. Such blastomere-like totipotent cells can be differentiated into ectodermal, mesodermal, or endodermal tissues, including placental tissues and germ cells. Moreover, when implanted into a mammal, such cells will not be teratogenic.04-23-2009
20090311220Bone forming compound composed of a mixture of osteoblast and biomatrix and method for producing the same - A compound for bone forming and a method for producing the same are provided using a mixture of an osteoblast and a bio-matrix. The method comprises: isolating osteoblasts from bone tissue and culturing the isolated osteoblasts to prepare an osteoblast suspension; and mixing the resulting osteoblast suspension with a bio-matrix to prepare an osteoblast therapeutic agent. A bone formation method is provided that results in no clinical graft rejection, and is capable of achieving effective and rapid bone formation via injection of a compound which has been pre-shaped to a certain extent, so as to alleviate problems associated with bone tissue formation in unwanted regions resulting from escape of injected osteoblasts from the targeted site for bone formation and then propagation thereof to other sites via the blood stream, which are caused by injection of an osteoblast suspension.12-17-2009
20090035281COMBINATION OF INTERLEUKIN-6 ANTAGONISTS AND ANTIPROLIFERATIVE DRUGS - The combination of an interleukin-6 (IL-6) antagonist and an antiproliferative drug is described. In its preferred embodiment, the present invention describes the combination of an IL-6 superantagonist, particularly a superantagonist totally incapable of binding gp130 and an antiproliferative drug belonging to the glucocorticoid class (SANT-7 and dexamethasone). The combination according to the present invention has shown surprising synergism in an animal model of multiple myeloma and the ability to overcome the resistance to the antiproliferative drug developed by myeloid cells. The combination according to the present invention is useful for the preparation of a medicament for the treatment of tumours, particularly IL-6-dependent tumours.02-05-2009
20110117063Methods For Producing Enriched Populations of Human Retinal Pigment Epithelium Cells For Treatment of Retinal Degeneration - This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.05-19-2011
20110117064ASSAY FOR THE PREDICTION OF THERAPEUTIC EFFECTIVENESS OF MESENCHYMAL STROMAL CELLS, AND METHODS OF USING SAME - The invention relates to assays for testing the therapeutic effectiveness of mesenchymal stromal cell (MSC) populations and methods of treating pathologies with passaged and/or frozen and thawed MSC populations.05-19-2011
20100196331COMPOSITIONS INCLUDING ANTHOCYANIN OR ANTHOCYANIDIN FOR THE PREVENTION OR TREATMENT OF ARTICULAR CARTILAGE-ASSOCIATED CONDITIONS - Methods of treating an arthritic joint of a subject, including administering a pharmaceutical composition by injection into the arthritic joint, wherein the composition includes an anthocyanin or anthocyanidin, glucose, and a pharmaceutically acceptable carrier.08-05-2010
20090155223CELL-BASED COMPOSITIONS AND METHODS FOR TREATING CONDITIONS OF THE NERVOUS SYSTEM - Disclosed herein are cell-based compositions for the treatment of conditions of the nervous system and methods for their use. In one embodiment, a cell-based composition comprises glial-restricted progenitors (GRPs) genetically modified to express a targeting ligand on their cell surface. Methods for the preparation of such cell-based compositions are disclosed. Also disclosed is a method for treating a subject suffering from a condition of the central nervous system by providing therapeutic cells (e.g., GRPs) through an intra-arterial route of administration.06-18-2009
20110002897DIRECTED DIFFERENTIATION OF STEM CELLS - Disclosed are compositions and methods for producing neural cells from stem cells and uses thereof.01-06-2011
20110305673COMPOSITIONS AND METHODS FOR TISSUE REPAIR - The invention features compositions comprising mesenchymal stem cells or multipotent stromal cells, agents secreted by such cells in culture, and methods featuring such cells for the repair or regeneration of a damaged tissue or organ. The present invention is based, at least in part, on the discovery that agents secreted by bone marrow mesenchymal stem cells or multipotent stromal cells (MSCs) were useful for the treatment or prevention of tissue damage related to ischemic injury (e.g., cerebral or cardiac ischemia).12-15-2011
20100254951Nerve Regeneration Promoting Agent - A neuronal differentiation promoting agent for neural stem cells comprising, as an active ingredient, at least one member selected from the group consisting of ω-3 unsaturated fatty acids and ω-6 unsaturated fatty acids having 18 to 22 carbon atoms, and derivatives thereof. The agent can be used for induction of differentiation of neural stem cells and is useful for treating and/or preventing a variety of neurological diseases, and in the fields of nerve transplantation and/or regenerative medicine for nerves.10-07-2010
20110305674Pathways to Generate Hair Cells - This disclosure relates to methods and compositions for modulating (e.g., increasing) Atoh1 activity (e.g., biological activity) and/or expression (e.g., transcription and/or translation) in vivo and/or in vitro, e.g., in a biological cell and/or in a subject. The methods and compositions described herein can be used in the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression in a biological cell.12-15-2011
20110305678USE OF MESENCHYMAL STEM CELLS FOR TREATING GENETIC DISEASES AND DISORDERS - A method of treating a genetic disease or disorder such as, for example, cystic fibrosis, Wilson's disease, amyotrophic lateral sclerosis, or polycystic kidney disease, in an animal comprising administering to said animal mesenchymal stem cells in an amount effective to treat the genetic disease or disorder in the animal.12-15-2011
20110305677HUMAN EMBRYONIC STEM CELL CULTURES, AND COMPOSITIONS AND METHODS FOR GROWING SAME - Human pluripotential embryonic stem cell cultures are provided, as are human feeder cells useful for growing the human embryonic stem cells, conditioned medium obtained from cultures of the human feeder cells, and factors derived from the conditioned medium. Also provided are methods of growing human embryonic stem cells in the presence of the human feeder cells, the conditioned medium, the factors derived from the conditioned medium, or a combination thereof. In addition to the human embryonic stem cell cultures grown according to such methods, isolated human embryonic stem cells obtained from such human embryonic stem cell cultures are provided, as are methods of using such isolated cells.12-15-2011
20110305676METHODS FOR ENHANCING HEMATOPOIETIC STEM/PROGENITOR CELL ENGRAFTMENT - Described herein are methods for enhancing engraftment of hematopoietic stem and progenitor cells using compounds identified using a zebrafish model of hematopoietic cell engraftment. The compounds can be used to treat hematopoietic stem cells ex vivo prior to transplantation of the cells. Alternatively, the compounds can be administered to an individual undergoing cell transplantation.12-15-2011
20110305675METHODS FOR EXPANSION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS - Described herein are methods and compositions for expanding hematopoietic stem and progenitor cells (HSPC) ex vivo and in vivo, and methods and compositions for transplanting HSPCs and treatment of anemia in a human subject. HSPCs are expanded in the presence of an inhibitor of serine threonine kinase 38 (STK38), wherein said inhibitor is preferably an RNAi agent.12-15-2011
20110081323Methods and compositions for organ and tissue functionality - Materials and methods for treating tissue defects in human or animal tissues using implantable cells are described. Further, culture techniques and factors for enhancing these procedures, and cell survival and adaptation are described. Many of the tissue defects may be treated with autologous cells, while applications involving non-autologous cells or stem cells are also described.04-07-2011
20120148538COMPOSITION FOR HARD TISSUE FORMATION AND, DENTIN OR PULP REGENERATION CONTAINING AMELOBLAST, APICAL BUD CELL OR ITS CULTURE FLUID AS AN ACTIVE INGREDIENT - The present invention relates to a composition for hard tissue formation and dentin, or dental pulp regeneration comprising ameloblasts, apical bud cells, or its culture fluid as an active ingredient. The ameloblasts, apical bud cells, or its culture fluid promotes the differentiation of odontoblasts, human dental pulp stem cells and osteoblasts, increases DSPP promoter activity, induces dental pulp regeneration of dental pulp stem cells, and induces hard tissue formation significantly in vivo, so that they can be effectively used for a composition for promoting hard tissue formation and dentin or dental pulp regeneration.06-14-2012
20120148539Methods and Compositions for Tissue Engineering - Disclosed herein are methods and compositions for promoting endochondral bone formation. The invention includes methods of promoting endochondral bone formation by down-regulating the expression of the DIO2 gene or the activity of the deiodinase protein. The invention also includes methods of up-regulating the activity of the FGFR3, ADAMTS9, HEY1, HAS3, and/or MFI2 genes and/or the activity of the expression products of those genes to promote endochondral bone formation. The invention also includes compositions of BMP-7 and agonists of FGFR3, ADAMTS9, HEY1, HAS3, and/or MFI2 proteins. Compositions can further include mesenchymal stem cells.06-14-2012
20100221229MODULATING BONE GROWTH IN TREATING SCOLIOSIS - The present specification provides, amongst other things, a method of treating scoliosis comprising delivering a therapeutically acceptable amount of a growth modulator to an epiphyseal growth plate to correct or compensate for disproportionate growth.09-02-2010
20090117084BACTERIOPHAGE AND PROPHAGE PROTEINS IN CANCER GENE THERAPY - The present invention relates to the use of a polypeptide having a proliferation inhibitory activity or a cell death inducing activity on animal cells. The invention provides further means and methods to use said polypeptide and the corresponding nucleic acids sequence containing the coding regions of said polypeptide. The invention further relates to vectors expressing said polypeptide, to pharmaceutical compositions and therapeutic methods for treating proliferative disorders or diseases like cancer. Last but not least the invention provides a method for a gene therapeutic approach using said polypeptide having a proliferation inhibitory activity or a cell death inducing activity on animal cells.05-07-2009
20080274090REVERSAL OF INSULIN-DEPENDENT DIABETES BY ISLET-PRODUCING STEM CELLS, ISLET PROGENITOR CELLS AND ISLET-LIKE STRUCTURES - The subject invention concerns new methods which make it possible, for the first time, to grow functional islet-producing stem cells (IPSCs), islet progenitor cells (IPCs) and IPC-derived islets (IdIs) in in vitro cultures. The subject invention also concerns the use of the in vitro grown IPSCs, IPCs and/or IdIs for implantation into a mammal for in vivo therapy of diabetes. The subject invention further concerns a process of using the implanted cells for growing a pancreas-like structure in vivo that has the same functional, morphological and histological characteristics as those observed in normal pancreatic endocrine tissue. The ability to grow these cells in vitro and pancreas-like structures in vivo opens up important new avenues for research and therapy relating to diabetes.11-06-2008
20110014163Differentiation of Human Embryonic Stem Cells - The present invention provides a method for lowering blood glucose levels in an animal by transplanting a population of pancreatic endocrine precursor cells into an animal.01-20-2011
20080279827PREPARATION AND XENOTRANSPLANTATION OF PORCINE ISLETS - The invention relates to developments in the treatment of diabetes in mammals. Particularly it relates to a method of preparing a xenotransplantable porcine islet preparation capable upon xenotransplantation of producing porcine insulin in an appropriate recipient mammal, the method including or comprising the steps of: 11-13-2008
20090169523HSC SELF-RENEWAL - The invention is related to methods for culturing stem cells, more particularly hematopoietic stem cells (HSC). The invention relates to methods for HSC expansion and the use of RASSF8 to increase the retention and/or expansion of KLS cells in vitro. The invention is also directed to cells produced by the methods of the invention. The cells are useful, among other things, for treatment of disorders or diseases (e.g. leukemia). The invention also relates to the development of small molecules that may increase HSC self renewal in vitro and in vivo.07-02-2009
20080206203Method for Inhibiting Tumor Metastasis - A leukotriene C4 and D4 antagonist is used to inhibit tumor metastasis by acting to inhibit tumor cell adhesion to endothelial cells, thereby preventing tumor cell extravasation.08-28-2008
20110059052CELLULAR THERAPEUTIC AGENT FOR INCONTINENCE OR URINE COMPRISING STEM CELLS ORIGINATED FROM DECIDUA OR ADIPOSE - The present invention relates to a cellular therapeutic agent for treating urinary incontinence, and more particularly to a cellular therapeutic agent for treating urinary incontinence, which contains stem cells derived from the decidua of the placenta or menstrual fluid or stem cells derived from adipose. The decidua-derived stem cells or adipose-derived stem cells show the effects of increasing leak point pressure and urethral sphincter contractility, and thus are useful as an agent for treating urinary incontinence.03-10-2011
20100143311ANTICANCER THERAPY BY TRANSPLANTING VASCULAR ENDOTHELIAL PROGENITOR CELLS - It is intended to provide anticancer therapy using autologous cells or the like, which induces the regression of cancer or has favorable drug delivery effects and brings about reduction or withdrawal of a hypoxic region(s) in tumor. Transplantation of endothelial progenitor cells, via intravenously or other methods leads to tumor growth inhibition, an increase of the vascular density with an enlargement of the vascular diameter, and reduction of a hypoxic region(s) in the tumor. Allogeneic transplantation of endothelial progenitor cells may be achieved to secure the cells for the therapy, however, autologous transplantation of endothelial progenitor cells from cancer patients would be desirable in order to evade rejection. When the autologous cells are used, mononuclear cells are separated from the peripheral blood or bone marrow of the patient and cultured using an endothelial differentiation medium containing cytokines such as VEGF to obtain adherent cells, which can then be collected and advantageously used as endothelial progenitor cells.06-10-2010
20100178278FORMABLE BIOCERAMICS - A formable bioceramic including hydroxyapatite nanocrystals, gelatin, and sol-gel-containing material is described. Also described is a process for making and using the bioceramic. The formable bioceramic displays superior mechanical strength, elasticity, biocompatibility and forming capabilities and is targeted for bone repairs and template-assisted tissue engineering applications.07-15-2010
20100178279Beta-Glucan Enhances Hematopoietic Progenitor Cells Engraftment and Promotes Recovery from Chemotoxicity - Methods to use beta glucans in the culture of cell populations containing CD34+ cells in order to expand the numbers of CD34+ subsets of progenitor and stem cells are provided. Methods to improve homing and engraftment of stem and progenitor cells by first culturing the cells with beta glucans, or co-administering with beta glucans, are also provided. Additionally, methods to ameliorate chemotherapy toxicity and promote development of functionally active neutrophils by administering beta glucans are presented. The beta glucans are preferably extracted from maitake mushroom (07-15-2010
20120039855FIBRIN BASED SCAFFOLD, PREPARATION AND USE THEREOF - The invention relates to a fibrin-based scaffold suitable for supporting a population of cells comprising mesenchymal stem cells (MSC) and/or umbilical tissue derived cells (UTC) at the site of administration for a prolonged period of time. The scaffold is capable of supporting at least 1×1002-16-2012
20120039857SYSTEMS AND METHODS FOR CARDIAC TISSUE REPAIR - The present application relates to cardiac stem cells and a method of using cardiac stem cells to repair damaged heart tissue. In one embodiment, cardiac stem cells, such as cardiosphere-derived cells and/or cardiospheres, can be seeded, embedded and/or cultured in a biomaterial or matrix made from, for example, a hydrogel, that is subsequently administered to a subject to repair damaged heart tissue.02-16-2012
20120039856COMPOSITION FOR TREATING BALDNESS WITH STEM CELL DERIVED FROM UMBILICAL CORD BLOOD - Provided is a therapeutic technique for treating baldness, using an umbilical cord blood-derived mesenchymal stem cell. Transplantation of a composition for treating baldness into a bald area of a patient can make great contributions to treatment for baldness, wherein the composition comprises stem cells isolated and cultured from umbilical cord blood in which 6 HLA (Human Leukocyte Antigen) are identical with a patient, or one or two HLA are not identical with the patient.02-16-2012
20120039854Nanoparticle Targeted Drug Delivery to the Lungs Using Extra-Testicular Sertoli Cells - A method of delivering a compound of interest to the lungs of a subject by the intravenous injection of Sertoli cells loaded with a plurality of chitosan nanoparticles coupled with the compound of interest is provided. Testis-derived rat Sertoli cells were pre-loaded with chitosan nanoparticles coupled with or without the drug curcumin, pre-labeled with a fluorescent cell marker and then injected intravenously into the control or asthmatic mouse model host. Intact pre-loaded, pre-labeled Sertoli cells were present in the lungs at 15 minutes post-injection, appeared entrapped in the pulmonary pre-capillary vascular bed around alveolar sacs but were not present one hour post-injection although Sertoli cell label and cellular debris was. Most of the of the injected nanoparticle to load (70%) and curcumin load (80%) was present in the lungs 15 minutes post-injection, and remained at 70% and 80%, respectively, one hour post-injection.02-16-2012
20120148537METHODS TO ENHANCE CELL MIGRATION AND ENGRAFTMENT - A method is provided to functionally select cells with enhanced characteristics relevant to cell engraftment, including both spontaneous migration and directional migration towards specific chemo-attractants. The cells are preferably undifferentiated cells, such as mesenchymal stem cells. The method involves entrapping or encapsulating the cells in a biomaterial barrier, optionally inducing cell migration, and selecting cells that migrated through the barrier. The cells selected by this method have better migratory activities and enhanced in vivo engraftment to injured tissues when they are supplemented systemically.06-14-2012
20120148536METHODS AND STORAGE AND RETRIEVAL OF FUNCTIONAL MATURE RETINAL CELLS - A method for the isolation, storage and retrieval of mature retinal cells is disclosed. The Method is applicable to adult mammalian cone cells, and more particularly human cone cells, and to healthy as well as pathological or otherwise altered cone cells. A kit for the isolation, storage and retrieval of mature retinal cells is also described.06-14-2012
20120148541COMPOSITIONS AND METHODS TO GENERATE PILOSEBACEOUS UNITS - The disclosure describes compositions and methods to generate pilosebaceous units. In one aspect, a biocompatible scaffold and an effective amount of dermal and epidermal precursor cells is described.06-14-2012
20090269317IRREVERSIBLE ELECTROPORATION TO CREATE TISSUE SCAFFOLDS - The present invention provides engineered tissue scaffolds, engineered tissues, and methods of using them. The scaffolds and tissues are derived from natural tissues and are created using non-thermal irreversible electroporation (IRE). Use of IRE allows for ablation of cells of the tissue to be treated, but allows vascular and neural structures to remain essentially unharmed. Use of IRE thus permits preparation of thick tissue scaffolds and tissues due to the presence of vasculature within the scaffolds. The engineered tissues can be used in methods of treating subjects, such as those in need of tissue replacement or augmentation.10-29-2009
20090191165FIBRIN GLUE COMPOSITION FOR REPAIRING NERVE DAMAGE AND METHODS THEREOF - A fibrin glue composition is for repairing nerve damage, and/or enhancing the functional recovery of a damaged nerve which includes fibrin glue and an amount of bone marrow stem cells (BMSCs) effective for repairing the nerve damage and/or enhancing at least partially the functional recovery. A method is also for repairing nerve damage, and/or enhancing the functional recovery of a damaged nerve in a subject which includes topically applying to the damaged nerve the fibrin glue composition of the invention.07-30-2009
20090311221BIOMATERIALS FOR REGENERATIVE MEDICINE - It was examined whether a cartilage-like tissue is formed under various reaction conditions using cartilage matrix components: glycosaminoglycan, proteoglycan, and collagen. The present inventors have discovered that proteoglycan bound to glycosaminoglycan through self-organization form an aggregate when the glycosaminoglycan was reacted with proteoglycan under specific concentrations and pH, and that a mesh structure composed of collagen fibers was constructed through self-organization using the aggregates as a skeleton when the aggregates were reacted with collagen molecules.12-17-2009
20110064702Methods and Kits for Enhancing Cell Survival, Stimulating Cell Proliferation, Treating Diabetic Patients, and/or Reinnervation - Methods for enhancing beta cell survival and/or for stimulating beta cell proliferation, comprise co-transplanting pancreatic islets, beta cells, and/or stem cells which can generate beta cells, with (i) neural crest stem cells (NCSCs), (ii) tetracycline-regulated gene expression system (Tet-System)-containing neural stem/progenitor cells (TetStock neural stem/progenitor cells), and/or (iii) pre-differentiated stem/progenitor neural cells. Methods for reinnervation in an organ or tissue transplant patient comprise co-transplanting with the organ or tissue (i) neural crest stem cells (NCSCs), (ii) tetracycline-regulated gene expression system (Tet-System)-containing neural stem/progenitor cells (TetStock neural stem/progenitor cells), and/or (iii) pre-differentiated stem/progenitor neural cells. Kits for conducting such methods employ at least one of (i) neural crest stem cells (NCSCs), (ii) tetracycline-regulated gene expression system (Tet-System)-containing neural stem/progenitor cells (TetStock neural stem/progenitor cells), and (iii) pre-differentiated stem/progenitor neural cells.03-17-2011
20110064705HEMANGIO COLONY FORMING CELLS AND NON-ENGRAFTING HEMANGIO CELLS - Methods of generating and expanding human hemangio-colony forming cells and non-engrafting hemangio cells in vitro and methods of expanding and using such cells are disclosed. The methods permit the production of large numbers of hemangio-colony forming cells, non-engrafting hemangio cells as well as derivative cells, such as hematopoietic and endothelial cells. The cells obtained by the methods disclosed may be used for a variety of research, clinical, and therapeutic applications. Human non-engrafting hemangio cells are a novel progenitor cell population that is related to but distinct from the hemangioblast and human hemangio-colony forming cells. The invention also provides compositions, preparations, and solutions comprising hemangio-colony forming cells, non-engrafting hemangio cells or cells differentiated therefrom. The compositions, preparations, and solutions include cryopreserved preparations and substantially purified preparations, as well as mixed compositions formulated in combination with related hemangioblast progenitor cell types that can engraft into the bone marrow.03-17-2011
20110064704SHIP-DEFICIENCY TO INCREASE MEGAKARYOCYTE AND PLATELET PRODUCTION - A method of increasing megakaryocytes and platelet numbers in a patient comprising the step of inhibiting SHIP expression, including SHIP's enzymatic activity and signaling functions, whereby normal blood clotting is induced.03-17-2011
20110064703BONE SUBSTITUTE COMPOSITIONS, METHODS OF PREPARATION AND CLINICAL APPLICATIONS - The present invention relates to bone substitute compositions and methods of their preparation, and their use in a wide variety of clinical applications. The compositions include calcium phosphate, acidic calcium salt, basic calcium salt, sodium hydrogen phosphate and porogen. The compositions further include a mixing liquid. The compositions can optionally include biological signaling molecules and/or a growth compound. Further, the compositions can optionally include a plasticizer.03-17-2011
20110064701Pluripotent embryonic-like stem cells, compositions, methods and uses thereof - The present invention relates to pluripotent stem cells, particularly to pluripotent embryonic-like stem cells. The invention further relates to methods of purifying pluripotent embryonic-like stem cells and to compositions, cultures and clones thereof. The present invention also relates to a method of transplanting the pluripotent stem cells of the present invention in a mammalian host, such as human, comprising introducing the stem cells, into the host. The invention further relates to methods of in vivo administration of a protein or gene of interest comprising transfecting a pluripotent stem cell with a construct comprising DNA which encodes a protein of interest and then introducing the stem cell into the host where the protein or gene of interest is expressed. The present also relates to methods of producing mesodermal, endodermal or ectodermal lineage-committed cells by culturing or transplantation of the pluripotent stem cells of the present invention.03-17-2011
20100068189Method for Expanding Adult Stem Cells from Blood and Compositions and Methods for Using the Same - A method for the expansion of adult stem cells from blood, particularly but not only peripheral blood, involves removing adult stem cells from blood of a mammal, immediately expanding the stem cells via in-vitro treatment with MCSF (Macrophage Colony Stimulating Factor) at a concentration of about 8-15 nM, and purifying the expanded stem cells. Compositions and methods of using the expanded adult stem cells are also described.03-18-2010
20120177618HEMATOPOIETIC STROMAL PROGENITOR CELLS AND USES THEREOF - The invention provides compositions and methods for modulating disease using hematopoietic stromal progenitor cells derived from hematopoietic tissues. The invention further provides methods for isolating, storing and culturing hematopoietic stromal progenitor cells.07-12-2012
20120177617Composition for Providing Relief of Undesired Body Odours - The present invention relates to a composition suitable for providing relief of undesired body odours caused by consumption of food and/or drink, comprising chlorella, parsley and a mouth refreshing agent. In particular, the food and/or drink comprises a plant, or part thereof, which belongs to the Allium genus. More in particular, the food and/or drink comprises onion, shallot, leek, bunching onion, chive, preferably garlic, any part thereof, or any combination thereof. The composition according to the invention comprises an amount of chlorella between 2 and 30, preferably between 4 and 25, more preferably between 5 and 20 percent by weight of the total composition.07-12-2012
20120177616Methods for augmentation collection of placental hematopoietic stem cells and uses thereof - The subject matter of this invention is a novel method to augment the process of obtaining populations of placental hematopoietic stem and progenitor cells for use in medical practices. A method of augmentation of stem cells collection from placenta is claimed comprising the steps of (a) infusing placental vessels cell preservation compound and a with a composition containing blockers of cell adhesion receptors, (b) incubating said placenta for a sufficient period of time, (c) placing placenta in a containment with sufficient intensity of electromagnetic or ultrasound field for a sufficient period of time; (d) eluting cell suspension from placental vessels, (e) collecting cell suspension and harvesting cells. Invention further claims a method of treatment a disease by means of administering therapeutic composition containing said placental-derived hematopoietic stem cells.07-12-2012
20090191164HUMAN HEMATOPOIETIC MULTIPOTENT PROGENITOR CELLS - A substantially enriched human multipotent progenitor cell population is provided, which is characterized as a progenitor cell capable of giving rise to the multipotent lineage but which lacks certain long-term self-renewal properties of the hematopoietic stem cell. Methods are provided for the isolation and culture of these cells. The cell enrichment methods employ reagents that specifically recognize CD34, CD38, CD90 and CD45RA, in conjunction with lineage specific markers. These cells give rise to all types of hematopoietic cells, e.g. myeloid and lymphoid cells, in vivo.07-30-2009
20120045419METHODS AND USES OF HYPOXIC COMPARTMENT CELLS - The disclosure relates to methods of maintaining and/or expanding an in vitro population of hypoxia compartment cells comprising culturing said population of cells optionally in an oxygen controlled environment, wherein the population of hypoxia compartment cells is exposed to an oxygen concentration of between about 1.5% and about 10%, preferably between about 2% and about 5%, and uses of cells expanded according to these methods.02-23-2012
20120045421METHODS FOR THE ISOLATION OF CARDIAC STEM CELLS - Method for the isolation, expansion and preservation of cardiac stem cells from human or animal tissue biopsy samples to be employed in cell transplantation and functional repair of the myocardium or other organs. Cells may also be used in gene therapy for treating cardiomyopathies, for treating ischemic heart diseases and for setting in vitro models to study drugs.02-23-2012
20120045420COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS - The present specification discloses compositions and methods of transplanting tissue useful for treating a soft tissue condition of an individual.02-23-2012
20120045418PHARMACEUTICAL PREPARATION COMPRISING SUPERNATANT OF BLOOD MONONUCLEAR CELL CULTURE - The present invention relates to a topical pharmaceutical preparation for treating an inflammatory skin condition, preferably a condition associated with ischemia, comprising a supernatant of a physiological solution obtainable by cultivating peripheral blood mononuclear cells (PBMCs) or a subset thereof in a physiological solution free of PBMC-proliferating and PBMC-activating substances for at least 1 h.02-23-2012
20120045417METHODS AND COMPOSITIONS FOR ISLET CELL PRESERVATION - Embodiments of the present invention illustrate methods of treating and preventing transplantation and side effects associated with transplantation. In particular, the present invention relates to compositions and methods for inhibition of graft rejection and promotion of graft survival. Thus, the invention relates to modulation of cellular activities, including graft rejection, promotion of graft survival, graft versus host rejection and conditions commonly associated with graft rejection. More particularly, the present invention relates to the inhibitory compounds comprising naturally occurring and man-made inhibitors of serine protease and inducers of other alpha 1-antitrypsin activities.02-23-2012
20110318315MESENCHYMAL STEM CELLS AND USES THEREFOR - Methods of treating graft versus host disease, or inflammatory diseases in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.12-29-2011
20110318314MESENCHYMAL STEM CELLS AND USES THEREFOR - Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount.12-29-2011
20110318313Modulation of Splenocytes in Cell Therapy for Traumatic Brain Injury - The invention provides methods for treating traumatic brain injury. The invention is generally directed to treating traumatic brain injury by administering cells that have one or more of the following effects in an injured subject: interact with splenocytes, preserve splenic mass, increase proliferation of CD412-29-2011
20120207719PANCREATIC ISLET-LIKE CELLS - The generation of pancreatic islet-like cells from isolated monocyte-derived stem cells (MDSCs) is provided. MDSCs may be differentiated into pancreatic islet cells by contacting the MDSCs with a differentiation factor or factors. Compositions comprising pancreatic islet cells and methods of using them are also provided.08-16-2012
20100150875INDEFINITE CULTURE OF HUMAN ADULT GLIA WITHOUT IMMORTALIZATION AND THERAPEUTIC USES THEREOF - Cell culture conditions for the isolation, maintenance, and indefinite expansion of human glia are established favoring the growth of neural precursor cells. Cultured cells proliferate indefinitely, express catalytic telomerase, and retain a non-immortalized phenotype. Compositions allow for the indefinite expansion of non-immortalized neural tissue for bioassay applications and restorative neuroscience.06-17-2010
20100278789METHODS OF GENERATING EXPANDED AND RE-DIFFERENTIATED ADULT ISLET BETA CELLS CAPABLE OF PRODUCING INSULIN - A method of increasing insulin content in adult islet beta cells is disclosed. The method comprises contacting the adult islet beta cells with an agent capable of down-regulating activity and/or expression of at least one component participating in a NOTCH pathway, the component being up-regulated in beta cell dedifferentiation above a predetermined threshold, thereby increasing the insulin content in adult islet beta cells. Methods of labeling dedifferentiated adult islet beta cells are also disclosed. Cell populations generated using the methods of the present invention and uses thereof are also disclosed.11-04-2010
20090155226Regenerative Dot cells - Methods and compositions are provided for the isolation, culture and use of highly regenerative somatic mammalian cells. The cells are very small, and have an undefined nuclear structure. The cells may be isolated from fetal or adult tissues, and are found in tissue including, without limitation, fetal dermal tissue, blood, and bone marrow. The cells are characterized as expressing one or more markers selected from E-cadherin, integrin β1, CXCR4, CD90 and CD34, and may be selected on the basis of such expression patterns.06-18-2009
20120003190LATERAL VENTRICLE CELL COMPOSITIONS AND USE FOR TREATING NEURAL DEGENERATIVE DISEASES - A pluripotent stem cell isolated from the lateral ventrical of the brain or choroid plexus is provided. Compositions and methods of isolating and using the cell also is provided.01-05-2012
20120003189Materials and Methods to Enhance Hematopoietic Stem Cells Engraftment Procedures - This disclosure is directed to the methods of enhancing hematopoietic stem cells (HSPC) and progenitor cell (HSPC) engraftment procedure. Treatment in vivo of a HSPC donor with compounds that reduce PGE01-05-2012
20120003188Compositions and Methods of Using Living and Non-Living Bioactive Devices with Components Derived from Self-Renewing Colony Forming Cells Cultured and Expanded In Vitro - The invention relates to methods and uses of cells for the prevention and treatment of a wide variety of diseases and disorders and the repair and regeneration of tissues and organs using low passage and extensively passaged in vitro cultured, self-renewing, colony forming somatic cells (CF-SC). For example, adult bone marrow-derived somatic cells (ABM-SC), or compositions produced by such cells, are useful alone or in combination with other components for treating, for example, cardiovascular, neurological, integumentary, dermatological, periodontal, and immune mediated diseases, disorders, pathologies, and injuries.01-05-2012
20120003187BIOLOGICAL MEDIUM FOR PRESERVING A PREPARATION OF INSULIN-SECRETING CELLS - A method for preserving a preparation of insulin-secreting cells includes the step of placing the preparation of insulin-secreting cells in contact with a biological medium, the biological medium including a nutritive product including albumin, and further includes a peptone or a mixture of peptones in sufficient quantity to preserve the insulin-secreting cells.01-05-2012
20120003186METHOD FOR DEDIFFERENTIATING ADIPOSE TISSUE STROMAL CELLS - A method for dedifferentiating adipose tissue stromal cells (ATSC) is provided. When the ATSC is treated under hypoxia condition and with a 4-(3,4-Dihydroxy-phenyl)-derivative (DHP-derivative), expression of stemness genes, cellular growth-related genes and cellular mobility-related genes increase, and expression of histone and DNA methylation-related genes decrease so that cell proliferation increases and pluripotency for differentiating into adipocytes, osteocytes, myocytes, beta cells and cartilage cells is acquired. When the dedifferentiated ATSC is implanted into animal model with spinal cord injury and diabetic animal model, effects of nerve regeneration and increased blood surge level are confirmed. As a result, the method for dedifferentiating the ATSC can be effectively used in the stem cell research, tissue regeneration and development of cytotherapeutic medicines.01-05-2012
20120003193Methods and Apparatus for Manufacturing Plasma Based Plastics and Bioplastics Produced Therefrom - Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided.01-05-2012
20120003191VALPROIC ACID, DERIVATIVES, ANALOGUES, AND COMPOSITIONS INCLUDING SAME AND METHODS FOR THEIR THERAPEUTIC USE - The present disclosure includes methods and compositions for treating any condition or disorder that benefits from activation of the Akt signaling pathway. These methods and compositions involve the use of valproic acid, derivatives, analogs and compositions including the same for treating muscular disorders, such as muscular dystrophy.01-05-2012
20120301446COMPOSITIONS AND METHODS FOR RE-PROGRAMMING CELLS WITHOUT GENETIC MODIFICATION FOR TREATMENT OF NEUROLOGICAL DISORDERS - The present inventions are directed to compositions and methods regarding the reprogramming of other cells (such as glial cells) into neurons without introducing exogenous genes to the samples. In particular, the present inventions are directed to transducible materials that are capable of transducing into the biological samples but are not genes or causing genetic modifications. The present inventions also are directed to methods of reprogramming the path of biological samples or treating diseases using the transducible compositions thereof.11-29-2012
20120301445TOOLS FOR ISOLATING AND FOLLOWING CARDIOVASCULAR PROGENITOR CELLS - The present invention provides new methods and tools for isolating pluripotent cardiovascular progenitors (MCPs), by transiently detecting the cell-surface expression of genes upregulated by Mesp1. Cells obtained by the method and there uses in research and clinical settings are also part of the invention. Using genome wide transcriptional analysis, the inventors found upstream and downstream members of the Mesp1 signaling pathway, which form potential new targets for both therapy and for the identification of MCPs and differentiation of MCPs into cardiovascular cells. This invention provides novel and important insights into the molecular mechanisms of cardiovascular specification and provides potential novel methods for dramatically increasing the number of cardiovascular cells for cellular therapy in humans.11-29-2012
20120301443METHODS FOR DEVELOPING ENDOTHELIAL CELLS FROM PLURIPOTENT CELLS AND ENDOTHELIAL CELLS DERIVED - Disclosed herein is a method for developing human endothelial cells (ECs) from human embryonic stem cells (ESCs). The method is based on inhibition of TGF signaling following mesoderm induction and during vascular differentiation of hESC-derived cells. Also disclosed herein is a substantially pure and stable population of ECs that maintains a high degree of proliferation and phenotypic homogeneity for extended culture periods. Related pharmaceutical compositions and therapeutic methods are also disclosed. A reporter hESC line useful for tracking the development of ECs is also provided.11-29-2012
20120301441DEXTRAN-HYALURONIC ACID BASED HYDROGELS - The invention provides a copolymer of hyaluronic acid (HA) grafted with a dextran-tyramine (Dex-TA) conjugate.11-29-2012
20120301440METHODS AND MATERIALS FOR INCREASING POTENCY OF CELLS - Disclosed herein are methods and materials for producing a more developmentally potent cell from a less developmentally potent cell. Specifically exemplified herein are methods that comprise introducing an expressible dedifferentiating polynucleotide sequence into a less developmentally potent cell, wherein the transfected less developmentally potent cell becomes a more developmentally potent cell capable of differentiating to a less developmentally potent cell of its lineage of origin or a different lineage.11-29-2012
20120301439INHIBITION OF CHOROIDAL NEOVASCULARIZATION - Methods of treatment of diseases that include or are characterized by inappropriate or pathological neovascularization are disclosed. These diseases include diseases of the eye, such as diabetic retinopathy, retinopathy of prematurity, and choroidal neovascularization which can occur in age-related macular degeneration (AMD). Disclosed methods include administering agents that cause directly or indirectly upregulation of the ABCA1 transporter protein in macrophages. These agents include, without limitation, LXR agonists. In some embodiments, inhibitors of CETP expression or activity can also be effective. Administration routes can include, without limitation, intraocular, periocular, or systemic administration.11-29-2012
20120301438Reprogramming Blood Cells to Pluripotent and Multipotent Stem Cells - The present invention is based on the seminal discovery that cord blood (CB) and adult bone marrow (BM) CD34+ cells can be reprogrammed to early stem cells. The invention provides the reprogramming of CB and adult bone marrow (BM) CD34+ cells from subjects without any pre-treatment. Provided are methods for reprogramming blood cells of a subject. Also provided are methods of disease modeling and methods of generating subject-specific differentiated cells. In addition, the invention provides methods of identifying an agent that alters a function of subject-specific differentiated cells as well as isolated pluripotent or multipotent stem cells reprogrammed from blood cells.11-29-2012
20120301437Technologies, Methods, and Products of Small Molecule Directed Tissue and Organ Regeneration from Human Pluripotent Stem Cells - Pluripotent human embryonic stem cells (hESCs) hold great potential for restoring tissue and organ function, which has been hindered by inefficiency and instability of generating desired cell types through multi-lineage differentiation. This instant invention is based on the discovery that pluripotent hESCs maintained under defined culture conditions can be uniformly converted into a specific lineage by small molecule induction. Retinoic acid induces specification of neuroectoderm direct from the pluripotent state of hESCs and triggers progression to neuronal progenitors and neurons efficiently. Similarly, nicotinamide induces specification of cardiomesoderm direct from the pluripotent state of hESCs and triggers progression to cardiac precursors and cardiomyocytes efficiently. This technology provides a large supply of clinically-suitable human neuronal or cardiac therapeutic products for CNS or myocardium repair. This invention enables well-controlled efficient induction of pluripotent hESCs exclusively to a specific clinically-relevant lineage for tissue and organ engineering and regeneration, cell-based therapy, and drug discovery.11-29-2012
20120301436POLYELECTROLYTE COMPLEX GELS AND SOFT TISSUE AUGMENTATION IMPLANTS COMPRISING THE SAME - The invention provides a polyelectrolyte complex gel comprising a chitosan and a γ-polyglutamic acid (γ-PGA) having a molecular weight from about 1 kDa to about 400 kDa or the salt thereof, wherein the chitosan and the γ-PGA are swollen with an aqueous solution. Also provided is a soft tissue augmentation implant, comprising a polyelectrolyte complex gel of the invention as a carrier or a filler and an optional additive. The polyelectrolyte complex gel and the soft tissue augmentation implant containing the same has long degradation time and better supportability so as to provide good maintenance for soft tissue.11-29-2012
20100183567Novel Mammalian Multipotent Stem Cells and Compositions, Methods of Preparation and Methods of Administration Thereof - This invention provides methods for preparing novel mammalian multipotent stem cells (MSCs), compositions thereof, and methods of preparing and administering the cells.07-22-2010
20110027235Targeted integration into stem cells - Disclosed herein are methods and compositions for targeted integration of sequences of interest such as lineage-specific or cell fate reporter constructs or protein encoding sequences into stem cells.02-03-2011
20090208464MESENCHYMAL STEM CELL ISOLATION AND TRANSPLANTATION METHOD AND SYSTEM TO BE USED IN A CLINICAL SETTING - A system and method for the percutaneous, autologous transplantation of mesenchymal stem cells and progenitor helper cells (PHC) from bone marrow to degenerated intervertebral discs or joints. This method is designed to be used by operating room staff in a clinical setting to isolate a mesenchymal stem cell population and PHC during the same surgical procedure as transplantation. The method can be used as a two step procedure where cells are harvested, then isolated, then reimplanted at a later time. In addition, experimental techniques are described to determine which bone marrow cells should be removed via negative selection to generate a PHC population most likely to regenerate certain tissue types in-vitro as well as which combination of fibrinogen and hyaluronic acid and which degree of gel maceration provides the best matrix for in-vitro and in-vivo regeneration of joints and intervertebral discs.08-20-2009
20120207720LAMININS, DERIVATIVES, AND COMPOSITIONS INCLUDING SAME AND METHODS FOR THEIR THERAPEUTIC USE - In various embodiments, the present disclosure provides a method of treating a subject using laminin or a composition that includes laminin. In one embodiment, the method is used to enhance muscle regeneration, maintenance, or repair in a subject. In another embodiment, the method is used to promote wound healing. The method, in yet another embodiment, is used to prevent or reduce muscle damage or injury. In specific implementations of these methods, the laminin or composition that includes laminin is administered in a therapeutically effective amount. In some implementations, the laminin is a complete laminin protein. In other implementations, the laminin is a laminin fragment, a laminin derivative, or a laminin analogue.08-16-2012
20120207717Methods for treating inhalation injury - The invention is directed to methods for treating inhalation injuries. Such methods utilize novel cell compositions such extraembryonic cytokine secreting (ECS) cells and Amnion-derived Multipotent Progenitor (AMP) cells and novel cellular factor-containing solution compositions such as extraembryonic cell-derived cellular cytokine solution, Amnion-derived Cellular Cytokine Solution (ACCS), and physiologic cytokine solution (PCS) compositions. The compositions may be used alone or in combination with each other and/or other agents.08-16-2012
20120207718THIN SHELL GRAFT FOR CARTILAGE RESURFACING - An articular cartilage shell graft is designed to treat the arthritic population for which current biologic treatments are insufficient and as a biological-stage repair for intervention before prosthetic knee arthroplasty.08-16-2012
20120207716Cardiac Muscle Regeneration Using Mesenchymal Stem Cells - Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.08-16-2012
20120207715METHODS AND SYSTEMS FOR STORING AND PROLONGING VIABILITY OF MATRIX DEPENDENT CELLS - The present invention relates to systems, methods and storage media for preserving and prolonging viability of cultured matrix dependent cells including multipotent progenitor cells, such as mesenchymal stem cells. The system and method of the invention are effective in ambient room temperature and apply during storage and shipment of said cells. The storage medium of the invention comprises fibrin microbeads and culture medium, and is suitable for the maintenance and storage of matrix dependent cells. The methods of the invention comprise use of said system, for attaching matrix dependent cells to fibrin microbeads in culture so as to form cell-fibrin microbead complexes.08-16-2012
20120207714COMPOSITIONS COMPRISING VASCULAR AND MYOCYTE PROGENITOR CELLS AND METHODS OF THEIR USE - The invention provides compositions of adult cardiac vascular progenitor cells (VPCs) and adult cardiac myocyte progenitor cells (MPCs) useful for the treatment of various cardiac conditions. The invention also encompasses methods of generating a biological bypass, repairing damaged myocardium, and treating or preventing hypertensive cardiomyopathy and heart failure with the compositions of the invention. Methods of isolating the cardiac progenitor cells are also disclosed.08-16-2012
20100303774METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF MUSCULOSKELETAL DISORDERS - Regenerative cells present in adipose tissue are used to treat patients, including patients with musculoskeletal diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, regenerative cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic musculoskeletal benefit.12-02-2010
20120009157CULTURE METHOD OF EMBRYOID BODIES AND/OR NEURAL STEM CELLS DERIVED FROM HUMAN DIFFERENTIATED CELL-DERIVED PLURIPOTENT STEM CELLS - A method for differentiating a human differentiated cell-derived pluripotent stem cell into a neural stem cell is provided, which includes the steps of: making an embryoid body from the human differentiated cell-derived pluripotent stem cell; and culturing the embryoid body in a medium containing LIF to differentiate into a neural stem cell, so that, when the neural stem cell is allowed to differentiate in vitro after multiple subculturing of the neural stem cell, it differentiate mainly into neurons but substantially not into glial cells.01-12-2012
20120009158VENTRICULAR INDUCED PLURIPOTENT STEM (ViPS) CELLS FOR GENERATION OF AUTOLOGOUS VENTRICULAR CARDIOMYOCYTES AND USES THEREOF - The present invention generally relates to methods and compositions to generate a secondary iPS (2iPS) cell to produce somatic cells of a rare differentiation cell type fate. In some embodiments, the method relates to an increase in efficiency of differentiation and production of high yields of somatic cells of a rare differentiation cell type fate produced from secondary iPS (2iPS) cells as compared to their differentiation from other pluripotent stem cell sources such as ES cells or primary iPS cells. In some embodiments, the present invention relates to compositions, methods and systems for reprogramming a first somatic cell into a primary iPS cell, where the primary iPS cell is then differentiated along a selected linage to produce a second somatic cell, which is then reprogrammed to a secondary iPS cell (2iPS) cell. The 2iPS cell has a high efficiency of differentiating into a cell of the same cell type as the second somatic cell, e.g., a somatic cells of a rare differentiation cell type fate such as but not limited to a ventricular cardiomyocyte, a pancreatic β-cell or a hepatic cell. In some embodiments, the first somatic cell is a fibroblast, or a cardiac cell, but is not limited to cardiac fibroblast cells. In some embodiments, the present invention relates to compositions, methods and systems to produce ventricular cardiomyocytes from secondary induced pluripotent stem cells (iPSC), where the iPSC are themselves generated from ventricular cardiomyocytes. The secondary iPS (2iPS) cell generated from ventricular cardiomyocytes have a higher cardiomyogenic potential and high cardiomyogenic yield as compared to primary iPSC, and are useful in drug discovery, disease modeling and cell-based therapy.01-12-2012
20100196333Device and Process for Producing Fiber Products and Fiber Products Produced Thereby - The present invention is directed to a fiber, preferably bone fiber, having a textured surface, which acts as an effective binding substrate for bone-forming cells and for the induction or promotion of new bone growth by bone-forming cells, which bind to the fiber. Methods of using the bone fibers to induce or promote new bone growth and bone material compositions comprising the bone fibers are also described. The invention further relates to a substrate cutter device and cutter, which are effective in producing substrate fibers, such as bone fibers.08-05-2010
20120009159BIOCOMPATIBLE SUBSTRATE FOR FACILITATING INTERCONNECTIONS BETWEEN STEM CELLS AND TARGET TISSUES AND METHODS FOR IMPLANTING SAME - Disclosed herein are substrates for cell delivery to target tissues requiring treatment for various diseases that induce cell death, damage or loss of function. The substrates are configured to provide seeded cells, including stem cells, with a structural support that allows interconnection with and transmission of biological signals between the cells and the target tissue.01-12-2012
20100291043IL-12 IMMUNOTHERAPY FOR CANCER - Compositions and methods for delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as leukemia.11-18-2010
20100196332Generation of brachial, thoracic and lumbar spinal motor neurons from embryonic stem cells in the absence of all-trans retinoic acid supplement - Disclosed are methods for generating a neuron expressing Hoxc8 transcription factor or a caudal motor neuron comprising culturing an embryonic stem cell in a composition which is essentially free of retinoids and comprises an isotonic salt solution, so as to generate the neuron which expresses Hoxc8 transcription factor or the caudal motor neuron. Disclosed are also methods for generating a caudal brachial motor neuron, a thoracic motor neuron, or a lumbar motor neuron from an embryonic stem cell in a composition essentially free of retinoids and comprising ADFNK medium, an amount of FGF-2, or Gdf11 respectively. Disclosed are also methods of transplanting a motor neuron into a subject comprising generating the motor neuron and transplanting the motor neuron into the subject. Disclosed is also a population of motor neuron cells enriched for motor neuron cells expressing Foxp1 and expressing a gene associated with Spinal Muscular Atrophy (SMA) or Amyotrophic Lateral Sclerosis (ALS).08-05-2010
20120058089TREATMENT OF ORGAN INJURIES AND BURNS USING PLACENTAL STEM CELLS - The present invention provides a method of extracting and recovering embryonic-like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta. A placenta is treated to remove residual umbilical cord blood by perfusing an exsanguinated placenta, preferably with an anticoagulant solution, to flush out residual cells. The residual cells and perfusion liquid from the exsanguinated placenta are collected, and the embryonic-like stem cells are separated from the residual cells and perfusion liquid. The invention also provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate endogenous cells, including, but not limited to, embryonic-like stem cells. The invention also provides methods for propagation of exogenous cells in a placental bioreactor and collecting the propagated exogenous cells and bioactive molecules therefrom.03-08-2012
20120058088Resveratrol-Containing Compositions And Methods Of Use - A resveratrol-containing composition capable of providing a therapeutic benefit to a subject such as modulation of a biological activity, improving cell transplantation therapy, or improving macular degeneration or dystrophy treatments. The compositions comprise trans-resveratrol, a metal chelator, and one or more additional antioxidants such as phenolic antioxidants or vitamin D.03-08-2012
20100226897METHOD FOR MODIFYING THE WETTABILITY AND/OR OTHER BIOCOMPATIBILITY CHARACTERISTICS OF A SURFACE OF A BIOLOGICAL MATERIAL BY THE APPLICATION OF GAS CLUSTER ION BEAM TECHNOLOGY AND BIOLOGICAL MATERIALS MADE THEREBY - The invention provides methods for surgical grafting of a tissue. The method comprises the steps of explanting a graft tissue from a donor, irradiating at least a first portion of the graft tissue with an ion beam, and surgically grafting the graft tissue into a recipient.09-09-2010
20120014929STEM CELLS FOR TREATING LUNG DISEASES - The invention is compositions and methods for treating lung diseases and conditions using mesenchymal stem cells. The preferred stem cells are those derived from a human umbilical cord, or from bone marrow.01-19-2012
20120014931HUMAN LATE STAGE MOTOR NEURON PROGENITOR CELLS - Motor neuron progenitor (MNP) cells and populations of MNP cells, are provided, in particular, populations of human late stage MNP cells having a purity of greater than about 65% late stage MNP cells and high-purity populations of MNP cells having greater than 95% viable cells, as well as method of making and using the same, including deriving late stage MNP cells from pluripotent embryonic stem cells, producing high-purity populations of late stage MNP cells, producing populations of viable MNP cells, transporting viable MNP cells, and transplanting MNP cells.01-19-2012
20120014928METHODS AND COMPOSITIONS FOR TARGETED CLEAVAGE AND RECOMBINATION - Disclosed herein are methods and compositions for targeted cleavage of a genomic sequence, targeted alteration of a genomic sequence, and targeted recombination between a genomic region and an exogenous polynucleotide homologous to the genomic region.01-19-2012
20120014926Activation of Precursor Cells for Cell Therapy - This invention relates to a method and compositions for activation of precursor cells via upregulation of CXCR4 surface receptor expression, to give the activated cells a better homing capability and higher viability. The method for activation involves incubation of the target cells with an isotonic activation solution containing an activation-effective amount of calcium. Such activated cells have a better ability to engraft into target tissues to execute the therapeutic function.01-19-2012
20120014925Self-Assembling Peptides Incorporating Modifications and Methods of Use Thereof - The invention relates to a novel class of self-assembling peptides, compositions thereof, methods for the preparation thereof and methods of use thereof. The invention also encompasses methods for tissue regeneration, increasing the production of extracellular matrix proteins, and methods of treatment comprising administering self-assembling peptides.01-19-2012
20120014924Compositions and Methods for Improving the Functional Efficacy of Stem Cell-Derived Cardiomyocytes - This invention provides an isolated stem cell modified to provide, enhance or contain the functional characteristics of the sarcoplasmic reticulum (SR) The isolated stem cells are modified by expressing a calcium channel protein, by expressing a calcium pump protein such as the sarcro/endoplasmic reticulum Ca2+-ATPase (SERCA) protein, by inhibiting or downregulating expression of the Na+/Ca2+ exchanger (NCX) protein, by expressing a calcium handling protein, by expressing a transverse (t)-tubule, and/or by expressing a transverse (t)-tubule biogenic protein The modified cells may be expanded to a substantially homogenous population of these cells or differentiated to a more mature cell type Compositions are also provided The cells and compositions can be administered to a host and used to regenerate cardiac tissue, improve cardiac function, restore action potential of cardiac tissue, and treat or prevent cardiac malfunction Use for diagnostic screening of therapeutic candidates is also provided01-19-2012
20120014927METHODS AND KITS FOR DETERMINING PREDISPOSITION TO CANCER - Provided are methods and kits for determining predisposition to cancer by determining the presence or absence in a heterozygote form of the KLOTHO functional variant. Also provided are methods of designing treatment and treating cancer based on the increased predisposition to the cancer, and to determine the prognosis of a subject diagnosed with cancer.01-19-2012
20120014930STEM CELLS FOR TREATING LUNG DISEASES - The invention is compositions and methods for treating lung diseases and conditions using mesenchymal stem cells. The preferred stem cells are those derived from a human umbilical cord, or from bone marrow.01-19-2012
20090285787Intracoronary, intracardia, or intravenous infusion of a mixture of autologous bone marrow derived mononuclear cells and autologous bone marrow derived mesenchymal stem cells for utilization and rescue of infarcted myocardium - The present invention is a method for improving cardiac function and myocardial regeneration in living subjects after the occurrence of myocardial infarction. The method is a combination stem cell therapy involving a mixture of bone marrow-derived mesenchymal stem cells and bone marrow derived mononuclear cells surgically implanted by using either a direct or catheter-mediated injection into damaged myocardium. Studies have shown that the implant improves heart function and myocardial regeneration as assessed by MRI, SPECT and echocardiographic measurements.11-19-2009
20110064700NEURAL STEM CELLS - The invention provides compositions and methods for obtaining neural stem cells from post-natal subjects and their use in treating neurological disorders.03-17-2011
20090068155METHODS, PHARMACEUTICAL COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR ADMINISTERING THERAPEUTIC CELLS TO THE ANIMAL CENTRAL NERVOUS SYSTEM - Methods and compositions for preventing and treating the damaged and/or degenerating CNS experiencing loss or death of CNS cells. Various embodiments of the invention transport a therapeutically effective amount of, inter alia, at least one therapeutic cell to the CNS by intranasal application to the upper-third of the nasal cavity, thereby bypassing the blood-brain barrier. A pharmaceutical composition according to the invention may comprise at least one therapeutic cell, at least one delivery-enhancement agent, at least one antibiotic, at least one regulatory factor and/or at least one immunosuppressive agent, wherein the composition is delivered to the upper-third of the nasal cavity. The therapeutic cells, once delivered to the CNS, migrate preferentially to the area of damage or degeneration or injury.03-12-2009
20090087414Materials and methods for altering an immune response to exogenous and endogenous immunogens, including syngeneic and non-syngeneic cells, tissues or organs - Disclosed herein are materials and methods for modulating an immunologically adverse response to an exogenous or endogenous immunogen, including a cell, tissue, or organ associated immunogen. An implantable material comprising cells, such as but not limited to endothelial cells, anchored or embedded in a biocompatible matrix can modulate an adverse immune or inflammatory reaction to exogenous or endogenous immunogens, including response to non-syngeneic or syngeneic cells, tissues or organs, exogenous immunogens or stimuli, as well as ameliorate an autoimmune condition. The implantable material can be provided prior to, coincident with, or subsequent to occurrence of the immune response or inflammatory reaction. The implantable material can induce immunological acceptance in a transplant patient, reduce graft rejection and reduce donor antigen immunogenicity.04-02-2009
20090162327BONE MARROW TRANSPLANTATION FOR TREATMENT OF STROKE - There is provided a treatment for patients suffering from neurodegenerative disease or neural injury including the steps of transplanting cultured bone marrow cells into the spinal cord or brain or injecting intravascularly bone marrow cells of a patient in need. Also provided is a method of activating the differentiation of neural cells in an injured brain including the steps of transplanting bone marrow cells adjacent to the injured brain cells and activating the endogenous central nervous system stem cells to differentiate into neurons. A method of treating injured brain or spinal cord cells is also provided including the steps of transplanting bone marrow cells near the injured brain cells and generating new neurons at the location of transplantation. A method of treating injured brain or spinal cord cells with a composite of MSCs and neurospheres.06-25-2009
20100183565INDUCTION OF HUMAN EMBRYONIC STEM CELL DERIVED CARDIAC PACEMAKER OR CHAMBER-TYPE CARDIOMYOCYTES BY MANIPULATION OF NEUREGULIN SIGNALING - The present invention is directed to methods of producing cardiomyocytes having a nodal/pacemaker phenotype and cardiomyocytes having an atrial/ventricular phenotype. Isolated populations of nodal/pacemaker and atrial/ventricular cardiomyocytes are also disclosed. Methods of treating a subject having cardiac arrhythmia and a subject in need of cardiac tissue repair using the isolated populations of nodal/pacemaker cardiomyocytes and atrial/ventricular cardiomyocytes, respectively, are also disclosed.07-22-2010
20100178275METHODS AND MEANS FOR STEM CELL PROLIFERATION AND SUBSEQUENT GENERATION AND EXPANSION OF PROGENITOR CELLS, AS WELL AS PRODUCTION OF EFFECTOR CELLS AS CLINICAL THERAPEUTICS - The invention is related to methods for expanding and differentiating hemopoietic progenitor cells in a medium comprising a collection of cytokines, desulphated glycosaminoglycan and human serum. The invention further relates to a collection of cells obtainable by a method of the invention, use of the collection of cells, and a kit of parts for expanding and differentiating hemopoietic progenitor cells.07-15-2010
20110081325NOVEL TREATMENT OF HEART DISEASES - Provided is a novel therapeutic approach for the treatment of heart failure and diseases associated therewith. In particular, vinca alkaloids are used for improving the viability of cardiomyocytes and preventing myocardial infarction.04-07-2011
20090269318PROGENITOR CELLS FROM WHARTON'S JELLY OF HUMAN UMBILICAL CORD - Human progenitor cells are extracted from perivascular tissue of human umbilical cord. The progenitor cell population proliferates rapidly, and harbours osteogenic progenitor cells and MHC−/− progenitor cells, and is useful to grow and repair human tissues including bone.10-29-2009
20100150876ENDODERMAL PROGENITOR CELLS - The present invention relates to endodermal progenitor cells and methods of isolation, culture, differentiation and use thereof.06-17-2010
20120156180COMPOSITIONS AND METHODS FOR THE TREATMENT OF KRABBE AND OTHER NEURODEGENERATIVE DISEASES - Provided are compositions and methods for the treatment of Krabbe and other neurodegenerative diseases, including storage diseases such as GM1 gangliosidosis, Niemann-Pick disease, Tay-Sachs disease, Sandhoff disease, metachromatic leukodystrophy, Canavan disease, Pelizaeus-Merzbacher disease, and storage conditions facilitated by aging of lysosomal functions, which are associated with psychosine (and/or other storage material)-mediated axonal degeneration. Compositions and methods employ (1) one or more inhibitor of a phos-photransferase activity of one or more kinase(s) such as, for example, CDK5, P38, jnk, src, CK2, PKC, GSK3α and β; (2) one or more inhibitor of a phosphotransferase activity of one or more phosphatase(s) such as, for example, the Ser/Thr protein phosphatase PP1 and Tyr protein phosphatase PP2; one or more inhibitor of a caspase/calpain activity of one or more caspases such as caspase 3 and calpains such as calpain 1 and 2; and (4) one or more inhibitor of a sodium/calcium exchange protein such as, for example, NCX1. Inhibitors include small molecules, including the GSK3β inhibitor L803 and the NCX1 inhibitor flecainide, and siRNA molecules that downmodulate cellular levels of one or more mRNA, including siRNA that are capable of downmodulating the cellular expression of PP1. Inhibitors disclosed can cross the blood-brain barrier and, thus, are available to the central nervous system (CNS) and effective in reducing psychosine-mediated axonal degeneration.06-21-2012
20120064048TREATMENT OF REPROGRAMMING FACTOR RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A REPROGRAMMING FACTOR - The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Reprogramming factor, in particular, by targeting natural antisense polynucleotides of a Reprogramming factor. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Reprogramming factors.03-15-2012
20120064049USE OF STEM CELLS FROM HAIR ROOT SHEATHS AND KERATINOCYTE PRECURSOR CELLS FOR THE REGENERATION OF AGED SKIN - The present invention relates to the use of stem cells from hair root sheaths and/or keratinocyte precursor cells for the regeneration of aged but otherwise healthy and non-injured skin for the cosmetic purposes and for the prevention of skin diseases. In addition, the invention is directed to a cosmetic method for the regeneration of aged skin.03-15-2012
20120064042XENO-FREE GENERATION OF TISSUE-SPECIFIC PROGENITOR CELLS - The invention relates to purified, tissue-specific progenitors, methods of making and using such tissue-specific progenitors.03-15-2012
20120064041Efficient Generation of Neurally-Induced Mesenchymal Stem Cells and Applications Thereof - The present invention provides methods and compositions for reprogramming mammalian mesenchymal stem cells, as well as to methods for using such cells, for example, to prevent or treat various injuries, diseases, and disorders in human and non-human animals.03-15-2012
20090169521Vascularized cardiac tissue and methods of producing and using same - An isolated composition of matter is disclosed. The composition comprises a heterogeneous population of cells seeded on a scaffold, wherein the heterogeneous population of cells comprises cardiomyocytes, endothelial cells and fibroblast cells. Pharmaceutical compositions comprising same and uses thereof are also disclosed.07-02-2009
20100203020METHODS OF GENERATING, REPAIRING AND/OR MAINTAINING CONNECTIVE TISSUE IN VIVO - This invention relates to a method for generating, repairing and/or maintaining connective tissue in a subject. In one embodiment, the invention relates to a method for generating, repairing and/or maintaining cartilage tissue in a subject. The present invention also relates to a method of treating and/or preventing a disease in a subject arising from degradation and inflammation of connective tissue.08-12-2010
20120156181THERAPEUTIC AGENT FOR LIVER-RELATED DISEASES - The present invention relates to a therapeutic agent for liver-related diseases, comprising adipose tissue-derived multilineage progenitor cells; and others.06-21-2012
20120156179METHOD FOR INDUCING EXTENDED SELF-RENEWAL OF FUNCTIONALLY DIFFERENTIATED SOMATIC CELLS - The present invention relates to a method for inducing proliferation of functionally differentiated somatic cells comprising a step of activating expression of a Myc family gene and a KIf family gene in said cells or contacting said cells with a Myc family protein and a KIf family protein.06-21-2012
20120156177METHODS AND DEVICES FOR HARVESTING AND PROCESSING CONNECTIVE TISSUE PRECURSOR CELLS FROM AUTOLOGOUS FAT - Methods and devices are disclosed for repairing injured, infected, or otherwise damaged connective tissues. Such repairs use injectable combinations of: (i) stromal precursor cells, which can be obtained from a patient via liposuction, and which can mature rapidly into muscle, ligament, tendon, or other types of connective tissue cells that are needed at a repair site; and (ii) platelets, which will accelerate and promote a repair process, and which can be obtained from the patient's blood. When mixed together, stromal precursor cells and platelet cells will act synergistically, to generate new tissue which can replace or repair damaged tissue. Devices and methods are disclosed for processing an already-centrifuged layer of “spun fat”, obtained from a liposuction extract, to remove unhelpful materials and concentrate the stromal precursor cells, before the stromal cells are mixed with platelet cells for injection into a patient.06-21-2012
20120156176THERMORESPONSIVE, BIODEGRADABLE, ELASTOMERIC MATERIAL AND USES THEREFOR - Provided are novel biocompatible copolymers and compositions comprising the copolymers. The copolymers are non-toxic and typically have an LCST below 37° C. Compositions comprising the copolymers can be used for wound treatment, as a cellular growth matrix or niche and for injection into cardiac tissue to repair and mechanically support damaged tissue. The copolymers comprise numerous ester linkages so that the copolymers are erodeable in situ. Degradation products of the copolymers are soluble and non-toxic. The copolymers can be amine-reactive so that they can conjugate with proteins, such as collagen. Active ingredients, such as drugs, can be incorporated into compositions comprising the copolymers.06-21-2012
20120156175COMPOSITION FOR INDUCING MIGRATION OF NEURAL STEM CELLS CONTAINING PERIOSTIN AS EFFECTIVE INGREDIENT - A novel use of periostin, and more particularly a composition for inducing the migration of neural stem cells, which contains periostin or a periostin-secreting cell as an active ingredient, based on the discovery of a novel function of periostin that induces the migration of neural stem cells. Periostin induces the migration of neural stem cells, and thus the composition for inducing the migration of neural stem cells, which contains periostin or periostin-secreting cells as an active ingredient, can be used in various applications based on neural stem cells. A pharmaceutical composition containing suicide gene-expressing neural stem cells and periostin allows the neural stem cells to effectively migrate to tumor tissues, and thus can be used as a cell therapeutic agent for treating cancer. Also, the pharmaceutical composition containing neural stem cells and periostin has improved effects on the stimulation of regeneration of nerve cells and the treatment of neural diseases.06-21-2012
20090208467P27 AND P21 IN GENE THERAPIES - The expansion of a population of stem cells or progenitor cells, or precursors thereof, may be accomplished by disrupting or inhibiting p2108-20-2009
20120156178TREATMENT OF PEYRONIES DISEASE - The invention relates to systems and therapeutic methods to reduce plaque causing Peyronie's disease. One approach uses high pressure injection of collagenase-containing composition into a penile plaque. Plaque disruption is enhanced by the mechanical force of the high pressure, followed by the enzymatic action of collagenase. Another approach uses collagenase as a pretreatment, followed by addition of adipose-derived stem cells ADSCs. The initial collagenase injection breaks down collagen (often more type III than type I in Peyronie's) to provide short term benefit. The longer-term benefit is provided by introduction of ADSCs to the plaque, which can produce cytokines and other signals for revascularization and restoration of normal penile tissue. The resulting combination advantageously reduces the bulk of the plaque early on with ongoing reduction through the revascularization of the tissue. In addition, the treatment provides an advantageous shift of elastin and collagen ratios.06-21-2012
20110076255COMPOSITIONS AND METHODS FOR TREATING PROGRESSIVE MYOCARDIAL INJURY DUE TO A VASCULAR INSUFFICIENCY - The described invention provides methods and regimens for treating adverse consequences of a persistent and progressive myocardial injury—due to a vascular insufficiency that occurs early or late in a subject in need thereof, and progressive myocardial injury-preventing compositions that contain a chemotactic hematopoietic stem cell product, and, optionally, an additional active agent.03-31-2011
20120107283HUMAN SKIN EQUIVALENTS EXPRESSING EXOGENOUS POLYPEPTIDES - The present invention relates generally to compositions for wound closure. More specifically, the present invention provides human skin equivalents engineered to express exogenous polypeptides (e.g., antimicrobial polypeptides and keratinocyte growth factor 2) and compositions and methods for making human skin equivalents engineered to express exogenous polypeptides. In addition, the present invention provides methods for treatment of wounds with human skin equivalents engineered to express exogenous polypeptides.05-03-2012
20110091428COMPOSITIONS OF ADULT ORGAN STEM CELLS AND USES THEREOF - Compositions of isolated adult organ stem cells, including hematopoietic stem cells, cardiac stem cells, and kidney stem cells, are disclosed. In particular, the present invention provides c-kit positive, lineage negative adult stem cells that can be isolated from adult organ tissue. Such stem cells are capable of generating all the cell lineages of the organ tissue from which they were isolated. Methods for repairing damaged organ tissue with the isolated organ stem cells are also disclosed.04-21-2011
20110091427METHODS FOR TREATING A KIDNEY INJURY - Provided herein are methods of treating a kidney injury in a patient, comprising administering to the patient hematopoietic stem cells (HSCs) in an amount effective to treat the kidney injury. In some embodiments, administration of the HSCs is delayed, such that the HSCs are not administered immediately after the kidney injury. In certain aspects, the HSCs are administered to the patient during the beginning of the repair phase of the kidney. Further embodiments and aspects of the invention, including related methods and compositions for use therein, are described herein.04-21-2011
20110091426Human brain endothelial cells and growth medium and method for expansion of primitive CD34+CD38- bone marrow stem cells - A novel co-culture system using human brain endothelial cells (HUBEC) which promotes the expansion of human CD3404-21-2011
20090142306METHODS AND SYSTEMS FOR TREATING ISCHEMIC TISSUES - Methods and systems for regenerating damaged tissue rely on direct injection of selected therapeutic cells into a tissue at or near the site of tissue damage. Direct injection is accomplished using an intravascular catheter having a deployable needle, and injection is usually targeted into the adventitial and peri-adventitial tissues surrounding the blood vessel from which the needle is deployed.06-04-2009
20100291047Use of Mesenchymal Stem Cells for Treating Genetic Disease and Disorders - A method of treating a genetic disease or disorder such as, for example, cystic fibrosis, Wilson's disease, amyotrophic lateral sclerosis, or polycystic kidney disease, in an animal comprising administering to said animal mesenchymal stem cells in an amount effective to treat the genetic disease or disorder in the animal.11-18-2010
20100291044Lunasin-induced regulation of disease-related gene expression - Methods are provided for screening a test compound for anti-neoplastic activity by providing a test compound to a cancer cell and measuring the acetylation of Lysine 16 of the N-terminal tail of histone H4. Methods are also provided for using a test compound for staging a cancer tissue and for measuring the degree of the test compound's anti-neoplastic activity upon a cancer tissue by providing a test compound to a cancer tissue sample and measuring the degree of methylation of nucleotides within the 5′ region in the cancer tissue sample.11-18-2010
20100291042MULTIPOTENT STEM CELLS AND USES THEREOF - The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The invention further provides a proliferative stem cell, which expresses genes including Oct-4, Nanog, Sox2, GDF3, P16INK4, BMI, Notch, HDAC4, TERT, Rex-1 and TWIST but does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The cells of the invention can be isolated from adult mammals, have embryonic cell characteristics, and can form embryoid bodies. Methods for obtaining the stem cells, as well as methods of treating diseases and differentiated the stem cells, are also provided.11-18-2010
20110104125EPISOMAL REPROGRAMMING WITH CHEMICALS - Methods and composition of induction of pluripotent stem cells are disclosed. For example, in certain aspects methods for generating essentially vector-free induced pluripotent stem cells with cell signaling regulators are described. Furthermore, certain aspects of the invention provide novel compositions comprising induced pluripotent stem cells essentially free of exogenous retroviral vector elements in the presence of a medium comprising signaling inhibitors. In certain aspects, feeder-free episomal reprogramming methods may be provided.05-05-2011
20110104123THERAPEUTIC PROTOCOL USING STEM CELLS IN TISSUE AND NEURONAL REPAIR, MAINTENANCE, REGENERATION AND AUGMENTATION - The present invention relates generally to the field of tissue and neuronal repair, maintenance, regeneration and augmentation. More particularly, the present invention encompasses an improved stem cell therapeutic protocol.05-05-2011
20110104126Human Hepatic Stem Cell, Method for Preparation of the Same, Method for Induction of Differentiation of the Same, and Method for Utilization of the Same - The present invention provides a human hepatic stem cell which is sorted based on the presence or absence of the expression of at least one marker selected from the group consisting of CD318, CD90, CD66 and CD13. A method of preparing the human hepatic stem cell, a method of inducing differentiation of the same and a method of using the same are also provided.05-05-2011
20110104124MESODERMAL-LIKE CELL POPULATION FOR TREATING ISCHEMIA IN MAMMALS - Compositions containing an effective amount of mesodermal-like multipotent mammalian mononuclear cells that express both CD34 and M-cadherin cell surface markers are used for preventing, treating or reducing the severity of tissue ischemia or an ischemia associated disorder in a mammal. Such uses may include repopulating an in vivo site with new myocytes and/or vascularizing an ischemic or adjacent tissue. Detection of the level and/or distribution of CD3405-05-2011
20120121547Methods and compositions for treating chronic wounds - The invention is directed to novel methods for treating wounds, in particular, chronic wounds such as diabetic ulcers. Such methods utilize novel cell and cell-product compositions in combination with insulin.05-17-2012
20120121548PRODUCTION OF REPROGRAMMED PLURIPOTENT CELLS - The present invention provides a method of producing a reprogrammed cell, said method comprising exposing Stro-105-17-2012
20120121550PRODUCTION OF OLIGODENDROCYTES FROM PLACENTA-DERIVED STEM CELLS - The present invention provides methods and compositions for the production of glial cells and oligodendrocytes from placenta stem cells. The invention further provides for the use of these glia and oligodendrocytes in the treatment of, and intervention in, for example, trauma, ischemia and degenerative disorders of the central nervous system (CNS), particularly in the treatment of demyelinating diseases such as multiple sclerosis.05-17-2012
20120219531Microcarriers for Stem Cell Culture - The present application discloses a method of generating bone tissue in vivo comprising implanting cells into a human or animal at a location where bone growth is required, wherein the cells have been obtained by the in vitro suspension culture of mesenchymal stem cells attached to microcarriers.08-30-2012
20120251508CYTOCOMPATIBLE ALGINATE GELS - The present invention relates to a method of making cytocompatible alginate gels and their use in the treatment of cardiomyopathy.10-04-2012
20120251507COMPOSITIONS FOR PREVENTING CARDIAC ARRHYTHMIA - Disclosed herein are compositions and methods for treating or preventing a cardiac arrhythmia in a subject.10-04-2012
20120251505HUMAN LYMPHOID TISSUE INDUCER (LTi) CELL COMPOSITIONS AND METHODS OF USE - The invention provides human lymphoid tissue inducer (LTi) cells, methods of producing human lymphoid tissue inducer (LTi) cells, and methods of using human lymphoid tissue inducer (LTi) cells. Such methods include treatment of a subject that would benefit from human lymphoid tissue inducer (LTi) cells, for example, an immunocompromised or immunosuppressed subject.10-04-2012
20120251504PLURIPOTENT STEM CELLS OBTAINED FROM DENTAL PULP - The present invention relates to pluripotent stem cells obtained from the dental pulp of patients of different ages, the invention furthermore comprises cultures of said cells, means for obtaining them and pharmaceutical compositions comprising them, as well as their application in tissue regeneration.10-04-2012
20090104159Vascular/Lymphatic Endothelial Cells - The present invention provides methods to culture and use vascular endothelial cells, including lymphatic, venous and arterial endothelial cells.04-23-2009
20100092435USE OF A VARICELLOVIRUS TAP-INHIBITOR FOR THE INDUCTION OF TUMOR-OR VIRUS-SPECIFIC IMMUNITY AGAINST TEIPP - The present invention provides a novel approach to the modulation of the immune response, directing it towards specific antigens, away from antigens against which no response is desired. The invention is based on the use of viral immune evasion proteins, such as UL49.5, which block antigen presentation to CD8+ T cells. The viral immune evasion proteins are used for: 1) the induction of tumor-specific or virus-specific immunity in cases where a conventional immune response is absent due to antigen processing defects; 2) the induction of empty MHC class I molecules at the cell surface that can be loaded with peptides of a desired specificity; 3) the inhibition of unwanted immune responses against transplanted tissues or organs, e.g. against islets of Langerhans in type 1 diabetes or allogeneic stem cells, or against self antigens in the case of autoimmunity.04-15-2010
20100092433VASCULARIZED ISLETS AND METHODS OF PRODUCING SAME - An isolated composition of matter is provided comprising a heterogeneous population of cells seeded on a surface of a scaffold, wherein the heterogeneous population of cells comprises at least one pancreatic islet, endothelial cells and fibroblast cells. Methods of generating same and uses thereof are also provided.04-15-2010
20100092432CELL PREPARATION CONTAINING MULTIPOTENTIAL STEM CELLS ORIGINATING IN FAT TISSUE - [Problems] To provide a novel use of multipotential stem cells originating in a fat tissue.04-15-2010
20100092434THROMBOPOIETIC ACTIVITY OF TYROSYL-TRNA SYNTHETASE POLYPEPTIDES - Thrombopoietic compositions are provided comprising tyrosyl tRNA synthetase polypeptides, including truncations and/or variants thereof. Also provided are methods of using such compositions in the treatment of conditions that benefit from increased thrombopoiesis, such as thrombocytopenia.04-15-2010
20120121544Method for Efficiently Proliferating and Differentiating Natural Killer Cells from Umbilical Cord Blood - The present invention relates to a method for efficiently proliferating and differentiating natural killer cells (NK cells) from umbilical cord blood, more precisely a method for efficiently proliferating and differentiating natural killer cells from umbilical cord blood comprising the following steps: 1) preparing CD3 negative cells by eliminating CD3 positive T-cells from umbilical cord blood derived mononuclear cells; and 2) culturing the CD3 negative cells after treating various cytokines thereto. The present invention is advantageous in obtaining high purity NK cells in a short period of time by inducing NK cells from CD3 negative cells, compared with the conventional method inducing NK cells from haematopoietic stem cells, and in promoting NK cell proliferation and differentiation by treating different cytokines together, for example by the co-treatment of IL-15 and IL-21. That is, the method of the present invention can induce NK cells with increased anti-cancer cytotoxicity, so that it can be effectively used for anti-cancer cell therapy.05-17-2012
20120121545Pharmaceutical Composition For Bone Disease Treatment Or Countering Inflammation, Comprising Cartilage Stem Cells As An Active Principle - Disclosed is a pharmaceutical composition for treating bone disease or countering inflammation containing cartilage stem cells as an active ingredient. The present disclosure provides a novel cell treatment regimen for bone disease and inflammatory disease using the cartilage stem cells as an active ingredient. When the cartilage stem cells of the present disclosure are administered into the articular capsule, the administered cartilage stem cells are highly effective in treating bone disease and inflammatory bone disease since they grow or differentiate into chondrocytes and exhibit an anti-inflammatory activity. Since the cartilage stem cells of the present disclosure do not express histocompatibility antigens which give rise to rejection in tissue or organ transplants, autologous cells or exogenous cells can be used during cell transplantation for treatment of bone disease and inflammation.05-17-2012
20120121557NEUREGULIN INDUCED PROLIFERATION OF CARDIOMYOCYTES - The present invention provides methods for inducing division of postmitotic mammalian differentiated cardiomyocytes. The invention can be used to repair heart tissue damaged by, for example, myocardial ischemia, hypoxia, stroke, myocardial infarction or chronic ischemic heart disease in vivo. In addition, the methods of the invention can be used to induce heart muscle cells to divide in vitro, in vivo and/or ex vivo, which can then be used in heart tissue repair.05-17-2012
20120121556METHODS OF USING REGENERATIVE CELLS TO PROMOTE WOUND HEALING - Cells present in adipose tissue are used to promote wound healing in a patient. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the regenerative cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic benefit.05-17-2012
20120121552METHODS FOR PURIFYING HEMATOPOIETIC STEM CELLS - Described herein are methods for purifying hematopoietic stem cells. Also described herein are methods for purifying EPCR+ cells. The invention also provides substantially pure isolated hematopoietic stems cells, including EPCR+ hematopoietic stem cells.05-17-2012
20120121555Compositions and Methods of Using Living and Non-Living Bioactive Devices with Components Derived From Self-Renewing Colony Forming Cells Cultured and Expanded In Vitro - The invention relates to methods and uses of cells for the prevention and treatment of a wide variety of diseases and disorders and the repair and regeneration of tissues and organs using low passage and extensively passaged in vitro cultured, self-renewing, colony forming somatic cells (CF-SC). For example, adult bone marrow-derived somatic cells (ABM-SC), or compositions produced by such cells, are useful alone or in combination with other components for treating, for example, cardiovascular, neurological, integumentary, dermatological, periodontal, and immune mediated diseases, disorders, pathologies, and injuries.05-17-2012
20120121554HMG-COA SECONDARY METABOLITES AND USES THEREOF - The present invention is directed, among other things, to using secondary metabolites in the mevalonate pathway (such as, for example, HMG) and/or structurally related compounds to mediate biological activities (e.g., for therapeutic applications) and/or as diagnostic agents. In some embodiments, the biological activities comprise one or more pleiotropic effects of statins (such as, for example, angiogenesis, promoting vascular function, anti-inflammatory action, immunomodulation, etc.). Also provided are methods of screening for mevalonate pathway secondary metabolites, methods of producing HMG, and methods of diagnosing comprising measuring amount of mevalonate pathway secondary metabolites.05-17-2012
20120164117METHODS OF GENERATING HUMAN CARDIAC CELLS AND TISSUES AND USES THEREOF - A method of generating cells predominantly displaying at least one characteristic associated with a cardiac phenotype is disclosed. The method comprises (a) partially dispersing a confluent cultured population of human stem cells, thereby generating a cell population including cell aggregates; (b) subjecting the cell aggregates to culturing conditions suitable for generating embryoid bodies; (c) subjecting the embryoid bodies to culturing conditions suitable for inducing cardiac lineage differentiation in at least a portion of the cells of the embryoid bodies, the culturing conditions suitable for inducing cardiac lineage differentiation including adherence of the embryoid bodies to a surface, and culture, medium supplemented with serum, thereby generating cells predominantly displaying at least one characteristic associated with a cardiac phenotype.06-28-2012
20120164116COMPOSITIONS AND METHODS FOR TISSUE FILLING AND REGENERATION - Injectable compositions are provided which include both a living cellular and a filler conducive to cell growth. The compositions are capable of providing both immediate tissue filling and long term tissue regeneration.06-28-2012
20120164114TREATMENT OF IMMUNE-RELATED DISEASES AND DISORDERS USING AMNION DERIVED ADHERENT CELLS - Provided herein are methods of using amnion derived adherent cells, and populations of, and compositions comprising, such cells, in the modulation of an immune response. In various embodiments, the immune response is graft-versus-host disease, an allergy, asthma, or an immune-related disease or disorder, e.g., an autoimmune disease.06-28-2012
20120164113ULTRASONIC CAVITATION DERIVED STROMAL OR MESENCHYMAL VASCULAR EXTRACTS AND CELLS DERIVED THEREFROM OBTAINED FROM ADIPOSE TISSUE AND USE THEREOF - Methods of treating using adipose tissue using ultrasonic cavitation to dissociate the fat cells and blood vessels contained within adipose tissue and thereby obtain mesenchymal or stromal vascular fractions for use in human subjects are provided. These methods preferably do not include the use of any exogenous dissociating enzymes such as collagenase and result in increased numbers of the cells which constitute the mesenchymal or stromal vascular fractions (about 10-fold greater) than methods which use collagenase to isolate these cells.06-28-2012
20120164112EXPANDING HEMATOPOIETIC STEM CELLS - A method of expanding hematopoietic stem cells. Also disclosed is a method of diagnosing primary or secondary bone marrow failure syndrome. The invention further includes a method of treating primary or secondary bone marrow failure syndrome.06-28-2012
20120164111NOVEL POST-TRANSLATIONAL FIBRINOGEN VARIANTS - Provided are novel post-translationally modified variants of fibrinogen, in particular human fibrinogen, a method for producing and isolating said variants, as well as methods of using the variant, in particular in systemic and local/topical treatment and prophylaxis of excessive bleeding.06-28-2012
20100247493Method for Identifying and Selecting Cardiomyocytes - The present invention relates to new and/or improved methods of identification and selection of cardiomyocytes from human embryonic stem (hES) cells. The method further comprises isolating the selected cardiomyocyte population. There is also provided method for the screening for cardiovascular compounds comprising subjecting the said cardiomyocyte population to test compound/s, and observing and/or interpreting a response of the cardiomyocytes to the test compound.09-30-2010
20100247495Treatment of Muscular Dystrophy - The present invention provides mesenchymal stem cells and mesenchymal-like cells useful for treatment of muscular dystrophies including Duchenne Muscular Dystrophy (DMD), as well as, Becker, limb girdle, congenital, facioscapulohumeral, myotonic, oculopharyngeal, distal, and Emery-Dreifuss dystrophies. Also provided are protocols for administration of cells for treatment of the above dystrophies and adjuvant protocols. Futhermore, the invention teaches methods of manipulating mesenchymal and mesenchymal-like cells in vitro and in vivo for augmentation of therapeutic effects. Particularly, use of endometrial regenerative cells, alone or in combination with mesenchymal stem cells is provided for treatment of DMD and Becker muscular dystrophy.09-30-2010
20100247491Potentiation of Stem Cell Homing and Treatment of Organ Dysfunction or Organ Failure - The invention provides methods and compositions for the treatment of multi-organ failure or kidney dysfunction, such as acute renal failure, by mesenchymal stem cells and a CD26 inhibitor, where inhibition of CD26 increases homing of the mesenchymal stem cells to a target tissue.09-30-2010
20120128639In Vitro Production Of Oligodendrocytes From Human Umbilical Cord Stem Cells - The invention provides a method of producing oligodendrocytes by in vitro differentiation of human multi-potent progenitor cells (MLPCs). The method comprises culturing isolated MLPCs on a first surface in a serum-free defined culture medium; replacing the culture medium with serum-free culture medium supplemented with bFGF, EGF and PDGF-AA for approximately 24 hours; changing the cultured MLPCs into the supplemented serum-free culture medium further supplemented with differentiation factors norepinephrine, forskolin. and K252a; establishing a 3D environment by covering the culture with a second surface opposite and spaced apart from the first surface, so as to contain the MLPCs therebetween; and continuing to culture until a majority of the MLPCs have differentiated into oligodendrocytes. Additionally included is a method of treatment for a subject afflicted by a disease characterized by central or peripheral nervous system demyelination, the method comprising transplanting into the subject oligodendrocytes produced according to the method disclosed.05-24-2012
20120128637Cellular Seeding and Co-Culture of a Three Dimensional Fibroblast Construct - The present invention provides methods for cellular seeding onto three-dimensional fibroblast constructs, three-dimensional fibroblast constructs seeded with muscle cells, and uses therefore.05-24-2012
20120128641METHODS AND COMPOSITIONS FOR IMPROVING THE VIABILITY OF CRYOPRESERVED CELLS - The present invention provides polymers and methods for increasing the viability of cryopreserved cells after thawing. Thawing cryopreserved cells in the presence of a polymer such as poloxymer P1 88 or other non-ionic polymers is thought to stabilize the membranes of the cells leading to increased post-thaw viability. Such methods may be used in the processing of cells and tissues for transplantation or for research purposes. Other agents such as antioxidants, vitamins, or osmotic protectants may also be added to cells to improve viability.05-24-2012
20120128640HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS - An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy useful for treatment of various disorders is provided.05-24-2012
20120128638PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF HEART DISEASES - The present invention is related to a pharmaceutical composition comprising cells committed to the generation of heart tissue and at least one pharmaceutically acceptable excipient produced according to internationally recognized standards for pharmaceutical product manufacture, a process for the manufacture of such a pharmaceutical composition and a kit for the administration of said pharmaceutical composition which comprises a container containing said pharmaceutical composition.05-24-2012
20120128642POTENCY MARKERS - Methods for identifying trichogenic dermal cells, including dermal papilla cells and dermal sheath cells, capable of inducing hair follicle formation when injected into skin are provided. Biomarkers have been discovered that can be used to detect, identify, and distinguish trichogenic dermal cells, i.e., that are able to induce hair follicle formation, from non-trichogenic skin cells. Populations of enriched trichogenic dermal cells can be produced by selecting for and enriching for dermal cells that the disclosed biomarkers. These enriched trichogenic dermal can be used for inducing hair follicle formation.05-24-2012
20120128636Gingiva Derived Stem Cell And Its Application In Immunodulation And Reconstruction - The present invention relates to gingiva derived messenchymal stem cells (GMSCs). More specifically, the invention provides compositions and methods of using GMSCs to regulate inflammatory response in the setting of normal versus pathological wound healing and to treat inflammatory and/or autoimmune diseases.05-24-2012
20100209397METHOD FOR NON-AUTOLOGOUS CARTILAGE REGENERATION - The present invention relates in general to the field of tissue engineering, and in particular to methods for repair and regeneration of diseased and injured bone and cartilage tissue by allotransplantation or xenotransplantation of neonatal mandibular condyle-derived chondrocytes. The composition may comprise mandibular condyle-derived chondrocytes in the form of a chondrocyte film, per se, or in combination with a scaffold.08-19-2010
20100209398Compositions of stem cells and stem cell factors and methods for their use and manufacture - Therapeutic stem cells and methods for their use and manufacture. Stem cells are produced under conditions in which the stem cells are exposed to at least one environmental factor, including decreased oxygen tension. The environmental factors and culture conditions of the invention produce stem cells having an enhanced therapeutic ability and enhanced proliferation in culture. Stem cells of the invention retain their plasticity through a higher number of cell passages relative to know methods of stem cell culture.08-19-2010
20100209402AGENT FOR PROMOTING CORNEAL ENDOTHELIAL CELL ADHESION - The invention provides an agent for promoting adhesion of a corneal endothelial cell, containing a Rho kinase inhibitor, as well as a culture medium for a corneal endothelial cell, a solution for preservation of cornea, and a method of producing a corneal endothelial preparation, which includes culturing the corneal endothelial cell using the aforementioned culture medium.08-19-2010
20100209400TAK1-Mediated Regulation of Osteogenesis - This invention is directed to methods, nucleic acids and compositions in TAK1-mediated regulation of SMAD activity. Promotion of TAK1 interaction with MH2 domains in SMADs negatively regulates SMAD biological activity. BMP-mediated SMAD activity is subject to TAK1 effects.08-19-2010
20100209403ADHERENT CELLS FROM ADIPOSE OR PLACENTA TISSUES AND USE THEREOF IN THERAPY - A method of treating ischemia in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of adherent cells of a tissue selected from the group consisting of a placenta and an adipose tissue, thereby treating the ischemia in the subject. A method of treating a medical condition requiring connective tissue regeneration and/or repair is also disclosed.08-19-2010
20110182867MODULATION OF BCL11A FOR TREATMENT OF HEMOGLOBINOPATHIES - The invention relates to methods and uses of modulating fetal hemoglobin expression (HbF) in a hematopoietic progenitor cells via inhibitors of BCL11A expression or activity, such as RNAi and antibodies.07-28-2011
20110182866ISOLATION OF STEM CELL PRECURSORS AND EXPANSION IN NON-ADHERENT CONDITIONS - Stem cells and compositions thereof are isolated, cultured and expanded. Culture conditions and methods of culturing the isolated stem cells provide non-adherent stem cells which are prophylactically and therapeutically more effective in patients, diagnostics, screening assays and other stem cell uses.07-28-2011
20120315251POSTPARTUM CELLS DERIVED FROM UMBILICAL TISSUE AND METHODS OF MAKING AND USING THE SAME - Cells derived from human umbilical cords are disclosed along with methods for their therapeutic use. Isolation techniques, culture methods and detailed characterization of the cells with respect to their cell surface markers, gene expression, and their secretion of trophic factors are described.12-13-2012
20120315253METHODS TO ENHANCE DELIVERY AND ENGRAFTMENT OF STEM CELLS INCLUDING THE IDENTIFICATION OF SPECIFIC PROSTAGANDIN E2 RECEPTORS - The receptor EP12-13-2012
20120315252Methods of Reducing Teratoma Formation During Allogeneic Stem Cell Therapy - The present application relates to methods and compositions for treating diseased or damaged cardiac tissue comprising regenerative cells harvested from donor cardiac tissue. In one embodiment, regenerative cells are harvested from an allogeneic source and after administration result in increased viability and/or functional improvement of damaged or diseased cardiac tissue.12-13-2012
20120134965METHOD FOR DIFFERENTIATION OF STEM CELLS INTO VASCULAR CELLS AND THE INDUCTION OF ANGIOGENESIS USING THE SAME - The present invention relates to a method for differentiating stem cells into vascular cells by culturing them in the form of a three-dimensional cell cluster and the use of the three-dimensional cell cluster for angiogenesis. Specifically, the present invention teaches a method for differentiating stem cells into vascular cells comprising culturing stem cells by adhering them onto a culture plate with a surface having a hydrophobic property or a culture plate onto which a growth factor is immobilized, wherein the cultured stem cells are later detached from the culture plate as their density increases to form a three-dimensional cell cluster and grown in the form of a three-dimensional cell cluster while differentiating into vascular cells. Also disclosed is the use of a three-dimensional cell cluster composed of the vascular cells differentiated from stem cells by the above method as a cell therapy agent for angiogenesis.05-31-2012
20120213748CARDIOMYOCYTES AND METHODS OF PRODUCING AND PURIFYING CARDIOMYOCYTES - The invention provides methods for producing a culture of cardiomyocytes and cultures of cardiomyocytes. Exemplary methods of producing and cultures of cardiomyocytes include a population of cells including cells having spontaneous and periodic electrical activity, and/or including nodal, sino-atrial or pacemaker cells; immature cardiomyocytes (cardiomyoblasts); mature contractile cardiomyocytes; or a mixed population of two or more of such cells.08-23-2012
20120213750USE OF ADIPOSE TISSUE-DERIVED STROMAL STEM CELLS IN TREATING FISTULA - Provided herein are novel methods and compositions utilizing adipose tissue-derived stromal stem cells for treating fistulae.08-23-2012
20120213749CARDIAC MUSCLE REGENERATION USING MESENCHYMAL STEM CELLS - Disclosed is a method for repairing or regenerating blood vessels in the heart of an individual, method of stimulating or promoting angiogenesis in the heart of an individual, or method of stimulating or promoting vascular endothelial growth factor (VEGF) expression in a heart of an individual by administering to the individual an effective amount of mesenchymal stem cells. These cells can be administered as a liquid injectable.08-23-2012
20120213746METHOD AND COMPOUNDS FOR GENERATION OF iPSCs - The present invention is based on the seminal concept of combining genomics and chemical biology to identify new agents useful for induced pluripotent stem cell (iPSC) generation. The invention provides a method of generating an iPSC utilizing agents that antagonize a cell specific gene or upregulate expression or activity of a nuclear reprogramming gene, as well as a method of screening for such agents.08-23-2012
20120134967Scaffolds For Cell Transplantation - A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated into or coated onto the scaffold composition such that the scaffold composition and/or a bioactive composition controls egress of a resident cell or progeny thereof. The devices mediate active recruitment, modification, and release of host cells from the material.05-31-2012
20120219533METHOD FOR THE PRODUCTION OF INTERVERTEBRAL DISK CELL TRANSPLANTS AND THEIR USE AS TRANSPLANTATION MATERIAL - The invention relates to a method for the in vitro production of intervertebral disk cartilage cell transplants from affected intervertebral disk tissue from patients and to the use thereof as transplantation material for the treatment of affected intervertebral disks. The invention also relates to a three-dimensional, vital, and mechanically stable intervertebral disk cartilage tissue and to the use thereof as transplantation material for the treatment of affected intervertebral disks and in testing active substances. Furthermore, the invention is directed to the surgical technique for incorporating the transplants, to the intervertebral disk cell transplants and intervertebral disk cartilage tissues produced, and to therapeutic formulations, e.g. injection solutions, which include said tissue and said cell transplants.08-30-2012
20120219532METHODS AND COMPOSITIONS FOR INCREASED SAFETY OF STEM CELL-DERIVED POPULATIONS - The invention provides methods and compositions relating to differentiated cell populations that derive from pluripotent stem cells. The methods relate to reducing the number of residual stem cells present in such populations. The compositions include differentiated cell populations that contain reduced number of stem cells or that contain no stem cells. Pluripotent stem cells may be reduced in number and/or function through exposure to low oxygen levels.08-30-2012
20120219530COMPOSITIONS AND METHODS OF GENERATING REPROGRAMMED ADIPOCYTE CELLS AND METHODS OF USE THEREFORE - The invention provides therapeutic compositions comprising reprogrammed adipocyte cells for use as disease models, therapeutic compositions comprising reprogrammed adipocyte cells for the treatment of conditions characterized by a reduction in cell number or tissue mass, and methods of generating such cells.08-30-2012
20120219529Silver ion compositions of pectins - The invention described herein relates to the preparation of silver compounds prepared from pectin and pectin derivatives and the process for preparing them. The silver derivatives thus prepared are amenable for use in the preparation of medical and/or veterinary dressings or implants.08-30-2012
20120134969PHARMACEUTICAL COMPOSITION CONTAINING NUCLEAR FACTOR INVOLVED IN PROLIFERATION AND DIFFERENTIATION OF CENTRAL NEURONAL CELLS - With an aim to provide a novel factor inducing proliferation of neural stem cells and differentiation of these cells into nerve cells, a pharmaceutical composition comprising 1) CRBN, 2) a nucleic acid encoding CRBN, or 3) a stem cell or a neural progenitor cell in which CRBN is expressed, a method including administering the pharmaceutical composition to a non-human animal and inducing proliferation of neural stem cells or neural progenitor cells of the non-human animal and differentiation of these cells into nerve cells, and a method for screening for a therapeutic drug for a disease of cerebral cortex or a surgical injury of cerebral cortex, using CRBN, are provided.05-31-2012
20120230962GP100-SPECIFIC T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE - The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein.09-13-2012
20120230963Methods and Compositions for Expanding, Identifying, Characterizing and Enhancing Potency of Mammalian-Derived Glial Restricted Progenitor Cells - Methods for producing a population of human-derived glial restricted progenitor cells (GRPs) with decreased potentially unintended or undesired cellular phenotypes and/or decreased standard deviation in the cells of the population are provided. Also provided are antibody panels and gene expression profiles to characterize GRPs and a method for its use in characterizing GRP cells. In addition methods for use of these GRP cells to generate astrocytes and/or oligodendrocytes, to re-myelinate neurons and to treat glial cell related and other neurodegenerative diseases or disorders or injuries or damage to the nervous system are provided. A method to manufacture neural cells depleted of A2B5 positive cells is also provided.09-13-2012
20120230959ENHANCEMENT OF PLACENTAL STEM CELL POTENCY USING MODULATORY RNA MOLECULES - Provided herein are methods of producing enhanced placental stem cells by modulatory RNA molecules. Also provided herein are methods of using enhanced placental stem cells, for example, to treat individuals having a disease, disorder or condition caused by, or relating to, an unwanted or harmful immune response. Further provided herein are compositions comprising said enhanced placental stem cells.09-13-2012
20120237487MESENCHYMAL STEM CELL AND THE METHOD OF USE THEREOF - Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells.09-20-2012
20100172879AMYLOID BETA PEPTIDES AND METHODS OF USE - The application describes several mutant amyloid beta peptides and specific regions which are useful in the therapeutic and diagnostic of neurological diseases. The application further describes methods of using these mutant peptides as treatment and reagents for diagnosis of diseases. The application further describes diagnostic kits and pharmaceutical compositions for use in therapy to treat neurological diseases including but not limited to Alzheimer's disease and various forms of mild cognitive impairments.07-08-2010
20100172883METHODS OF GENERATING CARDIOMYOCYTES - The present invention provides methods of generating cardiomyocytes from a cell other than a cardiomyocyte, the methods generally involving contacting the cell with an agent that increases the level and/or activity of a protein that links a transcription factor to a chromatin remodeling complex. The present invention provides a population of cardiomyocytes generated using a subject method; and treatment methods involving introducing the cardiomyocyte population in or around diseased myocardial tissue.07-08-2010
20100172878Polynucleotides encoding mhc class i-restricted htert epitopes, analogues thereof or polyepitopes - This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogues thereof and polyepitopes containing such epitopes and/or analogues. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer.07-08-2010
20100172884Cardiac Muscle Repair Or Regeneration Using Bone Marrow-Derived Stem Cells - Disclosed are compositions and methods for repairing and/or regenerating cardiac tissue by administering adult bone marrow-derived stem cells to an individual. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.07-08-2010
20100172881USE OF TAILORED RECOMBINASES FOR THE TREATMENT OF RETROVIRAL INFECTIONS - The present invention is directed to a method for preparing an expression vector encoding a tailored recombinase, wherein said tailored recombinase recombines asymmetric target sites within the LTR of proviral DNA of a retrovirus inserted into the genome of a host cell and is useful as means for excising the provirus from the genome of the host cell. The present invention further relates to an in vitro-method of optimising the treatment of a retroviral infection of a subject and to the use of tailored recombinases for the preparation of pharmaceutical compositions for reducing the viral load in a subjected infected by a retrovirus.07-08-2010
20100172885Multipotent Adult Stem Cells And Uses of Multipotent Adult Stem Cells To Treat Inflammation - Disclosed are cell preparations comprising multipotent adult stem cells and methods for using multipotent adult stem cells to treat autoimmune diseases, treat allergic responses, treat cancer, treat inflammatory diseases, treat fibrotic disorders, reduce inflammation and/or fibrosis, promote would healing, repair epithelial damage, and/or promote angiogenesis.07-08-2010
20120219535CRANIAL NEURAL CREST STEM CELLS AND CULTURE CONDITION THAT SUPPORTS THEIR GROWTH - Provided herein is a method to isolate a cranial neural crest stem cell and novel compositions containing the cell. Also provided are compositions and methods to clonally expand the population and differentiate the cells into various phenotypes. Therapeutic methods for the compositions are further provided.08-30-2012
20100028306Amnion-Derived Cell Compositions, Methods of Making and Uses Thereof - The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies.02-04-2010
20120219534FREEZE-DRIED FIBRIN MATRICES AND METHODS FOR PREPARATION THEREOF - Methods for treating diseased or injured tissue by implanting into the tissue at a site of the disease or injury a porous freeze-dried fibrin matrix formed from plasma proteins. The proteins include fibrinogen cleaved by the action of thrombin at varying concentrations sufficient to cleave the fibrinogen and Factor XIII. The matrix has less than 10% residual moisture and is devoid of exogenous anti-fibrinolytic agents, plasminogen and of organic chelating agents. Alternatively, the plasma proteins comprise partially purified plasma proteins that are devoid of plasminogen.08-30-2012
20120171174Methods of Inducing Tissue Regeneration - Methods are provided for producing cells within a lineage (lineage restricted cells) from post-mitotic differentiated cells of the same lineage ex vivo and in vivo, and for treating a subject in need of tissue regeneration therapy by employing these lineage-restricted cells. In addition, the production of lineage restricted cells from postmitotic tissues derived from patients with diseases allows for a characterization of pathways that have gone awry in these diseases and for screening of drugs that will ameliorate or correct the defects as a means of novel drug discovery. Also provided are kits for performing these methods.07-05-2012
20120171173PROCESS FOR PRODUCTION OF NATURAL KILLER CELLS - A process for producing a cell mass containing natural killer cells, characterized by involving a step of carrying out the expansion culture of a cell mass containing natural killer cells and/or cells capable of being differentiated into natural killer cells in the presence of a biological response modifier and cells that has been so treated as to lose a proliferation capability, and others.07-05-2012
20120171169COMPOSITIONS AND METHODS FOR TREATING, PREVENTING, OR ALLEVIATING BONE OR CARTILAGE DISEASES - The present invention provides pharmaceutical compositions, methods of preparations, and uses for treatments, preventions or alleviation of bone and cartilage diseases. The present invention discloses methods and pharmaceutical compositions comprising adipose tissue-derived stem cells, platelet rich plasma, calcium chloride, and hyaluronic acid for the treatments, preventions, or alleviation of bone diseases; methods and a pharmaceutical compositions further comprising of dexamethasone for treatments, preventions, or alleviation of cartilage diseases.07-05-2012
20120213747METHODS OF REDUCING TRANSPLANT REJECTION AND CARDIAC ALLOGRAFT VASCULOPATHY BY IMPLANTING AUTOLOGOUS STEM CELLS - The invention provides novel methods of reducing transplant rejection and cardiac allograft vasculopathy in humans by employing the implantation of autologous progenitor cells into the transplanted donor heart. The autologous progenitor cells can be vascular progenitor cells (VPCs) and/or myocyte progenitor cells (MPCs) isolated from the recipient's explanted heart. Alternatively, bone marrow progenitor cells (BMPCs) isolated from the recipient may also be used.08-23-2012
20120213745SERUM-FREE MEDIA AND THEIR USES FOR CHONDROCYTE EXPANSION - The present invention provides defined serum-free cell culture media useful in culturing fibroblasts, especially articular chondrocytes, that avoid problems inherent in the use of serum-containing media. The defined media comprise platelet-derived growth factor (PDGF), chemically defined lipids, oncostatin M (OSM), interleukin-6 (IL-6), leukemia inhibitory factor (LIF), or combinations of these compounds. In another aspect, the present invention also provides tissue culture methods that comprise incubating chondrocytes in the defined serum-free media. The methods enhance attachment and proliferative expansion of chondrocytes seeded at low density while maintaining their redifferentiation potential.08-23-2012
20120213744COMPOSITIONS AND METHODS FOR MODULATING STEM CELLS AND USES THEREOF - There are provided compositions and methods for modulating stem cell division decisions, in particular, division symmetry. It has been demonstrated that wnt7a acts through frizzled-7 receptor expressed on the surface of adult stem cells, e.g. satellite stem cells, to activate the planar cell polarity (PCP) pathway, thereby promoting symmetrical expansion of stem cells. The compositions and methods of the invention are useful, for example, in modulating stem cell division symmetry in vitro and in vivo, in replenishing and expanding the stem cell pool, and in promoting the formation, maintenance, repair and regeneration of tissue.08-23-2012
20120171172Methods Of Engineering Neural Tissue - In one aspect, the invention is a method of generating a neural conduit comprising neurotrophic factors and angiogenic factors ex vivo comprising introducing cells that enhance nerve regeneration into an isolated, naturally occurring epineural sheath, thereby producing a combination. The combination is maintained under conditions in which neurotrophic factors and angiogenic factors are expressed in the epineural sheath, thereby generating a neural conduit comprising neurotrophic factors and angiogenic factors ex vivo. In another aspect, the invention is directed to neural conduits such as a neural conduit produced by the methods provided herein. In other aspects, the invention is directed to an article of manufacture.07-05-2012
20120171171Methods and Compositions for In Vitro and In Vivo Chondrogenesis - Aspects of the present invention include methods and compositions related to the production, identification and use of embryonic progenitor cell lines that are capable of undergoing chondrogenesis. A number of exemplary chondrogenic cell lines derived from primordial stem cells are disclosed. The chondrogenic cell lines described herein are robust, can expand for >40 passages, and have site-specific purity, thus providing for compositions and methods of producing diverse cartilage types with unique molecular compositions for use in research and therapy.07-05-2012
20120171170TREATMENT OF COLLAGEN GENE RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A COLLAGEN GENE - The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Collagen gene, in particular, by targeting natural antisense polynucleotides of a Collagen gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Collagen genes.07-05-2012
20120171168METHOD FOR TREATING PANCREATITIS WITH MESENCHYMAL STEM CELLS - The present application discloses a method of treating pancreatitis by administering to the patient mesenchymal stem cells that are obtained by manipulating a biological sample of cells, which includes multi-lineage stem cells, progenitor cells, other marrow stromal cells: allowing the sample of cells to settle in a container; transferring supernatant from the container to another container; and isolating cells from the supernatant, which has comparatively lower density in the sample.07-05-2012
20100310523Method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of notch gene - There is provided a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of a Notch gene. Specifically, the invention provides a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells in vitro, which method comprises introducing a Notch gene and/or a Notch signaling related gene into the cells, wherein the finally obtained differentiated cells are the result of cell division of the bone marrow stromal cells into which the Notch gene and/or Notch signaling related gene have been introduced. The invention also provides a method of inducing further differentiation of the differentiation-induced neural cells to dopaminergic neurons or acetylcholinergic neurons. The invention yet further provides a treatment method for neurodegenerative and skeletal muscle degenerative diseases which employs neural precursor cells, neural cells or skeletal muscle cells produced by the method of the invention.12-09-2010
20110206646METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF THE LYMPHATIC SYSTEM AND MALIGNANT DISEASE - Aspects of the invention provides methods for preparing and using adipose-tissue-derived stem and progenitor cells, adipose-tissue-derived lymphatic endothelial cells, and cells capable of differentiating into lymphatic endothelial cells to treat disorders of the lymphatic system and to modulate expansion, repair, and/or regeneration of the lymphatic system. The invention further provides using adipose-tissue-derived lymphatic endothelial cells and cells capable of differentiating into lymphatic endothelial cells for delivery of therapeutic agents to tumor cells as a means for treating malignant disease, and assays to screen for drugs that modulate lymphatic system expansion, repair or regeneration.08-25-2011
20120076760COMPOSITIONS AND METHODS OF VASCULAR INJURY REPAIR CROSS-REFERENCE TO RELATED APPLICATIONS - The present invention relates to pharmaceutical compositions comprising a chemotactic hematopoietic stem cell product comprising an enriched population of CD34+ cells containing a subpopulation of CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic activity, methods of preparing these compositions and use of these compositions to treat or repair vascular injury, including infarcted myocardium.03-29-2012
20120076759TRANSPLANTATION OF BONE MARROW STROMAL CELLS FOR TREATMENT OF NEURODEGENERATIVE DISEASES - The present invention relates to a treatment of an autoimmune demyelinating disease/disorder. Also included in the present invention is the use of bone marrow stromal cells for the treatment of multiple sclerosis (MS).03-29-2012
20100047215STEM CELL TARGETING METHODS - The present invention is directed to methods for delivering stem cells to a target tissue in a mammal using glycoconjugate to traffic the stem cells to a desired organ in the mammal. The methods according to the present invention are especially applicable to administering stem cells such as those derived from the bone marrow or from umbilical cord tissue. The methods are also useful for targeting a gene of interest to a tissue in a mammal by introducing a cell containing the gene of interest and administering a glycoconjugate to the mammal.02-25-2010
20100047213CELL COMPOSITION AND METHODS OF MAKING THE SAME - Provided herein are improved methods for the formulation of compositions comprising placental stem cells, and improved compositions and cell formulations produced thereby.02-25-2010
20100047214Methods and Compositions for Treatment of Bone Defects with Placental Cell Populations - Provided herein are osteogenic placental adherent cells (OPACs), methods of using OPACs and OPAC populations, and methods of culturing, proliferating, expanding, or differentiating the OPACs. Further provided herein are methods of using the OPACs to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with OPACs and compositions comprising OPACs. Also provided herein are methods of using OPACs in the treatment and management of multiple myeloma, e.g., reducing the progression of, halting the progression of, or improving, one or more symptoms of multiple myeloma in an individual having multiple myeloma, comprising administering a plurality of OPACs to the individual.02-25-2010
20100047210Systems and Methods for Positioning of Needles and Other Devices Within Body Tissue - Systems and methods for delivering a substance (e.g., a therapeutic or diagnostic substance, drug, biologic, cells, etc.) or device (e.g., implantable device, sensor, electrode, etc.) to a specific location within a tissue mass (e.g., an organ, tumor, other mass of body tissue, etc.) that is located a spaced distance from an open or fluid-filled space, body cavity or body lumen.02-25-2010
20120177619COMPOSITION COMPRISING A HAEMATIC COMPONENT AND ITS USE FOR THE TREATMENT OF DEGENERATIVE JOINT DISEASE - A composition including a haematic component, including blood cell components and heat shock protein, also including PDRN, alternatively including a thickener or mesenchymal stem cells, the process for preparing it, as well as its use for the treatment of degenerative joint disease.07-12-2012
20120177614CULTURE METHOD TO OBTAIN AND MAINTAIN A PURE OR ENRICHED POPULATION OF MAMMALIAN NEURAL STEM CELLS AND/OR NEURAL/PROGENITOR CELLS THAT ARE PRONE TO DIFFERENTIATE INTO OLIGODENDROCYTE-LINEAGE CELLS IN VITRO - An isolated expandable human neural stem or progenitor cell wherein the cell is a progenitor cells or stem cell, maintains its capability to differentiate into neurons, astrocytes, and oligodendrocytes, maintains its ability to differentiate into oligodendrocyte lineage cells efficiently throughout subsequent passages, and the cell expresses at least cell surface antigens CD133 and CD140α. Also provided is a method of in vitro culturing an expandable neural progenitor or stem cell isolated from a mammalian central nervous system, and the culture itself, wherein said cell maintains its capability to differentiate into neurons, astrocytes, and oligodendrocytes and its ability to differentiate into oligodendrocyte-lineage cells efficiently. In addition, a method of treating a condition caused by a loss of myelin or a loss of oligodendrocytes is provided as is a composition comprising an isolated expandable neural stem cell or one cultured by the methods of the invention.07-12-2012
20120177610Manufacturing and Purification Processes of Complex Protein found in Fraction IV to make a separated Apo, Transferrin , and Alpha 1 Anti strepsin (A1AT) or A combined Transferrin / Apo/Human Albumin/A1AT and all new found proteins - Manufacturing and Purification Processes of Complex Protein found in Fraction IV to make a separated Apo, Transferrin, and Alpha 1 Antitrypsin (A1AT) or a combined Transferrin/Apo/Human Albumin/A1AT and all new found proteins. A complex of all proteins found currently in Plasma, Cryoprecipitate, Fraction III and many newly found proteins now being identified or any substances which are known proteins or unknown proteins which contain GOOD HEALTHY CELLS and the combination of any of these known or unknown proteins which contain any one of these GOOD HEALTHY cells: Neutrophil, Lymphocyte, Eosinophil, Basophil, and Marcophage, and their potential applications for treating a wide variety of diseases and other physical conditions and disorders, and for maintaining health.07-12-2012
20120177611Elastic substrates and methods of use in cell manipulation and culture - Methods are provided for the ex vivo manipulation of cells, stem cells and other reproductive cells, by manipulating the cells in a container or device comprising an elastic substrate, wherein the substrate has an elasticity that mimics the elasticity of a native microenvironment of the cell.07-12-2012
20100272692ANTICANCER COMPOSITION COMPRISING PLANT STEM CELL LINE DERIVED FROM TAXUS CAMBIUM OR PROCAMBIUM - The present invention relates to a composition for preventing or treating cancer, which contains, as an active ingredient, a 10-28-2010
20100272696Human Bone-Forming Cells In The Treatment of Inflammatory Rheumatic Diseases - The invention relates to novel therapeutic uses of isolated bone-forming cells, particularly in the treatment of inflammatory rheumatic diseases.10-28-2010
20100272694CLINIC COMPLIANT METHOD FOR BANKING HUMAN PLACENTAL MESENCHYMAL CELLS - The present invention relates to a method for processing human placental cell sample, a human placental cell sample obtained according to said method for processing human placental cell sample, a human placental cell bank, a method for banking human placental cells, a method for searching human placental cell sample in said human placental cell bank according to the present invention, a method for preparing human cord blood serum, use of human placental cells obtained by said method for processing human placental cell sample or human placental cell bank established by said method for banking human placental cells in treating human dysfunction and diseases due to cell injury or cell malfunction, as well as a method for treating human dysfunction and diseases due to cell injury or cell malfunction.10-28-2010
20100272693BONE SCAFFOLDS, INJECTABLE BONE REPAIR MATERIALS AND METHODS FOR BONE REPAIR - A method of bone repair that includes applying to a subject a composite that comprises at least one calcium phosphate, at least one polyamine polymer material; and a linking structure covalently crosslinking the calcium phosphate to the polyamine polymer material, wherein the linking structure is covalently bonded to the calcium phosphate via a —O—Si— moiety or an isocyanato moiety and the linking structure is covalently bonded to the polyamine polymer material via amine groups of the polyamine polymer. Also disclosed is a combination of ingredients comprising at least one polyamine polymer; and calcium phosphate particles that are substantially coated with at least one functional group that is covalently reactive with amine groups on the polyamine polymer; wherein the ingredients are adapted for injection into a subject for forming a bone replacement material in vivo.10-28-2010
20100040582Methods of selecting stem cells and uses thereof - A method of selecting stem cells from heterogeneous population of cells is disclosed. The method comprises contacting the population of cells with an apoptosis inducing agent under conditions which are apoptotic to non-stem cells and non-apoptotic to stem cells, thereby selecting the stem cells from the heterogeneous population of cells. The selected stem cells may then be used for a variety of applications including transportation and differentiation.02-18-2010
20090035286Intracoronary, intracardiac, or intravenous infusion of a mixture of autologous bone marrow derived mononuclear cells and autologous bone marrow derived mesenchymal stem cells for utilization and rescue of infarcted myocardium - The present invention is a method for improving cardiac function and myocardial regeneration in living subjects after the occurrence of myocardial infarction. The method is a combination stem cell therapy involving a mixture of bone marrow-derived mesenchymal stem cells and bone marrow derived mononuclear cells surgically implanted by using either a direct or catheter-mediated injection into damaged myocardium. Studies have shown that the implant improves heart function and myocardial regeneration and echocardiographic measurements.02-05-2009
20090060882Method Of Treating Mouse Carrying Human Hepatocytes - Human adult hepatocytes are transplanted into an immunodeficient hepatopathy mouse and then human growth hormone is administered to the mouse to thereby elevate twice or more the replacement ratio by the human adult hepatocytes having been transplanted. Further, human growth hormone is administered to an immunodeficient hepatopathy mouse carrying human young hepatocytes transplanted thereinto so as to improve fatty liver of the mouse in which about 70% or more of the hepatocytes have been replaced by the human hepatocytes.03-05-2009
20090060886TRANSLUMINAL APPLICATION OF ADULT STEM CELLS FOR BODY ORGAN TISSUE REPAIR - A method for repairing tissue of a selected organ from among heart, brain, liver, pancreas, kidney, glands, and muscles in a patient's body. Adult stem cells that have the capability to repair tissue of the selected organ are recovered by harvesting from the patient's body. The harvested stem cells are then intraluminally applied through a designated natural body vessel. During the time the stem cells are being applied to the targeted tissue downstream, the designated vessel or duct is selectively occluded to increase concentration and pressure of the applied adult stem cells by the vessel.03-05-2009
20090060885Composition For Treatment of Articular Cartilage Damage - Disclosed is a composition for the treatment of cartilage or bone damage or loss or defect. The composition comprises mesenchymal stem cells separated from umbilical cord blood and/or mesenchymal stem cells proliferated and/or differentiated. The composition also comprise chondrocytes and/or chondroblasts, or osteocytes and/or osteoblasts, differentiated from the mesenchymal stem cells separated from the umbilical cord blood.03-05-2009
20090060884CONCENTRATION OF STEM CELLS OBTAINED DURING ORTHOPAEDIC SURGERIES - Methods for isolating and concentrating bone marrow stromal cells drawn from various surgical sites (for example, the proximal humeral head during rotator cuff repair, or the distal femur during ACL surgery) during arthroscopic or open orthopaedic surgery. The pluripotent cells obtained from the bone marrow aspirate can then be reimplanted during the same surgery to improve healing.03-05-2009
20090060883COMPOSITION FOR PROMOTION OF BONE GROWTH AND MAINTENANCE OF BONE HEALTH - The present invention relates to a composition for maintenance of bone health or prevention, alleviation and/or treatment of bone disorders. It also relates to the use of the composition in the manufacture of a nutritional product, a supplement, a treat or a medicament; and a method of promoting bone growth or for the maintenance of bone health, which comprises administering an effective amount of the composition.03-05-2009
20120258083PLACENTAL VASCULAR LOBULE STEM CELLS - The present invention provides isolated populations of stem and progenitor cells from fetal vascular lobules of the placenta. The isolated populations of stem and progenitor cells of the invention express the markers CD144, CD105, and/or CD31 and lack expression of the hematopoietic-lineage marker CD45. Under specific conditions, cells of the invention may function as endothelial precursors and may provide therapeutic preparations, for example, in the treatment of ischemia.10-11-2012
20120258082PRODUCTION OF IFN-LAMBDA BY CONVENTIONAL DENDRITIC CELLS AND USES THEREOF - In the present invention, CD8+ conventional dendritic cells (CD8+ cDCs) and equivalents thereof (eCD8+ cDCs) in mouse and human have been established as major source of IFN-lambda (IFN-λ) in response to double-stranded (ds) nucleic acids. The invention relates to therapeutic applications of ds nucleic acids or analogs thereof targeting CD8+ and/or eCD8+ cDCs in the prevention and/or treatment of infectious diseases, preferably viral infections, or cancer. Furthermore, the invention relates to an in vitro method for producing IFN-λ and/or generating or obtaining a population of IFN-λ producing CD8+ or eCD8+ cDCs as well as in vitro method for detecting or screening for CD8+ and/or eCD8+ cDCs. In addition, the invention relates to a Flt3-ligand or a M-CSF receptor ligand for use in increasing the level of CD8+ and/or eCD8+ cDCs in a subject suffering from an infectious disease or cancer.10-11-2012
20120258081METHODS OF TREATING PROLIFERATIVE DISEASES - Provided herein are methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, or a pharmaceutically acceptable salt or solvate thereof, to human patients, including a specific patient population. Specifically, dosing, dosing schedules or dosing regimens are provided herein. Methods of treating proliferative diseases or FLT-3 mediated diseases in humans are also provided.10-11-2012
20120082649PERIVASCULAR MESENCHYMAL PRECURSOR CELLS - Mesenchymal precursors cells have been isolated from perivascular niches from a range of tissues utilizing a perivascular marker. A new mesenchymal precursor cell phenotype is described characterized by the presence of the perivascular marker 3G5, and preferably also alpha smooth muscle actin together with early developmental markers such as MUC 18, VCAM-1 and STRO-104-05-2012
20120263684Novel methods for modulating inflammatory and/or immune responses - The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents.10-18-2012
20120263685ANTI-TUMOR COMPOSITION COMPRISING HUMAN-DERIVED ADULT STEM CELLS - The present invention relates to a composition for preventing or treating cancer, which contains one or more selected from the group consisting of human adult stem cells and their secretory products, and to a method of preventing or treating cancer using the same. Particularly, the invention relates to the use of adult stem cells that exhibit the effect of preventing or treating cancer by activating the immune system. The human adult stem cells of the invention are administered by a simple method such as intravenous injection and are highly valuable as a cell therapeutic agent for treating various cancer (tumor) diseases. Thus, the adult stem cells will be highly useful in anticancer studies.10-18-2012
20120263686COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS - The present specification discloses compositions and methods of transplanting tissue useful for treating a soft tissue condition of an individual.10-18-2012
20120263683PREPARATION FOR REPAIRING CARTILAGE TISSUE, ESPECIALLY ARTICULAR CARTILAGE DEFECTS - Provided herein are preparations for repairing enchondral or osteochondral defects (10-18-2012
20120263687Use of Mesenchymal Stem Cells for Treating Genetic Disease and Disorders - A method of treating a genetic disease or disorder such as, for example, cystic fibrosis, Wilson's disease, amyotrophic lateral sclerosis, or polycystic kidney disease, in an animal comprising administering to said animal mesenchymal stem cells in an amount effective to treat the genetic disease or disorder in the animal.10-18-2012
20120263682CARDIAC MUSCLE REPAIR OR REGENERATION USING BONE MARROW-DERIVED STEM CELLS - Disclosed are compositions and methods for repairing and/or regenerating cardiac tissue by administering adult bone marrow-derived stem cells to an individual. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.10-18-2012
20090016995Method of Treating Cognitive Decline and Synaptic Loss Related to Alzheimer's Disease - A method treating a subject with Alzheimer's disease wherein Aβ-reactive immune cells, splenocytes and lymphocytes, are generated in vitro or in vivo, re-stimulated in vitro, and then adoptively transferred into the cognitively-impaired subject. The population of immune cells can be derived from a donor with a natural or adaptive immune response to Aβ, stimulated by exposure to Aβ in vivo. The donor cells are then collected and re-stimulated by subsequent exposure to Aβ in vitro prior to administration to the subject. Alternatively, the population of immune cells can be derived from the subject and then stimulated by exposure to Aβ in vitro.01-15-2009
20090016994Preparation of fibroblast-populated connective tissue substitute - Disclosed is a method for in vitro growing of connective tissue substitute, said connective tissue substitute being populated with fibroblasts, a connective tissue substitute obtainable by such a method, as well as a method for closing of a wound, wherein such connective tissue substitute is applied onto a wound.01-15-2009
20110123499CELLULAR DIFFERENTIATION PROMOTION - Neural precursor cells can be encouraged to form mature neural cells twice as quickly in the absence, or reduced expression of, thymosin β4.05-26-2011
20100239542PLURIPOTENT EMBRYONIC-LIKE STEM CELLS, COMPOSITIONS, METHODS AND USES THEREOF - The present invention relates to pluripotent stem cells, particularly to pluripotent embryonic-like stem cells. The invention further relates to methods of purifying pluripotent embryonic-like stem cells and to compositions, cultures and clones thereof. The present invention also relates to a method of transplanting the pluripotent stem cells of the present invention in a mammalian host, such as human, comprising introducing the stem cells, into the host. The invention further relates to methods of in vivo administration of a protein or gene of interest comprising transfecting a pluripotent stem cell with a construct comprising DNA which encodes a protein of interest and then introducing the stem cell into the host where the protein or gene of interest is expressed. The present also relates to methods of producing mesodermal, endodermal or ectodermal lineage-committed cells by culturing or transplantation of the pluripotent stem cells of the present invention.09-23-2010
20120230964THE ISOLATION AND CHARACTERISATION OF HEPARAN SULPHATES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT AND STEM CELL CULTURE MEDIA SUITABLE FOR CONDITIONS ASSOCIATED WITH BONE REPAIR - Heparan sulphates isolated from male and female murine liver, their characterisation and use in pharmaceutical compositions, methods of treatment and in stem cell culture media suitable for conditions associated with bone repair.09-13-2012
20080317719Regulating stem cells - A method is provided, including in vitro stimulating an initiating cell population (ICP) of at least 5 million cells that have a density of less than 1.072 g/ml, and at least 1% of which are CD34+CD45−/dim, to differentiate into a progenitor/precursor cell population (PCP). A method is provided, including in vitro stimulating an initiating cell population (ICP) of at least ten thousand cells that have a density of less than 1.072 g/ml to differentiate into a progenitor/precursor cell population (PCP). A method is provided, including separating lower density cells from higher density cells, the lower density cells defining an initiating cell population (ICP), and in vitro stimulating the ICP to differentiate into a progenitor/precursor cell population (PCP). Other embodiments are also described.12-25-2008
20080299093Premixed biological hydraulic cement paste composition and using the same - A premixed cement paste for use in medical or dental applications. The premixed cement paste remains fluid when stored in a hermetically sealed condition, but hydrates and hardens to set when placed in a physiological environment. The cement paste includes at least one calcium silicate compound and at least one substantially water-free liquid carrier mixed with the at least one calcium silicate compound; the substantially water-free liquid carrier avoids hydration of the mixture during storage, but undergoes exchange with aqueous physiological solutions so that the cement past hydrates and hardens to set when placed in a physiological environment. The paste may be placed in the physiological environment by injection, for example. The at least one calcium silicate compound may be, for example, calcium silicate, dicalcium silicate, tricalcium silicate, or mixtures thereof. The substantially water-free liquid may be, for example, ethylene glycol, polyethylene glycol, liquid glycerol, glycerin, ethyl alcohol, vegetable oil, animal oil, silicon oil, hydroxypropyl methylcellulose, or mixtures thereof. The substantially water-free liquid carrier preferably includes water in an amount less than about 20% by weight percent of the paste. The paste may include a secondary phase for enhanced properties, such as, for example, a fibrous or particulate material for enhanced mechanical properties, biodegradable or soluble materials that provide room for bone in-growth, bioactive materials such as antibiotics that elute into the physiological environment from the set cement, and radio-opaque materials that enhance X-ray imaging of the cement.12-04-2008
20080299091Patient-specific stem cell lines derived from human parthenogenetic blastocysts - Methods are disclosed for generating HLA homozygous parthenogenetic human stem cell (hpSC-Hhom) lines from both HLA homozygous and HLA heterozygous donors. These hpSC-Hhom lines demonstrate typical human embryonic stem cell morphology, expressing appropriate stem cell markers and possessing high levels of alkaline phosphatase and telomerase activity. Additionally, injection of these cell lines into immunodeficient animals leads to teratoma formation. Furthermore, in the case of HLA heterozygous donors, the hpSC-Hhom lines inherit the haplotype from only one of the donor's parents. SNP data analysis suggests that hpSC-Hhom lines derived from HLA heterozygous oocyte donors are homozygous throughout the genome as assessed by single-nucleotide polymorphism (SNP) analysis. The protocol as disclosed minimizes the use of animal-derived components, which makes the stem cells more practical for clinical application.12-04-2008
20080299089ENDOGENEOUS REPAIR FACTOR PRODUCTION PROMOTERS - It relates to an endogenous repair factor production accelerator which comprises one or at least two selected from prostaglandin (PG) 12 agonist, EP2 agonist and EP4 agonist. Since prostaglandin (PG) 12 agonist, EP2 agonist or EP4 agonist has various endogenous repair factor production accelerating action, angiogenesis acceleration action and stem cell differentiation induction action, it is useful as preventive and/or therapeutic agents for ischemic organ diseases (e.g., arteriosclerosis obliterans, Buerger disease, Raynaud disease, myocardial infarction, angina pectoris, diabetic neuropathy, spinal canal stenosis, cerebrovascular accidents, cerebral infarction, pulmonary hypertension, bone fracture, Alzheimer disease, etc.) and various cell and organ diseases.12-04-2008
20080299087Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition - Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases.12-04-2008
20080299086Cultured muscle cells with high metabolic activity and method for production of the cultured muscle cells - The object of the present invention is to provide a method of preparing excellent cultured muscle cells having high metabolic capacity and insulin responsiveness, and further provide a method for the measurement of sensitive metabolic capacity using the cells. Moreover, its purpose is to provide a culture system/culture apparatus that can smoothly translocate such highly advanced cultured muscle cells intact to activity evaluation systems of a number of drugs. Moreover, the object of the present invention is to provide cultured muscle cells that are very suitable for measurement of the membrane-translocation activity of GLUT4 in an extraneous stimulus-dependent manner such as insulin, etc., and to provide a method for the measurement of the membrane-translocation activity of GLUT4 using the cells. The present invention is a method of preparing myotube cells, comprising a step (1) of culturing myoblast cells, a step (2) of differentiation-inducing the myotube cells into the myoblast cells in a culture medium with a high content of amino acids, and a step (3) of applying an electric pulse to the differentiation-induced myotube cells, and a method for the measurement of insulin-dependent sugar uptake using the myotube cells prepared by said method, and relates to the method for the measurement, comprising applying insulin stimulation by culturing the cells in a culture medium containing insulin, culturing the cells in the culture medium further supplemented with sugar, and measuring the sugar uptake. Furthermore, the present invention relates to a differentiation-type culture myotube cell constitutively expressing a recombinant GLUT4 having a labeled substance at its extra-cellular site, which is prepared by co-culturing wild-type myoblast cells and recombinant myoblast cells constitutively expressing said recombinant GLUT4, and a method for the measurement of membrane-translocation activity of the recombinant GLUT4 using the cells, and particularly a method for the measurement of insulin-dependent sugar uptake activity.12-04-2008
20080299090Use Of Umbilical Cord Matrix Cells - The invention relates to the isolation and use of stem cells from amniote species (potentially any animal with an umbilical cord, including humans). More particularly the invention relates to obtaining stem cells that are at least multipotent and may be totipotent or nearly totipotent and are envisaged to have a variety of end uses. The cells of the present invention are immunosuppressive and may be used to inhibit the immune response in a subject.12-04-2008
20120263681COMPOSITION COMPRISING CELL AND BIOCOMPATIBLE POLYMER - It is an object of the present invention to provide a cell-containing composition capable of suppressing the outflow of the cells after transplantation and improving the survival rate of the cells. The present invention provides a composition which comprises any of bone marrow stromal cell-derived neural precursor cells, bone marrow stromal cell-derived Schwann cells, or bone marrow stromal cell-derived skeletal muscle cells; and a biocompatible polymer.10-18-2012
20110002899Lymph Nodes as a Site for Regeneration - Methods of transplanting cells, such as hepatocytes, are presented herein. Such methods are useful for treating liver disease as well as other disorders.01-06-2011
20110002898VACCINE COMPOSITIONS - The invention relates to tumour therapy. In particular, the present invention relates to vaccine compositions comprising allogenic cells modified with hypercytokines for the treatment of cancer in general and for the treatment of melanoma in particular.01-06-2011
20110002896METHODS AND RELATED COMPOSITIONS FOR REDUCTION OF FAT - Compositions and methods useful in the reduction of localized fat deposits in patients in need thereof using pharmacologically active detergents are disclosed. The pharmacologically active detergent compositions can additionally include anti-inflammatory agents, analgesics, dispersion or anti-dispersion agents and pharmaceutically acceptable excipients. The pharmacologically active detergent compositions are useful for treating localized accumulations of fat including, for example, lower eyelid fat herniation, lipodystrophy and fat deposits associated with cellulite and do not require surgical procedures such as liposuction.01-06-2011
20110002895COMPOSITION FOR AUTOTRANSPLANTATION OR ALLOTRANSPLANTATION USING DENTAL PULP STEM CELL, AND USE OF THE COMPOSITION - The object is to provide a novel use application of a dental pulp stem cell collected from a deciduous tooth or a permanent tooth. Disclosed is a composition for autotransplantation or allotransplantation, which is characterized by comprising a dental pulp stem cell collected from a deciduous tooth or a permanent tooth.01-06-2011
20110002893DIAGNOSIS AND TREATMENT OF CONGENITAL HEART DEFECTS USING NELL1 - The present invention provides diagnostic methods for detecting congenital heart defects, or increased risk thereof, based on the Nell1 gene, RNA and protein. The methods include obtaining a biological sample and assessing the presence of a mutation in the Nell1 gene, RNA or protein. The presence of a mutation in the Nell1 gene, RNA or protein can be assessed by determining the levels of Nell1 gene, RNA or protein in the biological sample. The present invention further provides therapeutic methods for treating congenital heart defects based on the Nell1 gene. RNA and protein.01-06-2011
20120328579HUMAN TROPHOBLAST STEM CELLS AND USE THEREOF - Existence of human trophoblast stem (hTS) cells has been suspected but unproved. The isolation of hTS cells is reported in the early stage of chorionic villi by expressions of FGF4, FGFR-2, Oct4, Thy-1, and stage-specific embryonic antigens distributed in different compartments of the cell. hTS cells are able to derive into specific cell phenotypes of the three primitive embryonic layers, produce chimeric reactions in mice, and retain a normal karyotype and telomere length. In hTS cells, Oct4 and fgfr-2 expressions can be knockdown by bFGF. These facts suggest that differentiation of the hTS cells play an important role in implantation and placentation. hTS cells could be apply to human cell differentiation and for gene and cell-based therapies.12-27-2012
20120328578PRIMED STEM CELLS AND USES THEREOF TO TREAT INFLAMMATORY CONDITIONS IN JOINTS - Disclosed are methods of treating inflammation within a synovial joint, comprising administering to the joint a composition comprising primed stem or progenitor cells in an amount effective to enhance recovery, and a pharmaceutically acceptable carrier.12-27-2012
20110044960MEDICAMENT, DENTAL MATERIAL, AND METHOD OF SCREENING - The present invention provides a novel and creative dental materials for treatment of pulpitis and/or enhancement of dentinogenesis. The dental materials of the present invention contain at least one of a protein having matrix metalloprotease 3 activities or matrix metalloprotease 3 precursor protein as an active ingredient. The dental materials of the present invention contain a carrier having biocompatibility. The dental materials of the present invention can contain at least one cell type among pulp cells, pulp stem cells, pulp progenitor cells, odontoblasts or cells that can differentiate into odontoblasts.02-24-2011
20110044959NOVEL COMPOSITION OF STEM CELLS FOR TRANSPLANTATION TOLERANCE - The present invention provides a simple, economical yet efficient method of creating transplant tolerance in organ transplant patients without the continuous need for costly immunosuppressive drugs with serious adverse effects. The invention essentially deals with the administration of a novel composition to the patient which consists of adipose tissue derived Mesenchymal Stem Cells (MSC) combined with bone marrow derived Haematopoietic Stem Cells(HSC) and MSC and peripheral blood stem cells (PBSC). This helps in creating transplant tolerance ie. Stable adequate allograft function with minimum/no rejection using very low dose of immunosuppressive medication. The invention also deals with a simple method of isolating Mesenchymal Stem cells from human adipose tissue without using any xenogenic material.02-24-2011
20110044958ACTIVATED MESENCHYMAL STEM CELLS FOR THE PREVENTION AND REPAIR OF INFLAMMATORY STATES - Inflammatory cytokines e.g. IFN-γ serve as initiating stimuli for MSC immunosuppressive activity in vivo. Other inflammatory cytokines, such as TNF alpha, the molecule hemoxygenase I, and TLR ligation of MSC may also provide such a response.02-24-2011
20110044957METHODS AND SYSTEMS FOR EXTENDED IN VITRO CULTURE OF NEURONAL CELLS - A cell culture system related to extended in vitro culture of mature neuronal cells and methods for preparing the cell culture system are provided. In a preferred embodiment the invention provides a cell culture system comprising a mixture of mature neuronal retinal cells and cells isolated from a ciliary body. Methods for identifying bioactive agents that alter neurodegeneration of neuronal retinal cells are also provided.02-24-2011
20110044956NELL-1 ENHANCED BONE MINERALIZATION - This invention pertains to the discovery that the human NELL-1 gene induces or upregulates bone mineralization. The NELL-1 gene or gene product thus provides a convenient target for screening for modulators of bone mineralization. In addition, NELL-1 can be used to facilitate repair of bone fractures and/or to generally increase bone density.02-24-2011
20110044955ALTERING MEMORY BY AFFECTING STAUFEN - The present invention provides cell-based screening methods for identifying pharmaceutical agents which are capable of modulating (have the ability to modulate) STAUFEN function by screening for STAUFEN function.02-24-2011
20110044953Methods and Compositions for Localized Secretion of Anti-CTLA-4 Antibodies - The present invention provides compositions and methods for effectuating the localized expression of anti-CTLA-4 antibody proximal to a target tissue in a patient.02-24-2011
20120269778METHODS OF GENERATING NEURAL STEM CELLS - The present disclosure provides methods of generating neural stem cells from differentiated somatic cells. The present disclosure also provides induced neural stem cells generated using a subject method, as well as differentiated cells generated from a subject induced neural stem cell. A subject neural stem cell, as well as differentiated cells derived from a subject neural stem cell, is useful in various applications, which are also provided in the present disclosure.10-25-2012
20120269782MATERIALS AND METHODS FOR GENERATING PLURIPOTENT STEM CELLS - The present invention relates to a method of reprogramming a somatic cell to produce an induced pluripotent stem (iPS) cell which is capable of differentiating into somatic cells derived from ectoderm, mesoderm or endoderm. The present invention also relates to the aforementioned iPS cells, methods of generating and maintaining iPS cells, and methods of using iPS cells.10-25-2012
20120269780Method For Preparing an Acellular Organic Tissue of Human or Animal Origin For Revitalization - The invention concerns a method for the preparation of an acellular organic tissue for revitalization, in particular for the introduction of living cells, comprising a stage in which the acellular organic tissue (10-25-2012
20120269786SYSTEMIC, ALLOGENIC STEM CELL THERAPIES FOR TREATMENT OF DISEASES IN FELINES - A method for treating preselected diseases comprising the steps of providing a therapeutic dose of a mesenchymal stem cell composition, the mesenchymal stem cell composition comprising mesenchymal stem cells harvested from at least one tissue selected from the group consisting of placental tissue, bone marrow, dental tissue, testicle tissue, and dermal tissue; and systemically administering the mesenchymal stem cell composition to the patient suffering from a preselected disease or diseased state through an intravenous injection.10-25-2012
20120269785SYSTEMIC, ALLOGENIC STEM CELL THERAPIES FOR TREATMENT OF DISEASES IN CANINES - A method for treating preselected diseases comprising the steps of providing a therapeutic dose of a mesenchymal stem cell composition, the mesenchymal stem cell composition comprising mesenchymal stem cells harvested from at least one tissue selected from the group consisting of placental tissue, bone marrow, dental tissue, testicle tissue, and dermal tissue; and systemically administering the mesenchymal stem cell composition to the patient suffering from a preselected disease or diseased state through an intravenous injection.10-25-2012
20120269781METHOD FOR PROLIFERATING HAIR FOLLICLE STEM CELLS - The present invention relates to a method of proliferating follicular stem cells in high yield, and more particularly, to a method of proliferating follicular stem cells in large amounts by culturing the cells using a specific medium containing a specific concentration of a Rho-associated kinase (ROCK) inhibitor and to a medium which is used in the method.10-25-2012
20120269779MESENCHYMAL STROMAL CELL POPULATIONS AND METHODS OF USING SAME - The invention relates to mesenchymal stromal cells produced by culturing the cells in platelet lysate supplemented media and methods of using these cells to treat neurological and kidney associated disorders.10-25-2012
20100135967CULTURED CARTILAGE/BONE CELLS/TISSUE, METHOD OF GENERATING SAME AND USES THEREOF - A method of generating cultured chondrocytes/endochondral bone cells is provided. The method comprising isolating chondrocytes from mandibular condyle tissue, and culturing the isolated chondrocytes. A method of isolating chondrocytes from mandibular condyle tissue is further provided. The method comprises isolating mandibular condyle tissue from a mammal and treating the mandibular condyle tissue so as to selectively remove fibroblast-like cells and/or myocytes therefrom, the modified mandibular condyle tissue including chondrocytes, and selectively collecting the chondrocytes from the modified mandibular condyle tissue.06-03-2010
20120321596KIT FOR ADHERING BIOLOGICAL HARD TISSUES - A kit for bonding to biological hard tissues, containing a phosphorylated polysaccharide, a polyvalent metal salt other than phosphates, and a solvent. The adhesive composition for biological hard tissues provided by the kit for bonding to biological hard tissues is suitably used in for medical uses, such as cement for bones or dental cement. In addition, since the adhesive composition has excellent bio-absorbability, it is useful as fusion materials for artificial joint prosthesis, fusion materials for spine fracture, fusion materials for extremity fracture, filling materials for bone tumors in the region of orthopedics, filling materials and restorative materials at dental caries-defective sites, luting materials for prosthetic restorative materials such as inlay and crown, pulp-capping and lining materials, implant surface treatment materials, periodontal disease therapeutic materials, hyperesthesia preventive materials, dental pulp capping materials, substrates for DDS, substrates for systems engineering, and tissue bonding materials in the dental region.12-20-2012
20110223141TREATMENT OF BRAIN OR SPINAL CORD INJURY USING PLACENTAL STEM CELLS - The present invention provides a method of extracting and recovering embryonic-like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta. A placenta is treated to remove residual umbilical cord blood by perfusing an exsanguinated placenta, preferably with an anticoagulant solution, to flush out residual cells. The residual cells and perfusion liquid from the exsanguinated placenta are collected, and the embryonic-like stem cells are separated from the residual cells and perfusion liquid. The invention also provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate endogenous cells, including, but not limited to, embryonic-like stem cells. The invention also provides methods for propagation of exogenous cells in a placental bioreactor and collecting the propagated exogenous cells and bioactive molecules therefrom.09-15-2011
20110223138Mesenchymal stem cells that express increased amounts of anti-apoptotic proteins - The invention includes a purified population of mesenchymal stromal cells that have been cultured under conditions, such as having been contacted with an apoptotic cell, to express increased levels of at least one anti-apoptotic protein. Such mesenchymal stem cells may be used to treat diseases, disorders, or conditions associated with apoptosis or with unresolved inflammation.09-15-2011
20110129447Methods for Cell Expansion and Uses of Cells and Conditioned Media Produced Thereby for Therapy - A method of cell expansion is provided. The method comprising culturing adherent cells from placenta or adipose tissue under three-dimensional culturing conditions, which support cell expansion.06-02-2011
20110236357BONE MARROW-DERIVED MESENCHYMAL STEM CELLS AS A SOURCE OF NEURAL PROGENITORS - Methods are provided for treating and/or reducing the severity of multiple sclerosis in a human, by administering autologous mesenchymal stem cell-derived neural precursors. Also described is an in vitro method for differentiating mesenchymal stem-cell derived neural precursor oligodengroglial and neuronal cell types.09-29-2011
20110236355DIFFERENTIATION OF STEM CELLS INTO DOPAMINERGIC CELLS - Methods for differentiating stem cells are disclosed herein. These methods can be used to generate neurons, including, but not limited to, dopaminergic neurons. The disclosed methods include culturing stem cells in the absence of fibroblast growth factor-2 to generate embryoid bodies and culturing the embryoid bodies in the presence of an effective amount of at least one of stromal cell-derived factor 1, pleiotrophin, insulin-like growth factor 2, and ephrin B1 on an extracellular matrix for a period of time sufficient to produce dopaminergic neuronal cells. The differentiated cells can be used to study pharmaceutical agents that affect dopaminergic neurons and can be used in the treatment of neurodegenerative disorders such as Parkinson's disease.09-29-2011
20100233142Stem Cells Derived from Uniparental Embryos and Methods of Use Thereof - Embryonic stem cells derived from uniparental embryos and methods of use thereof are disclosed.09-16-2010
20100233141Compositions And Methods For The Delivery Of Biologically Active RNAs - The present invention provides novel compounds, compositions, and methods for the delivery of biologically active RNA molecules to cells. Specifically, the invention provides novel nucleic acid molecules, polypeptides, and RNA-protein complexes useful for the delivery of biologically active RNAs to cells and polynucleotides encoding the same. The invention also provides vectors for expressing said polynucleotides. In addition, the invention provides cells and compositions comprising the novel compounds and vectors, which can be used as transfection reagents. The invention further provides methods for producing said compounds, vectors, cells, and compositions. Additionally, vectors and methods for delivering biologically active RNA molecules to cells and/or tissues are provided. The novel compounds, vectors, cells, and compositions are useful, for example, in delivering biologically active RNA molecules to cells to modulate target gene expression in the diagnosis, prevention, amelioration, and/or treatment of diseases, disorders, or conditions in a subject or organism.09-16-2010
20100233137Compositions and Methods for Modification of Target Cells and to Their Uses Thereof - Methods and compositions are described for preparing modified cells useful in various therapeutic applications.09-16-2010
20100233136ISOLATED POPULATIONS OF CELLS AND METHODS OF GENERATING AND USING SAME - An isolated homogeneous population of cells comprising a plurality of human ectodermal progenitor cells. Also provided are methods of generating and using the population of cells.09-16-2010
20100233135COMPOSITIONS AND METHODS FOR HEMATOPOIETIC STEM CELL EXPANSION OR FOR MODULATING ANGIOGENESIS - The present invention provides compositions and methods featuring ZBP-89 polypeptides or nucleic acid molecules for expanding a hematopoietic stem cell population or for modulating angiogenesis.09-16-2010
20100233140COLLAGEN-CONTAINING CELL CARRIER - The present invention relates to the use of a collagen-containing composition for the cultivation of biological cells, a method for the cultivation of biological cells, a method for the implantation of biological material into an organism and a method for the improvement of a composition in its suitability for the cultivation of biological cells.09-16-2010
20100233138Vocal Cord Augmentation Utilizing Muscle-Derived Progenitor Compositions, and Treatments Thereof - The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment vocal cord tissue following introduction (e.g. via injection, transplantation, or implantation) into the vocal cords. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, vocal cords in the treatment of various cosmetic or functional conditions, including vocal cord tissue weakness, voice and swallowing disorders. The invention also relates to the novel use of MDCs for the increase of vocal cord tissue mass in speakers, singers or other people in need of greater than average vocal cord tissue mass.09-16-2010
20100233134Use of Adipose-Tissue Cell Fractions for Post-Irradiation Tissue Regeneration - The present invention concerns the use of cells derived from the cellular fraction of the vascular stroma of the extramedullary adipose tissue to promote the regeneration of tissue following lesions caused by irradiation. More specifically, the use according to the invention aims to prepare a drug for promoting regeneration of the skin, and in particular to repair the cutaneous wounds caused by irradiation.09-16-2010
20100233133TISSUE REPAIR - According to the invention there is provided a cosmetic method for the augmentation of subcutaneous or dermal tissue in a subject, which method comprises the steps of: (i) providing a suspension of autologous dermal fibroblasts; and (ii) injecting an effective volume of the suspension into tissue subadjacent to the subcutaneous or dermal tissue so that the tissue is augmented; wherein the fibroblasts are suspended in HypoThermosol®, preferably HypoThermosol® FRS.09-16-2010
20100233132FORMATION OF VASCULAR NETWORKS USING EMBRYONIC STEM CELLS - In various aspects, provided are methods for providing CD3409-16-2010
20100150879Methods for the detection, isolation, and use of lipid phosphate phosphatase-3-positive stem cells - The present invention embraces antibodies that bind Lipid Phosphate Phosphatase-3, and use thereof in the detection and isolation of stems cells for promoting wound healing, neovascularization, and/or angiogenesis.06-17-2010
20120321595TREATMENT OF HEART DISEASE - Disclosed herein are methods, compositions and kits for treating cardiac stem cells to be administered to a subject in need thereof, e.g., with a damaged myocardium. The methods, composition and kits of the invention can be used to treat cardiovascular diseases such as heart failure, myocardial infarction and an age-related cardiomyopathy.12-20-2012
20120321597METHODS AND COMPOSITIONS FOR REGENERATING CONNECTIVE TISSUE - Connective tissue regenerative compositions and methods of repairing and regenerating connective tissue using such compositions are provided. The compositions generally comprise a bioactive hydrogel matrix comprising a polypeptide, such as gelatin, and a long chain carbohydrate, such as dextran. The hydrogel matrix may further include polar amino acids, as well as additional beneficial additives. Advantageously, the compositions include further components, such as osteoinductive or osteoconductive materials, medicaments, stem or progenitor cells, and three-dimensional structural frameworks. The compositions are useful for regenerating connective tissue, and can be administered to an area having injury to, or a loss of, connective tissue, such as bone, cartilage, tendon, and ligament.12-20-2012
20120321594METHODS OF CONTROLLING AXON OR DENDRITE DEVELOPMENT OF NEURONAL CELLS - One aspect of the present invention relates to a method of controlling axon or dendrite development in a neuronal cell population. This method involves providing a neuronal cell population and contacting the neuronal cell population with a modulator of R-type Ca12-20-2012
20120321593LOW OXYGEN CULTURE CONDITIONS FOR MAINTAINING RETINAL PROGENITOR CELL MULTIPOTENCY - The present invention relates to methods for culturing human retinal progenitor cells under low oxygen conditions to allow the cells to retain the ability to differentiate into photoreceptors following transplantation. The described methods provide cells that can treat a number of ocular diseases, including retinitis pigmentosa and age-related macular degeneration.12-20-2012
20120087899Heparan Sulphate - Heparan sulphate from bone marrow stroma is disclosed together with the use of heparan sulphate from bone marrow stroma in the differentiation and/or lineage commitment of stem cells.04-12-2012
20120328581TISSUE REPAIR - According to the invention there is provided a cosmetic method for the augmentation of subcutaneous or dermal tissue in a subject, which method comprises the steps of:12-27-2012
20120328580COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION - This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation.12-27-2012
20120282226Tissue Products Derived From Animals Lacking Any Expression of Functional Alpha 1, 3 Galactosyltransferase - The present invention provides tissues derived from animals, which lack any expression of functional alpha 1,3 galactosyltransferase (alpha-1,3-GT). Such tissues can be used in the field of xenotransplantation, such as orthopedic reconstruction and repair, skin repair and internal tissue repair or as medical devices.11-08-2012
20120282228METHOD OF PRODUCING PROGENITOR CELLS FROM DIFFERENTIATED CELLS - The present invention provides a method of producing progenitor cells, such as cells capable of being differentiated into a plurality of different cell types, from differentiated cells. Methods of using progenitor cells in differentiation and/or tissue or organ repair and/or regeneration and/or building are also provides. Methods of using progenitor cells in treatment and prophylaxis of conditions alleviated by administering stem cells or tissue or organ derived from stem cells to a subject or by grafting stem cells or tissue or organ derived from stem cells into a subject or by transplanting stem cells or tissue or organ derived from stem cells into a subject are also provided. Also included are progenitor cells and differentiated cells and/or tissues and/or organs derived therefrom, and kits comprising same.11-08-2012
20120282227METHODS AND COMPOSITIONS FOR THE INDUCTION OF HYPOTHERMIA - Provided herein are methods for the induction of hypothermia and the treatment of clinical insults in a subject through the administration of a regulated hypothermic multidrug combination. The compositions or multidrug combinations of the invention comprise a regulated hypothermic compound or a dopamine receptor agonist; a vasoactive compound; and an antiarrhythmic compound or a serotonin 5-HT3 receptor antagonist. Additional agents can be included in the composition including at least one of an antioxidant, a vitamin, N-acetylcysteine, and an antihyperglycemic compound. The invention further recognizes that a two phase delivery of multidrug combinations, a rapid infusion of the composition to induce hypothermia followed by a period of slow infusion to maintain the hypothermic state for a sustained period of time. Using the two phase delivery method of the invention, the composition may comprise ethanol and, optionally, at least one of a vasoactive compound, an antiarrhythmic compound, a serotonin 5-HT3 receptor antagonist, an antioxidant, a vitamin, N-acetylcysteine, and an antihyperglycemic compound. This two phase delivery method can be used to deliver any of the compositions of the invention and provides significant benefits to a patient.11-08-2012
20120328582Primate Embryonic Stem Cells - A purified preparation of primate embryonic stem cells is disclosed. This preparation is characterized by the following cell surface markers: SSEA-1 (−); SSEA-4 (+); TRA-1-60 (+); TRA-1-81 (+); and alkaline phosphatase (+). In a particularly advantageous embodiment, the cells of the preparation are human embryonic stem cells, have normal karyotypes, and continue to proliferate in an undifferentiated state after continuous culture for eleven months. The embryonic stem cell lines also retain the ability, throughout the culture, to form trophoblast and to differentiate into all tissues derived from all three embryonic germ layers (endoderm, mesoderm and ectoderm). A method for isolating a primate embryonic stem cell line is also disclosed.12-27-2012
20110305672COMPOSITIONS FOR MESODERM DERIVED ISL1+ MULTIPOTENT CELLS (IMPs), EPICARDIAL PROGENITOR CELLS (EPCs) AND MULTIPOTENT CD56C CELLS (C56Cs) AND METHODS OF PRODUCING AND USING SAME - The present invention relates to inter alia, methods for the generation and maintenance of Mesoderm-derived ISL1+ Multipotent Progenitors (IMPs), the production of a number of pluripotent cells including and epicardial pluripotent cells (EPCs) and using these cells to produce endothelial cells, cardiomyocytes, smooth muscle cells, vascular cells and other cells and related methods as otherwise disclosed herein. The invention also relates to compositions comprising a population of cells.12-15-2011
20100215625EFFICIENT PREPARATION OF NAPHTHOQUINONE ANTICANCER ACTIVE INGREDIENTS - One of the problems to be resolved by the present invention is to stably and sustainably produce active ingredients contained in Bignoniaceous plants of which a mass production is difficult in a conventional manner. The present invention relates to a method for efficiently preparing an anticancer active ingredient NQ08-26-2010
20100215624Pharmaceutical Compositions for Treating Rheumatoid Arthritis Comprising Semi-Mature Dendritic Cell - The present invention relates to a pharmaceutical composition for treating rheumatoid arthritis, which comprises (a) a pharmaceutically effective amount of a semi-mature dendritic cell; and (b) a pharmaceutically acceptable carrier. The semi-mature dendritic cell of this invention has a safe and remarkably improved potential to treat or prevent rheumatoid arthritis through the activity of the suppression of auto-immune responses.08-26-2010
20100215622TREATMENT OF IMMUNOSUPPRESSION-RELATED DISORDERS - Disclosed are methods of using blastomere-like stem cells to treat a number of immunodeficiency disorders.08-26-2010
20120100114MESENCHYMAL STEM CELLS AND SUPPORTS FOR TISSUE REGENERATION, REPAIR AND RECONSTRUCTION - Materials and methods for preparing mesenchymal stem cells are described such that the mesenchymal stem cells remain for a longer period of time than would normally be found at a site of tissue healing. The mesenchymal stem cells are pretreated to exhibit osteogenic characteristics and, when combined with extracellular matrix components produced from the pretreated cells, improve tissue healing. Co-administration of the pretreated cells and their secreted extracellular matrix components at an injured site or defect allowed the mesenchymal stem cells to co-localize at or near the injured or defect site for a longer period. The combination improves overall repair of the tissue by extending the retention signal of mesenchymal stem cells. A three-dimensional scaffold containing the pretreated cells with or without addition of the secreted extracellular matrix is also described. The conditioned scaffold is suitable for use in vivo and may be preserved cryogenically prior to use.04-26-2012
20120100113DIFFERENTIATION METHOD FOR PRODUCTION OF GLIAL CELL POPULATIONS - The present invention provides methods for generating oligodendrocyte progenitor cells from pluripotent cells, as well as methods for sustaining these oligodendrocyte progenitor cells in relatively pure cultures for long periods of time. The present invention also provides methods for further differentiating these oligodendrocyte progenitor cells into various glial cells.04-26-2012
20120100112MATERIALS AND METHODS FOR USING ADIPOSE STEM CELLS TO TREAT LUNG INJURY AND DISEASE - The present invention provides methods for treating patients with acute or chronic lung disease or injury to the lungs including injury caused by exposure to cigarette smoke other irritants or another cause of pulmonary distress. Typical conditions that can be treated include conditions that cause inflammation in the lung or the death of lung endothelial cells. Treatment of other conditions such as compromised bone marrow function and cachexia can also be treated by the inventive methods disclosed herein. These methods including contacting Adipose Stem Cells (ASC) or media conditioned by contact with ASC (ASC-CM) or various factors secreted by the same including the media or components of the media with lung tissue and cells. In some instances the ASC used is harvested from the patient's own adipose tissue while in other instances the source is an exogenous donor.04-26-2012
20120100111METHOD FOR TREATING CANCER - The present invention relates to a method for preventing or treating cancer in an individual comprising administering the individual with a prophylactically or therapeutically effective quantity of a gingival fibroblast-derived product.04-26-2012
20120100110PHYSIOLOGICAL METHODS FOR ISOLATION OF HIGH PURITY CELL POPULATIONS - The disclosure provides methods for isolating a pure or enriched population of differentiated cells derived from stem cells, comprising differentiating the population of stem cells; and migrating the differentiated cells through a porous membrane in a differentiation device to isolate the pure or enriched population of differentiated cells. The disclosure also provides a differentiation device for isolating a pure or enriched population of differentiated cells derived from stem cells, the device comprising a porous membrane; and an extracellular matrix.04-26-2012
20120288482THERAPEUTIC AGENT (Y-39983) FOR CORNEAL ENDOTHELIAL DYSFUNCTION - The present invention aims to provide a means for effectively and conveniently treating diseases wherein corneal endothelial cells poor in proliferative capacity in vivo are damaged. The present invention provides a therapeutic agent for corneal endothelial dysfunction containing (R)-(+)-N-(1H-pyrrolo [2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide or a pharmacologically acceptable salt thereof (compound (Ia)) as active ingredient, an agent for promoting adhesion of corneal endothelial cells, containing compound (Ia), a culture medium for corneal endothelial cells, containing the agent for promoting adhesion, an implant for corneal endothelial keratoplasty, containing corneal endothelial cells, scaffold and compound (Ia), and a production method of a corneal endothelial preparation, including a step of cultivating corneal endothelial cells using the culture medium.11-15-2012
20120288481TREATMENT OF HEART DISEASE - Disclosed herein are methods, compositions and kits for treating cardiac stem cells to be administered to a subject in need thereof, e.g., with a damaged myocardium. The methods, composition and kits of the invention can be used to treat cardiovascular diseases such as heart failure, myocardial infarction and an age-related cardiomyopathy.11-15-2012
20120288480CELL POPULATION COMPRISING ORBITAL FAT-DERIVED STEM CELLS (OFSCS) AND THEIR ISOLATION AND APPLICATIONS - The invention relates to a cell population comprising minimal volume of orbital fat-derived stem cells (OFSCs) and its isolation, purification, characterization and application. The OFSCs of the invention are capable of multilineage development and express at least CD90 and CD 105 but not hematopoietic and epithelial markers. The OFSCs have colony formation ability and multi-lineage differentiation ability. They possess at least osteogenic, chondrogenic and adipogenic differentiation capacity; besides mesodermal tri-linage differentiation, the OFSCs have corneal epithelial differentiation potential. Taking together, orbital fat tissues are a novel source for multi-potent stem cells which possess multiple therapeutic potential. Therefore, the OFSCs can be used in cell therapy and tissue engineering.11-15-2012
20100209401Use of SDF-1 to Improve Ischemic Myocardial Function - A method is provided for increasing trafficking of endothelial progenitor cells to an ischemic myocardium in a subject's heart comprising administering to the subject's heart an amount of Stromal-Derived Factor-1 (SDF-1).08-19-2010
20100203023ENHANCED COMPOSITIONS CONTAINING CELLS AND EXTRACELLULAR MATRIX MATERIALS - Described are medical graft materials and devices having improved properties relating to their component profiles.08-12-2010
20100203022METHODS AND COMPOSITIONS FOR DELIVERING THERAPEUTIC AGENTS TO THE CENTRAL NERVOUS SYSTEM - Methods are provided for targeting therapeutic agents to an injury site within the central nervous system.08-12-2010
20120134968Composition for manufacturing a scaffold for tissue engineering, and a method of making it - The invention relates to a composition comprising a mixture of at least one degradable hydrogel and at least one kind of degradable and surface cross-linked particle. The at least one kind of degradable and surface cross-linked particle comprises a material which degrades faster than the degradable hydrogel. The composition can further comprise one or more species of living cells. The invention relates also to a method of manufacturing the composition, as well as to a method of manufacturing a scaffold for tissue engineering using the composition.05-31-2012
20080305086HUMAN LATE STAGE MOTOR NEURON PROGENITOR CELLS AND METHODS OF MAKING AND USING SAME - Motor neuron progenitor (MNP) cells and populations of MNP cells, are provided, in particular, populations of human late stage MNP cells having a purity of greater than about 65% late stage MNP cells and high-purity populations of MNP cells having greater than 95% viable cells, as well as method of making and using the same, including deriving late stage MNP cells from pluripotent embryonic stem cells, producing high-purity populations of late stage MNP cells, producing populations of viable MNP cells, transporting viable MNP cells, and transplanting MNP cells.12-11-2008
20100178274APPLICATION OF SYNOVIUM-DERIVED MESENCHYMAL STEM CELLS (MSCS) FOR CARTILAGE OR MENISCUS REGENERATION - An object of the present invention is to provide a method for treating defects of articular cartilage or meniscus of a patient using in vivo chondrogenesis of synovium-derived MSCs. The present invention provides a method for treating a disease associated with defects of cartilage or meniscus. In the present invention, the method for treating a disease associated with defects of cartilage or meniscus comprises the following steps: culturing ex vivo autologous synovium-derived mesenchymal stem cells (MSCs); implanting the MSCs such that said cartilage defect site or meniscal defect site is covered by the MSCs; and regenerating cartilage tissue at the cartilage defect site or meniscal defect site in situ by differentiating the MSCs into cartilage cells.07-15-2010
20100172880DNA METHYLATION MARKERS BASED ON EPIGENETIC STEM CELL SIGNATURES IN CANCER - In particular aspects, stem-cell polycomb group (PcG) targets are more likely to have cancer-specific promoter DNA methylation than non-targets, indicating a stem-cell origin of cancer, where reversible gene repression is replaced by permanent silencing, locking the cell into a perpetual state of self-renewal and predisposition to subsequent malignant transformation. Exemplary aspects provide methods for identifying preferred DNA methylation markers for a cellular proliferative disorder and/or cancer and markers for developmental lineages and/or stages, based on identifying PcG protein or PcG repressive complex genomic target loci within a precursor cell (e.g., stem or progenitor cell) population, and determining, in cells of the proliferative disorder and/or cancer or cell of the particular developmental lineages and/or stages, a characteristic methylation status of the PcG target loci. Additional aspects provide methods for validating and/or monitoring a precursor cell (e.g., stem cell) population. Diagnostic and prognostic methods for ovarian and breast cancer are provided.07-08-2010
20090280097PLURIPOTENT CELLS - Pluripotent cells that are immunopositive for both the neural progenitor marker nestin and a pluripotent cell marker are provided. The cells exhibit rapid doubling times and can be maintained in vitro for extended periods. Also provided are cell cultures containing the pluripotent cells, a method of transplanting human pluripotent cells to a host, and a method of reducing seizure activity in a subject. These pluripotent cells, when transplanted into the ventricle of a host animal, migrate to the site of damage and adopt a suitably corrective phenotype, resulting in both structural and functional restoration.11-12-2009
20100040585METHODS FOR ISOLATING AND USING HEMATOPOIETIC AND EMBRYONIC STEM CELLS OF THE PERITONEAL CAVITY - The invention relates to the isolation and use of hematopoietic and embryonic stem cells. Additionally, the inventors identified the peritoneal cavity as a new source of hematopoietic stem cells. In one embodiment, the invention provides methods of isolating progenitor and/or stem cells from the peritoneal cavity. In another embodiment, the invention provides methods of transporting progenitor and/or stem cells from the peritoneal cavity to another organ. In another embodiment, the present invention provides methods of regenerating bioengineered tissues and/or reconstituting an hematopoietic system.02-18-2010
20100178276CONSTITUTIVE EXPRESSION OF COSTIMULATORY LIGANDS ON ADOPTIVELY TRANSFERRED T LYMPHOCYTES - The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen-recognizing receptor and a co-stimulatory ligand and methods of use therefore for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.07-15-2010
20130011371ESTABLISHMENT OF PATIENT- OR PERSON- SPECIFIC CARDIAC MYOCYTE CELL LINES FROM HUMAN INDUCED PLURIPOTENT STEM CELLS (iPSCs) - A composition and method for generating patient- or person-specific proliferative and substantially pure cardiac myocyte cell lines from pluripotent stem cells (iPSCs) is described herein. The patient-specific cardiac myocyte cell lines of the present invention find applications in research, drug screening and autologous cell-based therapy. The method of the present invention is simple and reproducible and generates cardiac myocyte cells having high purities and proliferating capacities.01-10-2013
20100166712BONE MARROW-DERIVED MESENCHYMAL STEM CELLS AS A SOURCE OF NEURAL PROGENITORS - Methods are provided for treating and/or reducing the severity of multiple sclerosis in a human, by administering autologous mesenchymal stem cell-derived neural precursors. Also described is an in vitro method for differentiating mesenchymal stem-cell derived neural precursor oligodengroglial and neuronal cell types.07-01-2010
20100166713EARLY MESODERM CELLS, A STABLE POPULATION OF MESENDODERM CELLS THAT HAS UTILITY FOR GENERATION OF ENDODERM AND MESODERM LINEAGES AND MULTIPOTENT MIGRATORY CELLS (MMC) - The present invention relates to the production of multipotent migratory cell (MMCs) which can be differentiated into mesoderm or endoderm lineages. Multipotent Migratory Cells (MMC) are stable and robust and can be passaged at least 20 times (perhaps indefinitely), can be recovered after freezing, reamplified and differentiated into multiple lineages. They are therefore storage stable. The method of producing these cells points to a way to generate a multipotent cell type (mesendoderm) from blastocycts for the generation of therapeutically useful cell types without going through a classical hESC state. The production of multipotent migratory cells, mesendoderm cells and mesoderm cells (Isl1+) is also described.07-01-2010
20100135965METHOD OF CHONDROGENIC DIFFERENTIATION FROM MESENCHYMAL STEM CELL, AND COMPOSITION COMPRISING CHONDROGENIC CELL DIFFERENTIATED USING THE METHOD TO TREAT DISEASE CAUSED BY CARTILAGE DAMAGE - Provided are a method of chondrogenic differentiation from mesenchymal stem cells and a composition comprising chondrogenic cells differentiated using the method to treat diseases caused by cartilage damage. In the method, a centrifugal force is applied to human mesenchymal stem cells to be differentiated into chondrogenic cells. The chondrogenic differentiation may be achieved at moderate cost without using expensive cytokines or growth factors by periodically applying only a centrifugal force. According to the method of chondrogenic differentiation from mesenchymal stem cells in the present embodiment, chondrogenic cells may be also differentiated from human mesenchymal stem cells.06-03-2010
20130017175ACTIVATED MESENCHYMAL STEM CELLS FOR WOUND HEALING AND IMPAIRED TISSUE REGENERATION - Inflammatory cytokines e.g. IFN-γ, serve as initiating stimuli for mesenchymal stem cell (MSC) immunosuppresive activity in vivo. Other inflammatory cytokines, such as TNF alpha, the molecule hemoxygenase I, and TLR ligation of MSC, may also provide such a response. Activated MSC's promote tissue regeneration in conditions such as aging, where regeneration is impaired. Wound healing in aged mammals was enhanced by restoring tensile strength to the levels of younger mammals. Activated MSCs were useful in treating wounds in diabetic primates.01-17-2013
20130017176COMPOSITIONS COMPRISING CARDIAC STEM CELLS OVEREXPRESSING SPECIFIC MICRORNAS AND METHODS OF THEIR USE IN REPAIRING DAMAGED MYOCARDIUM - The invention provides compositions comprising modified stem cells containing a transgene that affects the expression of at least one gene that inhibits or promotes cardiomyogenesis. In particular, the invention discloses compositions comprising cardiac stem cells, wherein said cardiac stem cells comprise a transgene encoding a microRNA. The compositions of the invention find use in the treatment of cardiovascular disorders, such as myocardial infarction. Methods of repairing damaged myocardium in a subject using the modified stem cells are also disclosed.01-17-2013
20130017178PREPARATION CREATED FROM AN IN VITRO CULTURE OF DEDIFFERENTIATED, NON-ELICITED CELLS OF THE ARGANIA TREE, USE THEREOF FOR TREATING SKIN AGEING, INFLAMMATION AND SCARRING, AND PRODUCTION THEREOFAANM Steward; NicolasAACI Pins-JustaretAACO FRAAGP Steward; Nicolas Pins-Justaret FRAANM Mandeau; AnneAACI ToulouseAACO FRAAGP Mandeau; Anne Toulouse FRAANM Castex-Rizzi; NathalieAACI ColomiersAACO FRAAGP Castex-Rizzi; Nathalie Colomiers FR - The invention relates to a preparation created from an in vitro culture of dedifferentiated, non-elicited cells of the Argania tree.01-17-2013
20130017177PHOTO-CROSSLINKED GELLAN GUM-BASED HYDROGELS: PREPARATION METHODS AND USES THEREOFAANM Da Silva Correia; Joana CatarinaAACI BragaAACO PTAAGP Da Silva Correia; Joana Catarina Braga PTAANM Antunes De Oliveira; Joaquin MiguelAACI Ponte GMRAACO PTAAGP Antunes De Oliveira; Joaquin Miguel Ponte GMR PTAANM Teixeira De Oliveira; Joao ManuelAACI MatosinhosAACO PTAAGP Teixeira De Oliveira; Joao Manuel Matosinhos PTAANM Amandi Romero De Sousa; Rui PedroAACI MatosinhosAACO PTAAGP Amandi Romero De Sousa; Rui Pedro Matosinhos PTAANM Goncalves Dos Reis; Ruic LuisAACI PortoAACO PTAAGP Goncalves Dos Reis; Ruic Luis Porto PT - This invention refers to photo-crosslinked hydrogel materials based in gellan gum suitable for tissue engineering and regenerative medicine applications or as drug delivery systems. Formulations of gellan gum with different degrees of acylation serve as precursor material for insertion of a polymerizable moiety. The materials are capable of free radical polymerization with a photo-initiator at mild temperatures and exposure to ultraviolet light, enabling control of reticulation and withstanding the encapsulation of human and animal cells and/or drugs, and any combination thereof. The physicochemical and biological properties can be adjusted by combining different formulations of gellan gum and reaction conditions. The matrix can be used either as an acellular or cellular system, dispensed manually or automatically by injection and crosslinked directly at the site of application, and can be processed using manual or automated systems in different types of scaffolds, such as hydrogels, fibres, 01-17-2013
20120148543SYNTHETIC GRAFT - The present invention relates to the use of a plastically-compacted collagen gel as a substrate for the growth of corneal cells, particularly limbal corneal epithelial stem cells. Cells grown on such a substrate can be cultured to produce artificial ocular epithelia which can be used in ocular toxicity testing or for transplantation.06-14-2012
20110158958Methods for treating ophthalmic disorders, diseases and injuries - The invention is directed to methods for treating ophthalmic disorders, diseases and injuries. In particular, the invention is directed to treating disorders, diseases and injuries of the cornea and ocular surface. Such methods utilize novel compositions including, but not limited to, trophic factor secreting extraembryonic cells (herein referred to as TSE cells), including, but not limited to, Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as Amnion-derived Cellular Cytokine Solution or ACCS), and Physiologic Cytokine Solution (herein referred to as PCS), each alone or in combination with each other and/or other agents.06-30-2011
20110158968METHODS OF MAKING ENHANCED, AUTOLOGOUS FAT GRAFTS - Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.06-30-2011
20110158967MESENCHYMAL STEM CELL AND THE METHOD OF USE THEREOF - Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells.06-30-2011
20110158966STEM CELLS CHARACTERIZED BY EXPRESSION OF GERMLINE SPECIFIC GENES - The present invention relates to adult stem cells derived from somatic sources characterized by the expression of the germline specific gene, DAZL. The somatic stem cells expressing the DAZL marker are further characterized by expression of additional markers and absence of expression of certain blood markers. In particular, the present invention discloses therapeutic and diagnostic uses, other than the germ cell potential use, of the DAZL multipotent stem cells isolated from somatic sources such as peripheral blood, bone marrow or umbilical cord blood.06-30-2011
20110158965Cardiac Muscle Regeneration Using Mesenchymal Stem Cells - Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.06-30-2011
20110158964Cardiac Muscle Regeneration Using Mesenchymal Stem Cells - Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.06-30-2011
20110158963THREE-DIMENSIONAL MATRICES OF STRUCTURED POROUS MONETITE FOR TISSUE ENGINEERING AND BONE REGENERATION, AND METHOD OF THE PREPARATION THEREOF - The present invention is comprised within tissue engineering and, specifically, within bone regeneration. The invention relates to a porous three-dimensional matrix of monetite which is biocompatible, has structured porosity and is predefined and reabsorbable, as well as to the method of synthesis capable of producing said material and the applications thereof. These matrices are a perfect base for cell colonization and proliferation, allowing the application thereof in tissue engineering and bone regeneration as a result of their advantageous properties of biocompatibility, reabsorption, osteoinduction, revascularization, etc.06-30-2011
20110158961MATERIALS AND METHODS RELATING TO CELL BASED THERAPIES - The invention relates to the provision of a novel cell population that can be used for tissue regeneration and the treatment of disease states associated with cell degeneration for age related tissue changes. The cell population are derived from adult stem/progenitor cells which are characterised by being positive or negative to the Thy1.1 cell marker.06-30-2011
20110158959IMMUNOPHENOTYPE AND IMMUNOGENICITY OF HUMAN ADIPOSE DERIVED CELLS - The present invention encompasses methods and compositions for generating an isolated adipose tissue-derived stromal cell exhibiting a low level of immunogenicity. The present invention encompasses methods and compositions for reducing an immune response associated with transplantation by administering the recipient with an amount of adipose tissue-derived stromal cells effective to reduce or inhibit host rejection and/or host versus graft disease.06-30-2011
20110158957Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases - Disclosed herein are methods and compositions for inactivating TCR genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided. Disclosed herein are also methods and compositions for expressing a functional exogenous TCR in the absence of endogenous TCR expression in T lymphocytes, including lymphocytes with a central memory phenotype. Polynucleotides encoding exogenous TCR, vectors comprising polynucleotides encoding exogenous TCR and cells comprising polynucleotides encoding exogenous TCR and/or cells comprising exogenous TCR are also provided.06-30-2011
20110158956TREATING CANCER - Provided is a cyclic peptide which comprises: 06-30-2011
20110158954METHOD FOR PRODUCING GAMMA DELTA T CELL POPULATION - A method for preparing a γδ T cell population, characterized in that the method includes the step of culturing a cell population containing γδ T cells, in the presence of (a) fibronectin, a fibronectin fragment or a mixture thereof and (b) an activating factor of γδ T cells. According to the present invention, a method for preparing a γδ T cell population is provided. The γδ T cell population obtained by the method is suitably used in, for example, immunotherapy. Therefore, the method of the present invention is expected to greatly contribute to a medical field.06-30-2011
20130022584METHODS AND COMPOSITIONS FOR THE REPAIR AND/OR REGENERATION OF DAMAGED MYOCARDIUM USING CYTOKINES AND VARIANTS THEREOF - Methods, compositions, and kits for repairing damaged myocardium and/or myocardial cells including the administration of cytokines, variants of cytokines, cardiac stem cells, or combinations thereof are disclosed and claimed. In addition, methods, compositions, and kits for forming coronary vasculature including the administration of cytokines, variants of cytokines, cardiac stem cells, or combinations thereof are described. In particular, administration of variants of hepatocyte growth factor, such as NK1, 1K1, and HP11, are useful for the repair and/or regeneration of damaged myocardium or formation of coronary vasculature. Methods of activating cardiac stem cells in vitro are also disclosed.01-24-2013
20130022583Direct Conversion of Cells to Cells of Other Lineages - Methods, compositions and kits for producing functional neurons, astroctyes, oligodendrocytes and progenitor cells thereof are provided. These methods, compositions and kits find use in producing neurons, astrocytes, oligodendrocytes, and progenitor cells thereof for transplantation, for experimental evaluation, as a source of lineage- and cell-specific products, and the like, for example for use in treating human disorders of the CNS. Also provided are methods, compositions and kits for screening candidate agents for activity in converting cells into neuronal cells, astrocytes, oligodendrocytes, and progenitor cells thereof.01-24-2013
20130022581PLACENTAL STEM CELL POPULATIONS - The present invention provides placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of differentiating the placental stem cells. The invention further provides methods of using the placental stem cells in assays and for transplanting.01-24-2013
20130022580PREPARATION AND USE OF MERISTEMATIC CELLS BELONGING TO THE DENDROBIUM PHALAENOPSIS, ANISELLIA, POLYRRHIZA, VANILLA, CATTLEYA AND VANDA GENERA WITH HIGH CONTENT OF PHENYLPROPANOIDS, HYDROSOLUBLE POLYSACCHARIDES AND EXTENSINS - The present invention relates to the preparation of plant cell cultures belonging to the 01-24-2013
20130022582MULTIPOTENT NESTIN-POSITIVE CELLS - The present invention relates to the use of at least one isolated multipotent stem cell for maintaining haematopoiesis in vitro, in which said multipotent stem cell is preferably a mesenchymal stem cell or, more preferably, said mesenchymal stem cell is a mesenchymal stem cell capable of expressing the nestin protein. The present invention also relates to an isolated cell population of adult nestin-positive mesenchymal cells from a mammal, including humans, to the use thereof for producing a drug for maintaining haematopoiesis in a mammal, for the prevention and/or treatment of at least one disease associated with a malfunction in maintaining haematopoiesis in a mammal, and for maintaining and expanding adult haematopoietic stem cells of said mammal, including a human. Furthermore, the present invention also relates to a method for maintaining haematopoiesis in vitro or to a method for evaluating the haematopoietic capacity of a mammal.01-24-2013
20130171112Methods for promoting hair growth - The invention is directed to methods for promoting hair growth. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), cell lysates derived therefrom, and cell products derived therefrom, each alone or in combination.07-04-2013
20100055076Mesenchymal stem cell-mediated autologous dendritic cells with increased immunosuppression - A method for preparing dendritic cells which have an enhanced potential to suppress immune responses, method for suppressing immune response by comprising administering them, dendritic cells carrying a potential to suppress immune responses, and a pharmaceutical composition comprising the dendritic cells capable of inducing immunosuppressive responses. The present dendritic cells having an enhanced potential to suppress immune responses can be utilized for treating or preventing various diseases or disorders through the suppression of immune responses. In addition, the enhanced immunotolerance potential of the dendritic cells ensures the cells to be effectively used as an immunosuppressive agent.03-04-2010
20080254007Human Mesenchymal Progenitor Cell - The present invention provides isolated pluri-differentiated human mesenchymal progenitor cells (MPCs), which simultaneously express a plurality of genes that are markers for multiple cell lineages, wherein the multiple cell lineages comprise at least four different mesenchymal cell lineages (e.g., adipocyte, osteoblast, fibroblast, and muscle cell) and wherein each of the markers is specific for a single cell lineage. The present invention also method for isolating and purifying human mesenchymal progenitor cells from Dexter-type cultures for characterization of and uses, particularly therapeutic uses for such cells. Specifically, isolated MPCs can be used for diagnostic purposes, to enhance the engraftment of hematopoietic progenitor cells, enhance bone marrow transplantation, or aid in the treatment or prevention of graft versus host disease.10-16-2008
20080254004Homogeneous Neural Precursor Cells - This invention provides pure populations of neural precursor cells, capable of differentiation into neurons, glial cells, and astrocytes. The populations are obtained by culturing stem cell populations (such as embryonic stem cells) in a cocktail of growth conditions that initiates differentiation, and establishes the neural precursor population. The precursors can be further differentiated in culture into a variety of different neural phenotypes. The neural precursors can be generated in pure form (at least 99%) and in large quantities for use in drug screening and the treatment of neurological disorders.10-16-2008
20080254002Bone Marrow Derived Oct3/4+ Stem Cells - The invention provides bone-marrow derived stem cells, e.g., cardiomyocyte precursor cells, differentiated cardiomyocytes generated from the precursor cells, and a method for treating cardiac dysfunction in a subject by administering such cells.10-16-2008
20080248005Isolation and Cultivation of Stem/Progenitor Cells From the Amniotic Membrane of Umbilical Cord and Uses of Cells Differentiated Therefrom - The present invention relates to a skin equivalent and a method for producing the same, wherein the skin equivalent comprises a scaffold and stem/progenitor cells isolated from the amniotic membrane of umbilical cord. These stem/progenitor cells may be mesenchymal (UCMC) and/or epithelial (UCEC) stem cells, which may then be further differentiated to fibroblast and keratinocytes. Further described is a method for isolating stem/progenitor cells from the amniotic membrane of umbilical cord, wherein the method comprises separating the amniotic membrane from the other components of the umbilical cord in vitro, culturing the amniotic membrane tissue under conditions allowing cell proliferation, and isolating the stem/progenitor cells from the tissue cultures. The invention also refers to therapeutic uses of these skin equivalents. Another aspect of the invention relates to the generation of a mucin-producing cell using stem/progenitor cells obtained from the amniotic membrane of umbilical cord and therapeutic uses of such mucin-producing cells. In yet another aspect, the invention relates to a method for generating an insulin-producing cell using stem/progenitor cells isolated from the amniotic membrane of umbilical cord and therapeutic uses thereof. The invention further refers to a method of treating a bone or cartilage disorder using UCMC. Furthermore, the invention refers to a method of generating a dopamin and tyrosin hydroxylase as well as a HLA-G and hepatocytes using UCMC and/or UCEC. The present invention also refers to a method of inducing proliferation of aged keratinocytes using UCMC.10-09-2008
20080248004Cell fractions containing cells capable of differentiating into neural cells - Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells.10-09-2008
20080248003Methods and Compositions for Growing Adipose Stem Cells - The present invention relates to adipose tissue-derived stem cells and to methods and compositions for enhancing growth and differentiation of such cells. The invention further relates to growing such cells in serum-free or low serum growth medium, and formulations thereof.10-09-2008
20080247999Treating Cancer - The present invention provides a peptide comprising an amino acid sequence that is part of the amino acid sequence of CDK4 protein, or homologous to part of the amino acid sequence of CDK4 protein, which peptide is cytotoxic to, and/or inhibiting to the growth of, a cancer cell and/or stimulating to the growth of a non-cancerous cell and/or a control cell. Methods of identifying such peptides and medical uses of such peptides are also disclosed.10-09-2008
20080247998Creation of a Biological Atrioventricular Bypass to Compensate for Atrioventricular Block - A method of creating an atrioventricular bypass tract for a heart comprises growing mesenchymal stem cells into a strip with two ends, attaching one end of the strip onto the atrium of the heart, and attaching the other end of the strip to the ventricle of the heart, to create a tract connecting the atrium to the ventricle to provide a path for electrical signals generated by the sinus node to propagate across the tract and excite the ventricle.10-09-2008
20080241110Targeting of sall4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (MDS) - The present invention discloses nucleic acids, proteins, and antibodies for SALL4 (including isoforms SALL4A, SALL4B, and SALL4C), a zinc finger transcriptional factor. Further, methods are disclosed which demonstrate that constitutive expression of SALL4 increases leukemogenic potential in cells of model animal systems. Moreover, constitutive expression of select isoforms (e.g., SALL4B) in transgenic mice demonstrate that these animals develop myelodysplastic syndrome (MDS)-like signs and symptoms, including subsequent acute myeloid leukemia (AML), which is transplantable. The disclosure also provides methods for identifying and purifying embryonic stem cells, adult stem cells, cancer stem cells, including leukemia stem cells, methods for identifying substances which bind to and/or modulate SALL4, methods for diagnosing MDS in a subject, and methods of treating a subject presenting MDS, AML and other forms of leukemia.10-02-2008
20080241108Bone Morphogenic Protein Binding Peptide - A cyclized peptide designated BMP Binding Peptide (BBP) is a synthetic peptide that avidly binds rhBMP-2. BBP increases the over-all osteogenic activity of rgBMP-2, increases the rate at which rhBMP-2 induces bone formation, and BBP induces calcification alone. Compositions and substrates including BBP, and methods of using BBP are useful in therapeutic, diagnostic and clinical applications requiring calcification and osteogenesis.10-02-2008
20090269313ENCAPSULATION SYSTEM - An encapsulation system for use in the treatment of diabetes (Types 1 or 2, and LADA) are provided. The system has (1) a delivery vehicle comprising a selectively permeable membrane that allows passage of glucose, insulin and other nutrients through the membrane, but prevents large molecules such as antibodies or inflammatory cells from passing through the membrane; (2) a population of islet cells or insulin producing cells encapsulated by said membrane; and (3) a biological response modifier that may be in contact with the membrane or encapsulated by the membrane. Generally, the biological response modifier is a compound, including resolved enantiomers, diastereomers, tautomers, salts and solvates thereof, having the following formula:10-29-2009
20100086524CELLULAR PREPARATIONS FOR USE AS A REVASCULARIZATION STIMULATING AGENT - The invention relates to a cellular preparation containing endothelial cell precursors (EPCs) and smooth muscular cell precursors (SMCs), as a combination product for simultaneous, separated or time-spread administration, used as a revascularisation stimulating agent. The invention also relates to the use of such a cellular preparation.04-08-2010
20080226609Transplantation of Glial Restricted Precursor-Derived Astrocytes for Promotion of Axon Growth - Provided herein are compositions and methods for the treatment of central nervous system (CNS) lesions comprising administration of glial restricted precursor (GRP) derived astrocytes (GDAs).09-18-2008
20080226608Methods of Isolating and Using Enriched Subpopulations of Bone Marrow Progenitors for the Treatment of Diabetes - Enriched subpopulations of bone marrow progenitors are obtained according to methods that involve the staining of bone marrow cells and the identification of bone marrow progenitors within the stained cell population having specific intracellular fluorescence or orthogonal light scatter properties. Enriched subpopulations of the described progenitors may be used to lower blood glucose levels and treat hyperglycemia, and in particular hyperglycemia caused by Type 1 or Type 2 diabetes.09-18-2008
20080226607COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER - Compositions and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Illustrative compositions comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly prostate cancer.09-18-2008
20080226606COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER - Compositions and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Illustrative compositions comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly prostate cancer.09-18-2008
20080226605Methods and Compositions Facilitating Entry of Compounds Into Cells - Disclosed are methods and compositions for facilitating entry of compounds to cells. In some forms, the compositions comprise one or more aminoglycosides and one or more lipids. The disclosed compositions can also comprise one or more compounds or compositions. It was discovered that the disclosed compositions increase the efficiency of delivery of compounds into cells. The disclosed compositions and methods increase both delivery into cells and the activity of compounds once delivered into cells. For example, the disclosed methods and compositions can be used to deliver nucleic acids to cells and to thereby increase the activity of such nucleic acids delivered to cells. The disclosed compositions can be used to deliver compounds and compositions to cells in vitro, ex vivo and in vivo. Delivery can be, for example, non-specific, non-directed, non-targeted, specific, directed or targeted.09-18-2008
20110262403Method of accelerating osteogenic differentiation and composition thereof - The invention discloses a method of accelerating osteogenic differentiation and a composition thereof. The method comprises a step of adding type II collagen into stem/progenitor cells or osteoblasts to accelerate the osteogenic differentiation of the added cells, and the composition comprises type II collagen, and stem/progenitor cells or osteoblasts. Type II collagen can accelerate osteogenesis of mesenchymal stem cells (MSCs) much faster than does type I collagen. The said composition is effective to facilitate bone repair upon introduction of the composition into various osseous defects.10-27-2011
20130171110COMPOSITIONS AND METHODS FOR DIFFERENTIATING PLURIPOTENT STEM CELLS INTO PRIMITIVE BLOOD CELLS AND USES THEREOF - Compositions and methods that employ various combinations of such factors as retinoic acid signaling inhibitors, antioxidants, BMP4, VEGF, prostaglandin E07-04-2013
20130171111METHOD OF MANUFACTURING A SCAFFOLD FOR TISSUE ENGINEERING OR REPAIR - The invention relates to a method of manufacturing a scaffold for tissue engineering or repair. The method includes providing a mixture comprising a degradable hydrogel, a degradable particle, and living cells. The mixture is then incubated under conditions which allow proliferation of the living cells and degradation of the degradable particle in the hydrogel. The degradable hydrogel of the incubated mixture is then degraded at least partially, followed by adding further living cells to obtain the scaffold.07-04-2013
20130171113METHOD OF TREATING GRAFT VERSUS HOST DISEASE - A method for preventing the development of or treating GvHD complications in a mammalian patient which comprises administering to the mammal a population of cells enriched for STRO-107-04-2013
20130171114ISLETS OF LANGERHANS TRANSPLANT USING ISLETS OF LANGERHANS AND ADIPOSE TISSUE DERIVED STEM CELLS - An object of the present invention is to provide a pancreatic islet transplantation technique that enables increase of graft survival rate of pancreatic islets after pancreatic islet transplantation, to maintain survival of pancreatic islets, and to reduce the number of transplanted pancreatic islets required for normalizing blood glucose level. When performing pancreatic islet transplantation, by transplanting pancreatic islets and adipose tissue-derived stem cells together, it is possible to significantly improve graft survival rate of transplanted pancreatic islets, and reduce by half the number of transplanted pancreatic islets required for normalizing blood glucose level.07-04-2013
20110274663PHARMACEUTICAL COMPOSITION CONTAINING HUMAN MESENCHYMAL STEM CELL - Disclosed are a method for producing a frozen pharmaceutical composition prepared from cultured human mesenchymal stem cells and a pharmaceutical composition containing human mesenchymal stem cells. This method is a method for producing a frozen pharmaceutical composition containing human mesenchymal stem cells, which comprises the following steps in this order: (a) adding trypsin to human mesenchymal stem cells in a culture vessel to detach the cells from the surface of the culture vessel; (b) adding a bicarbonate Ringer's solution containing human serum albumin to the detached cells to terminate the reaction with trypsin, and washing the cells with the bicarbonate Ringer's solution containing human serum albumin; (c) suspending the cells in a bicarbonate Ringer's solution containing human serum albumin and dimethyl sulfoxide; (d) putting the resulting suspension in a container which allows freezing of what is contained therein, and sealing the container; and (e) freezing the suspension put in the container.11-10-2011
20110274662Methods of Producing RPE Cells and Compositions of RPE Cells - The present invention provides improved methods for producing RPE cells from human embryonic stem cells or from other human pluripotent stem cells. The invention also relates to human retinal pigmented epithelial cells derived from human embryonic stem cells or other human multipotent or pluripotent stem cells. hRPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The hRPE cells described herein are useful for treating retinal degenerative diseases.11-10-2011
20110274668VOLUME MAINTAINING OSTEOINDUCTIVE/OSTEOCONDUCTIVE COMPOSITIONS - An osteoinductive/osteoconductive composition prepared from a quantity, of demineralized fibrous bone elements possessing an average surface area to volume ratio of about 100:1 to about 20:1, a quantity of mostly shaped regular non-fibrous bone elements possessing an average surface area to volume ratio of about 10:1 or less and a sufficient quantity of biocompatible fluid carrier sufficient to provide the composition as a deformable mass is provided herein. Also provided is a method of using the composition to repair a bone defect site.11-10-2011
20110274667METHODS FOR OBTAINING CELL POPULATIONS FROM ADIPOSE TISSUE - Provided herein are methods of efficiently obtaining large numbers of viable, freshly isolated cells from small amounts of adipose tissue, as well as methods of enriching or selecting for target cell populations found therein. In certain embodiments, the method of obtaining a population of cells from adipose tissue comprises incubating the adipose tissue in a solution comprising an enzyme at a concentration which is at least 200 U/ml solution and not more than about 319 U/ml solution. In some embodiments, the method is devoid of any steps which expand the population of cells obtained. In certain aspects, the method further comprises positive or negative selection steps for obtaining an enriched population of target cells from adipose tissue. Related methods of preparing a pharmaceutical composition comprising cells for administration to a patient and methods of treating a disease or medical condition in a patient are further provided herein.11-10-2011
20110274666METHOD OF ENGRAFTING CELLS FROM SOLID TISSUES - A method of repairing diseased or dysfunctional organs or of establishing a model system of a disease state is provided. For repairing diseased organs, the method involves engraftment of cells from healthy tissue of the diseased or dysfunctional organ admixed with gel-forming biomaterials and nutrient medium, signaling molecules and extracellular matrix components that can be made insoluble rapidly upon transplantation to form a graft. In this way, the graft mimics the complexity of the native microenvironment with a minimum number of components that allow transplantation of cells to successfully engraft, expand and then rebuild part or the entirety of the diseased or dysfunctional organ. In the case of using grafting methods for establishing a disease model, diseased cells may be transplanted in the biomaterials and into experimental hosts.11-10-2011
20110274665DOSAGE UNIT FORMULATIONS OF AUTOLOGOUS DERMAL FIBROBLASTS - Dosage units consist of an autologous cell therapy product composed of fibroblasts grown for each individual to be treated. The suspension of autologous fibroblasts, grown from a biopsy of each individual's own skin using current good manufacturing practices (CGMP), and standard tissue culture procedures, is supplied in vials containing cryopreserved fibroblasts or precursors thereof, having a purity of at least 98% fibroblasts and a viability of at least 85%, for administration of from one to six mL, preferably two mL, of cells at a concentration of from 1.0-2.0×1011-10-2011
20110274664HEPATIC PROGENITOR CELLS AND USES THEREOF - Disclosed are cells, compositions, and methods for treating liver diseases.11-10-2011
20090263362FERTILITY ENHANCEMENT USING LIPID CARRIERS AND BIOACTIVE MOLECULES - The invention relates to a composition and method for enhancing fertilization. Fertilization enhancement is achieved by effectively delivering bioactive molecules with a lipid anchor (GPI-linked proteins) to the surface of epididymal or ejaculated sperm. The process may be facilitated or promoted in the presence of Clusterin/APOJ, a well-known lipid carrier. The rate of delivery, or removal, of bioactive molecules is regulated by the concentration of lipid carrier present. The acquisition of these molecules, such as Sperm Adhesion Molecule 1 (SPAM1) can significantly impact sperm maturation and function.10-22-2009
20130142763CROSSLINKED CELLULOSIC POLYMERS - Crosslinked cellulosic polymers, crosslinked cellulosic polymer hydro-gels, and methods for their synthesis and use are described. The crosslinked cellulosic polymers include one or more cellulosic polymers and a one or more crosslinkers that crosslinks the one or more cellulosic polymers together. The crosslinking can be facilitated with a crosslinking agent capable of linking with a monomer the cellulosic polymer and crosslinking the cellulosic polymer intermoleculerly and/or intramolecularly. Crosslinked cellulosic polymers are well adapted for use in cell and tissue growth in vivo and in vitro. The crosslinked cellulose polymers may also be used as wound care devices.06-06-2013
20130177535WNT INHIBITORS FOR HUMAN STEM CELL DIFFERENTIATION - Methods and small molecule compounds for stem cell differentiation and treatment of animals with diseases are provided. One example of a class of compounds that may be used is represented by the compound of Formula I and II:07-11-2013
20130177536Enhancement Of Skeletal Muscle Stem Cell Engraftment By Dual Delivery Of VEGF And IGF-1 - An improved device and method for extended repair and regeneration of muscle tissue. An exemplary device comprises (a) a scaffold comprising an ECM component; (b) a combination of growth factors such as VEGF and IGF; and (c) a population of myogenic cells. Implantation of the device leads to muscle regeneration and repair over an extended period of time.07-11-2013
20130177537STEM CELLS AND METHODS FOR INCORPORATING ENVIRONMENTAL FACTORS AS A MEANS FOR ENHANCING STEM CELL PROLIFERATION AND PLASTICITY - Disclosed are methods for expanding stem cells that use a unique combination of environmental factors and cell culture conditions to produce stem cells having enhanced proliferation and differentiation characteristics. Also disclosed are methods for enhancing the engraftment and/or migratory potential of stem cells for therapeutic uses. Stem cells having unique proliferation, differentiation, migratory and engraftment characteristics are also disclosed.07-11-2013
20100040583COMPOSITIONS AND METHODS USING STEM CELLS IN CUTANEOUS WOUND HEALING - Provided herein are compositions and methods using stem/progenitor cells in a therapeutic approach for the treatment of, or promotion of healing of, acute and chronic wounds.02-18-2010
20090022695METHOD FOR EXPANSION OF TUMOUR-REACTIVE T-LYMPHOCYTES FOR IMMUNOTHERAPY OF PATIENTS WITH SPECIFIC CANCER TYPES - Methods for treating a patient suffering from a neoplastic disease are disclosed and described. A number of diseases can be treated under the present methods, including without limitation gall bladder cancer, hepato cellular cancer, ovarian cancer, small intestine cancer, lung cancer, mesothelioma, breast cancer, kidney cancer, pancreas cancer, prostate cancer, carcinoid cancer, leiomyosarcoma, or metastasis thereof. A general method for providing such treatment may include: 1) identifying in a patient one or more sentinel and/or metinel lymph nodes draining the neoplasm; 2) resecting the one or more nodes and, optionally all or part of the tumour or metastasis; 3) isolating tumour-reactive T-lymphocytes from said lymph nodes; 4) in vitro expanding said tumour-reactive T-lymphocytes; and 5) administering the thus obtained tumour-reactive T-lymphocytes to the patient.01-22-2009
20090016999Embryonic cell compositions for wound treatment - Compositions including formulations comprising stem cells, such as umbilical cord blood stem cells, or embryonic germ cell derivatives, or embryonic stem cells, are provided for enhancement of wound healing. Methods for using the compositions and formulations for enhancing would healing are also provided. Wounds to both soft and bony tissues are encompassed, and include wounds created by surgical procedures.01-15-2009
20120251506METHODS AND COMPOSITIONS RELATING TO NEURONAL CELL AND TISSUE DIFFERENTIATION - The invention relates to methods for isolating and purifying specific types of neurons, such as cortical or other projection neurons including corticospinal motor neurons, subcerebral projection neurons, and callosal projection neurons. The invention also relates to genes that are specific for particular neuronal subtypes, and the use of such genes in genetic/molecular control of cell development. The isolated cells and subtype-specific genes also have uses in diagnostics, therapeutics, and screening assays for pharmaceutical molecules.10-04-2012
20080286246Internally administered therapeutic agents for cranial nerve diseases comprising mesenchymal cells as an active ingredient - Intravenous administration of bone marrow cells collected from rat bone marrow or peripheral blood to a rat cerebral infarction model was found to be effective in treating cerebral infarction. Human and murine bone marrow stem cells showed similar effects. Mesenchymal cells such as bone marrow cells, cord blood cells, or peripheral blood cells can be used as agents for in vivo administration against cranial nerve diseases.11-20-2008
20090263357Therapeutic Reprogramming, Hybrid Stem Cells and Maturation - Therapeutically programmed cells and methods for making such cells are provided. Therapeutically programmed cells are stem cells which have been matured such that they represent either a more differentiated state or a less differentiated state after contact with stimulatory factors. The therapeutically reprogrammed cells are suitable for cellular regenerative therapy and have the potential to differentiate into more committed cell lineages. Additionally, hybrid stem cells suitable for therapeutic reprogramming and cellular regenerative therapy are provided.10-22-2009
20110268710METHODS OF TREATING STROKE USING STEM CELL-LIKE MENSTRUAL BLOOD CELLS - A cell type that is a complete match of the transplant recipient appears as an optimal scenario to open treatment options to a large patient population with minimal complications. The use of autologous bone marrow or umbilical cord blood has been proposed as a good source of stem cells for cell therapy. Menstrual blood is found to be another important source of stem cells. Assays of cultured menstrual blood reveal that they express embryonic like-stem cell phenotypic markers and neuronal phenotypic markers under appropriate conditioned media. Oxygen glucose deprivation stroke models show that OGD-exposed primary rat neurons, co-cultured with menstrual blood-derived stem cells or exposed to the media from cultured menstrual blood, exhibited significantly reduced cell death. Transplantation of menstrual blood-derived stem cells, either intracerebrally or intravenously, after experimentally induced ischemic stroke in adult rats also significantly reduced behavioral and histological impairments compared to vehicle-infused rats.11-03-2011
20110268707Ex-vivo treatment of peripheral blood leukocytes with IFN-lambda - The present invention provides an ex vivo method of treating plasmacytoid dendritic cells (pDC) in Th2- or Th17-associated diseases by modulating the cytokine expression or secretion using interferon lambda (IFN-λ). For the Th-2 or Th17-associated diseases, pDC cells from a patient having the disease are exposed ex vivo with IFN-λ in an effective amount to inhibit cytokine releases. The IFN-λ exposed pDC are administered back into the patient. The present invention also provides a method of ex vivo IFN-λ treatment of pDC, in conjunction with co-administration of a composition comprising IFN-λ.11-03-2011
20130115197Amnion-derived cell compositions, methods of making and uses thereof - The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies.05-09-2013
20130115196HYBRID HYDROGEL SCAFFOLD COMPOSITIONS AND METHODS OF USE - The present invention includes new hybrid hydrogel scaffolds comprised of a polyoxyethylene-polyoxypropylene (block) copolymer (a “poloxamer”) and a self-assembling peptide, which maintain the mechanical and bioactive properties of its individual constituents (as compared to when the individual constituents are scaffolds or hydrogels by themselves). The hydrogels of the invention can include a combination of materials from different origins or with different properties that provides a hybrid material that meets the multiple needs of a scaffold for tissue engineering.05-09-2013
20130095077Somatic Stem Cells - A somatic stem cell that is CD10+, CXCR4+, and CD31+ and another somatic stem cell that is CD 105+, CD44+, and nestin+. Also disclosed are both a method of preparing these stem cells and a method of using them to treat degenerative diseases, e.g., a muscle-degenerative disease. The invention further includes making and using liver cells derived from the somatic cell that is CD105+, CD44+, and nestin+.04-18-2013
20130095080COMPOSITIONS AND METHODS FOR PROVIDING HEMATOPOIETIC FUNCTION - The present invention relates to methods and compositions for providing hematopoietic function to human patients in need thereof, by selecting a pool of expanded human cord blood stem/progenitor cell samples for administration to the patient, wherein the samples in the pool collectively do not mismatch the patient at more than 2 of the HLA antigens or alleles typed in the patient; and administering the selected pool of expanded human cord blood stem/progenitor cell samples to the patient. Methods for obtaining the pools of expanded human cord blood stem/pro-genitor cell samples, banks of frozen pools of expanded human umbilical cord blood stem/progenitor cell samples, and methods for producing such banks are also provided herein.04-18-2013
20130095078METHODS FOR REGENERATING SKELETAL MUSCLE - An engineered muscle construct in the form of a braided collagen microthread scaffold is provided. The microthread scaffold can be used with or without cells as engineered skeletal muscle. The microthread scaffold can also be used to promote cell attachment and growth to deliver cells to a large muscle defect to stimulate muscle regeneration. Methods for making a muscle construct, seeding cells onto microthread scaffolds and treating muscle defects are also provided.04-18-2013
20130095079COMPOSITIONS AND METHODS FOR PROVIDING HEMATOPOIETIC FUNCTION WITHOUT HLA MATCHING - The present invention relates to methods and compositions for providing hematopoietic function in immunodeficient human patients, by selecting an expanded human umbilical cord blood stem/progenitor cell sample without taking into account the HLA-type of the expanded human cord blood stem/progenitor sample or the HLA-type of the patient; and administering the selected expanded human cord blood stem/progenitor cell sample to the patient. Methods for obtaining the expanded human cord blood stem/progenitor cell samples, banks of frozen expanded human cord blood stem/progenitor cell samples, and methods for producing such banks are also provided herein.04-18-2013
20130095075BONE MORPHOGENIC PROTEIN BINDING PEPTIDE - A cyclized peptide designated BMP Binding Peptide (BBP) is a synthetic peptide that avidly binds rhBMP-2. BBP increases the overall osteogenic activity of rhBMP-2, increases the rate at which rhBMP-2 induces bone formation, and BBP induces calcification alone. Compositions and substrates including BBP, and methods of using BBP are useful in therapeutic, diagnostic and clinical applications requiring calcification and osteogenesis.04-18-2013
20130095076Methods For Increasing Blood Flow And/Or Promoting Tissue Regeneration - Methods for increasing blood flow and/or regenerating tissue using compounds which bind to the chemokine receptor CXCR4 are disclosed. Preferred embodiments of such compounds are of the formula04-18-2013
20130095081COMPOSITIONS AND METHODS OF TREATMENT WITH STEM CELLS - The disclosure of the present application provides compositions and methods of treatment with stem cells. In at least one embodiment of a method for treating a patient with an insulin-related disorder, the method comprises the step of administering a cell-based composition to a patient with an insulin-related disorder to treat the insulin-related disorder, the cell-based composition comprising at least one mammalian stem cell and optionally at least one islet cell, the at least one mammalian stem cell capable of prolonging an effective life of the at least one islet cell.04-18-2013
20130101564METHOD FOR PREPARING DERMIS TISSUE CELLS AGGREGATION AND USES THEREOF - Dermis tissue cell aggregation, which comprises isolated dermis tissue cells with biological activity, is provided. The isolated dermis tissue cells are preserved in a mixed solution consisting of an isotonic saline solution for medical use, an anticoagulant, a nutrient for cells and a cell growth promoter, and a non-fluidity dermis tissue cell aggregation with adhesion is formed after several processes. A method for preparing the dermis tissue cell aggregation and the use thereof in preparing medicines for repairing scars are provided.04-25-2013
20130101561CLOSED SYSTEM SEPARATION OF ADHERENT BONE MARROW STEM CELLS FOR REGENERATIVE MEDICINE APPLICATIONS - A method for isolating and processing bone marrow derived stem cells, including the steps of: (a) collecting a biological sample containing adherent bone marrow stem cells in a receptacle with interior walls coated with a cell-adherent substrate; (b) incubating the bone marrow cells on the adherent substrate so that a layer of adherent bone marrow stem cells adheres to the substrate; (c) washing any non-adherent cells from the substrate; and (d) collecting the bone marrow stem cell layer. Isolation kits and use of bone marrow cells harvested for cell therapies are also described.04-25-2013
20130101563Compositions for Regenerating Defective or Absent Myocardium - Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.04-25-2013
20130115198HAIR FOLLICLE MESENCHYMAL STEM CELLS AND USE THEREOF - The present invention relates to a method for isolating hair follicle mesenchymal stem cells and to the use thereof for therapy and prophylaxis as well as for cosmetic treatments.05-09-2013
20130121969BIODEGRADABLE POLYURETHANE/UREA COMPOSITIONS - The present invention relates to biocompatible, biodegradable polyurethane/urea polymeric compositions that are capable of in-vivo curing with low heat generation to form materials suitable for use in scaffolds in tissue engineering applications such as bone and cartilage repair. The polymers are desirably flowable and injectable and can support living biological components to aid in the healing process. They may be cured ex-vivo for invasive surgical repair methods, or alternatively utilized for relatively non-invasive surgical repair methods such as by arthroscope. The invention also relates to prepolymers useful in the preparation of the polymeric compositions, and to methods of treatment of damaged tissue using the polymers of the invention.05-16-2013
20130121970METHOD FOR ELIMINATION OF SPACE THROUGH TISSUE APPROXIMATION - Acellular tissue matrix compositions for use in tissue approximation are provided. Also provided are methods for making and using the compositions to approximate tissue.05-16-2013
20130129689AGENT DERIVED FROM TORTOISE SPLEEN STIMULATING MAMMALIAN HEMOPOIESIS - The present invention relates to a proteinaceous extract derived from tortoise spleen and to a tetrapeptide FTGN, which have stimulatory activity on hematopoietic cells. In particular, this tetrapeptide enhances hemopoietic reconstruction, and bone marrow re-population, reduced as a consequence of a high dose of radiation or chemotherapy exposure. The invention further provides pharmaceutical compositions comprising as an effective ingredient the proteinaceous extract or the FTGN tetrapeptide and ex vivo and in vivo methods of treatment employing them.05-23-2013
20130129691Compositions For The Treatment Of Skin Conditions, Disorders Or Diseases And Methods Of Making And Using The Same - The present invention includes methods and compositions designed for treating a subject suffering from a skin condition, disorder or disease. The compositions include undifferentiated fetal skin cells that are either integrated with a collagen matrix or a carrier.05-23-2013
20130129690Compositions for Regenerating Defective or Absent Myocardium - Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.05-23-2013
20130129688Assay for the Prediction of Therapeutic Effectiveness or Potency of Mesenchymal Stem Cells, and Methods of Using Same - The invention relates to assays for testing the therapeutic effectiveness of mesenchymal stem cell (MSC) populations by determining the number of GT repeats in the heme oxygenase-1 (HO-1) promoter region of both alleles.05-23-2013
20130129687Generation of Lineage-Restricted Progenitor Cells from Differentiated Cells - Method for reprogramming differentiated cells into lineage restricted progenitor cells is provided. The method may include contacting differentiated cells with inhibitors of tyrosine phosphatases and apoptosis to de-differentiate differentiated cells into lineage restricted progenitor cells.05-23-2013
20130129686Reducing Inflammation Using Cell Therapy - The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component, including graft-versus-host disease. The invention is generally directed to reducing inflammation by administering cells that express and/or secrete prostaglandin E2 (PGE2). The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to express and/or secrete PGE2, such as PGE2 receptor agonists. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired levels of PGE2 expression and/or secretion. The invention is also generally directed to delivering cells directly to lymphohematopoietic tissue, such as spleen, lymph nodes, and bone marrow. The invention is, thus, also directed to a method for treating inflammation by administering cells directly into sites of lymphohematopoiesis, such as spleen, lymph nodes, and bone marrow. The administered cells include those that reduce the activation and/or proliferation of T-cells. Such cells may or may not express and/or secrete PGE2.05-23-2013
20090022696METHODS FOR IMMORTALIZING CELLS - The present invention provides methods for immortalizing precursor cells that are non-terminally differentiated cells such as stem cells, said methods comprising culturing the precursor cells in the presence of a Notch agonist and one or more growth factors that support the proliferation but not differentiation of the non-terminally differentiated cells. The present invention further provides methods to induce the differentiation of immortalized cells, comprising growing the cells in the presence of a Notch agonist and at least one growth factor which supports the differentiation of the cell into a more specialized cell type. The immortalized and/or differentiated cells of the invention can be used to repopulate cell populations that have been diminished, for example as a result of infection or exposure to certain drugs. The invention further provides a cell culture comprising a population of non-terminally differentiated cells immortalized by the methods of the present invention and kits comprising reagents that promote the immortalization of precursor cells. The invention further provides methods for screening for Notch modulators and for identifying genes involved in processes of cellular differentiation.01-22-2009
20130142761Method of Enhancing Hematopoietic Cell Transplantation - The invention relates to a method for enhancing the transplantation of hematopoietic cells to supplement or fully reconstitute the hematopoietic system. The method involves administering cells expressing CD34 and co-expressing HoxB4, wherein the HoxB4 is expressed at levels that provide therapeutically effective amounts of self-renewal of the administered cells. The method also involves administering cells expressing CD34 but not co-expressing HoxB4 or co-expressing HoxB4 in amounts so as to provide therapeutically effective amounts of differentiation of the administered cells into the various progeny cells of the hematopoietic system. To provide such cells to a subject, the invention relates to detecting such cells prior to treatment to ascertain whether such cells are present in clinically relevant amounts.06-06-2013
20130142762METHODS OF CARDIAC REPAIR - Provided herein is a new method to isolate and expand cardiac progenitor/stem cells from a placenta, which produces a cell population enriched in multipotent functional progenitor/stem cells. Cardiac progenitor/stem cells isolated by this method maintain their self-renewal character in vitro and differentiate into normal cells in myocardium, including cardiomyocytes, endothelial cells, and smooth muscle cells, after transplantation into ischemic hearts. Also provided in this application are substantially pure populations of multipotent cardiac progenitor/stem cells, and their use to treat and prevent diseases and injuries, including those resulting from myocardial infarction. A model for assessing the potential of cardiac stem cells for treatment of myocardial infarction is also provided.06-06-2013
20100278786USE OF THE OPPOSITE CELL DIFFERENTIATION PROGRAM (OCDP) FOR THE TREATMENT OF DEGENERATED ORGANS IN THE PATHOLOGICAL STATE - The present invention relates to a method for the treatment of organs which are degenerative and/or in the pathological state by means of the use of cells, which are phenotypically stably differentiating or differentiated but not necessarily ultimately predetermined with respect to development, from a donor organ selected according to the principles of the opposite cell differentiation program (OCDP) and also to the use of cells of this type for the treatment or for the production of a drug for treatment of the same. Furthermore, the present invention relates to pharmaceutical agents comprising suitable phenotypically stable cells, cells of a first organ which is different from the second organ with respect to organ type thereby being used, which, in the normal physiological state with respect to a predetermined set of expressed genes and/or phenotypical properties, have opposite properties to the second cells in the normal physiological state.11-04-2010
20100278784METHODS AND COMPOSITIONS FOR TREATING SKIN CONDITIONS - The invention features methods, kits, and compositions for treating aging-related skin conditions (e.g., wrinkles), pigmentation disorders, acne, and scar formation, as well as methods, kits, and compositions for preventing scar formation.11-04-2010
20090208462Methods of Treatment - The invention concerns the use of a nucleic acid encoding a photoactivator in the manufacture of a medicament for inducing photosensitivity in neuronal cells. In particular, the invention concerns the induction of photosensitivity in retinal ganglion cells (RGCs) for restoring sight and/or alleviating blindness in an individual. The invention further concerns vectors, cells and pharmaceutical compositions therefor.08-20-2009
20110217272TREATMENT OF RADIATION INJURY USING PLACENTAL STEM CELLS - The present invention provides a method of extracting and recovering embryonic-like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta. A placenta is treated to remove residual umbilical cord blood by perfusing an exsanguinated placenta, preferably with an anticoagulant solution, to flush out residual cells. The residual cells and perfusion liquid from the exsanguinated placenta are collected, and the embryonic-like stem cells are separated from the residual cells and perfusion liquid. The invention also provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate endogenous cells, including, but not limited to, embryonic-like stem cells. The invention also provides methods for propagation of exogenous cells in a placental bioreactor and collecting the propagated exogenous cells and bioactive molecules therefrom.09-08-2011
20080199441Use of ex-vivo cultured hematopoietic cells for treatment of peripheral vascular diseases - Methods for cell therapy of peripheral vascular disease by local administration of ex-vivo cultured hematopoietic cells are provided.08-21-2008
20080199440Tissue Repair Using Allogenic Dermal Fibroblasts - The present invention provides a method for the repair of subcutaneous or dermal tissue in a subject, comprising in one aspect the injection of a suspension of allogeneic dermal fibroblasts into the subject. By injecting a suspension of allogeneic cells, the invention provides, for example, long-term augmentation of the subadjacent tissue without the disadvantages that accompany the preparation and/or use of presently available materials such as autologous fibroblasts cells or collagen. According to a first aspect of the invention there is provided a method for the augmentation of subcutaneous or dermal tissue in a subject, which method comprises the steps of: (i) providing a suspension of allogeneic dermal fibroblasts; and (ii) injecting an effective volume of the suspension into tissue subadjacent to the subcutaneous or dermal tissue so that the tissue is augmented. The method is preferably cosmetic.08-21-2008
20080199439IAP-binding cargo molecules and peptidomimetics for use in diagnostic and therapeutic methods - The present invention features peptides, peptidomimetics and methods of their use for binding to Inhibitor of Apoptosis Proteins (IAPs) in cells and prevents the IAP's from exerting their apoptosis-suppressing function with caspases in the cell. An IAP binding cargo molecule having a binding portion mimicking the structural and biological features of the Smac amino-terminal tetrapeptide that is capable of relieving XIAP-mediated suppression of apoptosis in mammalian cells, and a cargo portion with a functional group having a detectable property or therapeutic function is disclosed.08-21-2008
20080199438Methods For Suppressing Tumor Proliferation - The present invention provides methods for suppressing tumor proliferation comprising the step of inhibiting the expression of PDGF-A or the binding between PDGF-A homodimers and PDGFRα. Activation of the PDGFRα-p70S6K signal transduction pathway by PDGF-AA is an important factor in tumor angiogenesis and relates to the prognosis of patients suffering from tumors. By inhibiting PDGF-A expression in tumors or in their surrounding tissues, or by inhibiting the binding between PDGF-A homodimers and PDGFRα, the formation and retention of tumor vasculature can be inhibited, thereby suppressing tumor proliferation.08-21-2008
20080199437Lrp4/Corin Dopaminergic Neuron Progenitor Cell Markers - The present invention relates to polynucleotide probes and antibodies for detecting Lrp4/Corin dopaminergic neuron progenitor cell markers, which enable the efficient separation of dopaminergic neuron progenitor cells; and methods for selecting the progenitor cells by the use thereof.08-21-2008
20110223142METHODS AND COMPOSITIONS FOR SOFT TISSUE REPAIR - Compositions and methods for tissue repair are provided including cell binding peptides and growth factor binding peptides. The cell binding peptides bind to one or more of stem cells, fibroblasts, or endothelial cells. The growth factor binding peptides include platelet derived growth factor (PDGF) binding peptides and growth differentiation factor (GDF) binding peptides. The tissue for repair includes tendon, muscle, connective tissue, ligament, cardiac tissue, vascular tissue, or dermis. Implantable devices for tissue repair are provided to which the cell and growth factor binding peptides are attached, such as acellular extracellular matrix having attached binding peptide.09-15-2011
20110223140METHOD FOR DIFFERENTIATION INTO RETINAL CELLS FROM STEM CELLS - Disclosed is a method for inducing stem cells to differentiate into retinal cells at high yield within a short period of time, without gene implantation and co-culture with retinal tissues, by implementing a differentiation process similar to the in vivo embryonic development in chemically defined conditions. Also, retinal cells including the photoreceptor cells and their progenitor cells, and various types of other retinal cells, generated according to the method, are disclosed. A composition comprising the retinal cells and a method are provided for treating retinal degeneration-related diseases. The differentiated photoreceptor cells, when transplanted into degenerated or injured retinas, can be engrafted and fused within the retinas to prevent or cure retinal degeneration.09-15-2011
20110229443Composition for Cancer Prevention or Treatment Containing as Active Ingredient Plant Stem Cell Line Dervied from Cambium of Panax Ginseng Including Wild Ginseng or Ginseng - The present invention relates to a composition for preventing or treating cancer, which contains, as an active ingredient, a 09-22-2011
20110229442Cells exhibiting neuronal progenitor cell characteristics and methods of making them - Disclosed are cells exhibiting neuronal progenitor cell characteristics, and methods of making them from marrow adherent stem cells by regulating cellular pathways in the marrow adherent stem cells that are associated with glial transdifferentiation of the marrow adherent stem cells.09-22-2011
20110243902METHOD FOR TREATING OR PREVENTING A PANCREATIC DYSFUNCTION - The present invention provides a method for improving pancreatic function in a subject in need thereof, the method comprising administering to the subject STRO-110-06-2011
20110243901Compositions and Methods for the Treatment of Lysosomal Storage Disorders - The present invention relates to methods for providing lysosomal enzymes to a subject by administering stem cells, preferably Multipotent Adult Progenitor Cells (MAPCs). The invention further relates to methods for treating lysosomal storage disorders by administering stem cells.10-06-2011
20110243899Wnt Signaling Inhibitor Comprising Insulin-Like Growth Factor-Binding Protein - Provided is a novel soluble factor that modulates morphogenesis and cell proliferation, such as cardiac development and/or cardiomyocyte differentiation. Specifically provided are: an inhibitor of Wnt signalling, comprising an insulin-like growth-factor-binding protein (IGFBP), the protein being binding to a Wnt receptor, and/or a polynucleotide encoding the protein; a medicament for prevention and/or treatment of a disease due to enhanced Wnt signalling, comprising the inhibitor of Wnt signalling, and a medicament for induction of cardiomyocyte differentiation; and a method for prevention and/or treatment of a disease due to enhanced Wnt signalling and a method of inducing cardiomyocyte differentiation, the methods each comprising using the inhibitor of Wnt signalling, and a cardiomyocyte, which is obtained by the method of inducing cardiomyocyte differentiation, and a use thereof.10-06-2011
20110243898SOMATIC CELL-DERIVED PLURIPOTENT CELLS AND METHODS OF USE THEREFOR - Provided are methods for producing a reprogrammed fibroblast. The methods can include growing a plurality of fibroblasts in monolayer culture to confluency; and disrupting the monolayer culture to place at least a fraction of the plurality of fibroblasts into suspension culture under conditions sufficient to form one or more embryoid body-like spheres, wherein the one or more embryoid body-like spheres comprise one or more reprogrammed fibroblasts that express one or more markers not expressed by a fibroblast growing in the monolayer culture prior to the disrupting step. Also provided are reprogrammed fibroblasts produced by the disclosed methods, formulations that include reprogrammed fibroblasts, and methods for treating an injury to a tissue in a subject by administering to a subject in need thereof a composition of reprogrammed fibroblast cells in a pharmaceutically acceptable carrier.10-06-2011
20130149288METHODS OF GENERATING OLIGODENDROCYTES AND CELL POPULATIONS COMPRISING SAME - A method of generating a population of cells useful for treating a brain disorder in a subject is disclosed. The method comprises contacting mesenchymal stem cells (MSCs) with at least one exogenous miRNA having a nucleic acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 15-19 and 27-35, thereby generating the population of cells and/or generating neurotrophic factors that may provide important signals to damaged tissues or locally residing stem cells. MSCs differentiated by miRs may also secrete miRs and deliver them to adjacent cells and therefore provide important signals to neighboring endogenous normal or malignant cells.06-13-2013
20110250184METHODS FOR DETERMINING EFFICACY OF A THERAPEUTIC REGIMEN AGAINST DELETERIOUS EFFECTS OF CYTOTOXIC AGENTS IN HUMAN - The invention provides drug screening methods and methods for determining efficacy of a therapeutic regimen in humans. In particular, the invention provides screening methods to determine efficacy of a therapeutic regimen to protect human subjects from deleterious effects of cytotoxic agents. The inventive method comprises i) extracting target cells from the human subject prior to exposure to a cytotoxic agent, ii) treating the subject with a cytotoxic protective drug; iii) extracting the target cells from the subject after treatment with the cytotoxic protective drug of step ii); iv) exposing the target cells of steps i) and iii) to the cytotoxic agent; and v) analyzing and comparing one or more parameters indicative of viability and growth conditions in target cells of step i) and step iii), wherein a favorable viability and growth condition of the target cells of step iii) as compared to target cells of step i) is indicative of the efficacy of the therapeutic regimen in the human subject.10-13-2011
20110256111ISOLATED MULTIPOTENT MESENCHYMAL STEM CELL FROM HUMAN ADULT GLOMERULI (HGL-MSC), A METHOD OF PREPARING THEREOF AND USES THEREOF IN THE REGENERATIVE MEDICINE OF THE KIDNEY - The invention relates to an isolated multipotent glomerular mesenchymal stem cell derived from adult human kidney (hGL-MSC), which is characterised by the marker profile CD13310-20-2011
20110256107TREATMENT OF BRAIN DAMAGE USING UMBILICAL CORD BLOOD CELLS - The invention relates to the treatment of chronic stroke, traumatic brain injury, and neurodegenerative disorders using umbilical cord blood cells.10-20-2011
20110256106Methods and Compositions for Treating Intervertebral Disc Degeneration - A fluid matrix comprising cross-linked remodelable collagen from a donor vertebrate animal is useful for regenerating hydrodynamic function in damaged intervertebral discs in vivo. The matrix may be injectable and may comprise cells and a plurality of purified cell growth factors. The matrix promotes cell growth and elaboration of proteoglycans to facilitate regeneration of native tissues. The collagen in the matrix may be cross-linked using photooxidative catalysis and visible light, and purified cell growth factors are preferably at least partly bone-derived.10-20-2011
20110256105CARDIAC STEM CELL AND MYOCYTE SECRETED PARACRINE FACTORS - The invention relates to secreted proteins from cardiac stem cells (cardiospheres and cardiosphere-derived cells) or myocytes for diagnostic and/or therapeutic use.10-20-2011
20130095083Method For Controlling And Accelerating Differentiation Of Stem Cells Using Graphene Substrates - The invention relates to methods for directing differentiation of stem cells comprising graphene. In additional embodiments, the invention relates to methods for repairing and improving bone tissue functions comprising accelerating differentiation in stem cell growth by exposing stem cells to graphene and transplanting the graphene with the exposed stem cells in the tissue at the site of repair.04-18-2013
20130149286METHODS FOR OBTAINING STEM CELLS - The present invention relates to methods for obtaining stem cells from mammalian cadavers, methods for obtaining or purifying stem cells from a sample likely to contain non-stem cells, methods of regeneration of injured tissues and methods of treatment.06-13-2013
20130149285ADIPOSE TISSUE-DERIVED STEM CELLS FOR VETERINARY USE - The invention provides for compositions and methods for making and using adipose-derived stem cells for treating non-human mammals for various medical conditions. In particular, the invention provides methods and compositions useful for repair of bone fractures, and for treatment of “dry eye” conditions, acute renal failure, and chronic renal failure in non-human mammals.06-13-2013
20120276070Induced Pluripotent Stem Cells and Related Methods - The present invention provides materials and methods to reprogram adult stem cells without transfection of foreign genes through the employment of appropriate environmental factors. Cells made via these processes are also provided. Methods to use the pluripotent cells are also provided.11-01-2012
20120276069HYDROGELS BASED ON POLYMERS OF DEXTRAN TYRAMINE AND TYRAMINE CONJUGATES OF NATURAL POLYMERS - The invention relates to composition comprising a dextran-tyramine conjugate and a conjugate selected from the group consisting of chondroitin sulphate-tyramine, collagen-tyramine, chitosan-tyramine, chitosan-phloretic acid, gelatine-tyramine, heparan sulphate-tyramine, keratin sulphate-tyramine, hyaluronic acid-tyramine and heparin-tyramine.11-01-2012
20120276068METHOD FOR TREATING CHRONIC NERVE TISSUE INJURY USING A CELL THERAPY STRATEGY - A method for treating a degenerative or traumatic injury to a nerve tissue or the brain by administering at or near the injury site a composition containing adherent bone marrow stem cells suspended in a pharmaceutically acceptable liquid in an amount effective to elicit axonal regeneration or re-myelination at the site of injury.11-01-2012
20120276067Assay for the Prediction of Therapeutic Effectiveness of Mesenchymal Stromal Cells, and Methods of Using Same - The invention relates to assays for testing the therapeutic effectiveness of mesenchymal stromal cell (MSC) populations and methods of treating pathologies with passaged and/or frozen and thawed MSC populations.11-01-2012
20120276066Peptide Linked Cell Matrix Materials for Stem Cells and Methods of Using the Same - Biostructures that comprises modified alginates entrapping one or more stem cells are discloses. The modified alginates comprise at least one alginate chain section to which is bonded by covalent bonding at least one cell attachment peptide. Pluralities of stem cells are also disclosed. Methods of preventing death of stem cells and cells differentiated there from are disclosed. Methods of preparing a plurality of stem cells are disclosed. Methods of treating an individual who has a degenerative disease, such as a neurological disorder, or injury involving nerve damage by administering stem cells to said individual are disclosed.11-01-2012
20120276065Dendritic Cell Populations that are Enriched for Cells that Bear the BDCA-1 Antigen - The invention provides antigen-binding fragments specific for dendritic cells and effective in treatment and/or diagnosing a variety of disorders. Methods of use are also provided as are methods for screening for additional such antigen-binding fragments and the products obtained thereby.11-01-2012
20120276064METHODS AND COMPOSITIONS FOR REJUVENATION AND EXPANSION OF STEM CELLS - The regenerative potential of stem cells is enhanced in vitro and in vivo by inhibition of the p38 MAPK signaling pathway.11-01-2012
20120276063PRIMING OF PLURIPOTENT STEM CELLS FOR NEURAL DIFFERENTIATION - Methods and composition for differentiation of pluripotent stem cells are provided. For example, in certain aspects methods including priming stem cells for neural differentiation in a culture medium essentially free of growth factors such as FGF and TGFβ. As an advantage, the neural cells may be provided with improved consistency and purity.11-01-2012
20120276062METHODS FOR TREATING ISCHEMIC TISSUE - Compositions and methods for treating ischemic tissue are provided herein.11-01-2012
20120276061CD117+ Cells and Uses Thereof - The present invention provides compositions comprising CD117+ cells and methods for using the same in allograft. In some aspects of the invention, methods are provided for prolonging allograft survival in a subject by administering CD117+ cells.11-01-2012
20130149284METHODS OF PRODUCING HUMAN RPE CELLS AND PHARMACEUTICAL PREPARATIONS OF HUMAN RPE CELLS - The present invention provides improved methods for producing retinal pigmented epithelial (RPE) cells from human embryonic stem cells, human induced pluripotent stem (iPS), human adult stem cells, human hematopoietic stem cells, human fetal stem cells, human mesenchymal stem cells, human postpartum stem cells, human multipotent stem cells, or human embryonic germ cells. The RPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The RPE cells described herein are useful for treating retinal degenerative conditions including retinal detachment and macular degeneration.06-13-2013
20100291046Equine Progenitor Cells - An isolated mammalian progenitor cell or its progeny, isolated from articular cartilage, is disclosed. Further is disclosed an equine progenitor cell isolated from the surface zone of equine articular cartilage tissue and uses thereof. Also disclosed are a method of tissue repair, a medicament, and a method of treating mammalian cartilage damage using such progenitor cells or progeny.11-18-2010
20100291045DYNAMIC VIBRATIONAL METHOD AND DEVICE FOR VOCAL FOLD TISSUE GROWTH - Dynamic vibrational methods and devices for inducing differentiation of stem cells into vocal fold fibroblast-like cells or for generating vocal fold-like tissue from cultured cells. Also provided are matrices providing sustained release of growth factors, and bioreactors generating and delivering a high frequency vibration with in-plane shear stress to cultured cells.11-18-2010
20130121975USE OF MESENCHYMAL STEM CELLS FOR COMPLETELY REPOPULATING HOST TISSUE - A method of treating a genetic disease or disorder such as, for example, cystic fibrosis, Wilson's disease, amyotrophic lateral sclerosis, or polycystic kidney disease, in an animal comprising administering to said animal mesenchymal stem cells in an amount effective to treat the genetic disease or disorder in the animal.05-16-2013
20100316614COMPOSITIONS AND METHODS FOR URINARY BLADDER REGENERATION - The present invention provides compositions and methods for the regeneration of tissue. In particular, the present invention provides mesenchymal stem cells (MSCs) and endothelial progenitor cells (EPCs) for bladder regeneration.12-16-2010
20100316613FEEDER CELL-FREE CULTURE MEDIUM AND SYSTEM - A cell culture medium and system are provided which eliminates or at least reduces the need for feeder cells. The cell culture medium comprises one or more factors that are normally secreted and/or produced by a feeder cell and a synthetic chimeric protein comprising IGF-I and a portion of vitronectin. The cell culture medium is particularly suitable for propagating human embryonic stem cells and keratinocytes. This invention also relates to compositions and methods which utilize the cells cultured in the cell culture medium of the invention.12-16-2010
20100316612PRIMED CELL THERAPY - The subject invention is directed to a composition comprising primed connective tissue cells and a pharmaceutically acceptable carrier thereof.12-16-2010
20090304647Production of Neural Stem Cells from Bone Marrow Tissue and Use Thereof - The invention provides reagents and methods for preparing mammalian mesenchymal-derived neural stem cells, especially autologous mesenchymal-derived neural stem cells, compositions thereof, and methods for using and administering the cells in a patient in need thereof.12-10-2009
20130156741Bone Augmentation Utilizing Muscle-Derived Progenitor Compositions, And Treatments Thereof - The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment non-soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of non-soft tissue (e.g. bone). Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, bone tissues in the treatment of various functional conditions, including osteoporosis, Paget's Disease, osteogenesis imperfecta, bone fracture, osteomalacia, decrease in bone trabecular strength, decrease in bone cortical strength and decrease in bone density with old age.06-20-2013
20130156742Scaffold-Free Three Dimensional Nerve Fibroblast Constructs - The invention relates to scaffold-free three dimensional nerve fibroblast constructs and method of generating the nerve fibroblast constructs. The invention also relates to methods or repairing nerve transection and replacing damaged nerve tissue using the nerve fibroblast constructs of the invention.06-20-2013
20130156743VITRO HEPATIC DIFFERENTIATION - This invention relates to the induction of hepatic differentiation by culturing induced pluripotent stem (iPS) cells in an endoderm induction medium to produce a population of anterior definitive endoderm (ADE) cells and then culturing the population of ADE cells in a hepatic induction medium to produce a population of hepatic progenitor cells, which may be optionally differentiated into hepatocytes. The endoderm induction medium is a chemically defined medium which has fibroblast growth factor activity, stimulates SMAD2 and SMAD3 mediated signalling pathways and SMAD1, SMAD5 and SMAD9 mediated signalling pathways, and inhibits phosphatidylinositol 3-kinase (PI3K) and glycogen synthase kinase 3β (GSK3β); and the hepatic induction medium is a chemically defined medium which stimulates SMAD2 and SMAD3 mediated signalling pathways. These methods may be useful, for example, in producing hepatocytes and hepatic progenitor cells for cell-based therapies or disease modelling.06-20-2013
20130156744METHODS OF RECELLULARIZING A TISSUE OR ORGAN FOR IMPROVED TRANSPLANTABILITY - Described herein are methods of recellularizing an organ or tissue matrix.06-20-2013
20130183272MESENCHYMAL STROMAL CELLS AND USES RELATED THERETO - The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and method sof treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies.07-18-2013
20130183273NATIVE WHARTON'S JELLY STEM CELLS AND THEIR PURIFICATION - Noncultured Wharton's Jelly stem cells and methods of their purification, storage and use are provided.07-18-2013
20130183274MAINTENANCE AND PROPAGATION OF MESENCHYMAL STEM CELLS - Various embodiments of the present invention include compositions, materials and methods for maintaining and propagating mammalian mesenchymal stem cells in an undifferentiated state in the absence of feeder cells and applications of the same.07-18-2013
20130183275Novel Use of Cryptotanshinone - Provided are a composition for stimulating differentiation of MSCs into osteoblasts, which includes cryptotanshinone, and an osteogenesis stimulator including cryptotanshinone and MSCs.07-18-2013
20100034783Medical kit and using method thereof - An aseptic/sterile medical kits are comprising a cartilage regeneration kit, a bone regeneration kit or an umbilical cord blood storage kit in a configuration that each process performs according to functionally-specialized kit sets for each step, via division of overall processes into corresponding steps for isolation, culture, collection and storage of cells, and implantation of desired cells into target sites of the body. The cartilage is regenerated by cartilage tissue collection; chondrocyte isolation; chondrocyte medium change and subculture; preparation of chondrocyte therapy product; media for isolation/culture/preparation/cryopreservation of cells; and media for isolation/culture/cryopreservation of cells, using the cartilage regeneration kit. The bone is regenerated by bone marrow collection; osteoblast isolation; osteoblast medium change and subculture; and preparation of osteoblast therapy product, using the bone regeneration kit. Additionally, the umbilical cord blood is stored by umbilical cord blood collection; hematopoietic stem cell isolation; and cryopreservation of hematopoietic stem cells, using the umbilical cord blood storage kit.02-11-2010
20110293582METHODS FOR ENHANCING HEMATOPOIETIC STEM/PROGENITOR CELL ENGRAFTMENT - Described herein are methods for enhancing engraftment of hematopoietic stem and progenitor cells using farnesyl compounds identified using a zebrafish model of hematopoietic cell engraftment. The compounds can be used to treat hematopoietic stem cells ex vivo prior to transplantation of the cells. Alternatively, the compounds can be administered to an individual undergoing cell transplantation.12-01-2011
20110293579Bi-specific fusion proteins - Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.12-01-2011
20110293578Use of Stem Cells to Prevent Neuronal Dieback - The invention is generally directed to treatment of neuronal injury. In particular, the invention is directed to reducing axonal retraction (“dieback”) that occurs as a result of the interaction of activated macrophages with dystrophic axons that are produced during nervous system acute or chronic injury. The invention is also directed to promoting axonal growth/regeneration. The invention is specifically directed to using stem cells or their secreted cellular factors, such as would be produced in conditioned cell culture medium, to ameliorate or prevent axonal dieback and/or promote growth/regeneration of axons.12-01-2011
20110311497Cell Suspension Preparation Technique and Device - The present invention provides for methods and devices suitable for producing a transplantable cellular suspension of living tissue suitable for grafting to a patient. In applying the method and/or in using the device, donor tissue is harvested, subjected to a cell dissociation treatment, cells suitable for grafting back to a patient are collected and dispersed in a solution that is suitable for immediate dispersion over the recipient graft site.12-22-2011
20110311496MESENCHYMAL STEM CELLS AND USES THEREFOR - The present technology provides compositions of mesenchymal stem cells for promoting wound healing or fracture healing and methods of promoting wound healing or fracture healing comprising the steps of administering mesenchymal stem cells in an effective amount.12-22-2011
20110311495ISOLATED POPULATIONS OF RENAL STEM CELLS AND METHODS OF ISOLATING AND USING SAME - Isolated populations of fetal renal stem cells and progenitor cells are provided. Also provided are methods of generating and using these isolated populations of cells.12-22-2011
20110311494METHODS OF REPROGRAMMING RENAL CELLS - A method of reprogramming a differentiated renal cell towards a progenitor phenotype is disclosed. The method comprises up-regulating in the differentiated renal cell an expression of at least one pluripotency associated gene and/or at least one renal stem cell associated gene, thereby reprogramming the differentiated renal cell towards a progenitor phenotype. Cell populations generated thereby and uses thereof are also disclosed.12-22-2011
20110311493METHODS FOR STABILIZING A BIOPROSTHETIC TISSUE BY CHEMICAL MODIFICATION OF ANTIGENIC CARBOHYDRATES - Methods are provided herein for modifying antigenic carbohydrate epitopes within a xenographic bioprosthetic tissue by oxidation of vicinal diols to form aldehydes or acids and subsequence reductive amination of aldehydes to form stable secondary amines, or amidation or esterification of acids to form stable amides or esters. Advantageously, methods provided herein mitigate the antigenicity of the bioprosthetic tissue while leaving the overall tissue structure substantially undisturbed, and thereby enhance the durability, safety and performance of the bioprosthetic implant.12-22-2011
20110311492MAINTENANCE/EXPANSION OF HSC's - The invention is related to methods for culturing stem cells, more particularly hematopoietic stem cells (HSC). The invention relates to methods for HSC maintenance and/or expansion through the use of soluble factors. The invention is also directed to cells produced by the methods of the invention. The cells are useful, among other things, for treatment of disorders or diseases (e.g. leukemia). The invention also relates to the development of small molecules that may increase HSC self renewal in vitro and in vivo.12-22-2011
20110311491TREATMENT OF SARCOIDOSIS USING PLACENTAL STEM CELLS - Provided herein are compositions and methods of treating individuals having sarcoidosis or a sarcoidosis-related disease or disorder, using placental cells, e.g., the placental stem cells and placental multipotent cells (PDACs) described herein. Also provided herein are kits comprising said cells or a composition thereof.12-22-2011
20130189233METHOD FOR USING DIRECTING CELLS FOR SPECIFIC STEM/PROGENITOR CELL ACTIVATION AND DIFFERENTIATION - A method is provided, including obtaining a population of isolated immature antigen-presenting cells; enriching a population of isolated stem/progenitor cells within a larger population of cells; activating the population of immature antigen-presenting cells; and following the activating, inducing at least one process selected from the group consisting of: differentiation, expansion, activation, secretion of a molecule, and expression of a marker, by exposing the enriched stem/progenitor cell population to the population of activated antigen-presenting cells. Inducing the at least one process includes generating a lineage specific precursor/progenitor population (LSP) from the enriched stem/progenitor cell population. In addition, (1) obtaining the population of immature antigen-presenting cells includes obtaining the population of immature antigen-presenting cells from umbilical cord blood, and/or (2) enriching the population of stem/progenitor cells includes obtaining the population of stem/progenitor cells from umbilical cord blood. Other applications are also described.07-25-2013
20130189234ULTRASONIC CAVITATION DERIVED STROMAL OR MESENCHYMAL VASCULAR EXTRACTS AND CELLS DERIVED THEREFROM OBTAINED FROM ADIPOSE TISSUE AND USE THEREOF - Methods of treating using adipose tissue using ultrasonic cavitation to dissociate the fat cells and blood vessels contained within adipose tissue and thereby obtain mesenchymal or stromal vascular fractions for use in human subjects are provided. These methods preferably do not include the use of any exogenous dissociating enzymes such as collagenase and result in increased numbers of the cells which constitute the mesenchymal or stromal vascular fractions (about 10-fold greater) than methods which use collagenase to isolate these cells.07-25-2013
20130189230INJECTABLE POLYMER COMPOSITION FOR USE AS A CELL DELIVERY VEHICLE - This invention provides a polymer composition comprising at least one thermal gelling polymer and at least one anionic polymer for cell delivery applications. These injectable polymer compositions are shear-thinning, thixotropic and resorbable. More specifically there is described a hyaluronan (HA) and methylcellulose (MC) based thermogelling cell delivery system (HAMC) that promotes cell survival both in vitro and in vivo. Importantly, HAMC (relative to media alone) enhances survival of transplanted stem/progenitor cells in the injured CNS. HAMC provides a minimally-invasive cell delivery strategy where the microenvironment can be further defined and the differentiation and regenerative capacity further explored. This hydrogel system has applications for minimally-invasive cell delivery to other tissues/organs in the body as well.07-25-2013
20130189231COMPOSITION FOR TREATMENT OF CARTILAGE DISEASE - The present invention provides a composition for regenerating cartilage or treating a cartilage disease containing a monovalent metal salt of alginic acid for which the endotoxin level thereof has been lowered to an extent that does not substantially induce inflammation or fever. As a result, it is possible to provide a composition for regenerating cartilage that improves cartilage regenerative action and ease of application to a cartilage injury lesion, and a composition for treating a cartilage disease, which has the effects of protecting cartilage from mechanical irritation, inhibiting degenerative changes in cartilage caused by wear and inflammation, repairing a cartilage injury lesion, and inhibiting inflammation and pain of joint tissue.07-25-2013
20130189232CELLULAR THERAPEUTIC AGENT FOR INCONTINENCE OR URINE COMPRISING STEM CELLS ORIGINATED FROM DECIDUA OR ADIPOSE - The present invention relates to a cellular therapeutic agent for treating urinary incontinence, and more particularly to a cellular therapeutic agent for treating urinary incontinence, which contains stem cells derived from the decidua of the placenta or menstrual fluid or stem cells derived from adipose. The decidua-derived stem cells or adipose-derived stem cells show the effects of increasing leak point pressure and urethral sphincter contractility, and thus are useful as an agent for treating urinary incontinence.07-25-2013
20130189235Methods of treating spinal cord injury and minimizing scarring - The invention is directed to methods of promoting the healing of spinal cord injury. The invention is further directed to methods of minimizing the extent of scarring following spinal cord injury. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), each alone or in combination with each other and/or other agents.07-25-2013
20110318312Rejuvenation or preservation of germ cells - Certain embodiments disclosed herein include, but are not limited to, at least one of compositions, methods, devices, systems, kits, or products regarding rejuvenation or preservation of germ cells or gametes. Certain embodiments disclosed herein include, but are not limited to, methods of modifying germ cells or gametes, or methods of administering modified germ cells or gametes to at least one biological tissue.12-29-2011
20120003192HYDROGEL-FORMING COMPOSITION COMPRISING PROTEIN AND NON-PROTEIN SEGMENTS - A hydrogel-forming composition is formed from a protein polymer derivative having a plurality of cross-linkable units depending therefrom, and a non-protein polymer derivative having a plurality of cross-linkable units depending therefrom, said non-protein polymer derivatives having hydrolysable units disposed between the polymer backbone of said derivative and at least some of said cross-linkable units. The use of a combination of protein and non-protein polymers provides for biodegradability of the hydrogel by hydrolysis of the hydrolysable units and/or enzymatic degradation of the proteins, along with mechanical properties such as strength and elasticity.01-05-2012
20120009156GERMLINE STEM CELL BANKING SYSTEM - Methods and systems are provided for the isolation, characterization, cryopreservation and banking of human germline stem cells and gonadal tissue. Also disclosed are methods for the transplanting of the cryopreserved cells to repopulate a sterile reproductive organ.01-12-2012
20120020937AUTOLOGOUS AND ALLOGENIC ADIPOSE-DERIVED STROMAL STEM CELL COMPOSITION FOR TREATING FISTULAS - The present invention relates to a method for producing clinically effective quantities of human adipose tissue-derived stromal cells for treating fistulas and a composition made with the same. The method of the present invention can efficiently produce clinically effective number of adipose tissue-derived stromal cells within a short period by improving conventional standard culturing methods. The adipose stem cells composition containing the adipose tissue-derived stromal cells obtained by the method of the present invention exhibit superior multipotency and immunomodulatory activity over those of a cell composition produced by conventional methods, and thus is more suitable for treating fistulas. The cell composition of the present invention has excellent clinical usages especially since immune response is suppressed in allogenic adipose-derived stem cells.01-26-2012
20120020936TREATMENT OF NEURODEGENERATIVE DISEASE USING PLACENTAL STEM CELLS - The present invention provides a method of extracting and recovering embryonic-like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta. A placenta is treated to remove residual umbilical cord blood by perfusing an exsanguinated placenta, preferably with an anticoagulant solution, to flush out residual cells. The residual cells and perfusion liquid from the exsanguinated placenta are collected, and the embryonic-like stem cells are separated from the residual cells and perfusion liquid. The invention also provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate endogenous cells, including, but not limited to, embryonic-like stem cells. The invention also provides methods for propagation of exogenous cells in a placental bioreactor and collecting the propagated exogenous cells and bioactive molecules therefrom.01-26-2012
20120020935CARDIAC STEM CELLS AND METHODS FOR ISOLATION OF SAME - Method for the isolation, expansion and preservation of cardiac stem cells from human or animal tissue biopsy samples to be employed in cell transplantation and functional repair of the myocardium or other organs. Cells may also be used in gene therapy for treating cardiomyopathies, for treating ischemic heart diseases and for setting in vitro models to study drugs.01-26-2012
20120020934MATERIALS AND METHODS FOR CRYOPRESERVED BONE CONSTRUCTS - The subject invention concern materials and methods for cryopreservation of HCG-cell constructs. In one embodiment, porous HCG scaffolds are provided in a perfusion bioreactor having perfusion chambers that can contain the HCG scaffolds, cells are then seeded in the HCG scaffolds in the perfusion bioreactor, cell culture media is perfused through and the bioreactor operated so as to allow for cell seeding and growth in the HCG scaffold. After a suitable period of time, the cell culture media is removed and the HCG containing cells (HCG-cell constructs) can be washed with a suitable buffer, such as phosphate-buffered saline (PBS). The HCG-cell constructs are then perfused in the bioreactor with a suitable cryopreservation fluid. The cryopreservant can comprise one or more of the following: DMSO, trehalose, glycerol, ethylene glycol, and serum for cell culture (e.g., fetal bovine serum (FBS)). In one embodiment, the HCG-cell constructs are perfused for a suitable period of time with cryopreservant fluid using transverse flow of the fluid in the bioreactor at a suitable flow rate. The HCG-cell constructs (or the perfusion chambers containing them) are then removed from the bioreactor and placed in a cryopreservant media and maintained at increasingly colder temperatures until temperatures reach about −80° C. The frozen HCG-cell constructs (or the chambers containing them) can then be stored at a suitable cryogenic temperature (e.g., in liquid nitrogen) until needed. When needed, frozen HCG-cell constructs can be removed from cold storage and thawed using suitable means (e.g., 37° C. water bath). Cells contemplated for use in the present invention include stem cells, such mesenchymal stem cells. Cells can be animal cells, such as mammalian cells. In one embodiment, the cells are human cells.01-26-2012
20120020933METHOD OF NERVE REPAIR WITH AMNION AND CHORION CONSTRUCTS - Improved methods for the surgical repair of a damaged or severed nerve are described. The improvement includes covering the surgically repaired nerve or a damaged neurilemma with at least one of an amniotic fluid and a construct, or replacing the damaged neurilemma with the construct prior to wound closing during the surgery. The construct contains an allograft having at least one layer of amnion and chorion tissues, and a shape adapted for enclosing a damaged or severed nerve or for covering or replacing the damaged neurilemma during the surgical repair. The products and methods improve the performance of the nerve surgery, e.g., by reducing inflammation, inhibiting fibrosis, scarring, fibroblast proliferation, post-operative infection while also promoting more rapid healing of damaged or traumatized nerve structures.01-26-2012
20120020932THERMOSENSITIVE HYDROGEL COMPOSITION AND METHOD - A hydrogel-forming composition is provided that comprises an extracellular matrix protein, hyaluronic acid, and a thermosensitive biocompatible polymer such as methylcellulose. The hydrogels can provide a therapeutic effect; further, the hydrogels may comprise an optional therapeutic agent such as cells or a pharmaceutical composition. The composition may be injected to an area in need of treatment by the therapeutic agent. The composition may form a gel at about 37° C., such that the gel maintains the therapeutic agent in the area of the body in need of such treatment.01-26-2012
20120020931THERAPEUTIC ENCAPSULATED EMBRYONIC STEM CELLS AND MESENCHYMAL STROMAL CELLS - This application discloses alginate microencapsulation-mediated differentiation of embryonic stem cells and use of the stem cell differentiation method for the development of effective treatment of various diseases and disorders. The microencapsulation of embryonic stem (ES) cells results in decreased cell aggregation and enhanced neural lineage differentiation through incorporating the soluble inducer retinoic acid (RA) into the permeable microcapsule system. This application also discloses a micro-encapsulation system for immobilizing mesenchymal stromal cells (MSCs) while sustaining the molecular communication. Thus, the invention provides the use of encapsulated mesenchymal stromal cells in the cellular transplantation therapies. Moreover, the invention provides methods for delivery of encapsulated MSCs into the central nervous system and therapies derived therefrom, such as, the treatment of spinal cord injury (SCI) and other inflammatory conditions.01-26-2012
20120020930METHODS FOR THE PREPARATION OF ADIPOSE DERIVED STEM CELLS AND UTILIZING SAID CELLS IN THE TREATMENT OF DISEASES - The present invention provides a method for the preparation of adipose derived stem cells for use in cellular therapy. In further aspects the present invention provides cells produced by the method of the invention, pharmaceutical compositions and kits suitable for use in treatment of patients.01-26-2012
20120020929METHODS AND COMPOSITIONS RELATING TO NEURONAL CELL AND TISSUE DIFFERENTIATION - The invention relates to methods for isolating and purifying specific types of neurons, such as cortical or other projection neurons including corticospinal motor neurons, subcerebral projection neurons, and callosal projection neurons. The invention also relates to genes that are specific for particular neuronal subtypes, and the use of such genes in genetic/molecular control of cell development. The isolated cells and subtype-specific genes also have uses in diagnostics, therapeutics, and screening assays for pharmaceutical molecules.01-26-2012
20120027733COMPOSITIONS TO EFFECT NEURONAL GROWTH - Compositions containing neurogenic agents for inhibition of neuron death and inducing proliferation of neural cells are disclosed.02-02-2012
20120027732THERMOREVERSIBLE COLLAGEN - This invention relates to collagen formulations. More particularly, this invention relates to thermoreversible collagen formulations and methods of their use and preparation.02-02-2012
20120027731HEMANGIO-COLONY FORMING CELLS - Methods of generating and expanding human hemangio-colony forming cells in vitro and methods of expanding and using such cells are disclosed. The methods permit the production of large numbers of hemangio-colony forming cells as well as derivative cells, such as hematopoietic and endothelial cells. The cells obtained by the methods disclosed may be used for a variety of research, clinical, and therapeutic applications.02-02-2012
20120027730USES OF MESENCHYMAL STEM CELLS - The invention relates to the use of mesenchymal stem cells (MSCs) for treating systemic inflammatory response syndrome (SIRS) in a subject. The invention provides compositions, uses and methods for the treatment of SIRS.02-02-2012
20120027729METHODS FOR TREATING DIABETES - Transplantation of multipotent stromal cells (MSCs) into diabetic mice lowers blood sugar, increases blood insulin levels, increases the number and size of islets, and improves renal pathology. Accordingly, the invention provides methods for treating or preventing diabetes by administering isolated MSCs. The invention also provides methods for treating or preventing complications which arise from diabetes, including diabetic nephropathy, by transplanting isolated MSCs.02-02-2012
20130195814TISSUE-SPECIFIC DIFFERENTIATION MATRICES AND USES THEREOF - In some aspects, this invention provides a method of making a bone marrow-derived tissue-specific stem cell proliferation, expansion, isolation and rejuvenation extracellular matrix. In other aspects, this invention provides a method of making a tissue-specific fibroblast-derived stem cell differentiation extracellular matrix. Also provided are methods of using such a cell-derived preservation or differentiation matrices to induce tissue-specific differentiation of pluripotent cells, repair damaged tissue, and treat a subject having a physiologic deficiency using the same.08-01-2013
20130195813METHOD FOR PRODUCING CELLS HAVING CHARACTERISTICS OF HEPATOCYTES - The present invention relates to a method of producing cells having at least one characteristic of human hepatocytes as well as to cells produced by said method and uses of these cells.08-01-2013
20130195812INDUCED PLURIPOTENT STEM CELLS - Described herein is a major breakthrough in nuclear reprogramming and induced pluripotent stem cell (iPSC) technology. Fusion of the powerful transcription activation domain (TAD) of MyoD to the Oct4 protein makes iPSCs generation faster, more efficient, purer, safer and feeder-free. Also, disclosed herein is the first report of the use of a TAD fused to a transcription factor as a method for making iPSCs. By combining transcription factors and TADs, this approach to nuclear reprogramming can have a range of applications from inducing pluriopotency to inducing transdifferentiation without transitioning through iPSCs.08-01-2013
20130195811Biomatrix Scaffolds - The present invention provides biomatrix scaffolds, a tissue extract enriched for extracellular matrix components and bound growth factors, cytokines and hormones, and methods of making and using same.08-01-2013
20130195810MULTIPOTENT STEM CELLS AND USES THEREOF - The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The invention further provides a proliferative stem cell, which expresses genes including Oct-4, Nanog, Sox2, GDF3, P16INK4, BMI, Notch, HDAC4, TERT, Rex-1 and TWIST but does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The cells of the invention can be isolated from adult mammals, have embryonic cell characteristics, and can form embryoid bodies. Methods for obtaining the stem cells, as well as methods of treating diseases and the differentiated stem cells, are also provided.08-01-2013
20130195809MULTIPOTENT STEM CELLS AND USES THEREOF - The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The invention further provides a proliferative stem cell, which expresses genes including Oct-4, Nanog, Sox2, GDF3, P16INK4, BMI, Notch, HDAC4, TERT, Rex-1 and TWIST but does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The cells of the invention can be isolated from adult mammals, have embryonic cell characteristics, and can form embryoid bodies. Methods for obtaining the stem cells, as well as methods of treating diseases and the differentiated stem cells, are also provided.08-01-2013
20130195808MESENCHYMAL STEM CELL AND A METHOD OF USE THEREOF - Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells.08-01-2013
20130195807AGONISTS OF GROWTH HORMONE RELEASING HORMONE AS EFFECTORS FOR SURVIVAL AND PROLIFERATION OF PANCREATIC ISLETS - Agonists of growth hormone releasing hormone promote islet graft growth and proliferation in patients. Methods of treating patients comprise the use of these agonists.08-01-2013
20130195806PHARMACEUTICAL PREPARATIONS OF HUMAN RPE CELLS AND USES THEREOF - This disclosure provides the first description of hESC-derived cells transplanted into human patients. Results are reported for one patient with each of Stargardt's Macular Dystrophy (SMD) and Dry Age-Related Macular Degeneration (AMD). Controlled hESC differentiation resulted in near-100% pure RPE populations. Immediately after surgery, hyperpigmentation was visible at the transplant site in both patients, with subsequent evidence the cells had attached and integrated into the native RPE layer. No signs of inflammation or hyperproliferation were observed. The hESC-derived RPE cells have shown no signs of rejection or tumorigenicity at the time of this report. Visual measurements suggest improvement in both patients.08-01-2013
20130195805MODIFICATION OF REACTIVITY OF BONE CONSTRUCTS - A method of enhancing the binding of growth factors and cell cultures to a demineralized allograft bone material which includes applying ex vivo an effective quantity of an ionic force change agent to at least a portion of the surface of a demineralized allograft bone material to produce a binding-sensitized demineralized allograft bone material and implanting the binding-sensitized demineralized allograft bone material into a host bone. The ionic force change agent may include at least one of enzymes, pressure, chemicals, heat, sheer force, oxygen plasma, supercritical nitrogen, supercritical carbon, supercritical water or a combination thereof. A molecule, a cell culture, or a combination thereof is administered to the binding-sensitized demineralized allograft bone material.08-01-2013
20090028832Compositions and methods for targeted tumor therapy - The present invention relates to a method of treating a human patient having one or more tumor cells. In one embodiment, the method comprises the step of implanting at or around the site of one or more tumor cells in the patient a cell population comprising one or more prostate cancer cells characterized in that the one or more prostate cancer cells have the propensity of metastasizing to skeleton and soft tissues which represent one or more lethal phenotypes of human prostate cancer.01-29-2009
20120034193TREATMENT OF NEUROTROPHIC FACTOR MEDIATED DISORDERS - An agent selected from A/B-cis furostane, furostene, spirostane and spirostene steroidal sapogenins and ester, ether, ketone and glycosylated forms thereof is used to induce self-regulated homeostasis of neurotrophic factors (NFs), for example BDNF and/or GDNF, NFs with limited and manageable side effects in a subject, by modulating NFs in a non-toxic manner under homeostatic control. An effective amount of at least one such agent is administered to the subject, particularly in the treatment or prevention of a range of NF-mediated disorders, particularly neurological, psychiatric, inflammatory, allergic, immune and neoplastic disorders, and in the restoration or normalisation of neuronal and other function in or in relation to any damaged or abnormal tissue, including when assisting tissue (for example, skin, bone, eye and muscle) healing and general skin, bone, eye and muscle health.02-09-2012
20120294835SUBSTITUTED PYRIDINES AND PYRIMIDINES - Provided is a compound of formula (I), and/or salt thereof,11-22-2012
20130101562Methods for handling biological drugs containing living cells - The present invention includes methods for handling live cell compositions in non-nutritive buffer. The cells in the compositions maintain their identity and functional characteristics after being stored in non-nutrititive media up to about 04-25-2013
20090104164ANGIOGENIC CELLS FROM HUMAN PLACENTAL PERFUSATE - Provided herein are the production of vasculogenic or angiogenic cells from placental perfusate. Also provided are methods of treating an individual having a cardiac or vascular insufficiency, disease, disorder or condition comprising administering to said individual placental perfusate, placental perfusate cells, or combinations of placental perfusate or perfusate cells with placental or non-placental hematopoietic stem cells or adherent placental stem cells.04-23-2009
20130202566METHOD FOR INDUCING DIFFERENTIATION OF MESENCHYMAL STEM CELLS TO NERVE CELLS USING SOUND WAVES - The present invention relates to a method for differentiation of mesenchymal stem cells. More specifically, the invention relates to a method for differentiating mesenchymal stem cells to neural cells by treating the mesenchymal stem cells with low-frequency sound waves. The differentiation method of the present invention can induce differentiation even with low-cost media rather than induced neural differentiation mediums which are expensive due to addition of growth factors, and the neural cells differentiated according to the present invention may be useful for treatment of neurological diseases.08-08-2013
20130202567TISSUE CULTURE MEDIA CONTAINING TRIMETHYLAMINE N-OXIDE - The present disclosure provides cell culture medium comprising trimethylamine N-oxide (TMAO). Progenitor cells cultured with such medium can form connective tissue with enhanced mechanical properties. Also provided are methods of forming connective tissue and methods of treatment for connective tissue defects.08-08-2013
20130202568Ameliorating Nervous Systems Disorders - The present disclosure provides methods for the treatment of a mammal having a neurological condition, disease, or injury. The methods involve increasing the number of functional GABAergic interneurons at or near the site of the neurological disease, injury, or condition.08-08-2013
20130202565METHOD FOR INDUCING DIFFERENTIATION OF ADULT STEM CELLS AND NERVE CELLS USING ELECTROMAGNETIC FIELD - The present invention relates to a method for differentiation of mesenchymal stem cells or dental pulp stem cells. More specifically, the invention relates to a method for differentiating stem cells to neural cells by applying mesenchymal stem cells or dental pulp stem cells with a low-frequency electromagnetic field. The differentiation method according to the present invention can induce differentiation even with low-cost mediums rather than induced neural differentiation mediums which are expensive due to addition of growth factors, and the neural cells differentiated according to the present invention may be useful for treatment of neurological brain diseases.08-08-2013
20130202564Systems and Methods of Cell Activated, Controlled Release Delivery of Growth Factors for Tissue Repair and Regeneration - This invention provides a composition for controlled-release of polypeptide growth factors useful in tissue repair or engineering. The composition include a polypeptide growth factor covalently cross-linked to a biocompatible substrate by a transgultaminase. The cross-linking tethers the growth factor to a substrate so that it will not diffuse away from the desired site of application. It also concomitantly inactivates the growth factor. Release and reactivation of the growth factor can be achieved by endogenously produced metalloproteinase (MMPs) or exogenously provided proteases such as collagenases. Also provided are scaffolds, transplant devices, methods for using the same and methods for making the same,08-08-2013
20130202563DECELLULARIZED ADIPOSE CELL GROWTH SCAFFOLD - Provided herein are methods of making a cell growth scaffold from adipose tissue, cell growth scaffolds having low lipid content and methods of using the cell growth scaffold.08-08-2013
20090035282Pluripotent embryonic-like stem cells derived from teeth and uses thereof - A stem cell which is obtainable from the non-embryonic tissue isolated from the dental follicle of tooth or wisdom tooth which are able to differentiate into a periodontal ligament like membrane structure.02-05-2009
20120064046MAINTENANCE AND PROPAGATION OF MESENCHYMAL STEM CELLS - Various embodiments of the present invention include compositions, materials and methods for maintaining and propagating mammalian mesenchymal stem cells in an undifferentiated state in the absence of feeder cells and applications of the same.03-15-2012
20120064045COMPOSITIONS AND METHODS FOR TREATING PROGRESSIVE MYOCARDIAL INJURY DUE TO A VASCULAR INSUFFICIENCY - The described invention provides methods and regimens for treating adverse consequences of a persistent and progressive myocardial injury-due to a vascular insufficiency that occurs early or late in a subject in need thereof, and progressive myocardial injury-preventing compositions that contain a chemotactic hematopoietic stem cell product, and, optionally, an additional active agent.03-15-2012
20120064044METHODS OF TREATING EDEMA RELATED TO ISCHEMIA-REPERFUSION - Methods are described for preventing or reducing edema related to ischemia-reperfusion by treating the organ or tissue being transplanted with an aminoalkyl glucosaminide phosphate.03-15-2012
20120064040SERUM FREE CULTURE MEDIUM AND SUPPLEMENT - Provided herein is a chemically defined method of endothelial cell (EC) derivation from embryonic stem cells (ESC). These progenitor cells are capable of low-density lipoprotein uptake, an important function of EC, and also express EC specific markers. By using chemically defined culture conditions, the reproducibility of the derivation as well as eliminate the possibility of unknown contaminants such as undefined growth factors and sundry animal proteins is improved. The differentiated cells can then be applied to a myriad of potential therapies such as tissue engineered vascular grafts, cardiac patches, and pre-vascularized tissue transplants.03-15-2012
20090269316Methods for Using a Three-Dimensional Stromal Tissue to Promote Angiogenesis - The present invention relates to a method for promoting blood vessel formation in tissues and organs. In particular, the method relates to implantation or attachment of an engineered three-dimensional stromal tissue to promote endothelialization and angiogenesis in the heart and related tissues. The three-dimensional stromal tissue of the present invention may be used in a variety of applications including, but not limited to, promoting repair of and regeneration of damaged cardiac muscle, promoting vascularization and healing during cardiac surgery, promoting blood vessel formation at anastomosis sites, and promoting vascularization and repair of damaged skeletal muscle, smooth muscle or connective tissue.10-29-2009
20120301442TREATMENT OF BONE FRACTURE - The use of mesenchymal stem cells cultured in the presence of HS-2 for the treatment of bone fracture. Repair of bone fracture using such cells is enhanced compared with the treatment of bone fracture using mesenchymal cells cultured without HS-2. These mesenchymal stem cells may be formulated in a pharmaceutical composition and injected directly into tissues surrounding the fracture or used in a biocompatible implant or prosthesis.11-29-2012
20130095082USE OF DES-ASPARTATE-ANGIOTENSIN I IN INFLAMMATION-RELATED PATHOLOGIES AND DISEASES - The present disclosure generally relates to the use of des-aspartate-angiotensin I and/or its derivatives in medicine. In particular, the present invention relates to the use of des-aspartate-angiotensin I and/or its derivatives for the treatment and/or prophylaxis of inflammatory diseases or pathologies, for inducing anti-inflammatory actions and/or reducing inflammation, and/or for treatment of inflammation-related conditions.04-18-2013
20120087898COMPOSITIONS COMPRISING FEMALE GERMLINE STEM CELLS AND METHODS OF USE THEREOF - The present invention relates to female germline stem cells and their progenitors, methods of isolation thereof, and methods of use thereof.04-12-2012
20120093784COMPOSITIONS AND METHODS FOR CONTROLLING STEM CELL AND TUMOR CELL DIFFERENTIATION, GROWTH, AND FORMATION - The present invention relates to the use of self-assembling peptide amphiphiles to prevent tumor formation by transplanted stem cells. The present invention further relates to the use of self-assembling peptide amphiphiles to treat cancers.04-19-2012
20120093783USE ADIPOSE TISSUE-DERIVED REGENERATIVE CELLS IN THE MODULATION OF INFLAMMATION IN THE PANCREAS AND IN THE KIDNEY - Aspects of the present invention relate to the field of medicine, specifically, the effect of adipose tissue and its components on modulating inflammation.04-19-2012
20120093782Enhanced Hematopoietic Stem Cell Engraftment - The invention relates to improved products, processes, and therapeutic methods relating to hematopoietic stem cells and hematopoietic stem cell transplantation. Included are methods for improving transplant efficiency of cord blood units comprising use of mixtures of expanded CD3404-19-2012
20120093781HUMAN MAST CELL LINE AND USES THEREOF - The subject invention pertains to the development of a novel human mast cell line, USF-MC1. USF-MC1 is a mast cell precursor present in human umbilical cord blood (HUCB) that may be sustained in culture in the absence of exogenous cytokines to serve as a convenient experimental model of human mast cell activation. The SCF-independent human mast cell line USF-MC1 responds to IgE-mediated and IgE-independent stimuli in a way comparable to that of LAD2. USF-MC1 cells are useful for investigation of IgE-mediated activation mechanisms of human mast cells, contributing to the development of effective treatments for allergic disorders and other disorders. The subject invention provides a ready source of human mast cells for research, including pharmacological studies for the screening of various agents, and toxicologic, e.g., for the cosmetic and pharmaceutical industries. The mast cells can also be used as biofactories, for the large-scale production of biomolecules.04-19-2012
20130209419Methods of Engraftment - Methods and compositions for improving the engraftment of stem cells are described. The method involves administering an effective amount of hemoglobin. The methods and compositions are useful in stimulating hematopoiesis and may be used to boost human hematopoietic re-engraftment for use in transplant recipients or in patients with bone marrow injury.08-15-2013
20130209414Expansion Of Stem/Progenitor Cells By Inhibition Of Enzymatic Reactions Catalyzed By The Sir2 Family Of Enzymes - Provided are ex vivo and in vivo methods of expanding renewable stem cells using agents capable of down-regulating Sir2 protein activity and/or expression, expanded populations of renewable stem cells, and uses thereof.08-15-2013
20130209415PURIFIED COMPOSITIONS OF CARDIOVASCULAR PROGENITOR CELLS - Composition and methods are provided for the prospective enrichment of human cardiovascular progenitor cells, which can be differentiated into cardiomyocytes, from in vitro cultures of stem cells. The stem cells are cultured in conditions permissive for differentiation into cardiovascular progenitor cells, and cardiovascular progenitor cells are sorted for expression of one or more of the markers ROR2, CD13, KDR and PDGFαR, where the progenitor cells positively express these markers. Highly enriched populations of cardiomyocyte lineage cells can be obtained.08-15-2013
20130209416METHODS AND COMPOSITIONS FOR PREPARING CARDIOMYOCYTES FROM STEM CELLS AND USES THEREOF - The present invention discloses novel compositions and methods for enhancing cardiac differentiation efficiency of stem cells or promoting ventricular and atrial cardiomyocytes formation from stem cells. The present invention also discloses the atrial and ventricular cardiomyocytes formed from the stem cells, and the uses of the cardiomyocytes for repairing cardiac injuries and screening for new medicaments for treating cardiac injuries.08-15-2013
20130209417ISOLATION OF ADULT MULTIPOTENTIAL CELLS BY TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE - The present invention relates to the use of tissue non-specific alkaline phosphatase (TNAP) as a marker for identifying and/or isolating adult multipotential cells. The present invention also relates to cell populations enriched by methods of the present invention and therapeutic uses of these cells.08-15-2013
20130209418METHODS AND COMPOSITION RELATED TO BROWN ADIPOSE-LIKE CELLS - Methods and therapeutics are provided for treating diseases, including metabolic diseases and other weight-related disorders. Generally, methods for making brown adipose-like including culturing a population of artery-derived cells in adipogenic induction medium for a period of time and under conditions sufficient to increase expression of at least one adipocyte marker at a higher level as compared to untreated artery-derived cells are disclosed. Isolated artery-derived, ex vivo differentiated brown adipose-like cells are also provided, including pharmaceutical compositions and cell delivery systems thereof. In another embodiment, a method of treating a subject is disclosed that includes obtaining a population of artery-derived brown adipose-like cells and administering the brown adipose-like cells into a target region in the subject.08-15-2013
20130209420Mixed Cell Populations for Tissue Repair and Separation Technique for Cell Processing - The present invention provides a fluid exchange cell culture technique and tissue repair cells (TRCs) made by these methods, as well as methods using these cells. The method includes a new wash step which increases the tissue repair properties of the TRCs of the invention. This wash step allows for the production of TRC populations with greater tissue repair and anti-inflammatory capabilities. Embodiments of the present invention include a post-culture process for cultured cells that preferably includes the steps of: a wash process for removing unwanted residual culture components, a volume reduction process, and a harvesting process to remove cultured cells. Preferably, all these steps are performed within a aseptically closed cell culture chamber by implementing a separation method that minimizes mechanical disruption of the cells and is simple to automate. The harvested cells may then be concentrated to a final volume for the intended use. In such embodiments, the final composition is a substantially purified and concentrated cell mixture suspended in a physiologic solution suitable for immediate use in humans without further washing, volume reduction, or processing. Embodiments are also applicable to harvesting (and/or washing) particles within a liquid or solution within a chamber.08-15-2013
20130209421INDUCED PLURIPOTENT STEM CELLS DERIVED FROM HUMAN PANCREATIC BETA CELLS - A method of generating pluripotent stem cells is described. The method comprises: 08-15-2013
20130209422"Pharmaceutical Composition Comprising Stem Cells Treated with NOD2 Agonist or Culture Thereof for Prevention and Treatment of Immune Disorders and Inflammatory Diseases" - The present invention relates to a pharmaceutical composition for the prevention or treatment of immune disorders and inflammatory diseases, comprising stem cells that are generated by culturing stem cells expression Nucleotide-binding Oligomerization Domain protein 2 (NOD2) with a NOD2 agonist or a culture thereof. More particularly, the present invention relates to a method for suppressing immune responses or inflammatory responses of a subject, comprising the step of administering the pharmaceutical composition, the stem cells or culture thereof to the subject, a method for preparing an immunosuppressive drug or an anti-inflammatory drug using the stem cells or culture thereof, a method for preparing PGE08-15-2013
20130209423METHODS FOR PROMOTING HEMATOPOIETIC RECONSTITUTION - The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E08-15-2013
20130209424COMPOSITIONS FOR PROMOTING HEMATOPOIETIC STEM CELL GROWTH - The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E08-15-2013
20130209425ENCAPSULATION OF PANCREATIC CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS - The present invention relates to methods for encapsulating pancreatic progenitors in a biocompatible semi-permeable encapsulating device. The present invention also relates to production of human insulin in a mammal in response to glucose stimulation.08-15-2013